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Preface 
 
Cervical cancer is the second most prevalent cancer among women worldwide, mainly 
affecting young women. Infection with Human Papilloma Virus (HPV) has been 
identified as the causal agent for this condition. The natural history of cervical cancer 
is characterized by slow disease progression, generally taking over 10 years, from the 
initial infection with HPV, to the diagnosis of cancer. In essence, cervical cancer is a 
preventable disease, and treatable if diagnosed in early stage. Historically, the 
introduction of the Pap smear has markedly reduced the number of new cases in 
countries with an effective prevention program. The burden of disease is highest in 
developing countries, with peak incidence in Eastern Africa. Recently, prophylactic 
vaccines became available, equally contributing to a better disease prevention. 
Unfortunately, the global burden of disease is still very high. 
In the first section of this book, clinical aspects of HPV related disease are highlighted. 
Innovative clinical diagnostic tools are discussed and Dr Fedrizzi has provided a 
highly illustrative contribution on the clinical manifestation of HPV related disease. 
The introduction of the HPV prophylactic vaccine has been an important recent 
development in the fight against cervical cancer. The second section focuses on HPV 
vaccine related issues. Immune responses of the current vaccine are presented by Dr 
Bourgault-Villada, and options for the next generation vaccines, or more efficient 
production strategies, are discussed. Although HPV is most prominently known from 
its role in cervical carcinogenesis, the virus is also involved in other conditions. In the 
third section, HPV in non-uterine disease is discussed. Epidemiology and role of HPV 
in head-and-neck tumors are addressed. HPV also affects men, and this section covers 
the impact of HPV on penile cancers and its prevalence in semen. 
This book will be a useful tool for both researchers and clinicians dealing with cervical 
cancer, and it will provide them with the latest information in this field. 
 
Dr Davy Vanden Broeck, MSc, PhD 
Team Leader HPV/Cervical Cancer Research 
International Centre for Reproductive Health 
Ghent University 
Belgium 
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Human Papillomavirus: 
Biology and Pathogenesis 
José Veríssimo Fernandes1 and 
Thales Allyrio Araújo de Medeiros Fernandes2 
1Federal University of Rio Grande do Norte 
2University of Rio Grande do Norte State  
Brazil 
1. Introduction  
The human papillomavirus (HPV) is one of the most common causes of sexually transmitted 
disease in both men and women around the world, especially in developing countries, 
where the prevalence of asymptomatic infection varies from 2 to 44%, depending on the 
population and studied region (Sanjosé et al., 2007). Most HPV infection is transient and 
some studies show that the majority of sexually active individuals are exposed to and 
acquire infection from this virus at some phase in their lives (Baseman and Koutsky, 2005; 
Trottier and Franco, 2006). HPV infection is more prevalent in young adults, at the 
beginning of their sexual activity, with a subsequent decline in the prevalence rate with 
increasing age, likely as a result of development of an immune response against the virus 
and reduction of sexual activity (Castle et al., 2005; Fernandes et al., 2009; Chan et al., 2010).  
HPV can infect basal epithelial cells of the skin or inner-lining tissues and are categorized as 
cutaneous types or mucosal types. Cutaneous types are epidermotropic and infect the 
keratinized surface of the skin, targeting the skin of the hands and feet. Mucosal types infect 
the lining of the mouth, throat, respiratory, or anogenital tract epithelium (Burd, 2003). 
Some HPVs are associated with warts while others have been well established as the main 
risk factor of invasive cervical cancers and their associated pre-cancerous lesions (Clifford et 
al., 2005; Zekri et al., 2006; Muñoz et al., 2006). However, only few HPV-infected individuals 
progress to invasive cervical cancer (Burd, 2003). Most infected individuals eliminate the 
virus without developing recognized clinical manifestation. (Bosch et al., 2008).  
Today, more than 150 different HPV types have been cataloged and about 40 can infect the 
epithelial lining of the anogenital tract and other mucosal areas of the human body.  Based 
on their association with cervical cancer and precursor lesions, HPVs can also be classified 
as high-risk (HR-HPV) and low-risk (LR-HPV) oncogenic types.  LR-HPV types, such as 
HPV 6 and 11, can cause common genital warts or benign hyperproliferative lesions with 
very limited tendency to malignant progression, while infection with HR-HPV types, 
highlighting HPV 16 and 18, is associated with the occurrence of pre-malignant and 
malignant cervical lesions (Muñoz et al., 2003; Bosch et al., 2002; Bosch et al., 2008). HR-HPV 
types are also associated with many penile, vulvar, anal, and head and neck carcinomas, 
and contribute to over 40% of oral cancers (Stanley, 2010). 
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Persistent infection with HR-HPV is unequivocally established as a necessary cause of cervival 
cancer (Trottier & Franco, 2006). The critical molecules for initiation and progression of this 
cancer are the oncoproteins E5, E6, and E7, that act largely by overcoming negative growth 
regulation by host cell proteins and by inducing genomic instability, a hallmark of HPV-
associated cancers (Munger et al., 2004; Moody & Laimins, 2010). 
Once HPV transmission to the genital tract occurs through sexual contact, the risk factors for 
the infection and cervical lesions, including cervical cancer, are the same classic risk factors 
for other sexually transmitted diseases. The number of sexual partners is the risk factor 
more consistently associated with genital HPV infection and therefore with cervical cancer. 
In addition, other indicators of sexual behavior and reproductive activities, heredity, 
immune and nutritional status, and smoking can contribute in some way to the 
development of cervical cancer (Tarkowski et al., 2004; Muñoz, 2006; Fernandes et al., 2010). 
In this chapter we will discuss the biology and pathogenesis of human papillomavirus, 
analyzing some specific aspects of their interactions with the infected host and specific host 
cell components. 
2. Biologic properties of HPV 
2.1 Structure of viral particle and regulation of gene expression 
The human papillomavirus (HPV) is a relatively small non-enveloped virus that contains a 
double-stranded closed circular DNA genome, associated with histone-like proteins and 
protected by a capsid formed by two late proteins, L1 and L2. Each capsid is composed of 72 
capsomeres, each of which is composed of five monomeric of 55kDa units that join to form a 
pentamer corresponding to the major protein capsid, L1. The L1 pentamers are distributed 
forming a network of intra- and interpentameric disulfide interactions which serve to 
stabilize the capsid (Sapp et al., 1995). In addition to L1, minor capsid proteins with 
approximately 75kDa exist within the virion and are called the L2 protein. To assemble the 
viral capsid, the pentamers join to copies of L2 that occludes the center of each pentavalent 
capsomere. (Jo & Kim 2005; Buck et al., 2008; Conway & Meyers, 2009). Thus, each virion 
contains 72 copies of the L1, the major component of the capsid, and a variable number of 
copies of L2, a secondary component of the viral capsid, forming a particle with icosahedra 
symmetry and approximately 50 to 60 nm in diameter ( Burd, 2003; Longworth & Laimins, 
2004; zur Hausen, 2009).  
 
Fig. 1. The structure of HPV. (Adapted from Swiss Institute of Bioinformatics, Viral Zone. -
Available in http://viralzone.expasy.org/all_by_species/5.html ) 
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The viral genome of the HPV consists of a single molecule of double-stranded and circular 
DNA, containing approximately 8000 base pairs and harboring an average of 8 open reading 
frames (ORFs) (Jo & Kim 2005; Zheng & Baker, 2006). In a functional point of view, the HPV 
genome is divided into three regions. The first is a noncoding upstream regulatory region 
(URR) or long control region (LCR) that has regulatory function of the transcription of the 
E6 and E7 viral genes; The second is an early region (E), consisting of six ORFs: E1, E2, E4, 
E5, E6, and E7, which encodes no structural proteins involved in viral replication and 
oncogenesis. The third is a late (L) region that encodes the L1 and L2 structural proteins. The 
LCR region of the anogenital HPVs ranges in size between 800-900 pb, representing about 
10% of the genome, and varies substantially in nucleotide composition between individual 
HPV types (Fehrmann & Laimins, 2003; Jo & Kim, 2005). 
Only one strand of the double-stranded DNA serves as the template for viral gene 
expression, coding for a number of polycistronic mRNA transcripts. (Stanley et al., 2007). 
The regulation of viral gene expression is complex and controlled by cellular and viral 
transcription factors. Most of these regulations occur within the LCR region, which contains 
cis-active element transcription regulators. These sequences are bound by a number of 
cellular factors as well as the viral E2 product (zur Hausen, 1996). A large number of cellular 
transcription factors have been identified and the dysfunction of some of them appears to 
play a significant role in papillomavirus-linked carcinogenesis (Thierry et al., 1992; Hamid & 
Gaston, 2009).  
The transcription start sites of viral promoters differ depending on the virus type, but, in all 
types, promoter usage is keratinocyte differentiation-dependent (Smith et al., 2007). The 
replication origin and many transcriptional regulatory elements are found in the upstream 
LCR region. The virus early promoter, differentiation-dependent late promoter, and two 
polyadenylation signals define three general groups of viral genes that are coordinately 
regulated during host cell differentiation. The E6 and E7 genes maintain replication 
competence. E1 E2, E4, E5, and E8 are involved in virus DNA replication, transcriptional 
control, beyond other late functions and L1 and L2, responsible for the assembly of viral 
particles (Bodily & Laimins, 2011). 
The regulation of expression of the late genes in genital HPVs is not well understood. 
However, it has been shown that the second, or later, promoter is initiated in a 
differentiation-dependent manner, and thus is activated only when cells are grown in the 
host’s stratifying/differentiating tissue. Once activated, the later promoter directs 
transcription from a heterogeneous set of start sites and will serve to produce a set of 
transcripts that facilitate the translation of L1 and L2 proteins (Smith et al., 2007; Conway & 
Meyers, 2009). Activation of the later promoter is accompanied by acceleration of viral DNA 
replication and by high levels of viral protein expression. As a result, virus copy-number 
amplifies from 50 copies to several thousands of copies per cell. So when a late promoter is 
activated, the expression of genes will occur, encoding the structural proteins L1 and L2, 
which join to assemble the capsids and to form virions (Stanley et al., 2007). 
2.2 Functions of viral proteins 
E1 Protein 
The E1 protein represents one of the the most conserved proteins among different HPV 
types. It has DNA-binding functions and a binding site in the origin of replication localized 
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in the LCR region. It assembles into a hexameric complex, supported by the E2 protein, and 
the resultant complex has helicase activity and initiates DNA bidirectional unwinding, 
constituting a prerequisite for viral DNA replication (Wilson et al., 2002; Frattini & Laimins, 
1994). The carboxyl terminal domain of E1 has an ATPase/helicase activity and is necessary 
and sufficient for oligomerization. This domain also interacts with the E2 protein and 
subunit p70 of DNA polymerase α, but is not sufficient to support replication (Amin et al., 
2000). A segment of approximately 160 amino acid residues upstream of the 
ATPase/helicase domain is the DNA-binding domain (Titolo et al., 2003). A stretch of about 
50 amino acids within the amino terminus of E1 acts as a localization regulatory region 
(LCR) and contains a dominant nuclear export sequence (NES) and a nuclear localization 
signal (NSL), which are regulated by phosphorylation (Deng et al., 2004).    
E2 protein  
The E2 open reading frame of HPV gives rise to multiple gene products by alternative RNA 
splicing. The proteins derived from the E2 gene are involved in the control of viral 
transcription, DNA replication, and segregation of viral genomes (McPhillips et al., 2006; 
Kadaja et al., 2009). These different E2 types represent the major intragenomic regulators 
(Bouvard et al., 1994).  
The E2 protein can bind to factors on mitotic chromatin and join the virus genome to host 
cell chromosomes during mitosis; it contributes to coordinating the HPV DNA replication 
with host cell chromosome duplication, allowing the viral genomes to be distributed to the 
daughter cell. This constitutes an important requirement for the persistence of virus DNA in 
undifferentiated basal cells (McPhillips et al., 2006). Furthermore, the E2 protein interacts 
with E1 and stimulates viral DNA replication, favoring the binding of E1 to the origin of 
replication ( Seo et al., 1993; Chow et al., 1994).  
In lesions containing HPV episomes, the E2 protein directly represses the expression of early 
genes as a mechanism to regulate the copy number. In addition, it has been reported that 
HPV E2 proteins are able to repress telomerase promoter activity mediated by the HPV E6 
protein (Hamid et al., 2009). Integration of the HPV genome in the host cell chromosome 
usually disrupts E2 expression, causing a deregulated expression of early viral genes, 
including E6 and E7, and this event can favor the transformation of human cells and the 
transition into a malignant state (Romanczuk & Howley, 1992)  
In addition to the full-length E2 protein, the infected cells can express an E8^E2C transcript, 
in which the small E8 domain is fused to the C-terminal domain of E2 (E2C). The full-length 
E2 protein forms heterodimers with repressor forms of E2, and these E2 heterodimers serve 
as activators of transcription and replication during the viral cycle. The single-chain E2 
heterodimer in the HPV 18 genome initiates genome replication, but is not sufficient for 
long-term replication of the HPV 18 genome. This is due to the capacity of HPV18 in 
encoding the repressor E8/E2, which acts as a negative regulator of HPV18 genome 
replication (Kurg et al., 2010).  Moreover, it has been shown that inactivation of E2 in the 
HPV16 genome increases E6/E7 transcription (Soeda et al., 2006), and that mutation of 
E8^E2C in the HPV31 or HPV16 genome increases the genome copy number and the E6/E7 
transcription, suggesting that the transcriptional repressing by E8^E2C has an important 
role in viral replication (Lace et al., 2008). It was also noted that the E2C domain not only 
mediates specific DNA binding but has also an additional role in transcriptional repression 
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by recruitment of co-repressors, such as the CHD6 protein. This suggests that repression of 
the E6/E7 promoter by E2 and E8^E2C involves multiple interactions with host cell proteins 
through different protein domains (Fertey et al., 2010). 
E4 protein  
Despite being considered an early protein, E4 is exclusively located in the differentiated 
layers of the infected epithelium (zur Hausen, 1996). Although its expression occurs in 
highly differentiated cells that express the capsid genes and synthesize new progeny virions, 
and coincides with the onset of vegetative viral DNA replication, E4 is not found in virion 
particles. The role of this protein in the virus life cycle has not yet been determined, but E4 is 
not required for transformation or episomal persistence of viral DNA, but interacts with the 
keratin networks and causes their collapse (Doorbar et al., 1991).  
It has been suggested that E4 may have an important role in favoring and supporting the 
HPV genome amplification, besides regulating the expression of late genes, controlling the 
virus maturation, and facilitating the release of virions (Londgworth & Laimins 2004). E4 
also interacts with and disrupts the organization of intermediate filaments. The role of E4 in 
providing the release of virus is supported by the association of E4 with the cornified cell 
envelope (CCE), a highly resistant structure under the plasmatic membrane of differentiated 
keratinocytes in the stratum corneum. Furthermore, E4 may play role in regulating gene 
expression and has been shown to induce G2 arrest in a variety of cell types (Londgworth & 
Laimins 2004).  
E5 protein  
The E5 protein is a small hydrophobic peptide, approximately 83 amino acids in size that 
localizes primarily to the endoplasmic reticulum. When expressed alone, HPV E5 has weak 
oncogenic properties. But in tissue culture assays, HPV E5 can enhance the transforming 
activity of E6 and E7, suggesting that it may have a supportive role in tumor progression. 
The localization of E5 to the endoplasmic reticulum suggests its activity may be related to 
the trafficking of cytoplasmic membrane proteins through this cellular compartment. E5 has 
also been reported to alter the activity of the epidermal growth factor receptor (EGFR), in 
addition to reducing the surface levels of major histocompatibility complex (MHC) class I 
proteins, modulating the MAPK pathway and altering the levels of caveolin 1 (Moody & 
Laimins, 2010). 
The E5 protein varies in length and primary amino acid sequence among the different 
papillomaviruses, but maintains its hydrophobic nature that promotes fusion between cells 
(Hu et al., 2009). HPV16 E5 has all the characteristics of fusogenic proteins, including 
localization in plasma membrane, high level of hydrophobicity, and the ability for dimmers. 
Moreover, HPV16 E5 has been identified to be necessary and sufficient to induce cell-cell 
fusion with formation of tetraploid cell and cytokinesis failure (Hu et al., 2009).  
The fusogenic activity of the HR-HPV E5 protein contributes to fusion among cells 
generating aneuploidy with tetraploid cells and chromosomal instability. These events seem 
to precede and favor integration of HPV genomes, which in turn, leads to expression of 
viral-cellular fusion transcripts and further enhances expression of the E6-E7 genes, 
rendering transformed cells strong growth advantages (Ziegert et al., 2003). Thus, the cell 
fusion HR-HPV E5-induced and cell cycle deregulation seems to have an important role in 
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the early stages of the transformation process. This suggests that HR-HPV E5-induced cell 
fusion can be a critical event in the early stage of the development of HPV-associated 
cervical cancer (Gao and Zheng et al., 2010). 
As the E5 gene is frequently deleted in cervical cancers, it is believed that the E5 protein may 
play a role in the early stages of the process of cellular transformation, but is dispensable for 
the maintenance of malignant transformation (zur Hausen, 1996).  
E6 protein  
The HPV E6 protein is formed by approximately 150 amino acids and contains two zinc-like 
fingers joined by an interdomain linker of 36 amino acids, flanked by short amino (N) and 
carboxy (C) terminal  domains of variable lengths (Howie et al., 2009). The best known 
property of the E6 proteins of HR-HPVs is the ability to bind and degrade the tumor-
suppressor protein p53, through the recruitment of the E6-associated protein (E6-AP), a 
cellular E3 ligase that does not bind to p53 in the absence of E6.  Both E6 proteins from HR-
HPV and LR-HPV bind to p53, but the interaction is stronger in HR-HPV (Lechner et al., 
1994).  
The E6 protein can overcome the cell arrest and proapoptotic activities of p53 by targeting 
p53 for degradation, inactivating the Mdm2 pathway. E6 can also inhibit the transcriptional 
activities of p53 independently of E6-AP (Thomas et al., 2005). Three different mechanisms 
have been proposed to explain this p53 inactivation: The first is inhibiting the binding of p53 
to its target sequence in the genome; second, E6 may be able to inhibit p53 signaling by 
maintaining it in cytoplasm; and third, the mechanism employed by E6 to inhibit p53 
activity is the abrogation of the transactivation of p53 responsive genes via interaction with 
either the CBP/p300 or hADA3 histone acetyltransferases. The E6 proteins have been shown 
to bind to p300, and this interaction inhibits p35 acetylation at p53 dependent sites, leading 
to decreased expression from p53. However, unlike p300, E6 interaction with hADA3 results 
in hADA3 degradation (Kumar et al., 2002). E6 may also inhibit p53 activation by blocking 
the p14/ARF pathway. Thus, E6 is able to modulate transcription of p53-dependent genes 
by both degradation of p53 and by interaction with the p300 and hADA3 transactivators 
(Shamanin et al., 2008). 
The degradation or blocking of the p53 function inhibit apoptotic signaling that would 
eliminate the HPV infection cell. There are two major apoptotic pathways that can be 
triggered by different stresses: the extrinsic and intrinsic pathways. The E6 protein is able to 
disrupt both pathways to facilitate a cytoprotective environment and prevent cell death 
(Howie et al., 2009). 
In addition, E6 is able to modulate transcription from other cellular signaling pathways as 
well as potentiating its ability to act as a diverse modulator of host cell signaling. It has been 
shown that E6 interact with three different proteins, such as a novel protein termed E6-
targeted protein 1 (E6TP1) in an E6-AP dependent manner (Wooldridge et al., 2007), beyond 
another protein with GAP activity, tuberin, that can also be bound and degraded by E6 
(Zeng et al. 2008). Furthermore, HR-HPV E6 has been shown to interact with two proteins 
that are part of the innate immune response to viral infection: interferon regulatory factor-3 
(IFR-3) and toll-like receptor 9 (TLR9) (Hasan et al., 2007). Exogenous expression of HPV16 
E6/E7 has been shown to inhibit TLR9 transcription, leading to a functional loss of TLR9 
signaling pathways within the cell (Hasan et al., 2007).  
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HR-HPV E6 is also able to interact with members of the PDZ family of proteins, promoting 
its proteasome-mediated degradation, an activity that seems to be required for induction of 
cervical cancer (Shai et al., 2007). HR-HPV E6 PDZ binding can mediate suprabasal cell 
proliferation and this is thought to occur by uncoupling the cell proliferation and polarity 
control that exist in a differentiated epithelium (Sterlinko et al., 2004). LR-HPV E6 does not 
contain the PDZ-binding motif and therefore cannot target these proteins. Degradation of 
PDZ proteins results in cellular transformation due to loss of cell-cell contact and loss of cell 
polarity (Storrs and Silverstein, 2007).  In addition, it has been demonstrated that the 
degradation of phosphatase PTPN13 by E6 results in anchorage-independent growth and a 
Ras-dependent invasive phenotype (Spanos et al., 2008).  
Another function of the HR-HPV E6 protein that is important for immortalization is their 
ability to activate the expression of the catalytic subunit of telomerase (hTERT). Thus, the E6 
protein is able to promote the maintanance of the telomere, through the action of 
telomerase. Interestingly, over-expression of hTERT in conjunction with E7 is sufficient to 
immortalize human primary keratinocytes. The HPV E2 proteins are reported to repress 
hTERT promoter activity, but the interplay of E6 and E2 during the regulation of this 
promoter has not been investigated (Hamid et al., 2009). 
E7 protein  
The E7 protein has around 100 amino acids in length  and contains three conserved regions: 
CR1, CR2, and CR3 (Münger and Howley, 2002). It will induce cellular proliferation  by 
binding to several cellular factors. The best characterized of these interactions is with the RB 
tumor suppressor and the related family members p107 and p130. The binding of high-risk 
E7 to pRB disrupts the interaction between pRB and E2F, a family of transcription factors, 
resulting in the constitutive expression of E2F-responsive genes, such as cyclin A and cyclin 
E, and promotes premature S phase entry, DNA synthesis, and the progression of cell cycle 
(Zerfass et al., 1995). Thus, in cells overexpressing the HPV E7 protein, this checkpoint 
control at G1/S transition is lost and the cells will continue their cell cycle, causing an 
uncontrolled cellular proliferation. Moreover, E7 induces the degradation of pRb via the 
proteasome-dependent pathway, using a mechanism that involves association with and 
reprogramming of the cullin 2 ubiquitin ligase complex (Jo & Kim, 2005; Huh et al., 2007).  
HPV E7 can also associate directly with cdk2/cyclin A and cylin E complexes, resulting in 
an increased cdk2 activity (Nguyen & Münger, 2008). Another action of E7 that contributes 
to cellular immortalization is its interaction with the CDK inhibitors (CKI) p21 and p27, 
efficiently neutralizing their inhibitory effects on CDK2 activities, an important factor for G1 
to S phase entry and progression (Moody & Laimins, 2010). The ability of E7 to inactivate 
these CKIs may contribute to its capacity to abrogate TGF-β mediated growth inhibition. 
Moreover, TGF-β also induces a cdk4/cdk6 specific CKI, P15Inkb, and p15Inkb-induced 
growth suppression, and these actions may require functional pRB, which is targeted for 
degradation by E7 (McLaughlin-Drubin & Münger, 2009). High-risk E7 has further been 
shown to increase the levels of the CDC25A phosphatase, which can induce tyrosine 
dephosphorylation of CDK2, promoting its activation (Moody & Laimins, 2010). 
E7 also affects the expression of S phase genes by directly interacting with E2F factors and 
with histone deacetylases (HDAC): E7-E2F6 interaction prevents repression of gene 
expression by E2F6, maintaining a S phase environment conductive for viral replication 
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(McLaughlin-Drubin et al., 2008), and E7-HDAC binding facilitates HDAC removal at 
promoters to activate transcription (Longworth & Laimins, 2004). 
Another major apoptotic pathway targeted by HPV proteins is anoikis, a form of apoptosis 
that is triggered when normal cells attempt to divide in the absence of a matrix (Tasaki et al., 
2005). E6 and E7 interact with some factors involved with anoikis, such as paxillin, fibulin 1, 
and p600 (Huh et al., 2005), promoting the prevention of anoikis.  
Furthermore, E6 and E7 interfere with the effects of various growth inhibitory cytokines that 
are induced following infection. High-risk HPV proteins repress the transcription of many 
IFN-inducible genes (Chang & Laimins, 2000; Kanodia et al., 2007; Tindle, 2002) and block 
apoptosis binding to TNF receptor 1, inhibiting the formation of the death-inducing 
signaling complex and consequent transduction of apoptotic signals (Filippova et al., 2002). 
The exsposure to E7 in a non-inflammatory epithelial environment can also be sufficient to 
induce a peripheral tolerance to E7 in the cytotoxic T lymphocytes population (Tindle, 2002). 
E6 also interacts with the adaptor protein FAS-associated protein with death domain 
(FADD) and caspase 8 to block cell death in response to FAS and TRAIl. Also, E6 can 
interfere with induction of the extrinsic and intrinsic (mitochondrial) apoptotic pathways 
through interactions with the pro-apoptotic Bcl2 members BAK and BAX, as well as by 
upregulation of the inhibitors of apoptosis such as the inhibitor of apoptosis protein 2 (IAP2, 
also known as BIRC2) and survivin (also known as BIRC5) (Garnett & Duerksen-Huges, 
2006). 
L1 protein 
The L1 gene corresponds to a sequence of about 1200 base pairs, which encodes a structural 
protein highly conserved among different HPV types, the (Xu et al., 2006). The L1 protein is 
formed by five monomeric units of 55kDa that join to form a pentameric structure, totaling 
72 per each capsid ( Buck et al., 2008). The L1 protein is highly immunogenic and has 
conformational epitopes that induce the production of neutralizing type-specific antibodies 
against the virus, which prevent the infection (Carter et al., 2003), making it the target of 
prophylactic vaccines (Villa et al., 2007; D’Andrilli et al., 2010). 
Comparison among L1 sequences of different papillomaviruses suggests a conserved 
heparin-binding domain at the C-terminus, and the cleavage of this domain from L1 
prevents  binding to both heparin and human keratinocytes (Culp et al., 2006; Selinka et al., 
2007). Thus, it is believed that the L1 major capsid protein contains the major determinant 
required for initial attachment of the viral particles to cell surface receptors, HSPGs, and 
therefore has an important role in infection (Schiller et al., 2010). 
L2 protein 
L2 is a secondary component of viral capsid and it is present in a variable number of copies 
per each capsid, being located on the inner surface in the central cavity below the pentamers 
of L1, where they are arranged to form the capsid (Buck et al., 2008). Despite the paucity of 
L2 in the virion, this protein has recently been shown to have many more functions than a 
simple structural role. L2 contributes to the binding of virion in the cell receptor, favoring its 
uptake, transport to the nucleus, and delivery of viral DNA to replication centers. Besides, 
E2 helps the packaging of viral DNA into capsids and, due to the presence of a usual 
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neutralization epitope in L2 proteins of many papillomaviruses, it may be instrumental in 
conferring immunity across different types of HPV. L2 also contributes to the interaction of 
virion in the cell surface. Two distinct regions in the N-terminal protein of L2 interact with 
the cell surface, and this interaction occurs after an initial low-specificity interaction between 
L1 and the cell surface. After this, a conformational switch occurs in the capsid, exposing the 
L2 epitopes and promoting interactions with a more specific secondary receptor. The 
cleavage of the N-terminus of L2 is necessary for the binding of L1 to the secondary 
receptor, an indication that L2 has an important role in HPV infection (Schiller et al., 2010) . 
 
Protein Functions 
E1 Viral DNA replication 
 
E2 Control of viral transcription, DNA replication, and segregation of viral 
genomes. 
 
E4 Favor and support the HPV genome amplification, besides regulating the 
expression of late genes, controlling the virus maturation, and facilitating the 
release of virions 
 
E5 Enhance the transforming activity of E6 and E7; Promotes fusion between cells, 
generating aneuploidy and chromosomal instability; Contribute to immune 
response evasion.  
 
E6 Bind and degrade the tumor-suppressor protein p53, inhibiting apoptosis; 
Interact with proteins of the innate immune response, contributing to immune 
evasion and persistence of virus;Activate the expression of telomerase. 
 
E7 Bind and degrade the tumor-suppressor protein pRB;  Increase cdk activity; 
Affects the expression of S phase genes by directly interacting with E2F factors 
and with histone deacetylases; Induce a peripheral tolerance in cytotoxic T 
lymphocytes (CTL)  and Downregulate the expression of  TLR9,  contributing 
to immune response evasion 
 
L1 Major capsid protein;  contains the major determinant required for attachment 
to cell surface receptors.  It is highly immunogenic and has conformational 
epitopes that induce the production of neutralizing type-specific antibodies 
against the virus. 
 
L2 Minor capsid protein; L2 contributes to the binding of virion in the cell 
receptor, favoring its uptake, transport to the nucleus, and delivery of viral 
DNA to replication centers. Besides, E2 helps the packaging of viral DNA into 
capsids.  
 
Table 1. The HPV proteins and functions 
3. HPV Infection 
The HR-HPVs have the ability to infect several types of epithelial cells, but they can cause 
cancer more frequently in the uterine cervix (Timmons et al., 2010). The cervical cancer 
arises preferentially in the cervical transformation zone (TZ), located in the boundary 
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between the squamous epithelium of ectocervix and the columnar epithelium of endocervix. 
Basal cells in the TZ retain the ability to differentiate, a property required for virion 
production (Crum & McKeon, 2010). The basal cells in TZ are more susceptible to HPV 
infection in that there are fewer overlying layers than in other locations. In addition, the 
presence of hormones, such as estrogen and progesterone, that orchestrate cervical changes 
during menstruation and childbirth, can help both HPV infection and cancer development 
(Timmons et al., 2010; Roberts et al., 2007; Chung et al., 2008).  
It has been reported that two types of cells are present in the basal layer of cervix. The first 
type comprises the transit amplifying (TA) cells, which are proliferating cells that are able to 
undergo terminal differentiation. TA cells divide and differentiate, representing the majority 
of cells in the suprabasal layers. The second class of basal cells is the stem cells, which have 
unlimited proliferation potential but divide only rarely in order to replenish the TA pool, 
serving as reserve cells to enable long-term maintenance of the tissue. Only one daughter 
cell of a stem cell division goes on to become a TA cell, while the other remains a stem cell.  
It is unclear which cells in the basal layer are the target of HPV infection, and perhaps both 
cell classes can be infected. If this is true, infection of stem cells could lead to one long-term 
persistent infection, whereas infection of TA cells could lead to short-term infections, 
followed by a cure (Jones et al., 2007).  
Studies in vitro and in vivo revealed that the L1 major capsid protein contains the major 
determinant required to the initial attachment of the viral particles to the cell surface 
receptor, the heparan sulfate proteoglycans (HSPGs). Laminin-5 can also contribute to the 
binding of viral capsids to the extracellular matrix (ECM) in the epithelial cell lines (Culp et 
al., 2006; Selinka et al., 2007).  
In vivo, the viral particles bound efficiently to regions of the basement membrane (BM) only 
after these regions had been exposed by mechanical or chemical trauma of the epithelium. 
The L1 capsid protein binds to HSPGs in segments of the BM exposed after epithelial 
trauma. After this, L1 undergoes a conformational change that exposes the N-terminus of 
the L2 minor capsid protein, which is cleaved by furin or the closely related protein 
convertase (PC) 5 and 6 (Richards et al., 2006). L2 proteolisis exposes a previously occluded 
surface of L1 that binds to an undetermined cell surface receptor on keratinocytes that have 
migrated over the BM to close the wound. This receptor is still unknown, but in vitro studies 
indicate the α6-integrin as a possible candidate (Kines et al., 2009).  The cleavage of L2 may 
be necessary due to the fact that the surface intact of the epithelia apparently contains 
sulfation patterns that do not bind capsids. Binding to the BM may promote the preferential 
interaction with basal keratinocytes that are migrating over the exposed BM to close the 
wound. Thus, papillomaviruses (PV) are the only viruses that initiate the infectious process 
at an extracellular site (Schiller et al., 2010). 
The capsids are internalized via the keratinocytes-surface receptor and subsequently surf 
toward the cell body. The first phase in infection is the internalization, which usually occurs 
2-4 h after cell surface binding (Culp et al., 2004). The pathway involved in internalization 
and intracellular trafficking is still unclear, but it seems to occur slowly and asynchronously 
over a span of several hours (Schiller et al., 2010). Clatrin-mediated endocytosis has been 
pointed out to be like the endocytic pathway for the majority of HPV types. However, some 
studies suggest that they can enter through a caveolae-mediated pathway and not via 
clatrin-mediated endocytosis (Smith et al., 2007). On the other hand, it has been proposed 
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that HPV-16 initially enters via clatrin-coated pits but the traffic occurs through caveosomes 
to eventually reach the endoplasmic reticulum (Hindmarsh et al., 2007; Laniosz et al., 2008). 
Moreover, it has been suggested that the capsids might be internalized via a novel pathway 
involving tetraspanin-enriched microdomains (Spoden et al., 2008).  
The uncoating is not observed until 8-12 h after cell surface binding, and it seems that L2 has 
a critical role in the endosome escape (Kamper et al., 2006). The cytoplasm transport along 
microtubules is mediated by protein complex, and L2 has been found to interact with the 
microtubule network via the motor protein dynein during infectious entry (Florin et al., 
2006). After the entry of the viral genome into the nucleus, the complexes predominantly 
localize in distinct punctate nuclear domains designated as ND10 bodies or promyelotic 
leukemia (PML) oncogenic domains (PODs). There is evidence that cell division is required 
for establishment and expression of the viral genome in the nucleus (Pyeon et al., 2009).  
4. Life cycle of HPV  
The HPV life cycle begins with infection of stem cells in the basal layer of the epithelium. 
After the entry in the cells, the virus requires the expression of E1 and E2 genes to maintain 
a low number of copies of genome. These proteins bind to the viral origin of replication and 
recruit cellular DNA polymerases and other proteins necessary for DNA replication (Hamid 
et al., 2009). In the suprabasal layer, the expression of genes E1, E2, E5, E6 and E7 
contributes to the maintenance of the viral genome and induces cell proliferation , 
increasing the number of HPV-infected cells in the epithelium, resulting in a higher number 
of cells that will eventually produce infectious virions (Hamid & Gston, 2009; Lazarczyk et 
al., 2009). In the more differentiated cells of this same layer of the epithelium occurs the 
activation of differentiation-dependent promoter and maintenance of gene expression E1, 
E2, E6 and E7. Furthermore, there will be activation of the expression of E4 gene, whose 
product will induce amplification of the viral genome replication, greatly increasing the 
number of virus copies per cell, at the same time that occurs the expression of genes L1 and 
L2 (Nakahara et al., 2005; Lazarczyk et al., 2009). In the granular layer, the products of late 
genes,  the major and minor proteins of the viral capsid, L1 and L2 respectively, gather to 
assembly of the viral capsids and formations of virions, which reach cornified layer of the 
epithelium and are released (Lazarczyk et al., 2009). 
For a better understanding, the life cycle of HPV was divided into two parts: a maintenance 
phase and differentiation-dependent phase (Bodily & Laimins, 2011).  
4.1 Maintenance phase 
HPV virions infect cells in the basal epithelial layer that become exposed through 
microlesions. The viral capsid binds initially to the basal cell layer and infection occurs 
when activated keratinocytes move into the wound, to the upper layers of the epithelium 
(Kines et al., 2009). HPV genomes replicate in the nucleus of the basal cell layer, where the 
viral replication is considered nonproductive and the virus establishes itself as a low-copy-
number episome by using the host DNA replication machinery (Moody & Laimins, 2010). In 
this way, viral proteins are expressed at very low levels in undifferentiated cells, and this 
contributes to immune avasion and persistence (Bodily & Laimins, 2011). 
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The maintenance of the viral episome in basal cells is the basic function of the early or 
maintenance phase of the viral cycle. The expression of E6, E7, E1, and E2 are necessary for 
continued episomal maintenance. E1 and E2 cooperate to initiate viral DNA replication, 
whereas E6 and E7 modulate cell-cycle regulators to maintain long-term replication 
competence (Conger et al., 1999). The E2 protein is probably a major regulator of this 
process because it is able to make both positive and negative control of the early viral 
promoter that regulates expression of E6, E7, and E1 as well as E2 itself (Steger et al., 1997).  
Following this establishment phase, viral DNA is replicated coordinately with host cell 
chromosomes, and virus genomes are distributed to the daughter cells. However, in the 
differentiated keratinocytes of the suprabasal layers of the epithelium, the virus switches to 
a rolling-circle mode of DNA replication, amplifying its DNA to a high copy number, 
synthesizing capsid proteins, and assembling the viral particle (Flores et al., 1999).  
HPV replication begins when the host cell factors interact with the LCR region of the HPV 
genome and begin the transcription of the early viral genes, highlighting the E6 and E7. The 
viral E6 and E7 gene products deregulate the cell cycle, subverting the cell growth-
regulatory pathways and modifying the cellular environment in order to faclitate viral 
replication in a cell that is terminally differentiated and has exited the cell cycle (Syrjânen & 
Syrjânen, 1999) 
4.2 Differentiation-dependent phase  
During the maintenance phase in undifferentiated cells, viral proteins are expressed in 
extremely low levels. However, when HPV-infected cells leave the basal layer, they undergo 
differentiation and high levels of viral proteins synthesis are induced. This restriction of 
viral protein synthesis to highly differentiated cells delays the expression of viral antigens to 
locations less susceptible to the host immune response (Frazer, 2009).  
This compartimentalization of gene expression by HPVs constitutes an important strategy to 
sustain long-term infection, but it creates some problems for the virus. To solve this, the 
virus forces the cell to remain active in the cell cycle, enabling productive replication in 
differentiating cells. The viral protein E7 is responsible for maintaining the replication 
competence in differentiated cells and this is accomplished in part by inactivation of pRB 
family members (Münger et al., 2004). The activation of the late viral promoter in response 
to host-cell differentiation occurs in the vicinity of the spinous epithelial layer and is 
responsible for high levels of viral protein expression. As a result, the virus copy-number 
amplifies from 50-200 copies to several thousands of copies per cell (Bedell et al., 1991).  
The viral proteins E1, E4, and E5 contribute to the activation of late viral functions upon 
differentiation (Wilson et al., 2005; Fehrmann et al., 2003). The E2-mediated down-regulation 
of E6 and E7 transcription results in the release of the p53 and pRB cellular proteins,  and 
allows the normal differentiation process of the host cell. Then, a putative late promoter 
activates the capsid genes, L1 and L2. Finally, the viral particles are assembled in the nucleus, 
and the complete virions are released when the cornified layers of the epithelium are shed. The 
virions are shed in an environment with desquamated cells in the absence of lysis or necrosis, 
and this further contributes to virus persitence because it avoids inflammation (Stanley, 2008). 
Most women infected with a specific HPV type will not show evidence of that same type 
after 6-12 months. It is not known whether the HR-HPV can be detected for periods similar 
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to those for LR-HPV. Some studies show similar duration (Richardson et al., 2003), but 
others reveal longer durations of infection for HR-HPV types (Franco et al., 1999; Ho et al., 
1998). It appears that HR-HPV, particularly HPV16, has a longer time to clearance and is 
more likely to develop persistent infection (Richardson et al., 2003). 
 
Fig. 2. HPV Cycle life (copied from Lazarczyk et al., 2009, with permission of the author). 
5. Pathogenesis 
5.1 Persistence x clearance 
The infection with HR-HPV typically lasts from 12 -18 months and is eventually cleared by 
the immune system (Richardson et al., 2003). However, approximately 10% of women fail to 
clear HPV infections, resulting in a persistent infection. The main consequence of persistent 
infection with HR-HPV is the development of lesions that may progress to malignancy, and 
this constitutes the most important risk factor for the development of cervical cancer 
(Stanley, 2008; Bodily & Laimins; Moody & Laimins, 2010;).  
Details about the immune response that results in clearance of HPV infection are still 
unknown. HPV clearance seems to result in long-term humoral and/or cellular protection 
against re-infection by the same HPV type; whether the protection is lifelong is not known 
(Stanley, 2006). Although the term clearance is used when an HPV infection can no longer 
be detected using sensitive test methods, the HPV presence might not be completely 
discarded because the latent state of HPV is still poorly understood. Reappearance of HPV 
from latency even in the absence of definite immunosuppression is common, but most cases 
are probably benign (Gonzalez et al., 2010). By contrast to HPV infections that clear, the risk 
of cancer increases dramatically in persistent HPV infections (Schiffman et al., 2010). 
It is important to remember that it is not easy to characterize a persistent HPV infection and 
differentiate persistent infection from healing followed by re-infection, although re-infection 
with the same HPV type appears to be uncommon. Many studies classify HPV infection as 
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persistent if the HPV was detected in two consecutive follow-up visits 4-6 months apart. 
However, because the interval between follow-up visits varies among studies and there are 
many unknown questions regarding the natural history of HPV, it is complicated to 
distinguish persistent and transience infections. Furthermore, an undetectable HPV 
infection could be a period of viral latency, in which the HPV levels are below the detectable 
threshold of current HPV DNA assays, instead of representing a cleared host (Baseman and 
Koutsky, 2005).  
The persistent nature of HPV infection and DNA viral integration into the genome of the 
cell contributes to increasing the risk of high-grade and malignant lesions because of 
genomic instability generated. E6 and E7 can induce centrosomal abnormalities resulting in 
abnormal centrosome reduplication, leading to abnormal numbers of centrosomes  
Furthermore, abrogation of cell-cycle checkpoints through the targeting of p53 and pRB 
family members allows retention of cells with chromosomal abnormalities (Münger et al., 
2004). This can result in genetic changes that accumulate over an extended period of time 
until resulting in a combination of genetic abnormalities, allowing cancer development 
(Bodily & Laimins, 2011).  
In benign and malignant HPV lesions, the cellular proliferation increases the demand for 
nutrients, generating a competition for nutrients and oxygen. To overcome this constraint, 
both HR-HPV and LR-HPV E7 proteins enhance the levels of the transcription factor 
Hypoxia-inducible factor-1 (HIF-1), as well as induce the increased expression of HIF-1 
target genes under hypoxia conditions (Nakamura et al., 2009). The enhancement of HIF-1 
activity results in an increased transcription of a subset of genes that favor angiogenesis, and 
this induction of angiogenesis is crucial to both persistence and growth of HPV lesions 
(Bodily & Laimins, 2011).  
5.2 Mechanism of immune evasion  
HPV infections are chronic, exclusively local and intraepithelial in which the virus remains 
in the host for many months, even years, during which the mechanisms of host defense 
apparently remains ignorant of the pathogen for long period of time Stanley, 2009b). So, the 
immune response to HPV infection is often insufficient to eliminate the virus so that the 
infected individuals do not heal but develop persistent infection. The main reason for this is 
an ingenious strategy developed by this virus in which viral DNA replication and virus 
assembly occur in a cell that will be terminally differentiated and die by natural causes 
(Staney, 2008). To achieve this lifestyle, HPV must avoid the host defense sytem, and the key 
to understanding how this occurs is the virus replication cycle which itself is an immune 
evasion mechanism that inhibits the host´s detection of the virus. The infection and 
vegetative HPV growth are absulotely dependent upon a complete program of keratinocyte 
differentiation (Doorbar, 2005).  
Papillomavirus late genes also contain codons that mammalian cells rarely use, implying 
that production of abundant papillomavirus capsid proteins is inhibited in mammalina 
basal-epithelial cells by the restricted availability of the appropriated tRNAs. The early viral 
proteins localize mainly to the nucleus, and they are produced in insufficient quantities 
and/or are not aceesible for immune recognition (Tindle, 2002). Besides, there is viral-
induced cytolysis or necrosis, and therefore no inflammation. For most of the duration of the 
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HPV infectious cycle, there is little or no release into the local milieu of pro-infammatory 
cytokines, which are important for antigen presenting cell (APC) activation and migration. 
This way, the central signals to kickstart the immune response in squamous epithelia are 
absent (Stanley, 2006). 
Even in the absence of cellular changes such as cytolysis, necrosis, or cell death, HPV-
infected keratinocytes should activate to the production of type 1 interferons, a powerful, 
generic antiviral and innate immune defense system. The type 1 Interferons, IFN-α and IFN-
β, have antiviral, antiproliferative, antiangiogenic, and immunostimulatory properties that 
act as a bridge between innate and adaptative immunity, activating immature DCs (Le Bon 
& Tough, 2002). High-risk HPV types actively inhibit the endogenous interferon response, 
down-regulate toll-like receptors and this combined with the low levels of viral protein 
generated during the infectious cycle and absence of infammation leads to inefficient 
activation of the innate immune response, with the consequent ineffectiveness of the 
adaptive immune response. Thus, the milieu becomes operationally HPV antigen-tolerant 
and host defences become irrevocably compromised. HPV antigen-specific effector cells are 
both poorly recruited to the focus and their activity is down-regulated (Stanley, 2009b). 
 It was demonstrated that infection with HR-HPV, especially HPV 16, downregulates IFN-α 
inducible gene expression, through E6 and E7 proteins that directly interact with 
components of the interferon signaling pathways (Konodia et al., 2007). Infected cells with 
episomal HPV are cleared after exposure to IFN-β, but cells with integrated HPV-DNA are 
resistant to this antiviral effect (Pett et al., 2006). T-cell response to E2 and E6 are lost or 
reduced in CIN 3 and carcinoma invasive. Thus, even if HPV antigen-specific cytotoxic T-
cells have been generated, regulatory T-cells increasingly dominate the lesion and abrogate 
the killer defense response (Kobayashi et al., 2004). High-risk HPV infected cervical 
keratinocytes expressing high level risk of E6 and E7 oncoproteins are not killed in this 
immunosuppressive tolerante mileu, nad progression to high-grade disease and cancer can 
result (Stanley, 2009b). 
As HPV infections are exclusively intraepithelial, theoretically, an HPV attack would be 
detected by the professional APC cells of squamous epithelia, the Lanherhans cells (LCs), 
which are the intraepithelial dendritic cells (DCs). Virus capsid entry is usually an activating 
signal for CDs, but there is evidence that LCs are not activated by the uptake of HPV 
capsids. The life cycle of HPV is organized to form a limited viral antigen synthesis in 
undifferentiated cells, and high-expression is restricted to highly differentiated cells.  
HPV replication and release does not cause cell death and inflammation since the 
differentiating keratinocyte is already programmed to die and this death by natural causes 
does not act as a danger signal in the infected site (Staley, 2009b). Besides, the absence of 
viremia, cell lysis, necrosis, or any other signals to trigger an inflammatory response reduces 
the possibility of an effective immune response in this site (Stanley, 2009a). Thus, the virus 
becomes pratically invisible to the host who remains indifferent to infection for long periods 
of time, facilitating the viral persistence (Staley, 2009b) 
The healing of the HPV-induced lesions is dependent on the mechanisms of the cell-
mediated immune response and is accompanied by interaction of CD8+ and CD4+ 
limphocytic. Langerhans cells (LCs) are the major dendritic cells (DCs) found in squamous 
epithelia, and these are probably responsible for triggering an anti-HPV immune response. 
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The function of LCs is disrupted by HPV at several levels. It has been shown that the 
infiltration of HPV-infected tissue by LCs and DCs is inhibited by HPV-induced changes in 
the pattern of cytokine expression (Stanley, 2008). The HPV L2 protein is able to suppress 
maturation, migration, and cytokine secretion by LCs. Furthermore, the interaction between 
LCs and keratinocytes can be disrupted by the reduction of E-caderin levels induced by the 
E6 HPV protein (Ghittoni et al., 2010). 
In immunosuppressed patients, HPV infection frequently leads to the appearance of 
abundant HPV-induced lesions, indicating that the immune system acts to limit HPV 
infection (Scott et al., 2001). Therefore, in order to persist, HPV must actively suppress both 
innate and adaptative immune response. One important mechanism of the innate pathway 
targeted by HPV acting in multiple ways is the interferon response (Samuel, 2001; Stanley, 
2008). Keratinocytes constitutively express a low level of interferon-inducible genes in 
absence of interferon. The cells infected with HR-HPV express E6 and E7, which repress the 
transcription of many interferon target genes including Stat-1, a transcriptional activator of 
Interferon-inducible genes (Nees et al., 2001). E6 can bind to and block the action of IRF-3, a 
regulator of the interferon pathway and also blocks activation of protein kinase R (PKR) as 
well as the activity of kinase Tyk2, responsible for activating Stat-1, while E7 can bind to 
IRF-1, that is also a regulator of the interferon pathway (Hebner et al., 2006; Stanley, 2009b). 
Both E6 and E7 can inhibit expression of the toll-like receptor (TLR9), which is important for 
sensing doubled-stranded DNA (Hasan et al., 2007). 
It is well known that keratinocytes constitutively express low levels of several cytokines that 
are upregulated following virus infection (Ghittoni et al., 2010). When these cells are 
infected with HPV show significantly reduced expression of the wide range of inlammatory 
cytokines including IL-1, IL-6, TNF-α, and TGF-β, at the same time, expression of the anti-
inflammatory cytokine IL-10 is increased (Alcocer-Gonzalez et al., 2006; Ghittoni et al., 
2010). Thus, HPV infection induces alteration in cytokine production, reducing the ability of 
immune cells to infiltrate the infected tissue. Keratinocytes constitutively express low levels 
of interferons α, β, and κ. The expression of interferon κ is suppressed in HPV positive cells 
and this could contribute to the inhibition of expression of interferon-inducible genes 
(Rincon-Orozco et al., 2009).  
Development of HPV-specific T-cell response is repressed or delayed in HPV-infected 
patients, this effect being more pronounced in HR-HPV compared with LR-HPV infections 
(van der Burg and Palefsky, 2009). One reason for this impairment is probably the 
downregulation of major histocompatribiliy complex (MHC) I expression, probably due to 
interactions occuring between the viral proteins E6, E7, and E5 and the host cell. 
Furthermore E7 has been reported to downregulate the transporter associated with antigen 
processing (ATP), thereby interfering with presentation of antigens via the MHC I pathway 
(Ghittoni et al., 2010). 
The expression of HPV E7 in epithelial cells does not directly impair, but rather slightly 
increase, MHC clase I expression. E7 expression is nevertheless associated with impairment 
of IFN-gama-induced enhancement of presentation of endogenous antigen to cytotoxic T 
lymphocytes (Zhou et al., 2011). Further mechanism of HPV-mediated immune escape 
involve viral proteins: HPV E7 has high and widespread similarity to several humans 
proteins, causing a limited immunogenicity (Natale et al., 2000); E6 can downregulate IL-18 
expression (Cho et al., 2001); E5 mediate acidification of endossomes, affecting antigen 
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processing and presentation in antigen presentation cells (Straight et al., 1995); E5 also 
downregulate CD1d, a MHC I-like glycoprotein that presents self or microbial lipid antigen 
to natural killer – the downregulation of this molecule is utilized by a variety of microbes to 
evade immune detection (Miura et al., 2010). Finally, natural killer (NK) cell activity is also 
reduced in patients with HR-HPV infection (Stanley, 2009a; O´Brien and Campos, 2002). 
5.3 The role of the physiology of the cervical epithelium 
The cervical and anal transformation or transition zones (TZs) are dynamic areas of a few 
millimeters in size, in which a columnar glandular epithelium coexists with a squamous 
epithelium, and result from an adaptive process called metaplasia (Mukonoweshuro et al., 
2005). These metaplastic conversions are influenced by the acidification of vaginal pH and 
by trauma such as that resulting from receptive anal intercourse, and can be considered as a 
stepwise progression of changes. Although these adaptive responses frequently occur at the 
cervical and anal squamocolumnar junctions, the molecular mechanism underlying the 
development and the maintenance of the metapastic epithelium are still not completely 
understood (Herfs et al., 2011). 
It is believed that this phenomenon could result from the reprogramming of adult stem cells 
and that the metaplastic epithelium is associated with a deregulated production of 
receptors, adhesion molecules, and soluble mediators of the inflammatory response, such as 
cytokines, chemokines, prostaglandins, and growth factors. These molecules might not only 
exercise influence epithelial differentiation but also alter the local antiviral immune 
response, favoring HPV infections. Importantly, a substantial majority of cervical and anal 
pre-neoplastic lesions develop within the metaplastic microenvironment of TZs (Bodily & 
Lamins, 2010). This implies that exogenous or endogenous factors specific to the anatomical 
milieu of squamocolumnar junctions could be conducive to persistent HPV infection (Herfs 
et al., 2011) 
In contrast to normal squamous epithelium, metaplastic epithelia have an altered 
maturation characterized by a weak expression of several keratin intermediate filaments and 
cell envelope components such as involucrin and loricrin (Herfs et al., 2008). The primary 
function of keratins and other cytoskeletal proteins is to provide resistance to mechanical 
and non-mechanical stresses that can cause cell rupture and death. Thus, because of their 
immature state, keratinocytes of the squamocolumnar junctions could be more vulnerable to 
the trauma required for HPV infection (Gu & Colombe, 2007). Therefore, the increased 
sensitivity of anal and cervical TZs to pre-neoplastic lesions can be attributed to the fact that 
both the basement membrane and the target actively dividing basal cells for HPV infection 
could be more accessible in metaplastic areas in which monostratified glandular and 
pluristratified squamous coexist (Herfs et al., 2011). 
Cervical TZs with squamous metaplasia have a higher density of estrogen and progesterone 
receptor-positive cells compared with normal squamous epithelia. Besides, the cervical TZs 
are more sensitive to the induction of squamous cell carcinogenesis by estrogen. Among the 
possible mechanisms by which sex hormones could facilitate HPV-induced carcinogenesis 
would be the stimulation of expression of E6 and E7 HPV genes, directly and/or indirectly 
through steroid response elements in the viral genome or still stimulating cellular 
proliferation (Bhattacharya et al., 1997; Yuan et al., 1999). 
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It is also possible that hormones sensitize the TZs to persistent HPV infection by altering the 
local immune microenvironment (Herfs et al., 2011). It has been observed that 17β estradiol 
can both reduce the migration and/or functional capacity of antigen-presenting cells and 
promotes the initiation of Th2 immune response, which is generally associated with the 
progression of the disease (Uemura et al., 2008). Together with these observations, the 
topography of the cervical TZs is affected by the hormonal status of women, suggesting that 
sex hormones might not only be involved in the development and maintenance of the 
metaplastic epithelium but might also be implicated in the high sensivity of TZs to HPV 
infection and cancer progression (Herfs et al., 2011).   
Also observed was a reduction of secretion of soluble factors of innate immune response 
involved in antiviral defense in the anal and cervical squamocolumnar junctions (Herfs et 
al., 2010). The β-defensin 2 is weakly expressed in cervical TZs and pre-neoplastic lesions 
compared with normal exocervical (Hubert et al., 2007). Furthermore, the density of 
Langerin-positive Langerhans cells (LCs) and their function are significantly altered in the 
anal and cervical TZs compared with the normal squamous epithelia (Herfs et al., 2008; 
Giannini et al., 2002) suggesting that keratinocyte-LC interaction could play an important 
role in the establishment of HPV infection in these regions (Herfs et al., 2011). It was also 
suggested that a Th2 immunoderivation of immune response could participate in the 
immunological escape of virus-infected cells (Herfs et al., 2011).  
Altering the local immune response, metaplastic cells might not only promote viral 
infections but might also be involved in the HPV-induced development of cervical and anal 
carcinoma in the TZs. This could explain, at least in part, why HPV-associated lesions 
located elsewhere in the anogenital tract outside the TZs, such as the vagina and vulva, are 
less likely to progress to cancer than those that develop within the TZs. Therefore, the 
anatomical, histological, physiological, and immunological features of TZs might not only 
promote the mucosal entry of HPV but also be involved in the HPV-induced development 
of cervical and anal carcinoma (Herfs et al., 2010). 
5.4 The oncogenics activities of HPV 
5.4.1 The role of the E5 protein 
The hydrophobic E5 protein is mainly found within the Golgi apparatus, as well as in the 
plasma membranes of HPV-infected cells. The E5 protein has weak oncogenic properties, 
which results in the increasing expression for the epidermal growth factor receptor (EGFR) 
(Tsai & Chen, 2003) and in the inhibition of the expression of the major histocompatibility 
complex (MHC) class I on the plasma membrane modulating the MAPK pathway and 
altering the levels of caveolin 1 (Moody & Laimins, 2010). 
The virus-induced cell fusion mediated by oncogenic viruses is a well-known event among 
human oncogenic viruses, including HPV, and it seems that this phenomenon plays an 
important role in the carcinogenesis process (Duelli et al., 2007; Hu et al., 2009). HPV16 E5 
has all the characteristics of fusogenic proteins, including the localization of the plasma 
membrane, the high level of hydrophobicity, and the ability for dimmers. More recently, 
HPV16 E5 has been identified as necessary and sufficient to induce cell-cell fusion with the 
formation of the tetraploid cell (Hu et al., 2009).  
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Aneuploidy with the presence of tetraploid cells is frequently found in precancerous lesions 
associated with HPV infection. It is reported that expression of either HPV E6 or E7 alone is 
sufficient to deregulate cytokinesis and consequently produce the tetraploid cell (Heilman et 
al., 2009). However, it was demonstrated that the formation of these cells is primarily 
attributed to E5-induced cell fusion, rather than E6, E7, and cytokinesis failure (Ho et al., 
2009). Tetraploid cells formed by accident cannot undergo normal mitosis which would 
trigger p53-dependent cell cycle arrest or apoptosis, whereas oncogenic virus-induced cell 
fusion is sufficient to induce chromosomal instability when fusion occurs concomitantly 
with expression of viral oncoproteins capable of perturbing p53 or apoptosis (Duelli et al., 
2007). 
In vivo and clinical studies reveal that chromosomal instability and aneuploidization seem 
to precede and favor integration of HPV genomes, which in turn leads to expression of viral-
cellular fusion transcripts and further enhances expression of the E6-E7 genes, which 
renders the strong growth advantages of transformed cells (Ziegert et al., 2003). The cell 
fusion HR-HPVE5-induced and cell cycle deregulation are two key events for initiation of 
transformation. This suggests that HR-HPVE5-induced cell fusion can be a critical event in 
the early stage of development HPV-associated cervical cancer (Gao & Zheng, 2010). As the 
open reading frame coding E5 is frequently deleted in cervical cancer, it is possible that this 
viral protein is not required for tumor maintenance, but that it can play a critical role in the 
early stage of HPV-associated cervical cancer. 
5.4.2 The role of the E6 protein 
The E6 HPV protein binds not only to cellular p53 and E6-AP but also to  a wide range of 
other cellular proteins, being known a more complete compendium of cellular factors that 
can interact with this viral oncoprotein. Among the other cellular proteins that interact with 
E6, the following may be cited: transcription factors such as p300, myc, interferon regulatory 
(IRF3), autocrine motility factor 1 (AMF-1/gPS2); factors that determine adhesion, 
cytoskeleton and polarity, such as paxillin, the human homologue of Drosophila disk-large 
tumor-suppressor gene product (DGL), and membrane-associated guanylate inverted-1 
(MAGI-1); apoptosis factors such as the pro-apoptotic Bcl2 and Bak; replication factors and 
DNA repair factors such as mcm7 and XRCC1; and other cellular proteins such as E6 target 
protein 1 (E6TP1). In addition, E6 induces telomerase activity by inducing the expression of 
human telomerase reverse transcriptase (hTERT) (reviewed in IARC, 2007). 
HR-HPV E6 proteins have a motif designated as S/TXV at their C-terminal which mediates 
binding to specific domains on cellular proteins known as PDZ proteins. PDZ domains are 
approximately 90 amino acid stretches found in a wide variety of cellular proteins. The 
importance of p53 in the orchestration of the cellular response to damage suffered by DNA 
as a result of exposure to cytotoxic agents becomes quite evident by the fact that 
approximately one-half of all human cancers present mutations in the p53 gene (Howie et 
al., 2009). Normally, p53 protein levels are regulated by the Mdm2 E3 ubiquitin ligase. 
However, Mdm2-mediated degradation of p53 is inhibited during viral infection and other 
stress conditions, allowing for stabilization of p53 protein levels and subsequent activation. 
In contrast, during an HR-HPV infection E6 induces p53 degradation by forming a complex 
with another E3 ubiquitin ligase, E6-AP. Only E6 HR-HPV is capable of binding to the core 
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region of p53 and this binding of the core region is required for p53 degradation mediated 
by E6. 
Three other mechanisms have been proposed to explain the interaction of the viral E6 
protein with p53. The first is by inhibiting the binding of p53 to its site-specific DNA 
sequence. In the second mechanism, E6 may be able to inhibit p53 signaling independent of 
protein degradation by means of the sequestration of p53 in the cytoplasm. The third 
mechanism employed by E6 to inhibit p53 activity is its abrogation of the transactivation of 
p53 responsive genes via interaction with either the CBP/p300 or hADA3 histone 
acetyltransferases. The E6 proteins have been shown to bind to p300, and this interaction 
inhibits p35 acetylation at p53 dependent sites, leading to decreased expression from a p53 
(Zimmermann et al., 2000). However, unlike with p300, E6 interaction with hADA3 results 
in hADA3 degradation (Kumar et al., 2002). E6 may also inhibit p53 activation by blocking 
the p14/ARF pathway (Shamanin et al., 2008). 
Thus, E6 is able to modulate transcription of p53-dependent genes by both degradation of 
p53 and by interaction with the p300 and hADA3 transactivators. In addition, E6 is able to 
modulate transcription from other cellular signaling pathways as well as potentiate its 
ability to act as a diverse modulator of host cell signaling. With respect to G-protein 
signaling, E6 has been shown to interact with three different proteins, such as a novel 
protein termed E6-targeted protein 1 (E6TP1), in an E6-AP dependent manner (Lee et al., 
2007), beyond another protein with GAP activity, tuberin, which also can be bound and 
degraded by E6 (Zeng et al., 2008). 
High-risk E6 has been shown to interact with two proteins that are part of the innate 
immune response to viral infection: interferon regulatory factor-3 (IFR-3) and toll-like 
receptor 9 (TLR9) (Hasan et al., 2007). IRF-3 becomes activated by dsRNA or viral infection, 
and this activation leads to the transcription of interferon-beta (IFN-β) (Hiscott, 2007). TLR9 
becomes activated by viral or bacterial dsDNA derived CpG motifs, and induces cytokine 
production as a means to defend the cell against the invading organism (Müller et al., 2008). 
Exogenous expression of HPV16 E6/E7 has been shown to inhibit TLR9 transcription, 
leading to a functional loss of TLR9 signaling pathways within the cell (Hasan et al., 2007).  
The p53 degradation or blocking of its function mediated by E6 has, as a consequence, the 
inhibition of apoptotic signaling that would otherwise eliminate the HPV infected cell. 
There are two major apoptotic pathways that can be triggered by different stresses: the 
extrinsic and the intrinsic pathways. The E6 protein is able to disrupt both pathways to 
facilitate a cytoprotective environment and prevent cell death, thus highlighting the critical 
signaling events that a cell undergoes following exogenous or endogenous stress (Howie et 
al., 2009). 
E6 is able to inhibit extrinsic apoptotic signaling at each of the stages, by interacting with 
TNFR-1, FADD, and caspase-8. It was shown that E6 is able to bind directly to the death 
receptor TNFR-1 and blocked TNFR-1 DD mediated apoptosis (Filippova et al., 2002). In 
addition to the TNF pathway, E6 is capable of inhibiting apoptosis stimulated by both Fas 
and TRAIL pathways. This inhibition is mediated by E6 binding to and degradation of both 
the FADD adapter protein and the effector caspase-8 (Garnett et al., 2006). As the binding of 
FADD is not dependent on the conserved PDZ domain of high-risk E6, but rather by a new 
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domain (Tungteakkhun et al., 2008), it is possible that other E6 proteins may inhibit these 
extrinsic pathways.  
HPV E6 proteins have been shown to inhibit intrinsic apoptotic pathway binding to Bak and 
to induce its proteasomal-dependent degradation (Underbrink et al., 2008). While E6-AP has 
been shown to play a role in Bak degradation, it has also been proposed that this may not be 
a universal mechanism for all of the HPV types (Simmonds & Story, 2008). Evidence has 
shown that Bak degradation is not constitutive, but rather occurs only after apoptotic signals 
have been initiated, indicating that a Bak conformational change and/or dissociation from 
its anti-apoptotic partner MCL-1 may be necessary for its interaction with E6 and E6-AP 
(Underbrink et al., 2008) 
Another important effect of E6 in the development of genital cancer is the activation of 
telomerase reverse transcriptase (hTERT) (Howie et al., 2009). HPV E6 induces histone 
acetylation at the hTERT promoter, and this acetylation depends on E6-AP (James et al., 
2006; Xu et al., 2008). To induce hTERT expression and telomerase activity in 
keratinocytes, HPV E6/E6-AP requires expression of NFX1-123 (Katzenellenbogen et al., 
2007).  
In addition to increasing the expression of hTERT, E6 also interacts with other proteins 
involved in maintaining chromosomal stability within the HPV-infected cell, for example, 
the minichromosome maintenance 7 (hMCM7) proteins. As MCM7 is involved in licensing 
DNA replication to ensure a single-round replication per cell cycle, it is thought that E6 
interaction with and/or degradation of MCM7 may lead to chromosomal abnormalities in 
the HPV-infected cell.  E6 can also interact with two proteins involved in single-strand DNA 
break repair: XRCC1 and O(6)-metylguanine-DNA methane transferase (MGMT). XRCC1 to 
be bound E6; this interaction reduces the ability of XRCC1 to repair metyl metane sulfate 
(MMS) induced DNA damage (Iftner et al., 2002).  E6 interaction with MGMT induces its 
proteasomal-mediated degradation via E6-AP, which has been hypothesized to sensitize 
HPV-infected cells to alkylating DNA damage (Srivenugopal & Ali-Osman, 2002). Finally, 
high-risk E6 mediated p53 loss inactivates the G1 checkpoint. Prolonged proliferation in the 
absence pf p53 can lead to the loss of the G2 checkpoint, which can result in aneuplody. 
Together, these interactions may lead to increased genomic instability and accelerate the 
progression to carcinogenesis (Howie et al., 2009).  
Another major apoptotic pathway targeted by HPV proteins is anoikis, a form of apoptosis 
that is triggered when normal cells attempt to divide in the absence of a matrix (Tasaki et al., 
2005). E6 has been shown to bind to paxilin and zyxin, adhesion molecules involved in 
tethering the cellular cytoskeleton to the extra cellular matrix (ECM) and transmitting 
signals along the actin network from the ECM to the nucleus. This interaction results in the 
disruption of actin fibers and a failure to maintain proper cell structure (Howie et al., 2009). 
HR-HPVE6 proteins also bind to hScrib, a protein involved in epithelial tight junctions, 
mediating the adhesion of basal cells to the ECM, and at least in some cell types it has been 
shown that E6 mediates hScrib degradation (Nakagawa & Huibregtse, 2000). Recently, it has 
been demonstrated that PTPN3, a membrane-bound tyrosine phosphatase that regulates 
growth factor receptors, is also a PDZ protein that binds and is disrupted by E6 (Jing et al., 
2007; Spanos et al., 2008). 
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5.4.3 The role of the E7 protein 
HR-HPVE7 proteins destabilize pRb through its proteosomal degradation via a mechanism 
that involves association with and reprogramming of the cullin 2 ubiquitin ligase complex 
by HPV E7 (Huh et al., 2007). The induction of the pRB degradation by HR-HPVE7 proteins 
and the resulting activation of E2F-mediated transcription represent an important 
mechanism by which these viruses achieve and maintain S-phase competence in 
differentiated epithelial cells. HR-HPVE7 proteins, in addition to targeting pRb proteasomal 
degradation, also contribute to cell cycle deregulation through several additional 
mechanisms involving cyclin-dependent kinases (cdks), motors that drive the cell division 
cycle (Zerfass et al., l995). 
HPV16 E7 has been shown to interact with and abrogate the growth-inhibitory activities of 
the cyclin-dependent kinase inhibitors (CKIs) p21CIP1 (Jones et al., 1997) and p27KIP1 (Zerfass 
et al., l996), which are induced by anti-proliferative signals, including growth factor 
withdrawal and loss of cellular adhesion (Fang et al., 1996). The ability of HPV E7 to 
abrogate CKIs, together with its ability to disrupt the pRB/E2F complex, which results in 
increased cyclin E and A levels, retains differentiating keratinocytes in a DNA synthesis 
competent state. HPV E7 can also directly associate with cdk2/cyclin A and cylin E 
complexes, resulting in increased cdk2 activity (Nguyen & Münger, 2008). 
It was demonstrated that HPV16 E7 induces pRb degradation, but the mechanism of cell 
death depends on the integrity of the p53 tumor suppressor pathway; it does not involve 
transcriptional activation of canonical p53 transcriptional targets. Intriguingly, E7 
expression generally interferes with the transcriptional activity of p53 (Eichten et al., 2002). 
Furthermore, the mechanism of cell death triggered by HPV16 E7 expression appears to be 
distinct from classic apoptosis; although caspases are active and DNA is degraded, cell 
death is mostly caspase independent (Eichten et al., 2004). Although HPV E7 signaling 
pathways have not yet been molecularly analyzed, HPV 16 E7 expression causes normal 
human epithelial cells to undergo cell death in response to growth factor deprivation (Zhou 
& Münger, 2009).  
High- and low-risk HPV E7 proteins are associated with the 600 KD retinoblastoma protein-
associated factor, p600 (DeMasi et al., 2005; Huh et al.,2005). Although its biological 
functions have not been fully elucidated in mammalian cells, p600 is implicated as a 
regulator of anoikis, a form of apoptosis that is triggered when normal cells attempt to 
divide in the absence of a matrix (Tasaki et al., 2005). Therefore, the interaction between E7 
and p600 may deregulate anoikis and protect detached cells from apoptosis, thereby 
contributing to viral transformation (DeMasi et al., 2007; Huh et al., 2005). Consistent with 
this idea, HPV16 E7 associates with p600 through the CR1 domain, which is necessary for 
the transformation capability of HPV16 E7 (DeMasi et al., 2007). 
It is known that HPV16 E7 can directly bind to E2F1 and enhance E2F1-mediated 
transcriptional. E2F1, which plays a role in mediating the transcriptional control of the E2F6 
gene, which is unregulated at the G1/S-phase transition, to exert an opposing effect on the 
activities of E2F-responsive promoters, thereby directing appropriate cell cycle exit and 
differentiation (Lyons et al., 2006). Interestingly, HPV E7 associates with E2F6 and abrogates 
its ability to function as a transcriptional repressor (McLaughlin-Drubin et al., 2008), 
suggesting that the functional deregulation of E2F6 by HPV E7 is needed to counterbalance 
the up-regulation of E2F6 as a consequence of the activation of E2F1 by E7, thus ensuring 
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that the cells remain in an S-phase-competent state, which is necessary for the viral cycle 
(McLaughlin-Drubin & Münger, 2009). 
Malignant progression mediated by HR-HPVoncogene expression of these cells occurs after 
prolonged passages in culture or when additional oncogenes, such as ras or fos, are 
expressed (Pei et al., 1993). This is comparable to the extended period of time between initial 
HPV infection and the development of invasive cervical carcinoma. Thus, while the 
expression of the HPV oncogenes is necessary and sufficient for initiation of cervical 
carcinogenesis, additional host genome mutations are needed for malignant progression. 
Indeed, cervical cancer cells have accumulated a wide range of numerical and structural 
chromosomal abnormalities (Mitelman et al., 2007). 
The presence of DNA repairs foci seen in HPV16 E7-expressing cells indicate that E7 may 
induce double-strand DNA breaks or interfere with break repair. This may facilitate viral 
genome integration. Consequently, E7 may be a driving force for integration of HR-
HPVgenomes into host cellular chromosomes, an event that frequently accompanies 
malignant progression of high-risk HPV-associated lesions. This may result in double-
stranded HPV DNA fragments breaking off of the circular genome and being integrated into 
the host genome via the endogenous DNA double-strand break (DSB) repair machinery. If 
the upstream regulatory region is integrated into the host DNA, it may be the site of 
continued “onion skin” replication as long as the viral E1 and E2 replication proteins are 
expressed  (Kadaja et al., 2007).  
Fanconi anemia (FA) patients have an increased incidence of squamous cell carcinomas at 
sites that are infected by HPVs, and oral cancers arising in FA patients are HPV positive at a 
significantly higher rate than in the general population. The possible contribution of HPV 
infection to the increase in incidence of cancer in these patients was reinforced by the 
demonstration that the FA pathway is activated by HPV16 E7 expression and that the 
capacity of HPV16 E7 to induce DNA repair foci is enhanced in the FA patient-derived cell 
lines (Spardy et al., 2007). 
Transforming growth factor β (TGF-β) is a potent inhibitor of epithelial cell growth, and 
acquisition of TGF-β resistance is the hallmark of epithelial tumor cervical carcinoma cell 
lines. Ectopic HPV16 E7 expression abrogates TGF-β-mediated growth inhibition. 
Acquisition of TGF-β resistance is a multi-step process, where TGF-β can repress HPV16 
E6/E7 expression, which has been correlated to Ski overexpession, but the exact mechanism 
of this is not yet known (Baldawin et al., 2004).  Both p21CIP1 and p27KIP1 have been 
implicated in TGF-β-mediated growth inhibition (Datto et al., 1995); and HPV16 E7 ability to 
inactivate these CKIs may contribute to its ability to abrogate TGF-β-mediated growth 
inhibition. TGF-β also induces a cdk4/cdk6-specific CKI, P15Inkb, and p15INKB-induced 
growth suppression may require functional pRB, which is targeted for degradation by 
HPV16 E7 (MaLac & Münger, 2009). 
The tumor necrosis factor- α (TNF-α) is an important part of the immune response mediator 
that is produced by the cytotoxic T cell in response to a viral infection normal in 
keratinocytes undergoing G1 growth arrest and cellular differentiation in response to tumor 
necrosis factor (TNF). HPV E7 also compromises interferon (IFN) signaling through 
association with and inhibition of the IFN-α-induced nuclear translocation of p48, the DNA-
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binding component of ISGF-3. Besides, HPV E7 can interfere with interferon regulatory 
factors (IRFs) associated with IRF-1 and impair its transcriptional activity (Park et al., 2000). 
Moreover, IFN-γ has been shown to inhibit HPV16 E7 expression, and the IFN-γ-induced 
suppressor of cytokine signaling-1 (SOCS-1)/JAB can associate with and induce the 
ubiquitin-mediated degradation of E7 (Kamio et al., 2004). HPV16 E7 may also interfere 
with insulin-like growth factor (IGF) signaling, which regulates cell survival. HPV16 E7 can 
associate with IGFP3 and accelerate its proteosome-mediated degradation (Santer et al., 
2007). 
E7 proteins are also associated with histone modifying enzymes and associated 
transcriptional co-factors (Bernat et al., 2003). HPV E7 interacts with class I histone 
deactylases (HDACs), which act as a transcriptional co-repressor by including chromatin 
remodeling by reversing acetyl of lysin residues on histone. The association between E7 and 
HDACs results in increased levels of E2F-mediated transcription in differentiating cells 
possibly influencing S-phase progression. (Longworth et al., 2005). E7 is also associated, 
directly or indirectly, with histone acetyl transferases (HATs) including p300, pCAF, and 
SRC1, and has been shown to abrogate SRC1-associated HAT activity (Baldwin et al., 2006). 
Moreover, the histone methyl transferase, enhancer of zeste homologue 2 (EZH2), has been 
identified as a transcriptional target of the HPV E7 protein (Holland et al., 2008). 
6. Conclusion 
HPV is a non-enveloped virus with double-stranded circular DNA genome, protected by an 
icosahedra capsid forming a particle with about 55 nm. HPV genome is divided into three 
regions: a long control region (LCR), an early region (E), consisting of six ORFs: E1, E2, E4, 
E5, E6, and E7, which encodes no structural proteins involved in viral replication and 
oncogenesis and a late region (L) that encodes the L1 and L2 structural proteins of the viral 
capsid. The regulation of viral gene expression is controlled by cellular and viral 
transcription factors. Most of these regulations occur within the LCR region. The virus early 
promoter, differentiation-dependent late promoter, and two polyadenylation signals define 
three general groups of viral genes that are coordinately regulated during host cell 
differentiation. The E6 and E7 genes maintain replication competence, E1 E2, E4, E5, and E8 
are involved in virus DNA replication, transcriptional control, beyond other functions. The 
products of the late genes L1 and L2 are responsible for the assembly of viral particles 
The HPV life cycle begins with infection of stem cells in the basal layer of the epithelium. 
After entering the cells, the virus requires the expression of genes E1 and E2 to maintain a 
low number of genome copies. The expression of E6, E7, E1, and E2 are required for 
episomal maintenance continued. E1 and E2 act together to initiate replication of viral DNA, 
while E6 and E7 modulate cell cycle regulators to maintain replication competency in the 
long-term. The activation of differentiation-dependent promoter leads to an increased 
production of proteins E1, E2, E5, E6 and E7, resulting in increased cell proliferation and 
therefore in the number of cells infected with HPV, as well as the number of viral genome 
copies per cell. Then there is the E4 gene expression that induces genome amplification, at 
the same time that occurs the expression of genes L1 and L2 and assembly of viral particles. 
Among the mechanisms that allow the persistence of the virus include a specific 
differentiation during of the life cycle of the virus, the mechanisms for keeping the number 
of copies of the genome in undifferentiated cells, angiogenesis, and strategies to evade of 
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both innate and adaptive immune surveillance. In most cases, host defenses prevail and 
HPV infections resolve themselves. In some cases, however, infections persist for longer 
periods, allowing the accumulation of additional cellular changes leading to cancer. 
The ingenious strategy developed by HPV, in which viral DNA replication and assembly 
occur only in in terminally differentiated cell and the fact that a local infection and 
intraepithelial, allows the virus to remain in host for many months, even years, invisible to 
the host defense mechanism. The HPV achieve this enviable lifestyle through a combination 
of abilities that contribute to avoid immune response. The viral infectious cycle is confined 
to the epithelial compartment, there is no viremia or blood-borne spread, and virus particles 
are eliminated from the mucosal surfaces far from vascular and lymphatic channels. As a 
result, there is little access to proteins of viruses and virus to the lymph nodes where 
adaptive immune responses are initiated. Besides, there is no necrosis or cell death virus-
induced, and the proinflammatory cytokines that activate APCs in the epithelium are 
absent. In addition, HPV downregulate interferon responses and disable epithelial LCs. This 
allows for long uninterrupted periods of viral replication in the epithelium in the absence of 
host defense mechanisms.This is a high risk strategy for the host when the infection is 
caused by oncogenic genital HPVs, it increases the risk that the host immune system may 
become tolerant or unresponsive to viral proteins. 
The development of cervical cancer involves a coordinated targeting of multiple pathways 
involving the HPV oncoproteins, where each one has a distinct role in malignant 
progression by interacting with many cellular proteins. The oncoproteíns of high-risk HPV 
usurp or disrupt multiple signaling pathways to maintain the proliferative state in infected 
cells to facilitate viral replication and persistence. One consequence of this, however, is the 
accumulation of mutations in cellular genes and increased genomic instability, which results 
in full transformation. The major viral factors responsible for altering these pathways and 
mediating the progression to malignancy are the E5, E6 and E7 proteins. The efficient 
interruption of the functions of p53 and pRb by E6 and E7 is essential for this process. 
Recent studies have identified other important cellular targets, including telomerase, 
members of the pathway of DNA damage and important factors for centrosome duplication 
and signaling proteins. HPV promotes cell proliferation by multiple pathways in the 
absence of active cellular mechanisms of defense. The new appreciation of the role of other 
viral proteins, such as E5, in the progression of HPV-induced disease is also emerging. 
Although the recently introduced vaccines are effective in preventing initial infections 
caused by the high risk HPV types comprised in the vaccine, they have no effect on existing 
lesions and cancer, nor will it protect against diseases caused by other HPV types. 
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1. Introduction 
During the last few decades accumulated epidemiological, clinical, and experimental 
evidence has revealed the important role of human papillomavirus (HPV) in the 
development of cervical carcinomas, an association almost unique in cancer epidemiology. 
Several important questions have been answered and a large number of scientific studies 
have paved the way for the introduction of new and effective vaccines, which will hopefully 
diminish the incidence of HPV-related carcinomas and precursor lesions in forthcoming 
years (Crum et al., 2003; zur Hausen, 1977, 2008). However, the exact recognition and proper 
treatment of clinically important lesions often poses problems both to pathologists and 
gynecologists.  
Morphology remains the gold standard for lesion diagnosis, despite the fact that it can be 
hampered by inter- and intra-observer variability. Additionally, the contribution of 
morphology in the field of human papillomavirus research cannot be overemphasized, since 
cytologic and/or histologic examination allow the recognition of viral cytopathic effects, 
and, with the aid of immunohistochemical and other in situ techniques, may reveal the exact 
cells, in which some main interactions take place. Thus, the correlation of cellular alterations 
with new sensitive methods of detection either for human papillomavirus nucleic acids or 
for HPV-related intracellular interactions might lead both to the identification of different 
groups of lesions according to their clinical significance, as well as to the correct application 
of current morphological criteria.  
The following chapter will focus on those immunohistochemical methods that can facilitate 
or confirm the detection of intraepithelial lesions of cervical squamous epithelium (SILs) in 
biopsy specimens, additionally presenting in brief some data concerning the mechanisms by 
which these specific cellular targets are related to important actions of HPV oncoproteins. 
Finally, a short comment concerning the application in diagnosis of methods other than 
immunohistochemistry has been added. 
1.1 HPV in carcinogenesis 
In the last three decades a large number of scientific studies have focused on the subject of 
cervical carcinogenesis.  These resulted in the accumulation of data linking several types of 
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human papillomavirus to the development of cervical cancer (Bosch et al., 2002; Bosch et al., 
2006; Crum et al., 1984; zur Hausen, 1977, 2009). The revealed strong association led to the 
suggestion that HPV is not only the main cause of cervical cancer, but also a necessary cause 
(Walboomers et al., 1999). Human papillomavirus is associated with more than 99% of all 
cervical cancer cases. In addition, a significant percentage of vulvar, vaginal, penile, anal 
and perianal carcinomas are HPV-positive (Fuste et al., 2010; Gross & Pfister, 2004; Insinga 
et al., 2008; Munoz et al., 2006), often containing HPV 16 DNA (zur Hausen, 2009), while a 
fraction of carcinomas in other sites of the human body has also been linked to high-risk 
(HR) HPV infections. Percentages of HPV positivity observed in carcinomas of the 
anogenital region are presented in Table 1.  
Human papillomavirus is estimated to comprise a causal agent in 5% of human cancers and 
is associated with more human cancers than any other virus (Bergonzini et al., 2010).  
Among them, cervical cancer represents a well-studied prototype of a human tumor related 
to a viral infection. 
Vaginal carcinomas 60-91% 
Vulvar carcinomas 50% 
Penile carcinomas 30-50% 
Anal and perianal carcinomas 60-94% 
Table 1. Percentage of HPV detection in carcinomas of the anogenital region other than 
cervical carcinoma (Munoz et al., 2006; zur Hausen, 2009). 
The most common viral types detected in cervical carcinomas include HPV 16, 18, 45, 31, 
33, 52, 58, and 35 (Clifford et al., 2003; Munoz et al., 2003). The fraction of squamous cell 
carcinomas or adenocarcinomas attributable to HPV16 and HPV18, which comprise the 
two most common types, is 70% and 86%, respectively. The paradox is that, although 
infection with oncogenic types of HPV is very common, malignancy is a rare outcome. 
This difference in incidence between infection and cancer development reveals the 
significance of complex interactions between viral, environmental and host-related factors 
(Frazer, 2009; Moscicki et al., 2006; Snijders et al., 2006; Whiteside et al., 2008; zur Hausen, 
2008). Viral persistence is an important determinant in this sequence of events, while 
immune status, viral integration into the host DNA, and infection with multiple HPV 
genotypes have significant roles. These multiple interactions are reflected in the long 
interval between infection and invasive carcinoma detection, often spanning a period of 
15 to 25 years (zur Hausen 2008). Other factors that may modify the risk for HPV DNA-
positive women include smoking, the use of oral contraceptives, and previous exposure to 
other sexually transmitted diseases (Bosch et al., 2006; Collins et al., 2010; Luie et al., 2011; 
Munoz et al., 2006). 
In recent years a large number of scientific studies have resulted in the introduction of 
effective vaccines, which are expected to diminish the incidence of HPV-related carcinomas 
of the uterine cervix and other organs (Bogaardts et al., 2011; Frazer, 2009; Stanley, 2010; The 
FUTURE I/II Study Group, 2010; zur Hausen, 2008). Moreover, they are expected to reduce 
the incidence of intraepithelial HPV-related lesions. A large number of the latter are caused 
by non-carcinogenic HPV types and do not constitute precancerous lesions, but still may be 
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the cause of significant anxiety and distress for the patients. Furthermore, in rare instances 
they can give rise to life-threatening conditions, like recurrent respiratory papillomatosis. 
Another main result of human papilloma virus research was the introduction in clinical 
practice of new diagnostic techniques (Cuzick et al., 2006; Gravitt et al., 2008; Poljak & 
Kocjan, 2010; Snijders et al., 2010). These allow for a more precise evaluation of the 
following: a) the presence of HPV in biologic specimens and the viral type present, b) the 
viral load, and c) the presence of an HPV-associated lesion demanding further therapeutic 
measures in cytological or biopsy material.  
Finally, an important aspect of human papilloma virus research is the fact that the complex 
interactions between HPV oncoproteins and their multiple cellular targets offer to 
investigators the opportunity to study important cellular pathways related to the 
carcinogenic process in general.  
1.2 Interactions between HPV oncoproteins and cellular pathways 
High-risk mucosal HPVs encode three transforming proteins: E5, E6 and E7. Their multiple 
biological activities have been extensively studied in the last few decades; however, several 
aspects remain to be elucidated (McLaughlin-Drubin M & Münger K, 2009a). 
HPV E5 is able to transform mouse fibroblasts and keratinocytes in culture (Straight et al., 
1993). It is believed to contribute to early stages of carcinogenesis and works in concert with 
E6 and E7 (Talbert-Slagle & DiMaio, 2009; Hu et al., 2009). The latter proteins are necessary 
for the induction and maintenance of the transformed phenotype. They inhibit the function 
of tumor suppressors p53 and pRb, respectively, whereas their expression enables cells to 
bypass normal cell cycle checkpoints. 
One of the main actions of HPV E7 proteins is the interaction with the retinoblastoma tumor 
suppressor protein, pRB, which controls S-phase entry through association with E2F 
transcription factor family members. They also interact with the related pocket proteins, 
p107 and p130. High-risk HPV E7 targets pRB for proteasomal degradation, while low-risk 
HPV E7 binds pRB with lower efficiency (approximately 10-fold lower) than HR- HPV E7 
(McLaughlin-Drubin M & Münger K, 2009a; Munger et al., 1991). E7 proteins cause aberrant 
activation of cdk2 (cyclin dependent kinase 2), which is associated with cyclins E and A, as 
well as cdk inhibitors, mainly p21CIP1 and p27KIP1. E7 expression results in dysregulated 
expression of cyclins E and A (McLaughlin-Drubin M & Münger K, 2009b; Zerfass et al., 
1995). It also results in retaining differentiating keratinocytes in a DNA synthesis competent 
state. 
High-risk HPV E6 proteins target p53 for proteasomal degradation through association with 
the cellular ubiquitin ligase E6AP (McLaughlin-Drubin M & Münger K, 2009b; Scheffner et 
al., 1990). Low-risk HPV E6 proteins can also associate with E6AP; however, high-risk HPV 
proteins target p53 for ubiquitination. 
Furthermore, HR-HPV E6 and E7 proteins cooperate to generate mitotic defects and 
aneuploidy through induction of supernumerary centrosomes and multipolar mitoses in 
epithelial cells (Duensing et al., 2000), while genomic instability results in the addition of 
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molecular alterations. The detection of abnormal mitoses is a useful morphologic indicator 
of high-risk HPV-associated lesions (Crum et al. 1984). 
Finally, integration of HPV genome into host chromosomes is an important event in cervical 
carcinogenesis (Hopman et al., 2006; Pett & Coleman, 2007), which occurs frequently during 
malignant progression and may result in dysregulation of E6/E7 expression due to 
disruption of E2, with associated loss of the inhibitory E2 action. 
2. Immunohistochemical stains in the diagnosis of Squamous Intraepithelial 
Lesions (SIL) 
Clinical management of preinvasive cervical disease consists of confirmation of SIL 
diagnosis by histopathological examination, followed by treatment or careful follow-up of 
certain lesions, according to the current guidelines. Histopathological diagnosis of CIN is 
based on well-defined criteria. However, in certain cases distinguishing both low- and high-
grade lesions from their mimics may pose problems (Crum & Rose, 2006; Kostopoulou et al., 
2001; Kurman et al., 1992), even to experienced gynecologic pathologists. The distinction of 
florid reactive changes, immature metaplastic patterns, and atrophic changes from HPV-
induced alterations may cause difficulties. Attempts have been made to redefine the 
traditional criteria for lesion diagnosis, while other efforts aimed at the adoption of new, 
more objective methods, which might support the former (Bollmann et al., 2005; Cho et al., 
2005; Guillaud et al., 2005; Prasad et al., 1994; Salvia et al., 2004; Scheurer et al., 2007). 
However, studies attempting to correlate HPV presence and replication to certain 
cytohistologic alterations are becoming less frequent and/or fruitful. 
In recent years molecular studies have revealed several markers that might be of utility in 
the diagnosis of squamous intraepithelial lesions, including cellular proteins targeted 
directly by viral oncoproteins, and markers related to the cell cycle, which is disturbed by 
multiple actions of the virus, as summarized in the above paragraphs. The 
immunohistochemical stains that are currently in use in several laboratories worldwide, as 
well as some new promising markers are presented in the following text. The terms low 
grade squamous intraepithelial lesion (LSIL) and high grade squamous intraepithelial lesion 
(HSIL) will be used interchangeably with CIN1 and CIN2/3, respectively. 
2.1 p16 
One extensively studied marker is p16 INK4A (hereafter referred to as p16), a cyclin-
dependent kinase inhibitor. p16 decelerates the cell cycle and functions as a tumor 
suppressor, while having a role in cellular senescence. p16 affects pRb-mediated regulation 
of the G1/S transition (Lukas et al., 1995; Ohtani et al., 2004; Quelle et al., 1995; Serrano, 
1997; Sano et al., 1998). 
The expression of p16 is altered in several human tumors by deletions, mutations, or 
methylation (Cohen & Geradts, 1997; Nakashima et al., 1999; O’Neill & McCluggage, 2006; 
Ruas & Peters 1998) and has also been altered in cervical carcinoma cases. However, 
increased expression is often observed in HPV-related intraepithelial lesions and this is 
mainly attributed to the presence of a feedback loop, which depends on the status of 
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retinoblastoma protein (pRb) and the potential of high-risk HPV E7 protein to inactivate 
the latter (Lukas et al., 1995; Giarre et al., 2001; McLaughlin-Drubin & Münger, 2009b). 
Correlation has been reported between HR-HPV oncogene expression and high scores of 
p16 positivity (Andersson et al., 2006), and enhancement of p16 RNA level has been 
observed in vitro after immortalization by high-risk HPV types (Nakao et al., 1997). 
Despite the presence of high levels of p16 in SILs, its suppressor function is not normally 
exerted. 
Several groups of investigators have examined immunohistochemically the expression of 
p16 in cervical squamous intraepithelial lesions (reviewed by Kostopoulou et al., 2011) and 
its possible correlation with HR-HPV types and/or lesion “progression”. Indeed, p16 is one 
of the best studied markers in gynaecologic pathology. However, percentages of 
immunohistochemical positivity vary among different studies, as presented in Table 2. In 
the latter, studies published in the last ten years and including more than 100 cases of 
squamous intraepithelial lesions in histopathologic specimens are summarized, and the 
reported percentages of p16 immunopositivity are presented, together with the criteria and 
the antibodies used by the authors. Importantly, different criteria have been used for p16 
immunoreactivity evaluation, with some authors focusing only on diffuse 
immunopositivity, some reporting any type of immunostaining, and others reporting 
nuclear and cytoplasmic staining separately. It should be also noted that some authors 
interpret focal positivity as a false-positive reaction. Positivity in the studies presented 
below varied from 5.6% to 100% for low-grade lesions and from 45.2% to 100% for high-
grade lesions (Table 2). The percentage of immunopositivity observed in non-neoplastic 
epithelia also varied between 0% and 32.7%. 
In a recent study (Kostopoulou et al., 2011) the two basic patterns of immunoreactivity, 
that is focal and diffuse, were further subdivided into groups as following: Focal 
positivity was subdivided into cases with occasional positive cells, dispersed or in small 
groups, observed mainly in the lower epithelial layers, and cases with occasional positive 
cells, dispersed or in small groups, commonly above the parabasal layer. Diffuse 
positivity (Figure 1) in the horizontal plane involved either all epithelial layers, or only 
the basal, parabasal and intermediate layers, without extending to the upper third of the 
epithelium. In HSIL, only diffuse positivity was encountered, observed in 24/25 cases 
(96%). In LSIL 41/55 cases (74.5%) showed some type of positivity, most commonly 
focal/sporadic (Figures 2 and 3). Interestingly, three out of eight LSILs showing diffuse 
immunoreactivity were characterized by markedly increased nuclear dimensions in the 
upper epithelial layers in comparison to other lesions characterized as low-grade. Another 
interesting finding of the above study was the different HPV type distribution observed 
between the two patterns of sporadic/focal positivity, involving lower vs 
intermediate/upper epithelial layers, and probably reflecting an earlier sporadic 
expression of E7 in certain lesions (Kostopoulou et al., 2011). The percentage of high-risk 
or probable high-risk HPV associated LSILs positive for p16 was 71.4% (25/35). This was 
not significantly different from immunopositivity observed in low-risk HPV associated 
lesions. Moreover, study of the pertinent literature revealed that a significant percentage 
of LSILs testing positive for HR-HPV by PCR or HC2 does not exhibit any p16 
immunopositivity. The percentage of p16 positivity reported for HR-HPV positive LSILs 
varied from 32.4% to 94.4% (Ishikawa et al. 2006; Kalof et al., 2005; Kostopoulou et al., 
2011). 
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Reference 
Number 
of SILs 
examined
LSIL 
positivity
HSIL 
positivity
Non-
neoplastic
epithelia
Evaluation of 
staining 
Antibody used 
in the study 
Agoff et al., 
2003 269 56.6% 84.5% 11.5% 
N and C
≥5% cells 
E6H4 
(MTM) 
Branca et al., 
2004 137 35% 81.2% 0% N and/or C
Polyclonal 
(Abcam) 
Negri et al., 
2004 127 74.7% 100% ND 
N and C
≥5% cells in 
lower third
CINtec p16 
Histology Kit 
(DakoCytomation) 
Volgareva et, 
al. 2004 113 37.2% 45.2% 3.2% N and/or C
E6H4 
(MTM) 
Wang et al., 
2004 113 72% 94.7% 32.7% 
Any
reactivity
E6H4 
(MTM) 
Dray et al., 
2005 104 74.1% 96.1% 7.0% N and/or C
JC8 
(Biocare Medical) 
Murphy et 
al., 2005 117 100% 98.7% 0% N or C 
p16 
(Pharmingen) 
Ishikawa et 
al., 2006 141 24.5% 87.5% 0% 
Moderate and 
strong
E6H4 
(MTM) 
Focchi et al., 
2007 153 90.9% 100% 7.9% 
C and N
≥5% cells
Ab7 16PO7 
(Neomarkers) 
Hariri & 
Oster, 2007 140 71.4% 100% 6% 
Continuous 
basal and 
parabasal
p16 Histology Kit 
(Dako) 
Van Niekerk 
et al., 2007 184 57.1% 96.9% 22.9% 
N and C
≥5% cells in 
each layer
E6H4 
(DakoCytomation) 
Godoy et al. 
2008 115 50% 96.2% 0% C and N 
CINtec p16 Kit 
(Dako) 
Dijkstra et al., 
2010 406 5.6% 96.7% ND 
Diffuse, >1/3 
of epithelium
Ab-4, 16P04 
(Lab Vision) 
Tan et al., 
2010 129 26.7% 79.7% 0% 
N and C
≥5% cells
p16 
(NeoMarkers) 
LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; N: 
nuclear; C: cytoplasmic; ND: no data  
a Only studies including more than 100 cases of squamous intraepithelial lesions in histopathologic 
specimens and published in the last ten years are presented. 
Table 2. p16 immunopositivity in low- and high- grade squamous intraepithelial lesions 
reported in the literaturea 
The results of the above studies point towards the use of p16 immunostain in conjunction 
with histopathologic evaluation. Addition of a consecutive p16-stained slide to the HE-
stained slides has been shown to improve significantly interobserver agreement for both 
punch and cone biopsies (Bergeron et al., 2010; Dijkstra et al., 2010; Horn et al., 2008), and to 
help in the identification of occult lesions (Ordi et al., 2008). The differential diagnosis from 
non-neoplastic alterations can be facilitated, especially in conjunction with other 
immunostains, as presented below. Moreover, lesion grading can be faster, especially 
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concerning aggressive-appearing low-grade lesions, which otherwise might be upgraded 
(Dijkstra et al., 2010). Awareness of the different patterns of immunoreactivity might allow 
for a most proper use in certain clinicopathological settings. However, significant variability 
remains in the reported percentage of cases that stain positively for p16 and several 
unresolved technical issues remain, underlining the need for standardization of sample 
preparation and evaluation protocols (Mulvany et al., 2008; Tsoumpou et al., 2009). 
 
(a) (b) 
Fig. 1. (a,b). High-grade squamous intraepithelial lesion (HSIL-CIN2): (a) Hematoxylin and 
eosin staining, (b) p16 immunostain showing diffuse positivity. 
 
(a) (b) 
Fig. 2. (a,b). Low-grade squamous intraepithelial lesion: (a) Hematoxylin and eosin staining, 
(b) p16 immunostain showing focal positivity. 
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It is of note that: (a) in several studies, especially with increasing number of cases, there 
often appears a small group of HSILs that do not show any immunoreactivity, and (b) a 
significant percentage of LSILs associated with HR-HPV, as detected by PCR or HC2, does 
not exhibit p16 immunopositivity (Kostopoulou et al., 2011). The above observations lead to 
the conclusion that a negative or equivocal p16 immunostain should be carefully evaluated 
in conjunction with the histopathologic findings and should not be used as the main 
criterion for diagnosis. However, p16 may also be of use in evaluating cauterized cervical 
resection margins, since the positive staining pattern of HGSIL is not affected by diathermy 
in LLETZ biopsies (Dray et al., 2005). 
Finally, another aspect of p16 immunostaining is the possibility of correlation with lesion 
“progression”. It has been suggested that certain phases of a given HR-HPV-associated 
neoplastic process may have different indices of p16 expression (Keating et al., 2001). 
Although the detailed examination of this subject is not included in the aim of the present 
text, it should be mentioned that in an interesting study by Hariri and Oster (2007) 25/26 
low-grade lesions with negative p16 staining (concerning diffuse staining) and a minimum 
follow-up period of five years had a benign or normal outcome, revealing a negative 
predictive value of p16 in predicting the outcome of CIN 1 cases as high as 96%. In a study 
including conization specimens with coexisting CIN1 and CIN3 areas, all CIN1 were p16 
positive (Negri et al., 2008), while p16 staining did not predict persistence or clearance of 
HR-HPV after treatment for CIN in a study by Branca et al. (2004). 
 
 
(a) (b) 
Fig. 3. (a,b). Common patterns of p16 positivity in low-grade lesions 
2.2 Cyclins 
Cyclins have been reported to be of help in the evaluation of cervical biopsies. Cyclin E is 
uncommonly expressed in epithelia not infected by HPV and its conspicuous 
immunopositivity may facilitate the recognition of SIL (Keating et al., 2001). In addition, 
cyclin B1 immunoreactivity above the basal/parabasal cells correlates significantly with 
HPV detection and could be a marker of HPV presence (Kostopoulou et al., 2008a). Cyclins 
D and A have been also studied as possible markers of HPV-related lesions. 
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2.2.1 Cyclin B1 
It has been reported that E6/E7 oncoproteins of HPV type 18 induced changes in the 
expression of cell cycle regulatory proteins very early and before immortalization (Pei, 
1996). Significantly increased expression was noted for cyclin B and its transcriptional 
activation was documented. In 2000, Southern et al. demonstrated increased cyclin B1 
expression in HGSILs. In their study cyclin B protein was up-regulated and persisted into 
the upper epithelial layers in parallel with cyclin A expression in high-grade squamous 
intraepithelial lesions.  
In a study performed in our laboratory cyclin B1 immunostaining above the basal/parabasal 
layers was observed in all cases of HSIL (100%), most often involving the superficial layers 
as well (Kostopoulou et al., 2008a). Furthermore, increased cyclin B1 immunopositivity was 
observed in 51/52 low-grade lesions (98.07%) (Figure 4), and in seven of 15 biopsies (46.6%) 
characterized as atypia of unknown significance (AUS). Six of these seven cases tested HPV-
positive by PCR.  
 
(a) (b) 
Fig. 4. (a,b). Low grade squamous intraepithelial lesion: (a) Hematoxylin and eosin staining, 
(b) Cyclin B1 immunostain, showing sporadic positivity in mature squamous polygonal 
cells above the basal layers. 
The essential feature of the staining pattern observed in low-grade lesions and AUS cases in 
the above study consisted of sporadic cyclin B1 staining in mature squamous polygonal cells 
often just above the basal layers, with slight differences between flat and elevated lesions. 
This pattern of immunoreactivity was seen in 52 of 55 cases with HPV infection detected by 
PCR, whereas it was seen in only 5 cases without PCR-proven HPV infection. In 4 of the 
latter cases, however, p16 immunopositivity was detected, suggesting that HPV could be 
present though not detected by PCR. 
The pattern of immunoreactivity observed in low-grade lesions and AUS cases could be 
perceived as cytoplasmic accumulation or retention of cyclin B1 in suprabasal squamous cells. 
Several mechanisms could be related to this reaction (Kostopoulou et al., 2008a), while this 
pattern might reflect early events in the inhibition of G2-to-M transition, a well-known 
phenomenon during HPV infection in vitro. The possibility was suggested that these cyclin 
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B1-positive cells could be viewed as a type of ‘‘prekoilocytes”, whose eventual progression to 
koilocytes would depend on several parameters related to the intricacies of HPV infection. 
 
Fig. 5. Cyclin B1 positivity in an HSIL.  
In conclusion, cyclin B1 positivity above the basal/parabasal layers correlates significantly 
with HPV detection and could be a marker of HPV presence. Thus, it might constitute a 
helpful finding in difficult to diagnose cases. Immunopositivity in a specimen showing non-
diagnostic atypia should prompt reevaluation and/or HPV testing, as it is likely that the 
case could represent a genuine low-grade intraepithelial lesion. 
2.2.2 Cyclin E 
Cyclin E, another important cell cycle regulator, which promotes G1 transition, has been 
reported to exhibit increased expression in squamous intraepithelial lesions and invasive 
cervical carcinomas, although the exact mechanisms are not clear (Keating et al., 2001). 
In a study by Keating et al., (2001) moderate to strong immunopositivity for cyclin E was 
observed in 92.6% and in 91.6% of low-grade and high-grade intraepithelial lesions, 
respectively, being positive in 38/41 HR-HPV positive cases. Furthermore, in a group of 
nondiagnostic squamous atypias cyclin E positivity was associated with HPV positivity.  
In a study by Bahnassy et al. (2007), cyclin E staining increased from CIN1 to invasive 
carcinoma (16.7% to 88.4%, respectively), while gene amplification was detected in 11.1% of 
CIN1 cases and in 88.4% of carcinoma cases. 
In conclusion, although cyclin E staining is not useful in the distinction of low-grade from 
high-grade lesions, it could be used to discriminate reactive from neoplastic epithelium 
(Crum & Rose, 2006), especially in conjunction with other markers, as discussed in other 
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parts of the present text. As is the case with the other immunostains examined in this text, 
standardization of staining and evaluation protocols are important for the appropriate 
application of these markers in certain diagnostic dilemmas.   
2.3 Other proliferation/cell cycle markers 
2.3.1 Ki-67 
Ki-67, an antigen expressed in the nuclei of proliferating cells, has also been studied as an 
indicator of CIN. Ki-67 is expressed in the nucleus during the whole cell cycle, except for the 
G0 and G1 early phases. Although positivity is observed under normal conditions in the 
lower compartments of the multilayered squamous epithelium, staining of the middle and 
upper layers is indicative of an intraepithelial lesion (Figure 6).  
Immunopositivity for Ki-67 increases as a function of increasing lesion grade (Arafa et2008; 
Conesa-Zamora et al., 2009; Carreras et al., 2007; Keating et al., 2001; Mimica et al., 2010; Pinto 
et al., 2008), but immunostains should be interpreted with caution, since reactive and 
inflammatory lesions may result in increased epithelial proliferation. It is well-known to 
pathologists that reactive and reparative changes may pose a problem in the examination of 
proliferation markers and in the case of Ki-67 immunostaining positive nuclei may extend 
through most of the epithelium. However, Ki-67 immunostaining can be used as an adjunct 
to other markers, as already discussed. 
It should be noted that Ki-67 immunohistochemical stain may be especially helpful in 
differentiating atrophic epithelial changes from high-grade lesions (Crum & Rose, 2006). 
(a) (b) 
Fig. 6. (a,b). Ki-67positivity in (a) a low- and (b) a high-grade intraepithelial lesion. 
2.3.2 Aberrant S-phase 
Two relatively new biomarkers include the minichromosome maintenance protein 2 
(MCM2) and DNA topoisomerase IIa (TOP2A) (Pinto et al., 2008). These two proteins have a 
significant role in the regulation of DNA replication during S-phase. They are overexpressed 
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when S-phase induction is aberrant and have been shown to be overexpressed in CINs and 
cervical carcinomas (Badr et al., 2008; Pinto et al., 2008; Shi et al., 2007). TOP2A is a nuclear 
enzyme that regulates the enzymatic unlinking of DNA strands during chromosome 
replication. MCM2 functions also during DNA replication by loading the pre-replication 
complex onto DNA and unwinding the latter through helicase activity to permit synthesis. 
ProEx C (Tambouret et al., 2008) is a recently developed immunohistochemical assay that 
targets these two proteins and appears to be efficient in distinguishing reactive epithelial 
changes from squamous lesions, alone or in conjunction with p16. 
According to Shi et al. (2007), ProEXC is a better marker than p16 for the detection of LSILs, 
showing positivity in 94% of the cases in a series of 34 LSILs. In a study by Badr et al. (2008) 
strong positive staining for ProEx C involving the lower and upper halves of the epithelium 
was observed in 92% of high-grade squamous intraepithelial lesions. Condylomas and CIN I 
showed greater variability in patterns of staining, with immunopositivity extending into the 
upper half of the epithelium in 48% of cases.  
Pinto et al. (2008) included in their study cases with the differential diagnosis of HSIL vs 
reactive epithelial changes. ProEx C showed 87% sensitivity and 71% specificity for SIL in 
biopsy material. The authors reported a larger number of cells stained by ProEx C in 
comparison to MiB-1 in both HSIL and LSIL cases. In addition, the combination of p16 and 
ProEx C predicted more NoSIL (including normal, reactive, and/or atrophic epithelia) than 
p16 and MiB-1 (61% vs 43%). These observations suggested that ProEx C could be more 
useful in the distinction of reactive epithelial changes from SILs than MiB-1, providing a 
lower false positive rate relative to the latter. 
In a study by Sanati et al. (2010) sensitivity, specificity, positive and negative predictive 
value of ProExC in distinguishing high-grade squamous intraepithelial lesion from 
squamous metaplasia were 89%, 100%, 100%, and 82%, respectively. In a recent study by 
Guo et al., (2011) diffuse positivity for ProExC significantly increased from benign 
cervix/CIN 1 to CIN 2 or 3/carcinoma, while the highest specificity for CIN 2+ and CIN3+ 
(100% and 93%, respectively) was achieved when immunostaining was positive for both 
ProExC and p16, suggesting that it is advantageous to use these two markers together in 
order to distinguish high-grade lesions from their mimics. 
Walts and Bose (2009) suggested as cost saving strategy the use of two markers initially, p16 
and ProExC, followed by Ki-67 immunostaining in discordant cases. According to the above 
authors, performing the two above stains initially and adding Ki-67 only when p16 and 
ProExC yield discordant results provided the same diagnostic accuracy while reducing the 
cost, since only one third of the cases required performance of the third stain. 
2.4 Other markers and applications 
In the present text an effort has been made to cover the immunohistochemical markers, 
which are currently most useful from a diagnostic point of view, and have been evaluated in 
several studies and laboratories.  
In addition to the above biomarkers, which are in use in many pathology departments 
worldwide, a large number of other markers have been examined for their potential utility 
in the diagnosis and/or prognosis of cervical precursor lesions and in resolving problematic 
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cases (Galgano et al., 2010; Khan et al., 2008; Kostopoulou et al., 2008b). The results of these 
studies have been described in detail in the pertinent literature. In addition, image analysis 
methods have been used in an attempt to bring more objectivity to the interpretation of 
biopsy specimens. Furthermore, although the detection of SILs in cytology material and the 
evaluation of screening strategies are beyond the scope of the present text, it should be 
mentioned that the contribution of the above markers is important in this context, as 
presented in brief in the following (Carozzi et al., 2008; Depuydt et al., 2011; Tsoumpou et 
al., 2009). 
2.4.1 L1 capsid protein 
One recently studied marker, which has been examined repeatedly in cytologic material, is 
L1. Nuclear positivity for HPV L1 capsid protein, the major structural protein of human 
papillomavirus, is mainly observed in productive lesions and is gradually lost in high grade 
lesions and carcinomas.  
It has been suggested that combined L1/p16 immunostaining may be helpful for clinical 
management, especially in cases in which the grade of the lesion is difficult to assess (Negri 
et al., 2008). 
In a study by Galgano et al. (2010), this protein, which should be highly correlated with a 
productive viral infection, was neither sensitive nor specific for any group of cervical 
neoplasia in biopsy material. This was attributed to the complexity of the temporal 
evolution of the HPV virion production which may be quite transient. It is interesting that 
L1 positive cases with a negative consensus diagnosis in this study had commonly at least 1 
reviewer diagnosis of CIN1, revealing once again the difficulties in the distinction of SIL vs 
negative for SIL and the importance of a panel of immunostains in this specific context. 
2.4.2 In situ hybridization techniques 
Detection of papillomavirus nucleic acids is currently performed by methods that can be 
broadly subdivided into methods based on target amplification and those based on signal 
amplification (Snijders et al., 2010). In addition to several existing liquid phase techniques, 
in situ hybridization (ISH) methods have been developed for cytological and histological 
specimens. Both fluorescent detection and coloured substrate deposition followed by bright-
field microscopy can be used, and can be combined with tyramide signal amplification. ISH 
assays can also be automated along the same lines as immunohistochemistry. Finally, except 
for HPV nucleic acids, other applications of in situ hybridization include the detection of 
amplification of the gene coding for the telomerase RNA component (TERC) at 3q26 
(Hopman et al., 2006; Zheng et al., 2010). 
Issues concerning sensitivity of the above techniques in comparison to PCR have been 
repeatedly raised. However, ISH techniques are becoming increasingly sensitive and can 
now detect low copy numbers of HPV DNA (Kelesidis et al., 2011; Montag et al., 2011). In 
addition, their important contribution to HPV research is the fact that they allow concurrent 
morphological evaluation of the areas examined, mainly in the case of histological 
specimens. Furthermore, the signal patterns observed in HPV ISH have been reported to be 
associated with the physical status of viral DNA in the cells examined, that is episomal or 
integrated. Specifically, the punctate pattern of positivity has been linked to the presence of 
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integrated viral forms in the host genome (Cooper et al., 1991; Evans et al., 2002; Hopman et 
al., 2005).  
In a study by Guo et al. (2008) ISH and PCR had fair to good agreement in detecting HPV 
DNA across CIN categories, but ISH detected significantly fewer HPV-positive cases in 
carcinomas than PCR did, probably as a result of lower copy numbers of episomal as 
compared to integrated HPV DNA in the latter. In addition, although the pure punctate 
pattern of HPV indicated a high level of viral integration, the level of HPV integration could 
not be accurately determined in cases with mixed signal patterns, probably due to a 
variation in the percentage of the two patterns in these cases. Recently, Ho et al. (2011) 
reported a punctate pattern in 8.7% of CIN1 lesions vs 34.0% of CIN3 lesions in cytology 
material, while Alameda et al. (2011) reported a correlation of the punctate pattern with 
lesion persistence in cytology specimens. 
According to Kong et al. (2007), in cases of atypical squamous metaplasia, p16 reactivity 
(focal strong and diffuse strong) was significantly more sensitive than ISH in correlating 
with the presence of human papillomavirus as detected by polymerase chain reaction. In a 
more recent study by Kelesidis et al. (2011), ISH exhibited a sensitivity of 89.5% for the 
detection of CIN2+ lesions, while PCR showed sensitivity of 94.7% for these lesions. A 
percentage of ISH-positive cases was not detected by PCR (performed on liquid-based 
sample media), emphasizing the technical problems and limitations of the techniques.  
Voss et al. (2009) compared a fluorescence in situ hybridization (FISH) HR-HPV assay to 
Hybrid Capture 2 (HC2) and polymerase chain reaction (PCR) for the detection of HR-HPV 
subtypes in cervical cytology specimens. FISH was concordant with HC2 and PCR in 85% 
and 82% of the specimens, respectively, while HC2 and PCR were concordant in 84% of the 
specimens.  
It is apparent from the above results that the applications of HPV ISH are partly dependent 
on the sensitivity of the assay and its sufficiency to carry a high negative predictive value 
(Crum & Rose 2006). This is especially important if clinical decisions are based on a negative 
result. However, ISH represents a useful tool for ancillary molecular HPV testing in cervical 
specimens, and may be important in certain clinicopathologic situations.  
2.4.3 Applications in cytology 
The preceding text focused mainly on the application of immunohistochemistry in SIL 
diagnosis in histopathology specimens. However, several of the above markers have been 
applied in cytopathology material, as presented in brief in the following paragraphs. The 
introduction of liquid-based techniques, which has been one of the most important advances 
in this field, has facilitated relevant applications. 
The most studied marker in cytology is p16. Positivity has been observed in 10%-86% of 
LSIL and in 42%-100% of HSIL, as reviewed by Tsoumpou et al. (2009). The lack of general 
consensus regarding threshold values for p16 positivity is especially important in cervical 
cytology specimens. Several authors have used both quantitative and qualitative criteria, 
evaluating the number of positive cells as well as cell morphology, recognizing the fact that 
p16 overexpression may be often detected in nondysplastic cells. In the contrary, other 
investigators used only quantitative criteria. 
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It has been suggested that p16 immunocytochemical testing can be used as a reflex test in 
conjunction with liquid-based cytology following a cytologic result of ASC-US or LSIL, or be 
used on destained conventional or liquid-based cytology specimens (Denton et al., 2010). 
p16 in conjunction with Ki-67 provide high sensitivity for the detection of CIN2+ lesions 
(Schmidt et al., 2011; Yu et al., 2010). 
The prognostic utility of L1 immunocytochemistry, especially in association with p16 in 
cytology, has been reported by several authors (Griesser et al., 2004; Sarmadi et al., 2011; 
Yoshida et al., 2008). 
The use of HPV in situ hybridization has already been discussed in the previous section. It is 
of note that, in a recent study, prior knowledge of HPV status resulted in significantly 
higher detection rate of CIN2+ in cytology specimens compared to screening blinded to 
HPV status, with limited loss of specificity (Benoy et al., 2011). This raises several important 
questions, although more research is needed to study the significance of this type of 
knowledge provided prior to cytological reading. 
3. Conclusion 
Although histopathology remains the ‘‘gold standard’’ for the diagnosis of SIL, both low- 
and high-grade, certain biomarkers have emerged as helpful adjuncts. Their combined use 
may assist in the histopathologic classification of preinvasive lesions and facilitate the 
distinction from non-HPV induced alterations. It is clear from the above that the diagnosis 
of a squamous intraepithelial lesion in a diagnostically challenging case cannot at present be 
based solely on any particular marker, but rather on a combination of markers with careful 
morphological evaluation, the latter comprising the most important part of the diagnostic 
procedure. Standardization of protocols and familiarity with the patterns of 
immunostaining, especially in nonneoplastic cervical tissue, are important requirements for 
the proper use of the above markers. Awareness of the strengths and limitations of each 
particular technique cannot be overemphasized. In addition, the performance of several 
markers and methods in the detection of lesions related to HPV types other than those 
addressed by the current vaccines remains to be carefully evaluated. 
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1. Introduction 
In this chapter I present the evidence about the performance of existing cervical cancer 
prevention technologies and discuss how HPV testing can be integrated. All screening and 
diagnostic test, including HPV DNA, and biomolecular tests, cervical cytology, colposcopy 
are the markers of risk of cervical cancer.  
A summary and update of recently published meta-analyses and systemic reviews on 
clinical applications of HPV DNA testing is provided in this chapter. 
1. triage of women with equivocal or low grade cytological alterations. 
2. follow-up of women with abnormal screening results who are negative at biopsy 
3. prediction of the therapeutic treatment of CIN 
4. primary screening HPV test, lonely and combination with traditional Pap smear to 
detect the precancer lesions. 
2. Screening 
Screening is a public health activity to detect disease among people thought a priori to be 
well. In the United States, the major cervical screening target is treatable CIN3 (or, to be 
especially cautious, CIN2), not invasive cervical cancer, for which treatment causes far more 
morbidity and is less certain to succeed. Therefore, cervical screening distinguishes between 
the few women who might become patients because they are at highest risk of cancer and 
the overwhelming majority of women who are at far lower risk. Screening that targets the 
common, minor, and typically benign cytological and histological evidence of acute HPV 
infection cannot be cost-effective because the risk of invasive cancer is so low However, 
finding a woman with CIN3 is considered a screening success because she has a high risk of 
invasive cancer and can be treated before cancer develops.demonstrated in Nordic countries 
and in the United Kingdom (Bulkmans et al., 2005; Sasieni & Adams, 1999.) 
2.1 Cytological screening 
Since the development of cytology-based cervical in the mid-20th century screening using 
Pap smear test the mortality of cervical cancer has decreased substantially. In the US rates 
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have fallen by 75 % or more since 1960s. The key aspects of the cervical screening programs 
based on cytology are the exfoliated cervical cells which are examined to predict the 
underlying risk of cervical cancer.  
The consistently observed substantial reduction of cervical cancer incidence after 
introduction of cytology screening and the marked difference in cervical cancer incidence 
between countries with and without screening programs indicates that Pap testing does 
prevent cervical cancer. (Gustafsson et al., 1997) 
Papanicolaou originally introduced cervical cytology with morphological classifications that 
were based on probability of underlying cancer. However, the current US cytology 
classification—the Bethesda system—incorporates a view of cervical carcinogenesis that is 
explicitly based on the natural history of HPV.  
For example, the classification of low-grade squamous intraepithelial lesion (LSIL) is based 
on microscopic signs of an acute HPV infection, whereas high-grade squamous 
intraepithelial lesion (HSIL) suggests the possibility of an underlying CIN3 (or the more 
uncertain precancer diagnosis, CIN2) (Smith et al., 2007) The great majority of HSIL and 
approximately two-thirds of LSIL are associated with carcinogenic HPV types. (Clifford et 
al., 2005) Very common and equivocal cytological changes, which are classified as atypical 
squamous cells of undetermined significance (ASC-US), form the boundary between normal 
and abnormal cytological interpretations; roughly half of changes classified as ASC-US are 
positive for carcinogenic HPV. In the United States, ASC-US is more common than all other 
abnormalities combined. Because this finding is common and some represent true 
abnormalities, a sizeable fraction of CIN3+ cases are detected by ASC-US cytology, despite 
poor interobserver reproducibility.( Kinney et al., 1998) 
With some noteworthy exceptions (Hutchinson et al., 1999; Kitchener et al., 2009) typically a 
single cervical cytological screen is insensitive for detecting CIN3; sensitivity estimates as 
low as 50%–60% have been reported in various settings. (Nanda et al., 2000.) 
Although a single negative high-quality Papanicolaou test does indicate a substantially 
lowered risk of cervical cancer lasting multiple years, stronger reassurance of safety (ie, a 
high negative predictive value) requires repeated rounds of screening to detect growing 
CIN3 lesions. (Wright et al., 2007.) 
In many countries, conventional Papanicolaou smears are still the standard of care. In the 
United States and a few other countries, liquid-based cytology techniques that create more 
uniform slides and computer-assisted cytology evaluation systems have been adopted to 
achieve greater laboratory productivity, but there is no evidence that they detect CIN3 more 
accurately than conventional cytology (Ronco et al., 2007; Siebers et al., 2009.); therefore, we 
do not distinguish among cytological techniques when considering the new role of HPV 
testing. 
In Central and South America, coverage may be high in places, but the quality of the 
cytology programmes and access to treatment are typically poor, and rates of cervical cancer 
remain some of the highest documented in the world. A notable exception is Chile, where 
high quality cytology-based screening has had a substantial impact on cancer incidence and 
mortality. (Sepulveda & Prado., 2005) 
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Cytology is a subjective test and in programmes without quality control/quality assurance it 
is virtually impossible to achieve and maintain the clinical performance of cytology. 
Cytology is labour intensive and to date has been refractory to high-throughput automated 
screening. Despite the low cost of consumables and because of the three reasons cited above, 
high-quality cytology is expensive in absolute terms and may not necessarily be the most 
cost-effective option for screening. (Goldie et al.,2005) Liquid-based cytology has logistical 
and operational advantages (interpretation at higher speed, lower rate of unsatisfactory 
smears and possibility of ancillary molecular testing using remnant fluid), but is more 
expensive and is neither more sensitive nor more specific than conventional cytology with 
respect to detection of histologically confirmed high-grade CIN. (Arbyn et al., 2008) We 
must continue to recognise both the strengths and limitations of cytology for cervical cancer 
screening. In populations vaccinated against HPV-16/18 we should anticipate that the 
positive predictive value (PPV) of cervical screening will be reduced because there will be 
fewer high-grade lesions amongwomen with cytological abnormalities. It is therefore 
rational to develop multiple, viable modalities for cervical cancer prevention, including 
methods that achieve similar or better screening performance than cytology alone but also 
meet the demands of underserved populations, suchas lowcost, the need for fewer than 
three visits (cytology, diagnostic colposcopy and treatment) in each intervention (screening) 
cycle and/or fewer interventions in a lifetime due to a greater negative reassurance of a 
single intervention. It is naive to think that one modality, whether it be cytology-based 
screening, visual inspection with acetic acid (VIA), HPV DNA testing or HPV vaccination 
will meet the demands of all populations throughout the world. Importantly, each screening 
method must be validated for its technical performance and must be cost-effective within 
the capacity of the region in which it is to be adopted. In other words, the cost-utility of one 
method versus another must be evaluated within the limits of acceptable expenditures and 
available resources in different settings. Papanicolaou (Pap) test originally introduced 
cervical cytology with morphological classifications of the cervical cells. However, the 
current cytology classification, the Bethesda system, incorporated a view of cervical 
carcinogenesis that is based on the way of HPV infection. 
2.2 HPV DNA test  
Human papillomavirus (HPV) infection is very common in young women after the onset of 
sexual activity and, when it persists, the viral oncoproteins produce perturbation of the cell-
cycle controls resulting in cervical intraepithelial neoplasia (CIN). At their mildest (CIN1), 
these lesions are generally no more than manifestations of HPV infection, but at their most 
severe (CIN3) the risk of progression to cancer is higher if not detected and treated. 
Fortunately, the transition to cancer usually takes years or decades, thus allowing the 
opportunity for detection by exfoliative cytology. The peak incidence of HPV infection 
occurs at about age 20, the peak incidence/detection of CIN3 occurs at about age 30, and the 
peak incidence of cancer occurs in the 40 s. It is estimated that without secondary 
prevention, cervical cancer would occur in around 3–5% of women who acquire a high-risk 
HPV infection, although for every cancer that occurs a far larger number of CIN lesions 
develop, of which the majority will spontaneously regress. Most of the pre-malignant and 
malignant lesions are of the squamous type, but around 15% are of the glandular type. HPV 
types -16 and 18 are the dominant oncotypes in squamous lesions but type -18 is relatively 
more important in glandular lesions. The recognition of the strong causal relationship 
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between persistent infection of the genital tract with high-risk HPV types and occurrence of 
cervical cancer has resulted in the development of a number of HPV DNA or RNA detection 
systems for screening.  
Here I briefly summarize the update results of the meta-analysis trials.  
There is now overwhelming evidence from randomized clinical trials that high risk HPV 
DNA screening is more sensitive than cytological screening for detecting histological proved 
CIN3. (Cuzick et al., 2008.) 
Based on the central role of persistent infections with carcinogenic human papillomavirus 
(HPV) in cervical cancer, DNA testing for carcinogenic genotypes of HPV has recently been 
introduced into cervical cancer screening. HPV testing is more reliable (Carozzi et al., 2005; 
Castle et al., 2004.) and more sensitive but less specific than routinely performed cytology 
for detection of cervical intraepithelial neoplasia grade III and cancer (grade III+) or grade 
II+. (Arbyn et al., 2006; Bulkmans et al., 2007; Cuzick et al.,2006; Mayrand et al., 2007; 
Naucler et al., 2007.) HPV testing might soon be widely accepted as an alternative to routine 
cytology for cervical cancer screening.  
In Castle’s trial the aim was to evaluate the cumulative incidence of cervical intraepithelial 
neoplasia II or worse (grade II+) or cervical intraepithelial neoplasia grade III+ after short 
term persistence of prevalently detected carcinogenic human papillomavirus (HPV) (Castle 
et al., 2009). 
 
Fig. 1. Cumulative incidence of cervical intraepithelial neoplasia (CIN) grade II or worse 
(II+) and grade III+ after repeat measurements of carcinogenic human papillomavirus 
(HPV) at about one year (Castle et al., 2009) 
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Fig. 2. In figure 2 The cumulative incidence of cervical intraepithelial neoplasia (CIN) grade 
II or more severe (grade II+) or grade III+ after repeat measurements of human 
papillomavirus (HPV) at about one year interval (9-21 months) in women who had 
persistent HPV 16, had persistent HPV 18, tested positive for carcinogenic HPV twice 
(Pos/Pos), tested positive for carcinogenic HPV at enrolment but negative at follow-up 
(“cleared”), tested carcinogenic HPV negative at enrolment but positive at follow-up 
(“acquired”), and tested negative at both time points (Neg/Neg). In right panels same 
groups are stratified by age. Time 0* indicates start time of analysis, 9-21 months after 
enrolment  (Castle et al., 2009) 
Among women aged <30, short term persistence of HPV 16 was highly predictive of a 
subsequent diagnosis of cervical intraepithelial neoplasia grade II+ (CIN2+), with a three 
(and five) year risk of 65.9% (40.4% to 91.5%). By comparison, among women aged ≥30, the 
three (and five) year risk after short term HPV 16 persistence was 27.2% (11.1% to 43.3%). 
There was no significant difference in the intensity of follow-up (median number of days 
between visits) by HPV status, although women who were in higher risk HPV groups (such 
as persistent HPV 16) naturally had fewer follow-up visits on average because of censoring 
treatments for diagnoses of grade 2+. In the summarise of Castle’s trial I can allocate that 
women who tested positive twice for carcinogenic HPV had an increased risk of CIN2+ and 
CIN3+, while the risk in women who test negative for carcinogenic HPV at either or both 
time points was low. They did not observe any appreciable differences in the risks between 
those women with a shorter and longer time intervals between the enrolment and follow-up 
visit, suggesting that these findings are robust to variability in which women return for 
follow-up testing. Among those who tested positive twice for carcinogenic HPV, all 
subsequent diagnoses of cervical intraepithelial neoplasia grade II+ were linked to 
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persistence of a specific HPV genotype. With the exception of HPV 16 and possibly HPV 18, 
however, detection of persistence of a specific genotype did not differentiate women at risk 
for CIN2+ qualitatively better than repeated detection of an aggregate of carcinogenic HPV 
types (Castle et al., 2009).  
Some trials’ results, which were highlighted at a press briefing held in advance of the annual 
meeting of the American Society of Clinical Oncology (ASCO), confirmed that for women 
with a negative HPV test and normal cytology, a 3-year follow-up appears to be safe and 
appropriate. Women who tested negative for HPV had a 5-year cancer risk that was similar 
to those who tested negative for HPV and had normal cytology (3.8 vs 3.2 per 100,000 
women per year; P = .8). This was half the cancer risk of women who had a negative result 
on Pap testing only (3.8 vs 7.5 per 100,000 women per year; P = .3). Concurrent HPV testing 
and cervical cytology (cotesting) is an approved and promising alternative to cytology alone 
in women 30 years and older. Screening guidelines from organizations such as the American 
College of Obstetricians and Gynecologists and the American Cancer Society have endorsed 
the use of cotesting in this age group as a safe alternative to Pap testing alone. The 
summarize of the results is shown at the 1. table. (Annual Meeting of the American Society 
of Clinical Oncology, 2011). 
Test Results  5-Year Risk (%) Excess Risk (%)  
HPV positive  7.6 7.4 
HPV negative  0.2   
Pap positive  4.7 4.3 
Pap negative  0.4   
HPV positive/Pap positive 12.0   
HPV positive/Pap negative 6.0   
HPV negative/Pap positive 0.9   
HPV negative/Pap negative 0.2   
Table 1. 5-Year Risk for Cancer/Precancer by Test Results 
3. HPV DNA screening in triage of women with equivocal or low grade 
cytological alterations 
In seven studies, where also repeat Pap smear was taken, the sensitivity of HPV DNA test 
was on average 14 % higher than repeat cytology, considering ASCUS or worse as a positive 
result for detection of CIN2+. The HPV DNA test and cytology triage showed similar 
specificity(Cuzick et al., 2008). The sensitivity of HC2 triage of women with an index smear 
showing low-grade squamous intraepithelial lesions (LSIL) was very high: 97.2% (95% CI: 
95.6–98.8%), pooled from 11 studies for the outcome of CIN2+ and 97.1% (95% CI: 94.0–
100%), pooled from six studies for CIN3+ (Cuzick et al., 2008; Kulasingam et al., 2002; 
Sherman et al., 2002; Schneider et al., 2000). However its specificity was very low: 30.6% 
(95% CI: 22.7–38.6%) for CIN2+ and 26.1% (95% CI: 15.1–37.1%) for CIN3+. Histologically 
confirmed CIN2+ and CIN3+ were present in respectively 17.6% (95% CI: 11.8–23.3%) and 
7.4% (95% CI: 2.9–12.0%). The very large majority of women with LSIL had a positive HC2 
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result: pooled estimate of 74.4% (95% CI: 67.0–81.9%; range: 58–85%). However, Cuzick’s 
overview trial found that for women aged 35 or more, the HPV positivity rate was much 
lower than for younger women and that the potential value of HPV DNA testing as an 
adjunct to cytology in this group was substantially better than for younger women (Ronco et 
al., 2007). Similar observations were made in the HPV in Addition to Routine Testing 
(HART) study (Cuzick et al., 2003).  However, another study found a high rate of HPV 
positivity in women older than 35 with only a small decreasing gradient with age, 
suggesting that specificity may not be improved very much in this group by using HPV 
DNA testing before referring to colposcopy (Moss et al., 2006). Furtherwork is needed to 
synthesise all the data on HPV triage of LSIL according to age. Even more important, a 
negative HPV test provides long- term risk stratification: 5-10 years of reassurance, due to 
the high negative predictive value of the HPV DNA test, of not developing CIN3 and even 
more stronger reassurance of not developing invasive cancer among HPV DNA negative 
women.  Because the vast majority of HPV infections represented acute HPV infection what 
are disappeared without causing cancer, HPV DNA testing has mediocre specificity and 
positive predictive value for cervical cancer screening.  ( Figure 3.) 
 
 
Fig. 3. Meta-analyses of the sensitivity (left) and specificity (right) of triage of women with 
cytological findings of ASC-US using the Hybrid Capture® 2 assay (RLU > 1) for identifying 
underlying CIN2 or worse (upper) or CIN3 or worse (lower). ASC-US: abnormal squamous 
cells of undetermined significance; CI: confidence interval; CIN2+: CIN grade 2 orworse; 
CIN3+: CIN grade 3 orworse; HC2: Hybrid Capture® 2 (Qiagen Gaithersburg, Inc. MD, 
USA (previously Digene Corp.); OR: odds ratio; RLU: relative light unit.( Castle et al., 2009; 
Pretorius et al., 2002) 
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4. Primary screening HPV test, lonely and combination with traditional Pap 
smear to detect the precancer lesions 
Successful risk stratification based on HPV screening depends on whether the infection 
found are persistent (high risk for CIN) or new (low risk for CIN), especially in elderly 
women.  
Women aged 30 years or older, who test positive for high risk HPV DNA, especially the first 
time they are tested (when the infections might already be persistent), are at sufficiently 
high risk of CIN3+ to merit intensified follow-up. 
There is now overwhelming evidence from randomized clinical trials that carcinogenic HPV 
DNA screening is more sensitive than cytological screening for detecting histological CIN3 
(Mayrand et al., 2007;  Ronco et al., 2010). Even more important, a negative HPV test 
provides long-term risk stratification: 5–10 years of reassurance (ie, a high negative 
predictive value) of not developing CIN3 and even stronger reassurance of not developing 
invasive cancer among HPV DNA–negative women. High negative predictive value permits 
safe and cost-effective lengthening of the cervical screening interval when HPV testing is 
used (Dillner et al., 2008; Khan et al., 2005) (Figure 4).  
 
 
 
Fig. 4. Cumulative incidence rate of cervical intraepithelial neoplasia grade 3 or invasive 
cervical cancer (CIN3+) over 15 years following a single human papillomavirus (HPV) test. 
A cohort of 20 000 women from Kaiser Permanente (Portland, OR) was followed up by 
conventional cytology screening for approximately 15 years (78). Archived cervical 
specimens obtained from the women at enrollment (baseline) were tested for carcinogenic 
HPV types. The risk estimates, adjusted for loss to follow-up, show primarily that in this 
older cohort (average age approximately 35 years), a negative HPV test predicts very low 
risk of subsequent CIN3+. Baseline test positivity for HPV16, HPV18, or HPV31 was most 
strongly linked to subsequent CIN3+. (Schiffman et al., 2011)   
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Overall, the sensitivity of HC2 for finding underlying high-grade intraepithelial neoplasia 
was 89.7% (95% CI: 86.4–93.0%)) but varied over a large range between 50% (Clavel et al., 
2001; Sankaranarayanan et al., 2004) and 100%. In North America and Europe, the pooled 
specificity was higher: 91.7% (95% CI: 90.3–93.1%; range: 85–95%). 
 
 
 
Fig. 5. Relative sensitivity (left) and specificity (right) of HPV testing using the Hybrid 
Capture® 2 assay compared to cytology in primary screening studies. ASC-US: abnormal 
squamous cells of undetermined significance; CI: confidence interval; CIN2+: CIN grade 2 
or worse; HC2: Hybrid Capture® 2 (Qiagen Gaithersburg, Inc. MD, USA (previouslyDigene 
Corp.); LSIL: low-grade squamous intraepithelial lesion ( Cuzick et al., 2008). 
Because the vast majority of HPV infections represent acute HPV infections that are destined 
to clear without causing cancer, HPV testing has mediocre specificity and positive predictive 
value for cervical cancer screening. The women who test HPV positive 3 years after a 
negative HPV test [the current recommendation for cotesting  are at much lower risk of 
CIN2 or CIN3+ than women who are HPV positive at their first screen and, therefore, may 
already have a persistent infection (Schiffman et al., 2011).   
This important fact mandates much longer HPV screening intervals than current cytology 
screening intervals of every 2 years and suggests that the current 3-year interval for 
cotesting  will still be too frequent. The corollary of high sensitivity of HPV testing for 
incipient as well as prevalent CIN3+ is a high negative predictive value that lasts for years 
(Schiffman et al., 2011).  Several studies have shown that HPV negativity alone or in 
combination with negative cytology signifies a longer disease free interval against CIN2+ 
than being negative for cytology alone. 
Early studies measured HPV retrospectively and did not use it for management. Sherman 
ME et al. followed 20,810 women for 10 years and found that in cytologically negative 
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women lesions were diagnosed much more rapidly in those who were HPV-positive 
compared to women who were HPV-negative (Sherman et al., 2003). In two Danish cohorts 
of women aged 22–32 years and 40–50 years HPV DNA was measured retrospectively and 
again not used for triage. The authors concluded that HPV DNA testing at five-yearly 
intervals offers protection similar to cytology testing at three-yearly intervals (Kjaer et al., 
2002). Clavel C et al. reported that 5 of 4,401 women with negative cytology and HPV DNA 
tests and followed-up for a median of 34 months developed high-grade lesions, compared to 
29 of 501 women who were initially cytology-negative but HPV-positive and concluded that 
a screening interval of three to five years was safe in double negative women (Clavel et al., 
2004). Similar conclusions were obtained by Bulkmans NW et al. in a cohort of 2,810 
cytology-negative women followed for five years, where 4 of 62 HPV-positive women 
developed CIN3+ compared to 1 of 2,175 HPV-negative women (Bulkmans et al., 2005). 
Long-term follow-up of the Hammersmith cohort and two large recent randomised trials in 
Sweden and The Netherlands have all shown that the higher detection rate for CIN2+, when 
HPV DNA testing was used as part of the initial screening process, led to lower rates of 
CIN3+ at the subsequent screening round and indicates that HPV DNA tests are highly 
sensitive to detect prevalent cases(Cuzick et al., 2008; Naucler et al., 2007). In the 
Hammersmith study, the cumulative proportion of CIN2+ within five-years after a negative 
HPV DNA test, when most women would have had at least one routine repeat smear was 
about half as high as for women who were originally cytology negative (0.6% versus 1.2%), 
and only after six or more years do the CIN2+ rates in women originally HPV-negative 
approach those seen after three years in women who were originally cytology-negative. In 
the Swedish study of women aged 32–38, the detection rate for CIN2+ associated with the 
addition of HPV DNA testing was increased 51% percent at the initial screen, but 42% lower 
in the follow-up period (mean: 4.1 years). For the Dutch study, the detection rate of CIN3+ 
was 70% higher initially but 55% lower in the 6.5 year mean follow-up period. The fact that 
the higher detection rate for CIN2+ when HPV DNA testing was used as part of the initial 
screening process led to lower rates of disease at the subsequent screening round (Bulkmans 
et al., 2007; Naucler et al., 2007). It also suggests that there is minimal over-diagnosis for 
women aged over 30, as the cumulative CIN2+ rates over two rounds were similar in all 
three studies, and also that the screening interval can be safely extended to at least 6 years 
with HPV DNA testing.   
Although the ability to lengthen screening intervals is a great advance, it poses a major 
challenge for transitioning from cervical screening programs that are based on repeated 
cytology. In particular, in the United States, the considerable general reluctance to move to 
long-interval screening is due at least in part to reasons unrelated to theoretical best public 
health practice. By contrast, in some European settings, where cervical cancer screening 
practices are dictated more directly by public health considerations, detailed planning is 
underway for a transition to long-interval HPV testing (Naucler et al.,2009).   
The limited data on follow-up beyond six to seven years does not allow evaluation of longer 
screening intervals at this time and further work is needed to see if even longer intervals might 
be safe, particularly for women with two or more negative HPV tests (Cuzick et al., 2008). 
Some professional organizations now recommend the routine use of HPV DNA testing for 
screening women aged 30 years and older.  
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Fig. 6. Proposed new screening algorithm which employs HPV DNA testing as the primary 
screening test and uses cytology to triage HPV positive women (Cuzick et al., 2008). 
5. HPV screening with triage by novel biomarkers 
Most of the biomarkers identified thus far are markers of HPV related  transformation , 
which reveals HPV infection.  These biomarkers are more prevalent in CIN3 than in acute 
HPV infection.  
Currently developed and used biomarkers can be shared as follow:  
a. markers of increased HPV oncogene expression, such as HPV mRNA,  
b. markers of increased cell proliferation, such as Ki-67, p16 
c. markers of chromosomal instability, such as HPV DNA integration 
At present, the most promising candidate as a biomarker for triage after a positive HPV test 
is immunocytochemical staining of cytology slides for p16 (Denton et al., 2010; Tsoumpou et 
al., 2009; Wentzensen et al., 2007).  
The p16 overexpression is associated with the disruption of the retinoblastoma cell cycle 
pathway by HPV E7 (Denton et al., 2010; Tsoumpou et al., 2009).  A combined stain for p16 
and Ki-67 that was recently introduced into the diagnostics market can highlight rare 
transformed cells (Denton et al., 2010). Because its sensitivity for CIN3 is far higher than 
cytology’s and almost equal to that of HPV testing and its specificity is comparable to 
cytology’s, this stain could be used as a triage following primary HPV testing if it proves 
reliable and the cost for routine use is low (Denton et al., 2010).  
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6. HPV DNA test as a subsequent management after negative biopsy and/or 
colposcopy 
Historically, colposcopically directed biopsies have been the clinical reference standard for 
diagnosing and grading pre-cancer into CIN1, 2, or 3. However, the choice of biopsy site 
and the histopathological diagnosis of resultant biopsies tend to be variable and subjective. 
Clinicians rely on colposcopy to determine the presence or absence of epithelial lesions, find 
the area of the cervix with the highest degree of the lesion and direct biopsy for histological 
diagnosis. Unfortunately well -trained gynecologists have false negative colposcopy rates as 
high as 20-40 % in patients with histological diagnosed pre-cancer lesion(Schiffmanet al., 
2007).The use of HPV DNA testing related to triage is in women who are referred for 
colposcopy, because of alteration smear, but no visible lesion on colposcopy allowable.  For 
these women, a negative HPV test provides additional reassurance, that there is unlikely to 
be any undetectable disease, while being HPV positive (especially for types -16 and 18), 
indicates a continuing risk needing for short–term repeat testing(Gravittet al.,2008). 
Especially for type -18, the possibility of an adenocarcinoma or its precursor lesion, 
adenocarcinoma in situ, should be excluded by careful examination of the endocervical 
canal. 
7. HPV testing after treatment of cervical intraepithelial neoplasia 
CIN is a very common disease especially in women of reproductive age and a balance is 
needed to maximize the prevention of cervical carcinoma and the same time avoid 
overtreatment. Management strategies of CIN include decision-making regarding the 
appropriateness of conservative approach versus treatment. Conservative strategies are 
appropriate for women with low-grade CIN, particularly in the younger age range.  High-
grade CIN  ( CIN2 or CIN3) should be treated. Conservative methods reduce overtreatment 
as low-grade CIN lesions may regress spontaneously. When HG-CIN is detected the 
treatment is mandatory.  CIN 3 which is the true precursor of cervical cancer will progress 
to cancer if left untreated at a rate of around 30 %  over 2 years (Kitchener& Stern,2008). CIN 
1 has been reported to progress to CIN 2/3 at a rate of 15 % over 2 years but some of these 
cases may harbour undetected CIN2/3 (Castellsague et al., 2006; Kitchener& Stern,2008). 
Screening programs that exploit the extra sensitivity for CIN3+ conferred by HPV testing 
must still minimize treatment of women that is unnecessary on both public health and 
individual grounds. In the United States, the predominant mode of treatment for CIN2 or 
CIN3 is the excision of the transformation zone using a wire loop cautery, commonly known 
as loop electrosurgical excision procedure (LEEP) or large loop excision of the 
transformation zone. This office-based procedure has two advantages: it can be performed 
under local anesthesia and it produces a tissue specimen. The concern over the risk of 
premature delivery following this treatment motivates recent efforts to reduce 
overscreening and overtreatment, especially among young women( Kyrgiou et al.,2006). 
However, the societal trade-offs that come from trying to prevent every case of cervical 
cancer, vs the desire to prevent overtreatment of many women , should and will be debated. 
HPV testing following treatment with LEEP can identify women who remain at high risk of 
recurrence (Kreimer et al., 2006). Successful treatment of the transformation zone often leads 
to HPV negativity in cervicovaginal specimens for the causative HPV type (Kreimer et al., 
2007)., although HPV infects the vagina (and vulva and anogenital skin) and not just the 
cervix. The reason for viral clearance even when the excision heals, thus creating a new 
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transformation zone, is not certain. The pre-reconisation HPV testing might be useful in 
reducing the number of reconisations in those cases where high-risk HPV test is either 
negative or does not confirm the same HPV type, as before (Koiss et al., 2001). Nonetheless, 
negative HPV tests after LEEP predict a high probability of cure (Kreimer et al., 2006).  The 
HPV test can be useful to replace cytology for the follow up due to the high negative 
predictive value.  
8. Conclusions 
In conclusion, much has been achieved during the last 10 years from research on prevention 
of cervical cancer through vaccination and screening.  It is imperative that planning for 
future prevention guidelines does not address vaccination and screening separately.  
Implementation of all components of an organized prevention would increase the efficiency 
of the process. Increased coverage of prevention activities, both vaccination and screening, 
will be of utmost importance (Koiss et al., 2010). It is abundantly clear that HPV DNA 
testing is substantially more sensitive than cytology at detecting high-grade CIN.  However, 
HPV testing is somewhat less specific than cytology due primarily to the detection of 
transient infections that have not produced cytologic alterations. Basic principles suggest 
that in such circumstances the more sensitive test should be applied first (i.e., HPV DNA 
testing) and the more specific test (i.e., cytology) should then be used only for HPV-positive 
women to determine management.  Management of HPV-positive, cytology-negative 
women presents a new challenge.  Management of HPV-positive, cytology-negative women 
presents a new challenge. Results from the HART, Swedish and the Amsterdam 
(POBASCAM) studies suggest they can safely be managed by repeating the testing with 
both cytology and HPV after one year and this is being further explored in several ongoing 
studies (Bulkmans et al., 2007; Cuzick et al., 2003; Naucler et al., 2007). Women double 
negative at that time could be returned to routine screening while positives could be 
referred to colposcopy. This approach of using  HPV DNA testing as the sole primary 
screening modality has several advantages: HPV DNA detection assays provide an 
automated, objective and very sensitive test. Implementation projects of the HPV/Pap triage 
screening strategy to demonstrate what could be acceptably safe intervals for both 
vaccinated and unvaccinated women should be initiated. We will also need to determine the 
best follow-up algorithms for HPV-positive/Pap-negative women. Genotyping tests, which 
specify the exact HPV types present on the cervix, and molecular markers of HPV targeting 
oncogene mRNA or proteins associated with deregulation of the cell cycle may prove to be 
useful for this purpose. If second-generation HPV vaccines targeting most hrHPV types are 
included in vaccination programs, screening activities will need to be reevaluated and 
algorithms modified. These prospects provide hope for a further decrease in cervical cancer 
incidence and mortality in the coming decades. 
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1. Introduction 
The Human papillomavirus infection is the sexually transmitted infection most frequent in 
man and woman (Koutsky, 1997; Worda, 2005). The probability of transmission of HPV 
through sexual intercourse varies from 5 to 100% with an average of 40%. The probability of 
transmission per partner (male-female) is estimated at 60% for HPV 16 and 60% for HPV 
that causes genital warts. Detection of HPV DNA by the molecular biological methods, does 
not necessarily represent the manisfestation of a disease (Burchell et al, 2006). According to 
The World Health Organization (WHO), more than 630 million men and women (1 in every 
10 people) are infected with HPV in the world (Ferlay et al, 2004; CDC, 2007). Clinical 
manifestation is present in less than 10% and the infection is often asymptomatic and can be 
unnoticed by the patient even though a lesion is present. It is believed, that approximately 
1/3 of all women en the world have some form of clinically manifested HPV infection. Also, 
half of all the women of the world sexually active are infected with this virus (Snoeck, 2006). 
It is believed as well that after exposure to HPV, the virus infects the entire lower genital 
tract epithelium (Shepherd & Bryson, 2008). The incubation period is highly variable, 
ranging from a few days to many years (20 to 30 years or more) (Sinal & Woods, 2005) 
(Figure 1). When the infection process starts, there is a proliferation phase ranging from 
from 3 to 6 months, when many lesions many lesions appear. After the response of B and T 
cells to the infection, what follows is the containment phase that also lasts for 3 to 6 
months, when regression will occur to more than 80% of the lesions. The other 20% will 
have an active disease or recurrence after variable disease-free intervals (Franco & Steben, 
2007). The clinical manifestations are variable and are associated with systemic and local 
immune response of each individual, with different environmental factors. Dependent on 
the host immune system, the course of the infection can take one of the three following 
forms. The most frequent is the Latent Infection, where no clinical manifestation of the 
infection occurs, and it is only detected by the HPV DNA detection methods. The second 
form is the Subclinical Infection with minimal clinical manifestation, that is usually 
diagnosed by colposcopy, cytology and histology. The third form, that is the least common   
is the Clinical Infection. In this form there is an active expression of the disease, manifested 
mainly by genital warts, precancerous lesions and invasive cancer (Chow et al, 2010). The 
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different manifestations are also dependent on different types of HPV (currently more 
than 200 types) and also the host immune system (Bernard, 2005). The low-risk HPV will 
mainly produce warts (condyloma) and the high risk HPV will mainly produce an 
intraepithelial lesion (Trofatter, 1997). 
 
 
 
 
 
Fig. 1. A 75-year-old woman sexually inactive for 25 years showing a wart  on the vulva that 
appeared 6 months ago. There is also a  VAIN  3 and an urethral cancer HPV 16 induced. 
2. Clinical lesions 
Clinical lesions (only 2 to 3% of HPV infections) are mainly represented by condyloma 
acuminatum,  Bowenoid papulosis (vulvar intraepithelial neoplasia usual type) and 
Buschke-Loewenstein tumor. The presence of acuminate lesions on the cervix (Figure 2) are 
infrequent (in 6% of the women that have vulvar condyloma) and this represents an 
indication of high-risk HPV infections (20% of these infections have associated an 
intraepithelial lesion) (Scheurer et al, 2005). Genital warts are easily recognized by papillary 
epithelial proliferations, often with vascular loops inside. Lesions may be single or multiple, 
scattered or confluent (Sadjadi et al, 2003) (Figure 3 and 4). 
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Fig. 2. Condyloma acuminata in the cervix 
 
Fig. 3. Multiple condyloma acuminata on the vulva 
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Fig. 4. Detail of a condyloma  acuminatum with a characteristic  central vessel. 
Vaginal warts can be detected by careful examination in more than one third of the cases of 
women who have vulvar warts. Generally, they are usually small and multiple and can be 
hidden by the speculum. The lesions may involve the entire length of the vagina, but most 
frequentely occur in the upper and lower thirds of the vagina (Figure 5). Although vaginal 
warts are usually asymptomatic, vaginal discharging and itching can occur, and less often,  
post-coital bleeding, may be present (Row et al, 1981).  
 
Fig. 5. Multiple vaginal warts  in the upper third of the vagina 
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The verrucous lesions in the vulvar region have increased in numbers in recent years, 
affecting mainly younger women. Vulvar warts generally occur in moist areas of the skin 
and in places subjected mostly to trauma during intercourse.  
About 25% of the women with vulvar warts have these lesions in the anal and perianal 
region as well, and are not necessarily associated with the practice of anal sex (Figure 3). 
These lesions may be sessile or pedunculated, papular, hyperkeratotic or hyperpigmented. 
Vulvar manifestations depend on each individual, ranging from small lesions (Figure 6) to 
gigantic such as in the cases of a Buschke-Loewenstein tumor (Ambriz-Gonzalez et al, 2005) 
(Figure 7). Papular and hypercrhromic vulvar lesions (vulvar intraepithelial neoplasia (VIN) 
usual type) (Figure 8) represent today, a high-grade intraepithelial neoplasia (Forcier   &  
Musacchio, 2010). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Small vulvar wart 
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Fig. 7. Buschke-Loewenstein tumor  in a woman of 18 years who begun  sexual activity  6 
months before with only the same partner 
 
Fig. 8. A typical example of VIN usual type with hyperchromic papules coalescing  
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Approximately 18% of women with vulvar condyloma have anal and perianal warts as well 
(Figure 9). Depending on the extent of the injuries, discomfort or bleeding may occur during 
evacuation. In these cases, the rectal examination should also be performed, since 
approximately 10% of women with anal warts, exhibit rectal lesions (Nadal et al, 1999). 
 
Fig. 9. Multiple condyloma acuminatum in the anal and perianal region 
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When evaluating male partners of women with genital disease associated with HPV, 
approximately 40 to 50% of them also have lesions. The lesions may manifest as penile 
warts, papules or papillae. The lesions appear mainly in areas of trauma, especially related 
to sexual activity (the penile shaft, preputial cavity, coronal sulcus and glans) (Figure 10). 
Urethral involvement  (Figure 11)  is more frequent in men  than women (10 to 28% of the 
men with genital warts and less than 5% of the women with genital diseases associated with 
HPV) (Buechner, 2002). 
 
Fig. 10. Genital warts  at the base of the penile 
 
Fig. 11. Condyloma in the urethra of a young man 
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3. Sub-clinical lesions  
Subclinical lesions represent 60% of the cases of external anogenital HPV and 95% of the 
cases of cervical HPV infection. The main symptoms are micropapillary, micropapular, 
spike, and keratotic lesions. The diagnosis of these lesions is accomplished primarily by 
colposcopy, cytology and histology (Forcier  &  Musacchio, 2010).  
The cytopathic effects of HPV infection, specifically koilocytotic atypia, dyskeratosis and the 
cellular multinucleation are detected in 2 to 3% of routine Pap smears (Figure 12). The 
cytological and histological patterns of HPV-induced lesions are essentially the same 
(Wright, 2006)  (Figure 13).  
 
Fig. 12. Cytopathic effects of HPV infection (koilocytotic atypia)  
 
Fig. 13. Histology of a cervical intraepithelial neoplasia with cytopathic effects of HPV 
infection (koilocytosis)  
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Cervical intraepithelial neoplasia (CIN) is the most common manifestation of HPV in the 
cervix. These lesions are manifested by colposcopy using acetic acid that produces aceto-white 
epithelium, punctation or mosaic. At the colposcopic exam, the cellular changes in the low-
grade squamous intraepithelial lesions (LSIL) are discrete (Figure 14) while in high-grade 
lesions (HSIL) are bigger (Figure 15), including an atypical vascularization. An aceto-white 
lesion outside the cervical transformation zone is highly suggestive of an HPV infection 
(Figure 16). The low-grade lesions often regress spontaneously, ranging from 25 to 60% in one 
year. The regression rate for high-grade lesions  is much smaller (Chase et al, 2008).  
 
Fig. 14. Colposcopy of a low-grade squamous intraepithelial lesion caused by the HPV 
infection (mosaiciform lesion) 
 
Fig. 15. Colposcopy of a high-grade squamous intraepithelial lesion caused by the HPV 
infection (atypical vessels) 
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Fig. 16. Aceto-white lesion outside the cervical transformation zone due to the HPV infection 
The manifestations of the HPV infection in the vagina is poor. Changes are usually aceto-
white, flat or the micropapillary lesion that are  visible after the application of acetic acid at 2 
to 5% (Figure 17) and are better visualized after applying Lugol's iodine (Figure 18). The 
punctation and mosaics caused by HPV should be differentiated mainly from the congenital 
transformation zone and may be related to a vaginal low or high-grade  intraepithelial 
neoplasia (Davis, 1993) . The natural history of  vaginal intraepithelial neoplasia (VAIN) 
based on a 3-year follow-up study of no treatment suggests a regression rate of 78%, 13% 
persistence, and 9% progression to cancer (Aho et al, 1991). 
 
Fig. 17. Colposcopy of a vaginal intraepithelial neoplasia after applying acetic acid 2% 
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Fig. 18. The visualization of a vaginal intraepithelial neoplasia with colposcopy is better 
after applying Lugol's iodine solution 
The colposcopic examination of the vulva after the application of acetic acid at 5% permits  the 
identification of the minimum changes associated with HPV, usually expressed by the aceto-
white epithelium. These changes are often multifocal and commonly involve the vaginal 
fourchette and labia minora. It is necessary, however, to have an expert colposcopist  to 
differentiate the subclinical alterations induced by HPV from inflammatory changes (Gagné, 
2008). The vulvar intraepithelial neoplasia (VIN) associated with HPV (VIN usual type) has a 
very small risk of progression to an invasive lesion. The most severe intraepithelial lesions 
(VIN differentiated type, that are not associated with HPV) tend to be multicentric and 
multifocal. These lesions may be associated with pruritus and local irritation (Heller, 2007).  
 
Fig. 19. A  hyperpigmented  and  aceto-white  lesion  of  a  vulvar  intraepithelial neoplasia 
(VIN usual type) of  the minor labia observed  by colposcopy  after applying acetic acid 5%.  
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Subclinical changes in the perianal and anal area  are much less frequent and pratically all 
are associated with an aceto-white epithelium of varying severity after the use of acetic acid 
at 5% (Chin-Hong  & Palefsky 2002)  (Figure 20). 
 
 
 
 
 
 
 
 
 
Fig. 20. Aceto-white epithelium of an anal intraepithelial neoplasia  observed by colposcopy 
after applying acetic acid 5% 
When evaluating with colposcopy (peniscopy) and acetic acid on male partners of women 
with genital disease associated with HPV, approximately 40 to 50% of them also have 
lesions associated with HPV. About 20 to 30% of partners of women with cervical 
intraepithelial neoplasia also have a penile intraepithelial neoplasia (PIN). Half of these 
lesions are subclinical. Circumcised men have a lower prevalence of subclinical disease due 
to the majority of the lesions being located on the foreskin. Penile intraepithelial neoplasias 
may also exhibit a hyperchromic (Figure 21) or reddish lesion. Rarely these lesions are 
symptomatic, but when this occurs, itching or burning is more frequent (Krebs & Schneider, 
1987). 
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Fig. 21. Penile  intraepithelial  neoplasia  observed  by  peniscopy  after applying acetic acid 
5% exhibiting hyperpigmented papules on the foreskin   
4. Latent infection 
In latent infections there are no clinical manifestation. In the general female population, the 
prevalence of the HPV infection ranges from 2 to 44%. Infection also occurs in 
approximately 8% of women who are not yet sexually  active and approximately 20% in 
women who have had sexual activity with women only. In men, the percentage of HPV 
infection can reach as high as 45%, depending on the population studied. The diagnosis of 
latent infection is performed using molecular biology methods, especially the hybrid 
capture and polymerase chain reaction (PCR) methods, due to the clinical examination, 
colposcopy, cytology and histology are normal (Chow et al, 2010). 
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1. Introduction 
Over the past 35 years, we have observed a remarkable and important increase in the 
prevalence of HPV infection, both in its clinical forms and appearance of its condyloma 
acuminate.  Colposcopic exploration of this area would be required, with special focus at the 
regions of introitus and inter-labial folds. Both genital and anal examinations (Guerra-Tapia 
et al., 2009) are necessary to determine the sub-clinical expression of HPV identified by 
cytological changes, colposcopy, and/or vulvoscopy and vaginoscopy. Clinical forms of 
HPV infections generally caused by LR-HPV strains (6, 11) tend to be benign. Sub-clinical 
forms include benign and pre-malignant lesions, and are generally caused by HR-HPV 
strains (16 and 18) (Fig. 1) (Rodríguez-Cerdeira C et al., 2008a, 2008b, , 2009a; Walboomers et 
al., 1999). In a recent study by the  International Agency for Cancer Research  (IACR) group 
in 13 areas in 11 countries including Spain, a high prevalence of HPV was seen in both 
Europe and Sub-Saharan Africa (International Agency for Research on Cancer [IARC], 1995; 
Muñoz et al., 2003). Furthermore, it was observed that HPV-16 infection was more frequent 
among European women. We observed the same genotype in a study involving 436 women 
aged between 16 and 80 years. Three samples from the cervix and vagina of each patient 
were cytologically examined (Rodríguez-Cerdeira C et al., 2009b).  
Thus, epidemiological studies supported by molecular techniques and liquid cytology have 
confirmed the incidental role of certain strains of HPV in the development of cervical, 
vulvar, vaginal, anal, and penile cancer (Fig. 2), the risk for which is greatly increased in 
human immunodeficiency virus (HIV)+ patients (Rodríguez Cerdeira C et al., 2011). An 
international series with high-sensitivity polymerase chain reaction (PCR) has proven that 
HPV DNA is present in 90.7% of cervical–uterine carcinomas and is present in all the cases 
confirmed by exhaustive histological examination. This also occurs in the majority of 
intraepithelial lesions of the lower genital tract (Walboomers et., 1999).  
Persistent HPV infection is considered the principal causative agent of cervical and other 
anogenital cancers. The finding that HPV DNA is present in practically all cases of cervical 
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cancer has great importance in developing preventive strategies (Fig. 3) (Rodríguez Cerdeira 
C et al., 2007; Mougin et al., 2001; Trottier et al., 2006). Integration of the viral genome with 
the host cell genome does not occur in all cases of cervical cancer and may be explained by 
mutations in repressive areas such as the region Ying-Yang (YYI), which would maintain the 
continued expression of E6 and E7 or by the production of a more stable ‘chimeric’ RNA, 
thereby permitting greater synthesis of these oncoproteins (Fig. 4) (Alba et al., 2009). 
 
Fig. 1. High-grade vulvar intraepithelial neoplasia  in a smoker 
 
Fig. 2. Penile intraepithelial neoplasia developing into invasive carcinoma with extensive 
exophytic ulcerous mass that invades the gland and projects beyond the preputial-balanic 
fold in a human papillomavirus-positive patient 
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Fig. 3. Interaction between the viral protein and the cell cycle 
 
Fig. 4. Integration of human papillomavirus in the host genome  
Over the recent years, the morbimortality and health costs associated with cervical, vaginal, 
vulvar, anal, and peneal cancers and their precursory lesions have provoked intense 
investigation (Kadish et al., 1992; Guerra-Tapia et al., 2009; Rodríguez-Cerdeira C et al., 
2008a) to achieve vaccine-based prevention of HPV infections, which would dramatically 
reduce the risk of these cancers. Experiences with girls or women with current infection 
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with 1 or more of the vaccine HPV types gained protection from the infections or diseases 
caused by the remaining vaccine HPV types, and they were also protected against re-
infection with the same HPV type after clearance of an infection caused by a vaccine HPV 
type. High seroconversion rates and high levels of anti-HPV antibodies were observed in all 
vaccinated individuals of all age ranges from 9 to 45 years. Rechallenge with a quadrivalent 
HPV vaccine produced a potent anamnestic humoral immune response (Rodríguez Cerdeira 
C et al., 2009a, 2009b; Alba et al., 2009). The vaccine is generally well tolerated, and is 
projected to be cost effective in most pharmacoeconomic models. However, there are some 
questions that we are faced with: Does the intensity of such a humoral immune response 
correlate with long-term protection? Although a direct correlation between antibody levels 
and protection may seem intuitively obvious, it is still unclear whether differing antibody 
titres indicate better disease protection or longer duration of immune protection. Given that 
virtually all vaccinated women are seroconverted, we may deduce that until now, we do not 
have any immunological correlates for protection. The question still remains unanswered: 
Why, when the body's natural antibodies respond so poorly, do the HPV vaccines that 
generate serum neutralizing antibodies work? The answer is that the quality and quantity of 
the immune response generated by the vaccine is different from those by natural infections. 
Is it stated that vaccines will induce a generation of long-lived memory immune cells that, 
after re-exposure to the relevant antigen, will generate a potent immune response, thus 
preventing HPV infections? Time is needed to suitably answer this question. In the opinion 
of other investigators, preventive HPV vaccination is an expensive practice, and it may be 
an insufficient tool to tackle cervical cancer worldwide. Therapeutic intervention is seeking 
for safe/effective vaccines inducing the activation of CD8+ cytotoxic T lymphocytes (CTLs) 
that are required to clear the tumour. Linking a tumour-specific antigen (i.e. E7 oncoprotein 
of ‘high-risk’ HPVs) to molecules able to increase its immune ‘visibility’ represents a 
strategy to force the immune system to fight cancer. They focussed on plants as sources of 
innovative immunostimulatory sequences. Thus, a new vaccination route for systemic and 
mucosal immunity, and other issues will be addressed throughout this chapter.  
2. HPV infection and immunity 
Any viral infection requires the presence of a cellular receptor that allows for the 
internalisation of the viral particles. This circumstance supposes the principal barrier to 
entry and explains the species-specific and even organ-specific nature of viral infections. 
Some viruses use the major histocompatibility complexes I and II (MHC I and II) as 
receptors for their internalisation, while others use molecules on the cellular surface (CD4, 
chemokines, growth factors, and β2 microglobulin). The HPV does not have a specific 
cellular receptor but rather has a well-conserved surface molecule with vital cellular 
functions, which makes its use impossible as a target for blocking infection. As opposed to 
other viruses, it does not appear that the surface receptors are implied in tissue or species 
specificity or in HPV tropism (Alba et al., 2009). 
Infection recognition by the host cell and specific tropism of each viral subgroup determine 
the cytopathic effects in specific tissues (Rodríguez-Cerdeira C et al., 2008a ); this makes it 
possible to distinguish between latent infections that do not show their effects for long 
periods and active infections that have practically immediate cytopathic effects. Based on 
these parameters, it is possible to qualify the antigenic or immunogenic level of each virus to 
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comprise the knowledge base for the manufacture of therapeutic or prophylactic vaccines 
(Alba et al., 2009; Rodríguez-Cerdeira et al., 2009c). 
2.1 Cellular and humoral immunity to human papillomavirus  
Cellular immunity is principally represented by T cells, which act at the local tissue level via 
close cell-cell contact. The humoral response is measured by B cells according to the 
instructions from T helper cells, through antibody production. The T cells recognise proteins 
on the surface of the HPV that are associated with the molecules from the cellular surface 
(human leukocyte antigen [HLA]), while the antibodies recognise both surface and soluble 
antigens. In the latter case, this is done with greater specificity. The T-cell receptors 
recognise specific sequences of small peptides presented by the MHC, while the antibodies 
recognise steric three-dimensional structures with determined structures. If correct 
presentation of the antigen is essential for inducing an immunological response, the kinetics 
of antigen-antibody joining and the number and distribution of these joins would be the 
factors determining the immunological response level. 
In general, after the first infection of the cervical epithelial cells by HPV, a non-specific 
response is provoked, accompanied by an inflammatory process, neutrophil 
chemoattraction, macrophage activation, natural killer (NK) cell intervention, production of 
natural antibodies, and activation of the complement system, which forms the first non-
specific yet defensive immunological barrier. Prolongation of the response over time and 
protection against future infections requires specific immunological mechanisms (Alba et al., 
2009; Kadish et al., 1992; Rodríguez-Cerdeira et al., 2009c). T CD4 lymphocyte activation 
requires recognition of the surface molecules exposed by the presenter cell. The viral 
peptide along with class II HLA will be recognised in the context of T cell receptor and CD4, 
but requires a ‘safety’ mechanism for deactivation process control. Thus, it is necessary that 
other molecules such as CD40 and B7 that are present on the presenter cell surface be 
recognised by their receptors (CD40 linking and CD28, respectively) for activation to occur. 
Each activated T CD4 lymphocyte will be converted into a type 1 or 2 lymphocyte T helper 
cell depending on a series of local tissue factors fundamentally comprising antigen entry 
route, processing mechanism, and the presence of different interleukins. The Th1 pathway 
will induce T CD8+ lymphocyte maturity towards cytotoxic effector cells (Fig. 5) (Alba et al., 
2009; Rodríguez-Cerdeira et al., 2009c, 2009d). 
 
Fig. 5. Lymphocyte activation towards cytotoxic effector cells 
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Specific cells existing in the cervical epithelium are capable of acting as antigen presenters. 
Although some keratinocytes develop this ability, Langerhans reticular cells are the true 
antigen presentation specialists in the cervical epithelium. These cells absorb the viral 
particles to digest them into endosomes and start an activation process that includes 
presentation on the antigen surface together with the presenter cell HLA. These activated 
cells will be recognised by the T CD4 lymphocytes in the case that they recognise every 
molecule in the correct environment, after which, they evolve into lymphocyte helpers (Th) 
in the local context of the expression of certain interleukins (IL). Depending on IL type, it 
will advance to differentiation towards a Th1 pathway that will induce the activation and 
proliferation of T CD8+ cytotoxins with specific immunity (CTL+8) or towards a Th2 
pathway that will induce the activation and expansion of B lymphocytes, which differentiate 
towards plasma-antibody producer cells for the viral base proteins of non-specific immunity 
that we could identify as prophylactic (Alba et al., 2009). CTL+8 would have the ability to 
act against the established viral infection, while the plasma B cells produce antibodies act 
against the external viral antigens that are exposed during this and successive HPV 
infections. 
The nature of antibody responses and duration following HPV vaccination plays a key role 
in long-term protection against HPV infection. The importance of vigorous and prolonged 
immune protection is also very important. In addition, it provides maximum benefit against 
cervical cancer and other HPV-related cancers (Alba et al., 2009; Rodríguez-Cerdeira et al., 
2008a, 2009c, 2009d ). Nevertheless, it should also be highlighted that long-term protection is 
not fully predictable at the introduction of any vaccine, because it varies according to many 
variables (e.g. cohort target, coverage, acceptance, catch-up) that are not strictly related to 
immune response. Although some researchers have developed a model to predict long-term 
immunity, it remains an ongoing and challenging issue. HPV is a family of many different 
genotypes. Ideally, a vaccine should cover at least the majority of the genotypes that are 
linked to tumour development, i.e. those that are considered HR-HPV. Nevertheless, the 
large number of different genotypes among the HPV viruses raises the question about the 
number of HPV viruses that must be included in the vaccine preparation process. Thus, the 
possibility of developing second-generation cross-reacting vaccines covering a larger 
portion of the HPV family must be considered in the HPV investigation (Mariani  & Venuti , 
2010) biological evolution is concerned, HPV strains are successful infectious agents. They 
induce persistent infections without causing frequent or serious complications for the host 
and shed virions for transmission to other naive individuals. To achieve this lifestyle and 
maintain a state of equilibrium, HPV must avoid the host's defence system. Many factors 
contribute to evading immune pools, particularly, the following:  
• Virus capsid entry is usually an activating signal for dendritic cells (DCs). 
• Free virus particles are shed from the surface of the squamous epithelia with poor 
access to the vascular and lymphatic channels and to the lymph nodes where immune 
responses are initiated. 
• Most DNA viruses have mechanisms for inhibiting interferon (IFN) synthesis and 
receptor signalling, and papillomaviruses are no exception. 
Despite HPV's ability to evade the host’s immune system and to down-regulate innate 
immunity, a primary HPV infection is cleared naturally in approximately 90% of the cases, 
thus indicating the central role of immunity in the resolution of cervical and anogenital 
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HPV-associated diseases. Innate immunity acts as the first line of non-specific defence 
against any pathogen (DCs, IFN-α, cytokines, neutrophils, and macrophages), and attacks 
by HPV should be detected by the intraepithelial DCs. There is evidence indicating that DCs 
are not activated by the uptake of HPV capsids, suggesting a limited role in the host’s 
response to HPV infection (Mariani  & Venuti , 2010; Fausch et al, 2002, 2003). 
Other critical point is in regards to the long-term clinical significance of immunity evoked 
by natural infection. Certain studies have showed that some women in the placebo group 
developed the disease despite consuming antibodies against the offending HPV types at 
enrolment, thus confirming, as stated in the recent WHO position paper, that host 
antibodies directed against the viral L1 protein do not necessarily protect against 
subsequent infection by the same HPV genotype (Fausch et al, 2002; Olsson et al., 2009; 
World Health Organization [WHO], 2009).  
3. Prophylactic vaccines against human papillomavirus 
Prophylactic vaccines against HPV infection, which are currently in the advanced stage of 
development and evaluation, seem to give more hope than the therapeutic ones, whose 
objective is to prevent new infections. Various approaches have been examined, namely, 
recombinant live vector vaccines, protein and peptide vaccines, vaccines without DNA, and 
innocuous vaccines. The most advanced vaccines against HPV consist of particles that are 
similar to the virus called virus-like particles (VLP). These substances are created by L1 and 
L2 proteins. These particles do not contain DNA and are synthesised through self-assembly 
of the proteins of the upper antigen of the L1 capsid. VLPs, constructed by genetic 
engineering, are structures that are identical to the native virus but do not have an infectious 
capacity. The lower structural protein L2 can assemble with L1 and form an even more 
stable VLP. Their antigenic similarities with the genuine HPV virions explain why VLPs 
introduce a powerful humoral response with neutralising antibodies (Rodríguez-Cerdeira et 
al., 2009c, 2009d). 
3.1 Do those vaccines activate the immune memory system?  
The WHO explicitly stated that the induction of immune memory should be assessed by 
means of evaluating immune responses to additional doses of vaccine administered at 
planned intervals following the completion of the primary series. Subsequently, the 
immune-memory anamnestic response using an antigen challenge has been reported for the 
quadrivalent vaccine. Nevertheless, the questions in vaccinated women include the 
following: Does natural re-exposure to the same HPV type vaccine significantly boost 
antibody levels, which contributes to the long-term persistence of anti-HPV responses, and 
consequently, does it improve protection over the next few decades? Time is needed to 
suitably answer this question (WHO, 2006; Olsson et al., 2007)  
Einstein et al. while comparing the immune response and reactogenicity of 2 vaccines by 
using the same pseudovirion-based neutralisation assay, stated that for any age strata, the 
positivity rates for the anti-HPV 16 and 18 neutralising antibodies in the cervicovaginal 
secretions and circulating HPV 16- and 18-specific memory B cell frequencies were higher 
after vaccination with the bivalent vaccine compared to the quadrivalent vaccine (Einstein et 
al., 2009). Regan et al. (24) considered transient infection in estimating the impact of an HPV 
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16 vaccine in Australia and showed that it has significant implications on patient immunity 
and overall vaccine effectiveness (Regan et al., 2007).  
In our experience, the vaccines induced very high concentrations of neutralising antibodies, 
much higher than those for natural infection, and the seroconversion rates in the trials 
approached 100%. In a recent study, we evaluated whether women with naturally acquired 
HPV antibodies who were HPV DNA-negative at the baseline were less likely to develop 
new infection with the same HPV type than the HPV antibody-negative and DNA-negative 
women were. HPV infection rates were assessed over a year. New infections were detected 
by type-specific PCR according to the baseline HPV 6/11/16/18 serostatus. Our findings 
suggest that natural immunity does not reliably protect against new infections with HR-
HPV types. Only a small proportion of women with naturally acquired antibodies had 
limited protection against incidental and persistent infection with 1 HPV type. Therefore, 
our results support vaccination of all women regardless of the naturally acquired-HPV 
antibody status (Rodríguez-Cerdeira C et al., 2009b). The medium-term objective of these 
vaccines is the prevention of precursory lesions of cervical cancer and cervical intraepithelial 
neoplasia (CIN), especially CIN 3. Furthermore, many studies have been published in 
favour of protection against vulvar and vaginal neoplasias by using the tetravalent vaccine 
(WHO, 2006). The final long-term objective of prophylactic vaccines for HPV is the 
prevention of invasive cervical carcinoma. Associated objectives include the prevention of 
other forms of HPV-related cancer, namely, those that target the vulva, vagina, anus, penis, 
and oropharynx (Olsson et al., 2007). 
Some researchers are much more sceptical about the effectiveness of trying to establish 
vaccines and new models of transmission of HPV infection. They postulate that the future 
aim of globally eradicating HPV-associated pathologies will be achieved by the local 
production of antigens with cross-reactivity among the different HPV types. In addition, 
they state that while sensitive methods are available for the detection of viral genetic 
material (DNA and RNA), we do not have a definitive method for determining the 
infectious state of an individual, from the perspective of transmission of infections. 
Furthermore, currently, as we do not have any reliable correlates of immune protection 
against infection, we are unable to precisely report whether an individual has acquired 
immunity to infection, either through exposure to infection or vaccination; what level of 
protection has been conferred or how long it will last; or whether this protection will 
prevent further transmission (Olsson et al., 2007). 
Clinical trials have shown that quadrivalent vaccine effective against anogenital warts but 
they have not ruled out the possibility that transient infection may lead to transmission. We 
have discussed several areas of uncertainty that are less important. The extent to which 
condoms and circumcision are protective against infections has not been firmly established. 
To date, modellers have assumed that transmission occurs via heterosexual penile-vaginal 
intercourse, because the greatest disease burden is cervical cancer and this mode of 
transmission is both the most studied and the best understood. However, other modes of 
transmission must be considered more closely if their role in other diseases such as anal and 
oropharyngeal cancers is to be studied. Unfortunately, for modellers, most studies of HPV 
natural history have not been designed to improve  models but rather to answer broader 
questions. Studies of transmission in couples have not been carried out on a large enough 
scale or with sufficient sampling to clearly observe and measure transmission. It is our hope 
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that as the demand for accurate quantitative modelling studies to evaluate the impact of 
vaccination programs increases, studies will increasingly be designed with model 
parameterisation in mind (WHO, 2006; Olsson et al., 2007; Regan et al., 2007). Other research 
regarding prevention indicates that oncogenic virus-mediated cell fusion induces 
chromosomal instability and tumours (Gao  & Zheng , 2011). 
An expanding body of work including tissue culture studies, mouse models, and human 
patients suggests that tetraploidy is a precursor of the chromosomal instability state and the 
diploid-tetraploid-aneuploid sequence. It has also been reported that tetraploid cells tend to 
activate a p53 response that leads to G1 arrest and ultimately senescence or apoptosis. Thus, 
deregulation of the cell cycle checkpoint and apoptosis will provide tetraploid cells an 
opportunity to undergo dysplasia and become oncogenic aneuploid cells, which has been 
verified by both in vivo and in vitro experiments. It is remarkable that all human oncogenic 
viruses can express proteins that have the ability to inhibit pRb and p53, two critical 
regulators of both the cell cycle and apoptosis (Storchova & Kuffer , 2008; Castedo et al., 
2006). 
Therefore, multicellular organisms need to be equipped with tools that allow them to detect 
and remove those cells. Multiple lines of evidence suggest that p53-dependent apoptosis is 
the major tool for eliminating accidental tetraploid cells, which cannot undergo normal 
mitosis and will trigger cell cycle checkpoints. Both p53 and pRb may function as tumour 
suppressors in this context. Nonetheless, tetraploid cells produced by oncogenic virus-
mediated cell fusion can sometimes overcome this arrest and continuously proliferate as 
human oncogenic viruses, expressing oncoproteins and having the ability to perturb pRb, 
p53, and/or apoptotic proteins. For example, HR-HPV E6 and E7 can inhibit the functions of 
p53 and pRb, respectively (Castedo et al., 2006; Narisawa-Saito & Kiyono, 2007). Once the 
tetraploid cells resulting from oncogenic virus-mediated cell fusion survive and proliferate, 
they may undergo dysplasia, a hallmark of most malignant tumours (Holland & Cleveland, 
2009).  
Chromosome stability is related to mitosis. The oncoprotein HPV-16 E5 was recently 
determined to have fusogenic activity and to lead to increased incidence of CIN, particularly 
in the presence of p53 and pRb inhibitors HPV 16 E6 and E7, respectively. Moreover, it 
should be noted that HPV-16 E5 must be expressed on both cells for cell fusion to occur. In 
this model, 2 cervical cells both expressing E5 fuse at a high rate and the resulting tetraploid 
cell undergoes CIN with the help of E6 and E7 to ultimately become an aneuploid cervical 
cancer cell. Of course, accumulation of deleterious mutations in the fused cells may also lead 
to the extinction of pre-malignant lesions before they become cancerous (Hu  & Ceresa, 
2009). 
However, this model is challenged by 2 facts. First, either HR-HPV E6 or E7 alone can also 
contribute to tetraploid cell formation by inducing cytokinesis failure (Incassati et al., 2006; 
Heilman et al., 2009; Duensing et al., 2001a). Second, it is widely accepted that increasingly 
deregulated expression of E6 and E7 has been identified as the major transforming factor in 
the pathogenesis of cervical dysplasia and derived cancers.  
However, our model and these 2 facts are not mutually exclusive. First, in vitro and clinic 
studies have revealed that CIN and aneuploidisation seem to precede and favour HPV 
genome integration, prior to which the expression of E6 and E7 is low for tight restriction in 
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host cells. Second, E5 is thought to play a role only in the early stage because E5 expression 
is inhibited by HPV genome integration, but E6 and E7 act throughout carcinogenesis, 
especially after integration. This model is also supported by a study showing that the 
formation of tetraploid cells is primarily attributed to E5 and E5-induced cell fusion rather 
than E6/E7 and cytokinesis failure. Therefore, cytokinesis failure induced by E6 or E7 in an 
over-expression system may only occur in the late stage, whereas E5-mediated cell fusion 
may play a key role in initial cell transformation (Duensing et al., 2001a, 2001b; Melsheimer 
et al., 2004). 
According to the mechanisms discussed above, cell fusion is also a potential and necessary 
mechanism for cancer progression since tumour cells would degenerate and become extinct 
for fusion among cancer cells with distinct potency and may also accelerate cancer 
evolution. This conjecture has been confirmed in a study that showed that in vitro or in vivo 
spontaneous fusion between the bone- and lung-tropic sub lines of human breast cancer cell 
line MDA-MB-231 can produce hybrids with dual metastasis organotropism. Cell fusion 
with metastatic cancer cells can also endow primary cancer cells the ability to resist the 
cytolytic activity of cytotoxic T lymphocytes. Given these considerations, the development 
of fusion inhibitors would be beneficial for cancer prevention and treatment of virus-
associated cancers, since they would inhibit the entry and spread of the virus and affect the 
oncogenic role (Lu & Kang, 2009; Lee et al., 2000).   
4. Therapeutic vaccines 
The investigation of therapeutic vaccines capable of providing specific cell-mediated 
immunity is justified. The possible indications for the therapeutic vaccine include: (1) post-
exposure, (2) diagnosis of low-grade squamous intraepithelial lesion (L-SIL), and (3) 
diagnosis of high-grade squamous intraepithelial lesion (H-SIL) or invasive cancer (15,-17). 
Data from dog and rabbit models hint that vaccines with E1 and E2 genes as targets would 
be suitable for both post-exposed and L-SIL women. Nonetheless, in women affected by 
CIN 2/3 or cancer, continuous expression of E6 and E7 oncogenes is essential for 
progression and maintenance of the malignant phenotype. The experimental E6 and E7 
vaccines have shown immunogenicity and effectiveness in transplantable tumour models in 
rodents. Nevertheless, human trials have demonstrated immunogenicity and safety but very 
limited effectiveness (Rodríguez-Cerdeira et al., 2009d; Fausch et al, 2002). 
Therapeutic vaccines should be able to induce specific immunity mediated by the cells 
capable of preventing lesion development or eliminating existing lesions or even malignant 
tumours by using recombinant peptides derived from E6 and E7 oncogenes (minigenes) 
(Rodríguez-Cerdeira et al., 2009d). Various vaccine approaches based on the E7 protein or 
peptides representing the T cell epitopes have been developed and tested in preventive and 
therapeutic pre-clinical tumour models. Although effective in preventing the growth of 
transplantable E7-expressing tumours in mice, these vaccines have demonstrated only 
moderate efficacy in therapeutic settings. Although the exact mechanism of the vaccine 
failure is yet to be defined and is probably complex, the active immune evasion mechanisms 
employed by the tumour may play a critical role. The success of E7 TAA-based therapeutic 
vaccines against cervical cancer, therefore, may require vaccine formulations containing 
adjuvants that not only generate E7-specific potent immune responses but also overcome 
the tumour-mediated immune evasion mechanisms.  
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Co-stimulation plays a critical role for the generation of adaptive immune responses. We 
recently proposed that vaccine formulations containing co-stimulatory ligands may have 
efficacy in therapeutic cancer settings. We particularly focussed on the 4-1BBL, a co-
stimulatory member of the tumour necrosis factor (TNF) family, because of the critical role 
played by 4-1BB signalling in the generation and maintenance of CD8+ T cell memory, 
which is critical for tumour eradication (Uno et al., 2006). Although 4-1BBL has no function 
as a soluble trimeric molecule, we generated a chimeric recombinant SA-4-1BBL in which 
the extracellular portion of this molecule was cloned at the C-terminus to the core 
streptavidin (SA). This chimeric molecule exists as tetramers and oligomers and has potent 
co-stimulatory activity on the CD4+ and CD8+ T cells in the soluble form. Vaccination with 
SA-4-1BBL and E7 peptide representing the dominant CD8+ T cell epitope resulted in 
effective eradication of the E7-expressing TC-1 tumours. The therapeutic efficacy of the 
vaccine was superior to other vaccine formulations containing an agonistic antibody (Ab) to 
the 4-1BB receptor or toll-like receptor agonists such as lipopolysaccharide, 
monophosphoryl lipid A, and CpG (Rabu et al., 2001; Elpek et al., 2007; Schabowsky et al., 
2009).  
Sharma et al. tested the efficacy of SA-4-1BBL as the immunomodulatory component of an 
E7 protein-based vaccine in the TC-1 tumour model as a prelude to phase I cancer. Use of 
whole E7 protein as the antigenic component of the vaccine alleviates the concerns related to 
the use of a single peptide representing a CD8+ T cell dominant epitope that includes the 
following: (i) saturation of immune response due to antigen exhaustion; (ii) lack of CD4+ T 
cell help, which can limit the vaccine’s anti-tumour efficacy; (iii) lesser magnitude and 
duration of the immune response towards a single epitope compared to the collective 
responses to multiple epitopes; (iv) higher possibility of immune-edited escape variants; and 
(v) requirement for HLA compatibility that will limit the target patient populations ( 
Sharma et al., 2010). .  
We herein showed that single vaccination with SA-4-1BBL and a recombinant whole E7 
protein resulted in the eradication of the established tumours in 70% of the test mice. The 
therapeutic efficacy of the vaccine was associated with robust primary and memory T cell 
responses, Th1 cytokines, enhanced intra-tumoural CD4+ and CD8+ T cell infiltration, and 
NK cell function. Taken together, these data corroborate the utility of SA-4-1BBL as a novel 
multifunctional immunomodulatory component of therapeutic vaccines and justify testing 
of the E7 protein-based vaccine formulation in human clinical trials. Sharma et al.  in there 
studies concluded that the therapeutic efficacy of whole E7 protein and SA-4-1BBL vaccines 
in the TC-1 tumour model was comparable to the efficacy obtained using a synthetic peptide 
representing the dominant CD8+ T cell epitope for E7 protein as the antigenic component of 
the vaccine. The comparable therapeutic efficacies of the peptide and whole E7 protein-
based vaccines may be due to both the vaccine formulation and the tumour model used in 
these studies. Both the vaccine formulations included equal amounts of antigen and 
therefore, more molar amounts of the peptide. The excess peptide amount and its faster 
kinetics of presentation by MHC class I molecules may allow robust generation of a CD8+ T 
cell response that curbs tumour growth ( Sharma et al., 2010, Yan et al., 2009).  
As much as the TC-1 tumour model uses transplantable tumours and has fast growth 
kinetics, antigen escape variants due to immunological pressure may not occur during the 
experiment. However, this may be different in a spontaneous tumour setting wherein 
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immunological pressure may possibly give rise to antigen-loss variants. Therefore, use of 
either whole E7 protein-based vaccine or those with both and E7 proteins may have better 
efficacy in a spontaneous setting due to the availability of not only multiple CD8+ but also 
CD4+ T cell epitopes (44). Consistent with this notion, we demonstrated potent primary and 
memory CD4+ and CD8+ T cell responses in mice vaccinated with E7 protein and SA-4-
1BBL. Although CD4+ T cells seem unnecessary for primary immune responses, it is critical 
for the generation and maintenance of long-term memory and recall responses (Gunn et al., 
2001; Kumaraguru et al., 2005).  
The development of non-toxic adjuvants that not only activate the effector arm of the 
immune system against tumours but also overcome various immune evasion mechanisms 
employed by the vaccines against cancer is important. Importantly, we previously reported 
the pleiotropic effects of SA-4-1BBL on the cells of innate, adaptive, and regulatory 
immunity (Alba et al., 2009), and treatment with SA-4-1BBL at therapeutic doses did not 
result in detectable signs of acute toxicity that were recently reported for agonistic 
antibodies to 4-1BB and were assessed by lymphadenopathy, lymphocyte proliferation, 
systemic cytokine response, and gross pathology (Fausch et al, 2002, 2003). Taken together, 
our findings support the notion that SA-4-1BBL is a potentially effective and safe adjuvant 
that can serve as a component of therapeutic vaccines. Testing its therapeutic efficacy in 
clinical trials will be important; if effective, this molecule may serve as a safe and effective 
platform for the development of therapeutic vaccines against cancer and chronic infections 
(Sharma et al., 2010).  
In order to evaluate the therapeutic potential of the responses of L1-specific CD4+ and CD8+ 
T lymphocytes in cervical cancer patients, L1 VLP-loaded DCs were used to stimulate 
peripheral blood lymphocytes from the cervical cancer patients, and such responses were 
compared to those elicited by the E7 oncoprotein. We showed by reverse transcriptase (RT)-
PCR that all the flash-frozen cervical biopsy samples collected from HPV 16-positive 
cervical cancer patients harboured L1 in addition to E6 and E7 RNA. The E7 RNA copy 
number (mean, 176.2) was significantly higher than those of E6 RNA (mean, 47.3) and L1 
(mean, 58.3) in HPV 16-positive cervical cancers (P < 0.0001 and P < 0.001, respectively). 
However, no significant differences between the levels of expression of E6 and L1 were 
noted. Kinetic studies of E6, E7, and L1 RNA and protein expression levels in primary 
tumours showed sharp reductions in L1 expression versus E6 and E7 expression after 
multiple in vitro passages. Autologous DCs pulsed with HPV 16 VLPs or recombinant full-
length E7 elicited strong type 1 L1- and E7-specific responses in CD4+ and CD8+ T cells 
from cervical cancer patients. Importantly, L1 VLP-specific CD8+ T lymphocytes expressed 
strong cytolytic activity against autologous tumour cells and were as effective as E7-specific 
cytotoxic T lymphocytes in lysing autologous tumour cells naturally infected by HPV 16. 
Taken together, these data demonstrate consistent expression of L1 in primary cervical 
tumours and the possibility of inducing effective L1/tumour-specific CD4+ and CD8+ T-
lymphocyte responses in patients harbouring HPV-infected cervical cancer. These results 
may have important implications for the treatment of patients harbouring established HPV-
infected lesions with L1 VLPs or combined E7/L1 DC-based vaccinations (Shedlock & Shen, 
2003; Bellone et al, 2009).  
One novel cancer therapy involves using the vascular disrupting agent 5,6-
dimethylxanthenone-4-acetic acid (DMXAA). In the current study, we aimed to test the 
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combination of DMXAA treatment and HPV-16 E7 DNA vaccination to enhance the anti-
tumour effects and E7-specific CD8+ T cell immune responses in treated mice. We 
determined that DMXAA treatment generates significant therapeutic effects against TC-1 
tumours but does not enhance antigen-specific immune responses in tumour-bearing mice. 
We then found that the combination of DMXAA treatment and E7 DNA vaccination 
generates potent anti-tumour effects and E7-specific CD8+ T cell immune responses in the 
splenocytes of the tumour-bearing mice. Furthermore, the DMXAA-mediated enhancement 
or suppression of E7-specific CD8+ T cell immune responses generated by CRT/E7 DNA 
vaccination depended on the time of DMXAA administration and was also applicable to 
other antigen-specific vaccines. DMXAA is a synthetic flavonoid that induces the production 
of local cytokines, including TNF-α. DMXAA has been shown to induce anti-tumour effects 
in animal models, especially in combination with established anti-cancer agents. It has also 
demonstrated a good safety profile and looks promising after phase I clinical trials (Peng et 
al., 2001 Shedlock & Shen, 2003; Silk & Finn, 2007). 
Mice were immunised with 2 μg of various DNA vaccines and received boosters with the 
same regimen as indicated in the figure legends. For vaccinia encoding SigE7LAMP1 
vaccination, 1 × 107 plaque-forming units (pfu) viruses were intraperitoneally injected in a 
volume of 100 μL. Splenocytes were harvested 1 week after the last vaccination. DMXAA 
treatment generates significant therapeutic effects against TC-1 tumours but does not 
enhance antigen-specific immune responses in tumour-bearing mice. To determine the anti-
tumour effects of DMXAA treatment, we first challenged groups of C57BL/6 mice (5 per 
group) with TC-1 tumour cells and treated them with a single dose of DMXAA that was 
administered on day 13 after tumour challenge via intraperitoneal injection, and monitored 
the tumour size over time. Tumour-bearing mice treated with DMXAA showed significantly 
lower tumour volumes over time compared to tumour-bearing mice not treated with 
DMXAA. We also characterised the E7-specific CD8+ T cell immune responses in these 
mice. One week after DMXAA treatment, the splenocytes from tumour-bearing mice were 
harvested and characterised for E7-specific CD8+ T cells by using intracellular IFN-γ 
staining followed by flow cytometry analysis.  
Combination of DMXAA treatment with E7 DNA vaccination generates potent anti-tumour 
effects and E7-specific CD8+ T cell immune responses in the splenocytes of tumour-bearing 
mice. In order to determine the therapeutic anti-tumour effects and E7-specific CD8+ T cell 
immune responses in TC-1 tumour-bearing mice treated with DMXAA and CRT/E7 DNA 
vaccination, we first challenged groups of C57BL/6 mice (5 per group) with TC-1 tumour 
cells and then treated them with CRT/E7 DNA vaccine with or without DMXAA. Seven 
days after the last vaccination, we harvested the splenocytes from the vaccinated mice and 
characterised them for the presence of E7-specific CD8+ T cells by using intracellular 
cytokine staining for IFN-γ followed by flow cytometry analysis. The tumour-bearing mice 
that were treated with CRT/E7 DNA vaccine in combination with DMXAA experienced 
better therapeutic anti-tumour effects than the mice treated with any other regimens. 
Furthermore, mice treated with the DNA vaccine in combination with DMXAA also 
generated the highest number of E7-specific CD8+ T cells compared to the mice treated with 
any of the other regimens.  
In summary, the authors tried to show that the combination of DMXAA treatment and 
HPV-16 E7 DNA vaccination can enhance or suppress the anti-tumour effects and E7-
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specific CD8+ T cell immune responses in treated mice depending on the time of DMXAA 
administration. These results may have potential implications for future clinical translation. 
Therefore, further work needs to be done to complete this study (Bellone et al, 2009; Peng et 
al., 2001; Shedlock & Shen, 2003; Silk & Finn, 2007). 
5. Vaccines, prophylactics, and therapeutics  
In the study by Petrone et al. (Petrone et al, 2011) that aimed to obtain a highly 
immunogenic E7 preparation, they did not focus on obtaining identical particles since 
particles of different sizes can be taken up by different types of antigen-presenting cells such 
as the DCs, macrophages, and polymorphonuclear leukocytes, sustaining a more potent 
immune response (Uno et al., 2006; Rabu et al., 2001). However, we standardised the 
different preparations by using semi-quantitative counting of the particles on EM 
micrographs (not shown). The immunogenicity of Escherichia coli-derived E7 fused through 
the N-terminus to either HPV16 E6 or GST was also investigated in mice. An antigen-
specific immune response of Th2 polarity was obtained when the fusion proteins were 
administered to the mice without an adjuvant (data not shown). However, we were unable 
to observe the typical micro- and nanoparticles in these E7-fusion proteins prepared from E. 
Coli. Recently, the cytosolic accumulation of E7 oligomers shown in HPV 16 cervical cancer 
cell lines and in clinical samples by indirect methods supports a new hypothesis regarding 
the presence of E7 isoforms and their role in different cell compartments (Dantur et al., 2009; 
Knapp, et al. 2009). The presence of E7 in different aggregation forms and cell compartments 
could affect E7 processing and presentation by MHC I and II molecules, assessing both the 
strength as well as the quality of the host’s anti-HPV immunity. More studies on 
recombinant E. coli-derived E7 assembled in different forms would contribute to explaining 
the stimulation of the different branches of the immune system in the HPV16 mouse tumour 
model (Knapp et al., 2009). 
Significant differences exist between the HPV 16 mouse tumour model and human HPV 16-
dependent diseases. However, studies on the immunoglobulin G (IgG) subclasses and their 
FcgR receptors between mice and humans are comparable. HPV 16 E7 immunogenicity 
studies in mouse will provide insights into the understanding of the protective immunity 
against human HPV 16 infections as well. 
Commercial preventive HPV vaccines have high production costs, which has prevented 
the implementation of widespread vaccination programs. Recently combined preventive 
and therapeutic HPV vaccines produced in E. coli have been described (Knapp, et al. 2009; 
Schädlich et al., 2009; Bian et al., 2008), and the data presented here suggest a possible use 
of E. coli-derived E7 in the particle form in subunit vaccines. The E. coli-expressed proteins 
represent a well-studied and cost-effective means for vaccine production. These methods 
require reduced time, cost, and labour, and can be easily scaled up to industrial-scale 
production. Generation of new low-cost HPV vaccines could represent the only possibility 
for women living in developing countries to gain access to HPV vaccination programs in 
order to prevent or treat pre-cancerous lesions and cancer (Rubio I et al., 2009). In this 
paper, the author describes, for the first time, the use of recombinant HPV 16 E7 
assembled in vitro into particulate form to induce protective immunity against an HPV 16-
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related tumour in an HPV-16 mouse tumour model. Data show that E7 particles used 
without adjuvant are excellent stimulators of the immune system. In C57BL/6 mice, the 
E7 preparation induces anti-tumour immunity sustained by both humoral and cell-
mediated immune responses. This E7 protein (derived from E. coli) that does not require 
an adjuvant could represent, along with the recently proposed E. coli-derived HPV 
antigens ((Knapp, et al. 2009; Yan et al., 2009), a low-cost constituent for the development 
of a new generation of HPV 16 vaccines that combines prophylactic and therapeutic 
activities.  
Numerous methods have been developed to introduce foreign genes into mammalian cells, 
including chemical-based procedures, electroporation, gene gun, and mammalian viral 
vector-based systems. These methods have the following advantages: ease of use, gene 
capacity, cell specificity, cytotoxicity, efficiency, safety, and reproducibility. High cost of 
these methods can be the only limitation. To overcome this problem, recombinant 
baculoviruses have been widely developed using baculovirus/mammalian expression 
systems. These recombinant baculoviruses will be used extensively for gene therapy and 
vaccines, nevertheless, the authors did not observe substantial spot numbers in any of the 
mice treated with wild-type baculovirus. However, when we performed immunostaining 
for the splenocytes harvested from the mice intramuscularly injected with wild-type 
baculovirus, we observed non-specific IFN-γ production in 2 of the 6 mice. Several recent 
studies indicated that baculoviruses may induce innate immune responses (Strauss et al, 
2007;  Li et al., 2009; Abe et al, 2003, 2005; Huang et al.,2009). Although baculoviruses do not 
replicate in mammalian cells and thus can serve as safe DNA vaccine vectors, additional 
information is required on the pre-existing anti-vector immunity from the use of live 
baculoviruses for vaccine development. 
In another study (Liao et al., 2008), a recombinant pseudotype baculovirus (BV-G-E) was 
generated by inserting the JEV E gene fragment into the pFastBac-VSV/G vector. The 
authors demonstrated that BV-G-E could elicit high protective immunity in mice. The 
amounts of BV-G-E injected into mice were 1 × 108, 1 × 109, and 1 × 1010 pfu. In yet another 
study, without the use of recombinant baculovirus, mice were inoculated intramuscularly 
with a single dose of 5 × 106 pfu of recombinant attenuated vesicular stomatitis virus 
(rVSV) expressing HPV16E7 protein. The authors suggested that rVSV-based vaccination 
should be explored as a therapeutic strategy for cervical carcinoma. Other recherche 
group (Lee et al., 2010) developed a novel DNA vaccine for HPV; a recombinant 
baculovirus-bearing human endogenous retrovirus (HERV) envelope protein, which 
cannot replicate in mammals, was used as a nano-carrier for the HPV-16L1 DNA vaccine 
(AcHERV-HP16L1). For the in vivo test, mice were injected intramuscularly with 107 
particles of the constructs, with 2 boosters given at 2-week intervals. Compared to 
Gardasil® (25 μl/dose), the AcHERV-HP16L1-immunised mice showed similar high levels 
of humoral immunity in IgG/IgA and in HPV pseudovirion neutralisation. Combined 
immunisation (AcHERV-HP16L1 primer and Gardasil® booster) induced slightly higher 
neutralising activity. Compared to the group treated with Gardasil®, the mice immunised 
with AcHERV-HP16L1 showed 450- and 490-fold increases in IFN-γ at 5 and 20 weeks 
after the first priming, respectively. The safety levels were comparable. The combined 
immunisation conferred lower T cell immunity than AcHERV-HP16L1 treatment. The 
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advantages of our novel AcHERVHP16L1 vaccine over Gardasil® include higher cellular 
immunogenicity and considerably lower production costs.  
The recombinant baculovirus used for HPV16L1 gene delivery does not replicate in the 
host. Its advantages include safety, ease of processing, and most importantly, the ability 
to induce both humoral and cellular immunity. Therefore, we suggest that the AcHERV-
HPV DNA vaccine be developed as an efficient prophylactic and therapeutic vaccine. On 
the basis of its advantages, we anticipate that the developed AcHERV- HP16L1 will 
contribute to global HPV prevention (Chen et al., 2000; Velders et al, 2001; Mahdavi & 
Monk, 2005). 
Acceptance of the vaccine among adolescents and parents, protection against sexually 
transmitted infections (STIs), and adequate health support and recommendation are the 
keys to the success of HPV vaccines. Recent studies have shown that although some parents 
find the vaccine acceptable, others believed that their children are not at real risk of 
contracting an STI or expressed concern that vaccination may encourage the practice of risky 
sexual behaviours. In a recent survey, mothers of children aged between 8 and 14 years 
expressed a willingness to vaccinate their daughters (67%) or children (66%). Those who 
refused the vaccine cited the risk of unknown side effects, lack of sexual activity at the time, 
and the lack of a direct benefit in male children. In another parent survey, vaccination rates 
of 10–15-year-old children increased from 55% to 75% after the parents read a newsletter. 
Therefore, it is essential that accurate information about the disease and the vaccine be 
distributed by health professionals to ensure broad participation in the vaccination 
programs (Roberts et al., 2010; Tsakiroglou et al., 2011; Tan et al., 2010). 
6. Future directions 
In the development of therapeutic HPV vaccines, we have focused on identifying and 
targeting the most relevant antigens associated with cervical cancer, the E6 and E7 HPV 
oncoproteins, which represent tumor-specific antigens and potentially ideal targets for 
therapeutic HPV vaccines. It is important to consider using strategies such as prime-boost 
regimens and/or combinations strategies using molecules that are capable of blocking the 
negative regulators on T cells to further enhance the T cell immune responses. Furthermore, 
increasing understanding of the molecular mechanisms that hinder immune attack in the 
tumor microenvironment will lead to the identification of novel molecular targets that can 
be blocked in order to enhance the therapeutic effect of HPV vaccines. It is conceivable that 
effective therapy against HPV-associated malignancies will probably require a combination 
of therapeutic HPV vaccines with the employment of innovative agents that are capable of 
eliminating the suppressive factors present in the tumor microenvironment. With continued 
endeavor in the development of HPV therapeutic vaccines, it can foresee that HPV 
therapeutic vaccines will become an important approach that can be combined with existing 
forms of therapy such as chemotherapy and radiation therapy to generate better control of 
HPV-associated malignancies (Hung et al., 2008) 
Neutralizing IL10 at the time of PV VLPs immunization increases cytotoxic T cell responses. 
PV VLPs incorporating PV early protein E2, 6 and 7, together with immune stimulator that 
promote strong type 1 responses, and at the same time blocking the effect of IL10 may have 
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therapeutic effect against HPV infection related diseases and are worth further basic and 
clinical investigation (Chen et al., 2011). 
After a long period of scepticism and disbelief, tumour viruses are today recognized as a 
significant cancer risk factor for humans. Much has been learned about the viral 
transforming mechanisms and prophylactic vaccines have been developed against tumour 
viruses’ HPV. Yet, many important issues of tumour virology remain unresolved and 
exciting new ones are emerging from recent discoveries. They define future research 
directions for the field and include (Hoppe-Seyler et al., 2011): 
• Novel strategies for tumour virus hunting. 
• Tumour viruses as experimental tools to study human carcinogenesis.  
• The interplay between viruses and the world of small non coding RNAs.  
• Epigenetic interactions between tumour viruses and the host cell. 
• The role of virus/virus interactions for viral carcinogenesis  
• Novel strategies for prevention and therapy of virus-associated cancers.  
Further study into the tumour microenvironment and molecular mechanisms impeding 
immune attack against HPV will lead to novel targets for therapeutic intervention in the 
future. Discovery of such targets, development of new adjuvants, and improved 
understanding of tumour biology will allow HPV vaccines to be used in combinational 
therapies in a synergistic manner in the future.  
7. Conclusion  
Doubts do remain unresolved, and therefore, the existence of cross-protection evidence in 
the bivalent vaccine against other subtypes of 16/18 capsular structure very similar protein 
suggested that the cause of this cross-immunity would be an extra-immune response 
induced by adjuvant use in the vaccine is unknown. Additional benefit that would represent 
this phenomenon in clinical practice, but how they behave subtypes prevalent highly 
uncertain risk to cause protection from the vaccine subtypes prevalent now? Will it be 
replaced? Because it has been reported that HPV 16/18-positive women are at 5–7-times 
greater risk of acquiring a subsequent infection with HPV 5/7 than the uninfected women, 
can infection be prevented using subtype vaccination?  
We continue with the questions such as whether to vaccinate at-risk populations and what 
type of vaccine to use. We know that the vast majority of HPV infections are diagnosed in 
people at medium risk without appreciable risky behaviours. Protection of these people 
would be very effective because it would disrupt the chain of transmission. One option 
under discussion would be to vaccinate the gay population, which currently has relatively 
high rates of anal cancer linked to HPV and could greatly benefit from the preventive effects 
of the vaccine. Nonetheless, assuming that the vaccine does, in fact, prevent HPV-related 
anogenital and head and neck cancers in males and prevents male-to-female and male-to-
male viral transmission, compelling arguments exist for a gender-neutral approach to 
vaccination. These arguments include the following: (1) female-only vaccination will not 
protect men who have sex with men from contracting HPV and HPV-related diseases and 
(2) the fastest way to achieve the greatest protection for females from cervical cancer and its 
precursors is to vaccinate both females and males. 
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Finally, the economic evaluation of any HPV vaccination strategy requires the measurement 
of clinical benefits and the economic benefits associated with an effective intervention. As 
newer vaccines targeting morbidity rather than mortality are being launched in the market, 
quantification of disease burden and modelling of the cost-effectiveness of intervention 
options are becoming more important when determining the best way to allocate scarce 
health care funds. 
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1. Introduction 
Human Papillomavirus (HPV) are epitheliotropic for stratified malpighian epithelia such as 
those of the cervix, vulva or anal canal. Mucosal papillomaviruses are responsible for 
several clinical lesions and can be classified as non oncogenic and oncogenic viruses. The 
first ones are responsible for benign lesions such as external genital warts (EGW) or 
condyloma due to HPV 6 and 11. The second ones include oncogenic viruses such as HPV 
16 and 18, the most common ones, and HPV 45, 31, 33, 52 etc which are involved in invasive 
cancers preceded by cervical, vulvar, penile or anal intraepithelial neoplasia. Oncogenic 
HPV are detectable in 99.7% of cervical cancers (Bosch et al, 1995). Cellular immunity plays 
a key role in controlling and killing infected or transformed keratinocytes. Nevertheless, 
around 10% of women having infected cervical mucosa are not able to control oncogenic 
HPV and develop cervical intraepithelial neoplasia (CIN). High grade CIN (CIN3) require 
surgical treatment before their progression to invasive cancers in 30% of cases (McCredie et 
al, 2008; Ostor et al, 1993). A great priority is then to develop a preventive vaccine to protect 
against HPV infection. In women with CIN, therapeutic vaccine could be used to eliminate 
previously infected or transformed keratinocytes and avoid surgical treatment.  
2. Virology 
Following a breach in the malpighian pluristratified epithelium, HPVs infect basal stem cells 
of keratinocytes. The virus initially remains in episomal form with synthesis of E2 protein. 
This protein is a major regulator of viral vegetative cycle and is required for transcriptional 
regulation as well as viral DNA replication together with the E1 helicase (Desaintes et al, 
1996). In contrast, E2 is generally undetectable in cancers due to a preferential integration of 
the viral genome in the cell genome and disruption of the E2 open reading frame (Berumen 
et al, 1994; Collins et al, 2009). Therefore E2 is a marker of viral infection and is specific for 
the early stages of the viral gene expression in infected cells. This was formally 
demonstrated in a recent work that showed a strong staining of the E2 protein in the 
intermediate differentiated layers of HPV16-infected tissues and low grade CIN (Xue et al, 
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2010). The high expression of HPV16 E2 in low grade lesions therefore represents a marker 
for HPV infection even before any clinical manifestation.  
After integration of the genome of oncogenic HPVs into the host genome, viral oncogenic E6 
and E7 proteins are synthesized in large quantities in the inner third of the epithelium. 
During maturation of keratinocytes from the basal layer to the epithelial surface, viral 
capside proteins L1 and L2 are synthesized and expressed at the surface of mature 
keratinocytes in order to form a new viral particle which is able to infect adjacent healthy 
epithelium and to contaminate sexual partners.  
3. Epidemiology of oncogenic HPV and related diseases 
HPV infections occur preferentially in young women under 25 years of age (Boulanger et al, 
2004). Several stages of lesions can be observed following oncogenic HPV infection. The first 
stage is a simple infection of keratinocytes that become koilocytes and develop into 
condyloma. The following stages are related to the transformation of infected keratinocytes 
into malignant cells. The depth at which malignant cells are found defines the disease stage: 
low (as CIN1) or high grade squamous intraepithelial lesions as CIN2/3. The latter is 
diagnosed on the basis of Pap smears, followed by colposcopy and biopsies and can evolve 
towards invasive cancer. HPV16 is found in more than 50% of cervical cancer cases and 
HPV18 in 17%. The incidence of cervical cancer remains very high with 500 000 new cases 
per year in the world, essentially in developing countries where the level of screening by 
Pap smear is very low. It annually leads to 230 000 deaths.  
The premalignant lesions of HPV-related grade 3 usual vulvar intraepithelial neoplasia 
(usual VIN or VIN3) involve the mucosal and/or cutaneous epithelium of the vulva, 
perineal and perianal region. Usual VIN occurs in adult women and commonly resembles 
persistent anogenital warts that are often multifocal pigmented papular lesions 
disseminated on the vulva and/or the perianal skin. Usual VIN is characterized by the 
presence of poorly differentiated or undifferentiated basal cells and highly atypical 
squamous epithelial cells (McClugagge et al, 2009). The oncogenic HPV most frequently 
found in usual VIN is HPV16 that plays a direct role in up to 91% of the cases (Srodon et al, 
2006).  
The overall incidence rates of anal cancer has recently increased, particularly among men 
who have sex with men (MSM) and HIV-infected patients (Piketty et al, 2008) Combination 
antiretroviral therapy does not prevent nor revert anal cancer in the latter patients (Piketty 
et al, 2010). Despite several HPV coinfections in particular in HIV-infected patients, HPV16 
is the most common one in anal cancer (Abramowitz et al, 2011). 
4. Humoral immune response after HPV infection 
Serum antibodies against HPV are directed against viral capside antigens and in 
particular against L1 protein. Their synthesis is late (6 to 12 months after infection) and 
antibody concentration remains limited because of the absence of HPV viremia (Carter et 
al, 2000). However, these antibodies persist in many women for at least 10 years (af 
Geijersstam et al, 1998). Only 70% of women having persistent HPV16 DNA in the genital 
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mucosa have detectable antibodies (Ho et al, 2004; Kirnbauer et al, 1994). These antibodies 
do not play any neutralizing role against HPV after virus entry in basal stem cells of 
keratinocytes (de Gruijl et al, 1999) because L1 protein is not expressed at the surface of 
these cells.  
5. Antibodies detected after HPV infection do not protect against a new 
infection  
Antibodies synthesized after HPV infection do not protect against a new infection with the 
same HPV genotype, as observed in a cohort study of women with and without such 
antibodies (Viscidi et al, 2004, 2005). There was no difference over time between the two 
groups with respect to HPV16 DNA detection in the genital mucosa. This is not surprising 
since the level of the anti-HPV antibodies found in mucosal secretions is lower than in the 
serum where the level of antibodies is already very low (Lowe et al, 1997; Nardelli-Haefliger  
et al, 2003). Local secretory IgA could not stop the spread of HPV infection (Bard et al, 2004). 
6. Cellular immune response after HPV infection 
Cellular immune responses play a critical role in HPV infections by controlling or 
eliminating the virus. The incidence of HPV-induced diseases is increased in T-cell 
immunodeficient individuals, such as HIV-infected (Sun et al, 1997), transplanted patients 
(Arends et al, 1997), patients treated by immunosuppressive drugs (Ulrich et al, 2008) or in 
primary immunodeficiencies (Lawrence et al, 2005). In patients with high-grade CIN 2/3 or 
invasive cervical carcinoma, blood cytotoxic T lymphocytes (CTL) directed against HPV-16 
E6 or E7 proteins are barely detectable (Nakagawa et al, 1997, 2000). Proliferative responses 
of CD4-lymphocytes against these two proteins seem to correlate with the infection stage. 
Indeed, high frequency specific interleukin-2 (IL2)–producing CD4 lymphocytes have been 
observed in asymptomatic HPV-16–infected women (de Jong et al, 2002) whereas they 
decrease during disease progression toward high-grade CIN or invasive cancer (Tsukui et 
al, 1996).  
In a woman who completely cleared usual vulvar intraepithelial neoplasia (VIN) lesions 
eight months after disease onset (Figure 1), an immunohistochemical study showed a 
marked dermal infiltrate containing a majority of CD4+ T lymphocytes and an epidermal 
infiltrate made up of both CD4+ and CD8+ T cells (Figure 2) (Bourgault Villada et al, 2004). 
Before clinical regression, high frequency anti-E6 and anti-E7 effector blood T-cells by ex vivo 
IFNγ ELISPOT assay was evidenced (Figure 3). This appears to be the first evidence of an 
association between spontaneous regression of usual VIN lesions and HPV-specific T cell 
responses detectable in the blood. Hence, an increase of HPV-specific effector T lymphocyte 
responses by vaccine-based therapeutic strategies might be useful to clear the lesions in 
usual VIN disease.  
On the contrary, in chronic nonregressive CIN3, lymphocyte infiltrates in the epidermis 
mainly contain CD8+ lymphocytes and no CD4+ cells. It is likely that CD8+ lymphocytes 
play a major role in the defense against HPV infections by killing infected keratinocytes. 
However, CD4+ lymphocytes that synthesize IFNγ and IL2 are required for an optimal 
induction of high affinity tumor-specific memory CD8+ effector T-cells. 
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Fig. 1. Clinical lesions of multifocal pigmented usual VIN before spontaneous clinical 
regression 
 
     
CD3 lymphocytes CD4 lymphocytes CD8 lymphocytes 
Fig. 2. Immunohistochemical study of the vulvar biopsy just before spontaneous regression 
 
 
Fig. 3. IFNγ ELISPOT assay performed just before clinical regression 
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7. Presentation of HPV antigens to T and B lymphocytes after HPV infection  
During infection, viral particles enter through epithelium up to basal basal stem cells of 
keratinocytes and sometimes can penetrate into the chorion. In the epithelium, they can be 
captured by Langerhans cells and they are quickly internalized (Bousarghin et al, 2005; 
Fausch et al, 2005; Malejczyk et al, 1997) and degraded into short and large peptides 
(Combadière et al, 2008; Herbst et al, 1996; Offringa et al, 2003; Yan et al, 2004). The classical 
view of the role of Langerhans cells is one of antigen uptake in the epidermis, and migration 
through the dermal lymphatics to the lymphoid organs, where they present antigen to 
lymphocytes that then home back to the tissue to carry out their effector function. Matthews 
et al (2003) have previously reported that Langerhans cells number is significantly reduced 
in HPV16 lesions without Langerhans cells depletion in the surrounding uninfected tissue. 
During HPV infection, the migration of Langerhans cells towards mucosal follicle is 
followed by presentation of short and large viral peptides by HLA class I and HLA class II 
molecules to CD4+ and CD8+ T lymphocytes, respectively. After stimulation, CD4+ and 
CD8+ T lymphocytes can circulate and migrate within the HPV-infected epithelium by 
using their surface molecules such as cutaneous lymphocyte antigen (Grover et al, 2006). 
The presentation of whole viral particles to B lymphocytes requires that HPV binds to 
dermal dendritic cells that are able to carry the whole virus to follicular dendritic cells 
present in mucosal follicle (Palucka et al, 2010). 
8. Does a T-cell marker of viral control exist?  
We recently tested by proliferative assays, intracellular cytokines synthesis and IFNγ 
ELISPOT the cellular immune responses against the HPV16 E2 protein that is early 
synthesized after HPV infection when the virus is episomal in eight women presenting with 
HPV16-related usual VIN and their healthy male partners (Jacobelli et al, 2011, unpublished 
data). We showed that anti-E2 polyfunctional CD4 T-cell responses (proliferative responses 
and synthesis of IFNγ and/or IL2) appear when the clinical lesions heal or when the HPV 
infection remains silent. Blood proliferative T-cell responses against HPV16 E2 peptides 
have been also observed in 50% of healthy women, who presumably previously cleared 
HPV16 infection (de Jong et al, 2004) and in 9 out of 22 regressive CIN3 cases (Dillon et al, 
2007). In another studies, the lack of anti-E2 proliferative responses was reported in 16 of 18 
patients (89%) affected with usual VIN lesions (Davidson et al, 2003) and in 7 of 8 and 9 of 
12 women affected with CIN3 (Dillon et al, 2007; de Jong et al, 2004). These observations 
reinforce the strong role of T-cells in the control of HPV replication. 
9. Why the male partners of women having CIN3 or usual VIN do not have any 
lesion?  
Men are vectors of oncogenic HPV infection (Buckley et al, 1981). However, while HPV 
infection was found in 71 to 90% of the partners of HPV-infected women (Hippelainen et al, 
1994; Nicolau et al, 2005), only 52% harbored the same HPV subtypes (Reiter et al, 2010). 
Moreover, penile intra-epithelial neoplasia is rare and detected in less than 2% of the men in 
contact with oncogenic HPV (Giraldo et al, 2008). We thus analyzed HPV infection and anti-
HPV16 E2 blood T-cell responses in asymptomatic male partners chronically exposed to 
HPV16 during sexual intercourses with their wives affected with usual VIN (Jacobelli et al, 
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2011, , unpublished data). We had hypothesized that male partners exposed to replicative 
HPV16 could develop immunologic responses against the early E2 viral protein and thus 
clear infection. We indeed observed HPV16-E2-specific proliferative responses and 
intracellular synthesis of single IFNγ, dual IFNγ/IL2 and single IL2. These T-cell responses 
indicate a striking link between the absence of HPV-related lesions and the presence of 
spontaneous anti-E2 specific polyfunctional T-cell response in male partners. It is tempting 
to speculate that E2-specific responses prevent HPV16-related lesions. Since E2 protein is 
not encapsidated in the viral particle, the strong E2-specific T cells responses measured in 
partners of women with usual VIN demonstrates that the virus effectively replicates in 
males. Our results suggest that male are an important reservoir of genital HPVs and provide 
a strong argument in favor of prophylactic HPV vaccination of young men with Virus Like 
Particles to decrease HPV16 infection in men, and thus fight against the spread of mucosal 
HPV diseases in the population.  
10. Balance between cellular immunity and infected / tumoral cells: 
Mechanisms of tumor escape 
The impairment of HPV-16–specific CD4 lymphocytes and CTL responses can occur many 
years after infection / transformation of keratinocytes. It could be related to the tumor or to 
T-cell responses. The tumor cells can down-regulate their MHC class I molecules, synthesize 
TGFβ or decrease the number of viral peptides on their surface. Mechanisms of T-cell 
tolerance to HPV includes presence of regulatory T-cells (Treg) at proximity of the tumor 
cells (van der Burg et al, 2007) and sometimes in the blood (Molling et al, 2007; Visser et al, 
2007), engagement of PD1 or CTLA4 in the immune synapse and inhibition of CD3 zeta 
expression on infiltrating tumor T-cells (Patel et al, 2009; Zehbe et al, 2006). 
11. Prophylactic vaccines can prevent infection 
The vaccination against HPV can have two different purposes. The first one is a preventive 
strategy aiming at blocking primary infection by preventing the entry of the virus into their 
target cells i.e. the basal basal stem cells of keratinocytes. In this aim, a vaccination able to 
induce transudated serum antibodies at the epithelial surface is a good strategy and is 
obtained by using viral L1 particles as vaccine. Large quantities of L1 are produced in vitro 
by splicing the L1 gene into plasmids (for expression in yeast) or recombinant baculoviruses 
(for expression in insect cells). The Virus Like Particle is formed by self aggregation of 72 L1 
capsomers into a sphere. This spherical structure is similar to the viral capside, but it is 
empty without DNA or RNA and non infectious. After systemic immunization, it is able to 
induce the synthesis of neutralizing antibodies that can recognize the conformational 
structure of the real viral capside. Inversely, after HPV infection, antibodies are ineffective 
and only therapeutic vaccines can be considered to induce T lymphocytes able to kill HPV 
infected keratinocytes. These therapeutic vaccines must target oncogenic E6 and E7 viral 
proteins early expressed in the basal epithelial cells.  
Merck has developed Gardasil®, a vaccine directed against four HPV types. It contains 
Virus Like Particles (L1) from HPV-6, 11, 16, and 18, with aluminum hydroxyphosphate as 
an adjuvant. Cervarix® is a bivalent vaccine developed by GSK. It targets HPV-16/18 VLP 
(L1) and contains a novel adjuvant named ASO4 co-formulated with aluminum. ASO4 
contains phospholipids from Salmonella minnesota membrane and binds to TLR4 at the 
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surface of dendritic cells. Activated dendritic cells synthesize type I IFN, IL6, IL12, TNFα 
that allows recruitment and stimulation of Th follicular cells that increase antibodies 
production by B lymphocytes.  Both vaccines must be administrated by intramuscular route. 
Three injections should be performed, at M0, M2 and M6 for Gardasil® and M0, M1 and M6 
for Cervarix®. Gardasil® and Cervarix® have been commercialized worldwide and each 
country should define their own recommendations. 
Phase I trials of Gardasil® were performed with only HPV16 L1 VLP in 300 16 to 23 years old 
women, who had less than 5 sexual partners and had never been exposed to HPV16 (Harro et 
al, 2001). The immunogenicity of the vaccine was excellent with the induction of very high 
levels of blood anti-L1 antibodies, 50 to 100 times those observed after natural HPV infection. 
The tolerance of the vaccine was good with only a slight pain, swelling and erythema at the 
injection sites. Phase II trials included about 2 000 subjects, they showed preliminary proof of 
efficacy using also HPV16 VLP versus a placebo (Koutsky et al, 2002). Subsequent phase III 
trial were carried out on more than 25 000 subjects, using the quadrivalent vaccine containing 
VLP from HPV 6, 11, 16 and 18. 98 to 100% protection was obtained against HPV -6, 11, 16, and 
18 related diseases such as CIN2/3, vulvar and vaginal condyloma, usual VIN and VaIN3 
(Garland et al, 2007; Joura et al, 2007; Munoz et al, 2010). Protection against persistent infection 
(for 6 months) by HPV16 or 18 was obtained in 99% of cases. Gardasil® obtained an FDA 
approval for the vaccination of girls and women aged 9 to 26 years to prevent cervical cancer, 
precancerous genital lesions and genital warts. Recently, 90% protection was obtained against 
extragenital warts in males (Giuliano et al, 2011). Efficacy of Gardasil® obtained against 
HPV31-induced CIN2/3 is around 55%. Finally, 43% protection was obtained against CIN2/3 
induced by 14 oncogenic and non oncogenic genotypes of HPV (HPV 6, 11, 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59) 3.7 years after vaccination.  
As for Cervarix®, phases I and II (Harper et al, 2004, 2006) studies showed 98 to 100% 
protection against CIN 2/3 similar to that of Gardasil®. The phase III trial involved more 
than 20 000 subjects (Paavonen et al, 2007) and was approved by the FDA and European 
Medical Agency. 70% protection was obtained against CIN2/3 related to 14 oncogenic HPV 
genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) 3 years following 
vaccination (Paavonen et al, 2009). The efficacy of Cervarix® against HPV31-induced 
CIN2/3 is around 92%. Protection against persistent infection (for 6 months) by HPV33 and 
45 was obtained in 76 and 77% of cases respectively.  
Nevertheless, many questions remain unanswered. How long will the protection last ? Does 
thresholds of antibodies exist to allow the protection ? What will be the impact of the 
vaccination on the ecology of other HPVs, HPV screening by Pap smears and on adolescent 
sexual behavior and their use of condoms for HIV protection ? Will parents, preteens, 
physicians and the public at large, accept vaccination of young girls ? Will it be interesting 
to vaccinate young men to decrease HPV16 infection in men, viral transmission from men to 
women and more importantly spread of mucosal HPV diseases in the population ? Are 
MSM the future candidates for vaccination against anal cancer ?  
12. Protection by the quadrivalent prophylactic vaccine against cutaneous 
external genital warts  
A paradox exits between the protection by prophylactic vaccines against cutaneous EGW 
(related to HPV6 and 11 replicative viruses) and the absence of detectable antibodies on the 
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keratinized  skin surface. Following a breach in the epithelium, HPVs bind via L1 first to the 
basement membrane and then to the cellular receptor on the basal stem keratinocytes (Kines 
et al, 2009). Anti-L1 antibodies induced by prophylactic vaccines could block both of these 
interactions (Day et al, 2007). Indeed, this process of virus entry is slow, between 12 to 14 
hours (Sapp et al, 2009) and, since the breach is accompanied by a serum exudate, exposure 
to serum antibodies is rapid. Another explanation for protection could be a stronger 
stimulation of anti-HPV CD4+ and CD8+ T-cells after infection. Indeed, in the presence of 
memory anti-L1 CD4+ T-cell, the CD8+ cytotoxic T-lymphocytes could be more strongly 
stimulated, with multiple specificities and higher affinity (Sauzet et al, 1995). The killing of 
infected keratinocytes could be then more effective. 
13. Prevention of infection by other oncogenic HPVs by divalent prophylactic 
vaccine  
Recently, it has been demonstrated that Cervarix® is able to prevent CIN2/3 induced by 
HPV 16 and 18 and also by HPV 31, 33 and 45 (http://www.ema.europa.eu/, cervarix®, 
summary of product characteristics). An efficacy of 70% and 43% was obtained against 
CIN2/3 related to 14 oncogenic HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) with 
Cervarix® and 12 oncogenic HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) with 
Gardasil®, respectively (http://www.ema.europa.eu/, gardasil®, summary of product 
characteristics). A high level of anti-HPV antibodies usually correlates with a broad 
recognition of B-cell epitopes. Such epitopes can be shared by several other closely related 
HPVs. In Cervarix®, the use of ASO4 adjuvant allows to obtain high anti-HPV16 and 18 
antibodies levels, that are able to prevent infection by numerous other oncogenic HPVs 
(McKeage et al, 2011).  
14. Alternative to L1 VLP vaccines 
A particularly attractive strategy is to vaccinate with a linear N-terminal highly conserved 
sequence of the viral capsid L2 protein. In a properly immunogenic context, neutralizing 
antibodies to this B cell epitope-containing region are elicited and they have broadly 
neutralizing capacities against a wide range of HPVs (Conway et al, 2011). Immunization 
with adjuvanted chimeric HPV16L1-HPV16L2 VLP have also induced neutralization or 
cross-neutralization of HPV16, -18, -31, -45, -52, and -58; HPV6 and -11; and HPV5 
(Schellenbacher et al, 2009). These new types of vaccine are very promising. 
15. How to cure infection / tumorigenesis? Therapeutic vaccines 
Preventive vaccines do not address the current need for better treatment for women 
previously infected by HPV 16 or 18. Other types of vaccines must be used to increase or 
induce new specific anti-HPV cellular immunity (CD4+ and CD8+ T lymphocytes) in order 
to kill transformed epithelial cells. Several approaches can be used in this aim. To stimulate 
cytotoxic or antiviral CD8+ T lymphocytes, the vaccines must target the cytoplasm of 
dendritic cells. The degradation of vaccine antigens by proteasomes results in short peptides 
that can bind to HLA class I molecules and migrate at the surface of dendritic cells. To 
stimulate CD4+ T lymphocytes, endocytosis of vaccinal antigens is essential, followed by 
degradation of antigens by lysosome/endosome in large peptides that associate with HLA 
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class II molecules before migrating at the surface of dendritic cells. All these therapeutic 
vaccines must target E6 and E7 viral proteins and contain recombinant viruses (vaccinia 
viruses for example), DNA or peptides.  
Peptidic or lipopeptidic vaccines were tested within phases I-II for treatment of women 
having CIN3 or metastatic cervical cancer. The chosen peptides were E7 11-20 and E7 86-93, 
two peptides able to bind HLA-A2 molecules in association with a CD4+ epitope (PADRE) 
able to bind numerous HLA-DR molecules (Ressing et al, 2000; Steller et al, 1998; van Driel 
et al, 1999). In women with invasive cervical cancer, 25 to 30% of cellular immune responses 
were observed without any clinical improvement. Another trial in 18 women with CIN3 has 
shown a clinical improvement in 50% of them (Muderspach et al, 2000). Recently, an open 
clinical trial was performed by the Melief’s group (Kenter et al, 2009) in twenty women 
presenting with usual VIN using 13 large peptides spanning the whole E6 and E7 proteins. 
Forty five percent of complete (9/20 women) and 25 % (5/20) of partial remission were 
observed 12 months after immunization. These important results would be even more 
interesting if the investigators had included a placebo group (Bourgault Villada, 2010a). A 
new trial with a placebo group is currently under way.  
Vaccinia virus was used in a recombinant vaccine containing E6 and E7 genes from HPV16 
and HPV18 (TA-HPV) to vaccinate usual VIN patients. A clinical complete or partial 
response was observed in 8/18 treated women (Davidson et al, 2003). More recently, 
vaccination against usual VIN was also performed with another recombinant vaccinia virus, 
TA-L2E6E7 from HPV16 (Daayana et al, 2010). Two months before vaccination, 19 women 
were treated by topical imiquimod and then vaccinated by intramuscular route with 3 doses 
of recombinant vaccinia virus. Imiquimod is an immunomodulator that increases the 
synthesis of type I IFN by dendritic cells after its fixation to the TLR7 in human dendritic 
cells. Complete remission was obtained in 58% of vaccinated women.  
Vaccination against CIN 2/3 was also performed by Transgene using a recombinant 
vaccinia virus, MVA, associated with the genes coding for E6 and E7 proteins and IL2 
cytokine in 18 women. The disappearance of the lesions was observed by colposcopy 6 
months later in 10 patients, without any CIN at biopsy in 9 cases. The important conclusion 
of this trial was that the vaccine was clinically effective, thus avoiding conization for 50% of 
the women with HPV16-related CIN2/3. A phase II trial including a placebo group is 
presently undertaken.  
A phase II clinical trial has also been performed to evaluate the potential use of the MVA-E2 
in treating CIN 2/3 (Garcia-Hernandez et al, 2006). Thirty-four women received the 
therapeutic vaccine injected directly into the cervix once every week over a 6-week period. 
Nineteen patients (59%) showed no lesion nine weeks later and histological analysis showed 
total elimination of high-grade lesions in 20 patients. All patients developed Ab against the 
MVA-E2 vaccine and showed a specific cytotoxic response against papilloma-transformed 
cells.  
DNA containing E6 and E7 genes from HPV 16 and 18 (ZYC101a) was administered on 86 
women having CIN2/3 (Garcia et al, 2004). Conization was performed 6 months later. 
Resolution of CIN was observed in 73% of the younger (less than 25 years old) women with 
a significant difference compared to a control group. This therapeutic vaccine is also very 
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promising as CIN 2/3 treatment. New phase II trial is currently under way, testing DNA 
from E6 and E7 genes versus placebo.  
All these results are very important and encouraging for the development of therapeutic 
vaccines for HPV induced cancers. Nevertheless the proof of efficacy in CIN 2/3 should be 
carefully demonstrated because therapeutic vaccine should be more efficient that surgery. It 
is important to note that these therapeutic vaccines should avoid relapse of HPV infection 
after treatment by increasing HPV-specific cellular immunity.   
Other vaccines were tested to fight high grade anal intraepithelial neoplasia (AIN3) in HIV+ 
patients. HSPE7 including Mycobacterium bovis BCG heat-shock protein 65 (Hsp65) and 
HPV16 E7 protein was tested. Clinical complete and partial responses were observed in 5 
vaccinated patients out of 15 (33% of efficacy) (Palefski et al, 2006). A better vaccine with 
adjuvant is presently developed.  
The safety and immunogenicity of the human papillomavirus type 16 (HPV16) or HPV18 
(HPV16/18) E7 protein-pulsed mature dendritic cell vaccination (phase I) were evaluated as 
adjuvant therapy for 10 patients with stage IB cervical cancer treated by radical 
hysterectomy (Santin et al, 2008). All patients developed CD4+ T-cell and Ab responses to 
DC vaccination and 8 of them E7-specific CD8+ T-cells. DC vaccination was well tolerated 
and no significant toxicity was recorded. New trials (phase II) in cervical cancer patients 
harboring a limited tumor burden or who are at significant risk of tumor recurrence are 
warranted to show an efficacy of this immunotherapy.  
Condyloma have been also treated by immunotherapy. Two trials were performed using the 
VLP of HPV6 (Zhang et al, 2000) or the fusion protein L2E7 fron HPV6 (Lacey et al, 1999; 
Thompson et al, 1999; Vandepapeliere et al, 2005) with a clearance of condyloma obtained in 
75 and 20% of cases, respectively. In the absence of control group in these trials, it is too 
early to make conclusions about the efficacy of these vaccines. In a phase I/II trial, thirty 
males presenting with intraurethral flat condyloma were treated with either a recombinant 
vaccinia viral vaccine MVA-E2 (expressing the E2 gene of bovine papillomavirus) (Albarran 
et al, 2007). 28/30 patients treated with MVAE2 vaccine were free of clinical or histological 
lesion or HPV at 4 weeks. 
16. How to determine the epitopic regions for a therapeutic vaccine?  
In a study including 16 women presenting with usual VIN, we have determined the 
strongly immunogenic regions from HPV16 E6 and E7 proteins for CD4+ and/or CD8+ T 
lymphocytes (Bourgault Villada et al, 2010b). Among 18 large peptides of the proteins E6 
and E7, two were recognized in proliferative assays as immunodominant by T cells from 10 
out of 16 women (62%) at the entry in the  study, namely E6/2 (aa 14-34) and E6/4 (aa 45-68) 
peptides. Four other peptides, E6/7 (aa 91-110), E7/2 (aa 7-27), E7/3 (aa 21-40) and E7/7 (aa 
65-87) were recognized by only 12% of the women in proliferative or IFNγ ELISPOT tests. 
The regions of E6 and E7 proteins implicated in T cell recognition during HPV infection 
were not yet well defined because of the usually low frequency of anti-HPV blood T cell 
responses and of the difficulties of their study.  
In protein E6, some peptides included in, including or overlapping our peptides E6/2 (aa 
14-34) and E6/4 (aa 45-68) have already been described as preferentially recognized by 
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CD4+ T cells. Among them, peptide E6 42-57 that is restricted by HLA-DR7 has already 
been identified (Strang et al, 1990). Regions E6 1-31, 22-51 and 24-45 can be also 
immunogenic for CD4+ T cells as shown in CIN or sexually active healthy women (Kadish et 
al, 1997). The region E6 42-71, which includes peptide E6/4 (aa 45-68), has also been 
described as a target of proliferative responses in CIN patients (Kadish et al, 1997). Another 
E6 111-158 region was previously described as inducing proliferative responses in infected 
asymptomatic subjects or in patients with CIN3 (Kadish et al, 1997; Strang et al, 1990) as 
well as E6 127-141 peptide in healthy young women (Gallagher et al, 2007). Similarly, 
peptides E7 43-77, E7 50-62 and E7 58-68 which are restricted by DR3, DR15 and DR17, 
respectively, were defined as epitopic peptides for CD4 + T cells (Strang et al, 1990; van der 
Burg et al, 2001; Wang et al, 2009). E7 region 51-98, including our E7/7 (aa 65-87) peptide, is 
also very immunogenic for proliferating T lymphocytes (de Gruijl et al, 1998; Luxton et al, 
1996; Nakagawa et al, 1996).  
The characterization of E6 and E7 HPV-16 epitopes and the HLA restriction of their 
recognition by CD8+ T lymphocytes are more precise: E6 29-38, E7 11-20, E7 82-90 and E7 
86-93 epitopes are presented by HLA-A2 (Evans et al, 2001; Ressing et al, 1995, 1996), E6 80-
88 and E7 44-52 by HLA-B18 (Bourgault Villada et al, 2000) and E6 49-57 by HLA-A24 
(Morishima et al, 2007). In women who cleared HPV 16 infection, cytotoxic T lymphocytes 
(CTL) responses are directed against epitopes preferentially located in the N-terminal half of 
the E6 protein (region 16-40) (Nakagawa et al, 2005). In this fragment, the dominant epitope 
E6 29-37 is restricted by HLA-B48, E6 31-38 by HLA-B4002 and the subdominant epitope E6 
52-61 by HLA-B35 (Nakagawa et al, 2007). The same group had also shown that the peptide 
E6 33-42 61 is recognized by CD8+ T lymphocytes in association with HLA-A68, peptide E6 
52-61 in association with HLA-B57 and –B35, peptide E6 75-83 in association with HLA-B62, 
peptide E7 7-15 in association with HLA-B48 and peptide E7 79-87 in association with HLA-
B60 (Nakagawa et al, 2004, 2007; Wang et al, 2008). In addition, E7 7-15 is also able to bind 
HLA-A2 and -B8 to be recognized by CTL (Oerke et al, 2005; Ressing et al, 1995). From the 
latter results, two hot spots of CD8+ T-cell epitopes in protein E6 may be located in the 
regions E6 29-38 and 52-61 and another one in protein E7 (E7 7-15) (Nakagawa et al, 2007). 
Nevertheless, a poor immunogenicity of E7 protein was observed in many studies during 
both HPV 16 infection and after peptidic vaccination using long peptides spanning both E6 
and E7 (Kenter et al, 2008; Welters et al, 2008) such as those used in our study. 
The epitopes E6/2 (aa 14-34) and E6/4 (aa 45-68) hence could be strongly recognized by 
CD4+ and / or CD8+ T lymphocytes and could be particularly relevant in the design of a 
peptide vaccination. We may hypothesize that the T cell responses that we observed were 
able to contain the tumor cells into the epithelium. Therefore, E6/2 (aa 14-34) and E6/4 (aa 
45-68) peptides could play a major role in the protection against invasive cancer by 
stimulating T lymphocytes.  
17. Conclusion 
HPV infections are very frequent. Eighty percent of women more than 25 years old have 
been infected. Two third of them have been infected by a oncogenic HPV and 10% of them 
will develop an intraepithelial neoplasia, mainly CIN. Preventive vaccines are very effective 
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means of avoiding CIN and cervical cancer with an efficacy of 70% against CIN 2/3 related 
to 14 oncogenic HPVs. Some questions persist about this preventive vaccine: How long will 
the protection last ? Boosts will be necessary ? Young boys should be also vaccinated ? What 
is the best age to perform the vaccine with the highest immunogenicity ?  
Women previously infected by HPV 16 or 18 and presenting with intraepithelial neoplasia 
are not good candidate for prophylactic vaccines. Therapeutic vaccines should be good 
alternatives to surgery for CIN2/3, VIN3 and AIN3 and they are being continuously 
improved.  
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1. Introduction 
Infection by human papilloma virus (HPV) attracted attention in connection with cervical 
cancer in humans (zur Hausen, 1996). HPV type 16 alone accounts for approximately 50% of 
all cases of cervical cancer. The virus icosahedral capsid is composed of the L1 major and the 
L2 minor proteins. L1 alone has the capacity to self-assemble into virus-like particles (VLPs) 
without participation of L2 or other proteins. Because of similar immunogenicity compared to 
infectious virions, VLPs can be produced and used as a safe prophylactic vaccine against viral 
transmission of cervical cancer. During recent years two highly efficient VLP-based HPV 
vaccines (e.g. Gardasil, Merck MSD and Cervarix, GlaxoSmithKline) become available. For 
commercial production of vaccines and recombinant therapeutics, plants are often considered 
as a cost-effective alternative with several benefits. Firstly, production in plants can be easily 
scaled up in the case of acute demand for production and secondly, produced proteins are 
unlikely to be contaminated by human or animal pathogens, toxins and oncogenic sequences. 
Moreover, plants provide a convenient environment for protein expression and storage 
including the possibility of direct administration as edible vaccine if expressed in the 
appropriate plant tissue. In this article, we report recent promising advances in the production 
of prophylactic and therapeutic vaccines against HPV by expression of the relevant antigens in 
plants, and discuss future prospects for the use of such vaccines. 
2. HPV vaccines 
2.1 Structure of HPV capsid and neutralizing epitopes on its surface 
Papilloma viruses (PVs) are small tissue specific double-stranded DNA tumor viruses, 
classified in the taxonomic family of Papillomaviridae. The Human Papilloma Viruses (HPVs) 
are phylogenetically closely related with similar biological properties among each other and 
with animal papillomaviruses that are host-specific to other vertebrates including amphibians, 
reptiles, birds and a variety of land and sea mammals. Animal PVs have been studied either as 
disease carrier and transmitters in animals or as models of human PV infection (Brandsma et 
al.; 1994; Campo 1997). Due to etiological connection with the high-rate mortality cervical 
cancer, the main attention is concentrated on the genital high-risk HPV types 16, 18, 33 and 58 
as the leading cause of cancer (Munoz et al., 2003). The low-risk types 6 and 11 are associated 
with benign epithelial papillomas or warts that occur in 5–12% of normal women (Heim et al, 
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1995), however, HPV6 and 11 are the most commonly diagnosed to coinfect and comorbid in 
immunosuppressed individuals with malignant HPVs (Jay & Moscicki, 2000). 
Papillomavirus infection induces type-specific immune response, directed mainly against the 
major capsid protein L1, rather than L2 minor protein, which also participates in the formation 
of the shell of native HPV particles. The viral capsid is primarily composed of 360 copies of L1 
protein organized into 72 L1-pentamers (capsomeres) and associated with 12 or more copies of 
the minor L2 protein. When expressed in various recombinant system, L1 readily self-
assembles, even in the absence of L2, into noninfectious virus-like particles (VLPs). VLPs are 
also organized into 72 capsomeres of L1 protein (Fig. 1C) and are immunologically 
indistinguishable from the native virions (Fig. 1B). The 504-residue of the L1 protein chain 
contains 12 β-strands, 6 loops, and 5 α-helices that form “jelly roll” β-sandwich (Fig. 1D).  
 
Fig. 1. Structure of the HPV capsid. (A) Small (T=1) VLPs derived from HPV-L1; (B) Full-
size (T=7) Papillomavirus particles; (C) HPV16 capsomere (L1-pentamer) in the 
conformation found in small VLPs (Chen et al., 2000). Three subunits are shown in green, 
blue and red. The C’-terminal arms are in gray, to indicate that these portions of the subunit 
rearrange when L1-pentamers assemble into virions or into full-sized capsids; (D) The 3D 
structure of human papillomavirus 16 L1 monomer (HPV16L1). Secondary structural 
elements are labeled, with letters B–J for β-strands and h1–h5 for the 5 α-helices. Loops 
between strands are labeled B–C, C–D, etc. The first and the last residues are marked N (20) 
and C (474), respectively. The two cysteines that participate in the interpentamer disulphide 
bonding within the virion or in the virion-sized particles are shown in yellow, together with 
their residue numbers, 175 and 428. (Modis et al., 2002) 
Some residues in the L1 protein, such as Asp202, Cys175, and Cys428 of HPV16 L1, are very 
important for VLP formation  (Slupetzky et al., 2001), however some residues at the C’-
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terminus can be truncated and replaced with heterologous epitopes or short polypeptides up 
to 60 amino acids without disrupting the assembly of VLPs (Paintsil et al., 1996; Müller et al., 
1997; Paz De la Rosa et al., 2009). These chimeric VLPs (cVLPs) can induce strong immune 
responses against not only the inserted epitopes or polypeptides, but also the VLP shell 
(Freyschmidt et al., 2004; Varsani et al., 2003a; Xu et al., 2006). Experiments in vitro showed that 
a short N’-terminal segment of the L1 polypeptide chain acts as a switch between T=7 (72 L1-
pentamer) and T=1 (12 L1-pentamer) VLP assembly (Fig. 1B) (Chen et al., 2000). 
Structural analysis has revealed that BC, EF, FG, HI and DE hyper variable loops of L1 (Fig. 
1D) are exposed on the outer surface of the L1-pentamer and form a broad pocket, which 
participate in receptor interaction.  The rim of the pentamer pocket is extremely variable 
contrary to its floor. With a few exceptions, all HPV-neutralizing monoclonal antibodies 
analyzed so far are type-specific and recognize conformational epitopes within these 
surface-exposed hyper variable loops (Pastrana et al., 2004; Fleury et al., 2006). HPV16 and 
HPV11 VLPs epitopes recognized by neutralizing mAbs are shown on Fig. 2 (Roden et al., 
1997a; Ludmerer et al., 1997).  
 
Fig. 2. Surface of the HPV 11 and 16 L1 pentamers. The surface loops are colored differently 
on the surface: BC (orange), DE (violet), EF (yellow), FG (green), and HI (slate). (A) HPV11; 
(B) HPV16. Neutralizing epitopes are schematically indicated on pentamers. Black squares, 
H11.F1 and H11.G5; orange square, H11.H3; red ellipse, H16.V5 and H16.E70. (Bishop et al., 
2007) 
2.2 HPV vaccines of the first generation. The need for second-generation vaccines 
The first applied strategy for HPV prophylactic vaccination aimed on induction of 
neutralizing antibodies against L1 capsid proteins. Currently two vaccines composed of 
HPV-L1 self assembled into VLPs have been developed and are commercially available, a 
Glaxo-Smith Kline bivalent vaccine Cervarix and a Merck, Sharp and Dohme quadrivalent 
vaccine Gardasil (also marketed as Gardisil or Silgard). Bivalent vaccine Cervarix protects 
primarily against HPV 16 and 18 that are produced separately using a recombinant 
Baculovirus expression system. Purified VLPs of each HPV type are formulated with the 
AS04 adjuvant system composed of aluminium hydroxide and 3-O-desacyl-4.-
monophosphoryl lipid A (MPL). Cervarix is stored as a sterile turbid liquid suspension for 
intramuscular injection at 2-8°C with a proposed shelf life 3 years. Gardasil is combination 
of Saccharomyces cerevisce produced HPV 16, 18, 6 and 11 VLPs and has amorphous 
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aluminum hydroxy-phosphate sulfate (AAHS) as an adjuvant. Administrations of vaccine to 
HPV naive women have demonstrated almost complete protection against infection by the 
targeted HPV types. Number of medical trials confirmed the safety of currently used vaccines, 
their efficiency to induce immune response was equal or even higher than that observed 
during a natural infection and to maintain protection for 5 and 7.3 years in the case of Gardasil 
and Cervarix, respectively. (McCormack & Joura, 2010; Schwarz, 2009). The induction of HPV 
neutralizing antibody reaches maximum titers at month 7 after the first vaccination, i.e. 1 
month after administration of the last, third dose. Then the titer decline until month 24 and 
remain stable thereafter (Dillner et al., 2007). Interestingly, the immune response to the 
Gardasil, the tetravalent vaccine, inversely correlates with the age. The induction of 
neutralizing antibody is higher in males and females aged 10 to 15 than in those of an age 
group 16 to 23 year (Villa et al., 2005). For sexually active women in the general population the 
efficiency of vaccination is expected to be much lower. Moreover, total period of protection 
afforded by vaccination is not yet known (Wright et al., 2006). 
Along with the questions who should be vaccinated and at what age the vaccination is the 
most effective (Villa, 2011), issues related to vaccine formulation, production and 
administration have to be also adequately resolved (Schiller & Nardelli-Haefliger, 2006). 
Firstly, multispecific VLPs based vaccines are expensive to manufacture, since they are 
produced in eukaryotic cell culture and extensively purified. Both commercially available 
vaccines require 3 intramuscular injections over a 6 months course to achieve prophylaxis, 
and the direct vaccine cost excluding administration and medical visits is about USD 375 per 
recipient in the United States (Armstrong, 2010), reflecting also costly cold chain handling, 
distribution and storage of a vaccine. More to it, the protection with current vaccines is 
predominately type specific, and so they are not expected to protect against the almost 30% 
of cervical cancers that are HPV16 and 18 independent. Last, but not least, therapeutic 
activity against external genital lesions has not been reported (Villa, 2011). 
Suitable vaccine formulations ensuring VLPs stability in liquid were established for both 
Gardasil (Shank-Retzlaff et al., 2006) and Cervarix (Le Tallec et al., 2009) vaccines. However 
during production fibrous aggregates of VLPs were occasionally observed. This is why 
marketed solutions of concentrated VLPs are protected against aggregation by high 
concentrations of salt. Many other factors including excipients maintaining pH, storage 
stability, temperature and time effectively influence VLPs. For example at high pH and low 
salt concentration, VLPs disassemble into capsomeres with weaker immune response than 
VLPs (Thönes et al., 2008) and denatured L1 protein does not induce any virus neutralizing 
antibody response (Shinje et al., 1991). Stabilization of protein antigens against aggregation 
and degradation in solution is important for antigen purification as well as vaccine 
formulation. Lyophilized VLPs might be an alternative to aqueous droplets for mucosal 
delivery in a powder formulation of a vaccine (Schiller & Nardelli-Haefliger, 2006; Gerber et 
al., 2001). Papillomavirus virions are resistant to desiccation and retain their native 
conformation after freeze-drying (Roden et. al, 1997b; Šmídková et al., 2010). However, both 
commercial vaccines contain an alum adjuvant, which during freeze-drying extensively 
coagulate into gel-like consistency, the state suspected to inhibit the release of antigen upon 
rehydration (Maa et al., 2006). The loss of efficient immune induction has been reported after 
freezing or freeze-drying of VLPs in aqueous solutions (Shinje et. al, 1991). The use of non-
ionic stabilizers, such as methylcellulose (Corbett et al., 2010) or polysorbate PS80 (Shi et al., 
2005) helps to avoid this effect. Another solution could be the use of another, physically and 
chemically more suitable adjuvant(s), but this strategy would further add to the cost of vaccine 
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and principally could raise safety concerns. This is why convenient dry formulation, meaning 
at least longer shelf life at higher temperatures for marketing purposes is currently missing. 
The examples of the alternative adjuvants to alum are discussed in Section 3. 
Several alternative methods of vaccine needle delivery have been developed. The tattoo 
delivery of DNA has been found as a cost-effective method that may be used in laboratory 
conditions when more rapid and more robust immune responses are required (Pokorná et 
al., 2009). The second method, a novel dry-coated densely packed Macroflux® 
microprojections array skin patch, was established as an alternate delivery system to 
intramuscular injection for delivering an alum adjuvanted vaccine Gardasil (Shi et al., 2005). 
Besides the effort to improve the formulation, storing properties and methods of vaccine 
delivery, the first generation of HPV prophylactic vaccines based on IM delivery of HPV 
antigens of the recombinant VLPs reached its limits with two vaccines produced in 
baculovirus and yeast cell culture on the market. In parallel with development of these 
vaccines there were successful attempts to produce recombinant VLPs also in various plant 
expression systems (see Section 2.4). Plant expression of HPV vaccines pursues several 
objectives as the cost efficiency, production of uncontaminated safe product, scale up and 
potential edible vaccine format. Currently HPV VLPs are readily produced in several plant 
systems with newly developed technologies for industrial large-scale transient production 
that can successfully compete with current production of L1 based VLPs vaccines. 
Nevertheless the cost of clinical trials, of approval and implementation of new technologies 
is so inhibitory high that there will be hardly any HPV vaccine of the first generation 
produced in plants that will reach the market. More realistic expectation is that developed 
plant technologies will compete with established procedures for production of new, 
improved generation of vaccines, when their advantages will surplus currently marketed 
vaccines and expected market success will justify the cost of clinical trials and production. 
2.3 Vaccines of the second generation 
2.3.1 L2 based vaccines 
The limitation of current vaccines is that neutralizing antibodies induced by immune response 
to L1 based VLPs are type-restricted (Wakabayashi et al., 2002). Addition of other HPV types 
VLPs to the existing vaccines would be viable approach only in the case of a small increase in 
the overall cost of the vaccination scheme. In contrast to L1, Pastrana et al. (2005) showed in in 
vitro assays that antigen determinant present on the N’-end of L2 coat protein can induce 
broad range of cross neutralizing antibodies in mouse and rabbit sera. These results raise the 
possibility that a monovalent vaccine could protect against a broad range of genital HPV 
types. Unfortunately, neutralizing antibody titers against the papillomavirus type from which 
the L2 vaccine was derived were generally higher than the titers against heterologous types 
and lower than those induced by L1 VLPs (Pastrana et al., 2005; Roden et al., 2000). This can be 
avoided by construction of concatenated multiple L2 fusion proteins derived from known 
cross-protective epitopes of several divergent HPV types. These fusion proteins, consisting of 
L2 epitopes of 3-22 HPV types, were able to induce high neutralizing antibody titers against all 
heterologous HPVs tested at a level comparable to that induced by L1 VLPs. In addition, L2 
polypeptides have the advantage that they could be produced in E. coli, and therefore 
manufacturing would be easier and cheaper in comparison to production of VLPs. The most 
promising approach of the non-VLPs second generation of HPV vaccines includes L1 
capsomeres and L2 protein (Stanley, 2010). 
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2.3.2 Therapeutical vaccines 
The therapeutic vaccines reduce or eradicate existing disease or infections by targeting cells 
expressing tumor-associated or tumor-specific antigens on their surface (Ma et al., 2010). 
There are many different types of therapeutic vaccine candidates based on viral gene 
peptides and proteins (Xie et al., 2011; Kenter et al., 2008; Melief et al., 2007; Fiander et al., 
2006), DNA (Alvarez-Salas et al.; 2008, Sheets et al., 2003) and various viral and bacterial 
vectors (Brandsma et al, 2009, Davison et al, 2003). They all aim to induce specific cell-
mediated immunity and in most cases the targets are the E6 and E7 proteins. Whereas L1 
and L2 are expressed only in terminally differentiated keratinocytes, E6 and E7 are 
constitutively expressed at all layers of epithelium-infected cells (Fig. 3).  
 
Fig. 3. Cervical stratified squamous epithelial cell architecture and the expression of HPV 
proteins after infection. Daughter cells of epithelial stem cells divide along the basement 
membrane and then mature vertically through the epithelium without further division. 
After introduction of HPV into stem cells in the basal layer of the epithelium, expression of 
viral non-structural proteins E1-E7 occurs. Under the regulation of these proteins, the 
dividing-cell population expands vertically and epithelial cell differentiation is delayed and 
is less complete. Viral proteins are expressed sequentially with differentiation as shown, and 
mature virions are produced only in the most superficial layers of the epithelium. 
Intraepithelial antigen-presenting cells (APCs) are depleted in the HPV-infected epithelium. 
(http://www.ircm.qc.ca/LARECHERCHE/axes/Biologie/Virologie/Pages/Projets.aspx) 
E6 and E7 bind p53 and pRB human tumor suppressor genes (Duensing et al., 2000). These 
oncoproteins are involved in the malignant transformation of HPV-infected cells and are 
thought to be required for continued tumor growth. They are the primary targets of 
therapeutic vaccines, most of which have been designed to treat later stages of the disease. 
The E1 and E2 proteins are necessary for HPV replication within the cell before the virus is 
integrated into the host DNA (Doorbar et al., 1991). Because E1 and E2 are expressed 
already early in the progress of at HPV infection and at higher levels than E6 and E7, they 
may be the best targets for a therapeutic vaccine designed to treat early stages of the disease, 
such as low-grade dysplasia (Carvajal et al., 2007). Many candidate vaccines with 
therapeutic potential are currently tested in ongoing trials; however, there is low expectation 
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that any of the current therapeutic vaccines will have a substantial public health impact in 
the near future (Ma et al., 2010). 
2.4 Vaccine production in plants 
2.4.1 Posttranslational modification of the therapeutic proteins in plants 
Therapeutic recombinant proteins are produced in many hosts from prokaryotes to human 
cells. When the protein of interest is of eukaryotic origin, one of the production objectives 
besides yield, solubility and stability is a posttranslational modifications (PTM) required for 
structural integrity and biological activity of the protein. Microbial expression systems are 
generally used for expression of simple proteins, because, PTM, including signal peptide 
cleavage, propeptide processing, protein folding, disulfide bond formation and 
glycosylation, might not be achieved in prokaryotes. Contrary to prokaryotes, plants are 
capable of PTM as other higher eukaryotes for safe and low cost production biologically 
active proteins (Dieryck et al., 1997; Ma et al., 1995). The correct folding and assembly of 
plant-produced antibody molecules, which requires interactions with several chaperones 
and with processing and glycosylation enzymes, illustrates that most co- and 
posttranslational events are similar in plants and mammals (Table 1). 
Protein glycosylation is assumed as the most important PTM with significant effects on 
protein folding, conformation, distribution, stability and activity. In plant cells, as in other 
eukaryotic cells, N-glycosylation starts during co-translation in ER, when an oligosaccharide 
precursor is added to Asn residues that is constituent of the N-glycosylation-specific 
sequences Asn-X-Ser/Thr. The differences in the maturation of plant and mammalian N-
glycans appear during the late processing in Golgi apparatus, when core alpha(1,6)-linked 
fucose residues and terminal sialic acid are attached in mammals, whereas beta(1,2)-xylose 
and core alpha(1,3)-fucose residues in plants (Fig.4).  
 
Fig. 4. N-glycan structures in human and plant. N-glycosylation patterns processed in plant 
cells differ from those of mammal 
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Posttranslational modification Location of the reaction in animal cell Identification in plants and location 
Glycosylation 
O-glycosylation Secretory pathway, nucleus   and cytosol Yes. Sugar addition on Hyp, Ser, Thr 
N-glycosylation Secretory pathway Yes. Minor differences in modification 
Glycation Yes 
Proteoglycan Secretory pathway Yes 
Attachment of fatty acids 
S-acylation Cytosol Yes 
N-myristoylation Cytosol Yes 
Prenylation Cytosol Yes 
Glypiation Cytosol Yes 
Cholesterol link Cytosol Not identified. 
Attachment of ions 
Phosphorylation Cytosol, secretory pathway Yes. No mannose-6-phosphate in plant N-glycans 
Sulfatation Secretory pathway Not identified in secretory pathway 
Gamma-carboxylation ER Not identified. 
Proteolysis 
Cleavage of signal peptide ER Yes. ER 
Cleavage of propeptide ER/Golgi Yes. ER, Golgi, vacuole 
Other posttranslational  modifications 
Hydroxylation ER Yes. ER, Golgi 
Cross-linking modifications ER Yes. ER, cytosol 
Acetylation Secretory pathway and cytosol Yes. Function not yet understood in plants 
Oligomerization ER Yes. ER 
Selenoprotein Cytosol Not identified in higher plants, described in C. reinhardtii 
Deamidation Intra- and extracellular Yes 
Oxidation Intra- and extracellular Yes 
Table 1. Protein modifications in plant and animal cells. (Gomord & Faye, 2004, modified) 
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Plant specific residues were described to be constituents of the glycol-epitopes of some plant 
allergens, showing IgE binding and causing mediator release by human basofils (van Ree et 
al., 2000). Moreover, the injection of a plant glycoproteins or plant-made antibodies 
containing plant-specific N-glycans was found to elicit production of antibodies specific for 
beta(1,2)-xylose and alpha(1,3)-fucose-containing glyco-epitopes in most laboratory 
mammals and non-allergic human blood donors. Their presence may induce a rapid 
immune clearance of plant-glycosylated therapeutics from the blood steam (Bardor et al., 
2003). One strategy to prevent the addition of immunogenic glycans is to store therapeutic 
proteins carrying KDEL signal within ER (Ko et al., 2003). Second strategy is based on the 
inhibition of Golgi glycosyltransferases of plants. The moss Physcomitrella patens is the only 
known plant with high frequency of homologous recombination, thus allowing relatively 
easy knockouting of target genes. The knockout of alpha(1,3)-fucosyltransferase and 
beta(1,2)-xylosyltransferase genes in the moss Physcomitrella patens prevents the production 
of plant-specific glyco-epitopes without effecting the secretion of the protein (Koprivova et 
al., 2004). Third attractive strategy to “humanize” plant N-glycans is expressing of 
mammalian glycosyltransferases in plants. Like N-glycosylation, O-glycosylation is 
important for protein function. Surprisingly, little attention is paid so far to O-glycosylation 
status of plant produced therapeutic proteins. 
2.4.2 L1 based prophylactic vaccines and the yields of L1 produced in different plant 
systems 
L1 when expressed in plants readily assemble into VLPs indistinguishable in size from 
baculovirus expressed VLPs in insect cells (Fig. 5). Sucrose sedimentation analysis also 
showed that there is a large amount of not, or only partially assembled molecules, 
presumably capsomeres (fractions 18–24), as well as other larger aggregates (fractions 1–8) 
when compared to the insect cell-produced protein (Maclean et al., 2007). L1VLPs can be 
produced either in transgenic plants stably transformed with an expression cassette or 
transiently using one of several available plant-virus derived expression systems. Initially 
published yields of L1 expression was low, in a range of 1% of the total soluble protein, 
which is far lower than industrial demand of more than 5% (Rybicky, 2010). For example, 
Warzecha et al. (2003) obtained approximately 20 ng HPV-11 L1 per g in transgenic potato 
tubers; Varsani et al., 2003b, 2006 obtained 4 ng HPV-16 L1 per g of leaf tissue in 
transgenic tobacco and approximately 40 ng per g of Nicotiana benthamiana leaves 
transiently transformed with a tobacco mosaic virus vector and Kohl et al. (2006) and Liu 
et al. (2005) achieved approximate yield of L1 at the range 0.05% TSP in transgenic 
tobacco. 
Nevertheless, during passed years, necessary steps to improve L1 gene expression were 
recognized and applied. Firstly it was removal of the carboxy-terminal nuclear 
localization signal sequence (NLS) of L1 that has been shown to enhance expression in 
transgenic plants. Moreover, the results indicated that full-length L1 is localized 
essentially entirely within the nucleus (Fig. 6A), whereas cells that express truncated form 
of L1 in a diffuse pattern within entire cell (Fig. 6B.) (Warzecha et al., 2003). Transient 
expression of full-length L1 protein in cytoplasm of tobacco leaf cells after agroinfection 
was described by Šmídková et al. (2010) (Fig. 6C).  
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Fig. 5. Sedimentation analysis of transiently expressed HPV-16 L1 protein isolated from 
Nicotiana benthamiana plants (left panel) and insect cells (right panel) in sucrose gradient. 
The concentration of L1 in fractions was estimated by capture ELISA (closed circles); open 
squares – ELISA analysis of control, no expressing plants; open circles and right axis - 
refractive index. Fraction 1 corresponds to the bottom of the centrifuge tube (Maclean et al., 
2007). 
 
Fig. 6. Expression of HPV L1 proteins in tobacco cells. Transgenic tobacco expressing either 
full-length (A) or truncated (B) L1 coding sequence fused in frame at the carboxy terminus 
of GFP. Fluorescence appears as bright areas (Warzecha et al., 2003) (C) Localization of L1 in 
cryosections of Nicotiana benthamiana leaves agroinfected with plant TRV viral vector 
expressing optimized L1h gene (pTVL1h). The protein was detected by immunofluorescence 
microscopy at 400X magnification. Nuclei were counterstained with DAPI (Šmídková et al., 
2010). 
Biemelt et al. (2003) after failure to express L1 in transgenic potatos, changed amino-acid 
codon usage of L1 gene to that of potato (L1p) and of canonic human cells (L1h). Despite the 
presence of codons rarely used by plant cells and for plant genes atypical high GC content, 
expression of L1h led to high accumulation of L1 protein in transgenic plants, even higher 
than expression of L1p. The effect of increased GC content on expression efficiency of L1 in 
plants has been confirmed by several groups (Maclean et al., 2007; Šmídková et al., 2010), 
nevertheless the published yields of L1 differ significantly one from each other, depending 
on the plant expression system used. For example the change of tobacco cultivar used for 
transgenic expression from Nicotiana tabacum cv. Xanthi to cv. SR1 allowed a 100-fold 
increase in expression of the native L1 from viral isolate (Rybicky, 2010). The transient 
expression of the same L1 using TMV plant viral expression vector resulted in further, one 
order of magnitude, increase of L1 over the expression in transgenic tobacco (Varsani et al., 
2006). A strategy of optimization procedure for L1 transient expression described recently 
Šmídková et al. (2010). The results are summarized on Fig. 7, depicting A) The course of L1 
expression from original virus isolate sequence (41% GC) and L1p sequences optimized for 
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Solanace plants expression (39% GC) and from canonic human cell optimized sequence L1h 
(61% GC); B) In three plants: tomato and Nicotiana benhamiana and Nicotiana tabacum 
tobaccos; C) In two plant viral expression vectors: PVX and TRV and by D) Two 
transformation methods: agroinfection (method in which a virus infects a host as a part of T-
DNA of Ti plasmid carried by Agrobacterium tumefaciens) and Agrobacterium mediated 
transfer of expression cassette into cells after infiltration of leaves. The optimization of L1h 
transient expressed from pTRV vector after Agrobacterium infiltration of tomato host plants 
yielded 45 mg of VLPs per kilo of fresh leaves, the yield that is close to industrial acceptable 
level. 
 
 
Fig. 7. Time course of the L1 transient expression. (A) Expression of original native HPV L1 
gene sequence L1ori and sequences optimized for expression either in plants L1p or in 
mammalian cells L1h from plant TRV-based vector pTV00; (B) Expression of L1h from 
pTV00 vector in leaves of Nicotiana benthamiana, Nicotiana tabacum and Solanum lycopersicum 
L. (tomato); (C) Comparison of the expression of L1h gene from plant tobamo virus (TRV) 
based expression vector pTV00 and from potato virus X (PVX) based vector pGR106; (D) 
The yield of L1protein reached by viral agroinfection or by Agrobacterium mediated transfer 
of expression cassette into leaf cells of Nicotiana bentamiana (Šmídková et al., 2010). 
Nevertheless the highest yield (3 g/ kg fresh leaves; 24% TSP) of plant-produced L1 ever 
was achieved by Fernández-San Millán et al. (2008) when expressing unmodified L1 
sequence of primary HPV16 virus isolate from expression cassette stably integrated in 
tobacco chloroplasts genome. Expression in plant chloroplasts is an emerging system when 
compared to nuclear transformation. Plastid genome engineering offers many advantages 
over nuclear genome, including targeted recombination based integration, high levels of 
transgene expression due to high copy number, absence of epigenetic effects, transgene 
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containment via maternal inheritance and multi-gene expression in a single transformation 
event (Chebolu and Daniell, 2009). Recently the expressions of transgenes in plastids as high 
as 70% and 72% of total leaf protein was reported by Oey et al. (2009) and Ruhlman et al. 
(2010), respectively. 
Results of L1 expression in various plant systems up to date are summarized in Table2. 
  
Antigen Production system and yield Efficacy data 
HPV-16 L1 
Agrobacterium-transformed Nicotiana 
tabacum cv. Xanthi plants 
Assembled in VLPs 
4 μg/kg ww 
Weakly immunogenic in rabbit 
HPV-11 L1 
Transgenic potato tubers 
Assembled in VLPs 
20 μg/kg 
Weakly immunogenic in orally 
vaccinated mice 
HPV-16 L1 
Transgenic potato tubers 
Assembled in VLPs 
12 mg/kg 
Weakly immunogenic in orally 
vaccinated mice 
HPV-16 L1 
Transgenic tobacco plants 
Assembled in VLPs 
20 mg/kg ww 
Highly immunogenic in mice 
injected with purified product 
HPV-16 L1 
Protein expressed in Nicotiana 
benthamiana by TMV-derived vector 
40 μg/kg wet leaves 
ND 
HPV-11 L1 
Transgenic N. tabacum 2 mg/kg ww 
Transgenic Arabidopsis thaliana 12 
mg/kg ww 
N. benthamiana via rTMV 10 mg/kg ww
ND 
HPV-16 L1 
Agroinfiltrated N. benthamiana, human 
codon usage-optimized gene; protein 
targeted to chloroplasts, assembled in 
VLPs 
500 mg/kg ww 
Antibodies elicited in mice by 
injection of crudely purified 
extracts neutralized HPV-16 
pseudovirion transfection of 
HEK293TT cells 
HPV-16 L1-
Rubisco/ 
ATPase peptide 
fusion 
Protein produced in chloroplasts of 
transplantomic tobacco plants from 
native or chloroplast-optimized genes
60 mg/kg ww 
ND 
HPV-16 L1 
Protein produced from unmodified 
genes in chloroplasts of transplantomic 
tobacco plants 3 g/kg ww 
Mice injected intraperitoneally 
with partially purified VLPs with 
Freund’s or aluminium hydroxide 
adjuvants produced neutralizing 
antibodies 
Table 2. Plant-derived HPV antigens for the development of prophylactic vaccines. HPV: 
Human papillomavirus; ND: No data; PVA: Potato virus A; PVX: Potato virus X; rTMV: 
Recombinant tobacco mosaic virus; TMV: Tobacco mosaic virus; VLP: Virus-like particle; 
ww: Wet weight. (Giorgi et al., 2010) 
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2.4.3 The structure and stability of plant derived L1 
The assembly of VLPs in plants after transient (Fig. 8 A, C) or stable (Fig. 8D) L1 expression 
was confirmed by electron microscopy of leaf crude extracts.  
 
Fig. 8. Electron microscope images of uranyl acetate negatively stained HPV VLPs expressed 
in various systems: (A) Extracts prepared from freeze-dried leaves of Nicotiana benthamiana 
transiently expressing L1. V - HPV16L1 55-nm VLPs particles, C - HPV16 L1 capsomeres, T - 
flexible rods of plant TRV virus (Šmídková et al., 2010); (B) CsCl-purified baculovirus 
expressed VLPs in insect cells; (C) Crude extracts from top leaves of Nicotiana benthamiana 
expressing HPV VLPs from plant TMV virus. Two rods of TMV are shown together with 
VLPs (Varsani et al., 2006); (D) CsCl-purified VLPs from transgenic potato plants. VLPs have 
band density 1.32g/ml (Biemelt et al., 2003). 
The structure of VLPs is not stable upon freezing and thawing, but plant expressed VLPs 
retain their structure during freeze-drying in both, the plant extracts and the plant tissue 
Fig. 8 and 9 (Maclean et al, 2007). 
 
Fig. 9. Stability of L1 VLPs transiently expressed from pTV00 vector in Nicotiana benthamiana 
leaves: (A) after freezing and thawing extract from fresh leaves. Approximately 50% of VLPs 
loses 3D structure when extract is stored at -20°C or –70°C, respectively; (B) Upon freeze-
drying of leaves and extraction cycle. More than 90 % of L1 retains conformation in extracts 
from freeze-dried leaves (third column) in comparison to extract prepared from fresh leaves 
(first column). Controls are extracts from leaves prepared the same way, but from plants 
inoculated with an empty pTV00 vector.  
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2.4.4 Immunogenicity of plant derived L1 
The first report on production of HPV VLPs in plants and testing of their immunogenicity 
appeared in literature in 2003. Varsani et al. (2003b) was the first to express full-length 
native HPV-16 L1 gene in transgenic Nicotiana tabacum cv. Xanthi. This plant-produced 
protein assembled into recognizable VLPs and was immunogenic, when injected into rabbits 
with Freund’s incomplete adjuvant. Since then, several groups has observed induction of 
specific antibodies after subcutaneous injection of either purified plant-derived HPV16 L1 
VLPs (Biemelt et al., 2003) or of the crude extract from the tobacco leaves expressing HPV16 
L1 protein (Fig. 11A) (Maclean et al., 2007; Šmídková et al., 2010). Despite the fact that in 
plant extracts majority of expressed L1 protein was present as capsomeres besides VLPs Fig. 
8A, the extracts were highly immunogenic without any additional adjuvant (Maclean et al., 
2007, Šmídková et al., 2010). The antibodies induced by immunization with plant extract 
depicted on Fig. 8A preferentially recognized fully assembled L1 VLPs (Fig. 12A) and 
neutralized in vitro HPV16 virions (Fig. 12B). Plant expressed L1 in crude extract also 
induces CTL (Fig. 11B). 
These findings suggests that principal antigenic determinant is either entire VLP or 3D 
structure specific for fully assembled VLPs and these antigens are present in crude 
extracts from plants transiently expressing L1 in enough quantity to elicit immune 
response equal or higher than purified VLPs from insect cells. Moreover immunization 
with plant L1 crude extracts induce cellular responses characteristic for active vaccine 
(Šmídková et al., 2010). 
Mucosal delivery has several advantages over needle administration. Immune response is 
best achieved by direct application of a vaccine to mucosal surfaces and in addition mucosal 
application of a vaccine can also induce humoral, cell-mediated and systemic immune 
responses (Rigano & Walmsley, 2005). HPV VLPs are immunogenic when administered 
orally and stable in the environment of the gastrointestinal tract. Rose et al (1999) and 
Gerber et al. (2001) reported that as little as 1-10 micrograms are sufficient to induce high 
titers of L1 specific antibodies after oral application when administered with LT or CpG 
DNA adjuvants. Besides VLPs also capsomeres (L1-pentamers) and T=1 particles (12 L1-
pentamers) depicted on Fig. 10 were investigated for oral immunogenicity in mice. Mutated 
L1 gene (L1_2xCysM) with two cysteines replaced by serines was used to generate 
capsomeres and T=1 particles. Compared to capsomeres, VLPs induced higher titers of 
neutralizing and IgA secreted antibodies, while cytotoxic T cell responses was comparable. 
The induction of secreted IgA antibodies was observed after oral but not after subcutaneous 
immunization (Thönes & Müller, 2007). 
The concept of using tissue of plants expressing vaccine antigens as an edible vaccines 
attracted already a lot of attention and is still of special interest. A number of clinical studies 
demonstrated the induction of specific antibodies after oral immunization using crude plant 
material containing, for example, hepatitis B or Norwalk virus antigens (Lal et al., 2007). 
Likewise, oral immunization using crude potato tubers expressing L1 protein can induce 
specific antibody (Warzecha et al., 2003, Biemelt et al., 2003). Moreover, HPV L1-E6/E7 
based chimeric VLPs have been successfully expressed in tomato fruits, which were able to 
elicit humoral and cytotoxic T-cell activity in mice (Paz De la Rosa et al., 2009). 
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Fig. 10. Analysis of different L1 assembly forms by electron microscopy. Capsomeres (L1-
pentamers), T1-particles (12 L1-pentamers) and VLPs (T7 particles of 71 L1-pentamers) 
purified from infected insect cells expressing the wild-type HPV 16 L1 gene (L1wt) or 
mutated L1 (L1_2xCysM) were analyzed by electron microscopy after uranyl acetate 
negative staining (Thönes & Müller, 2007). 
 
 
 
 
 
 
 
Fig. 11. Antibody (A) and cytotoxic T-lymphocytes (B) induction by L1-VPLs. Response 
elicited by control plant extracts (mice 1 - 5), control plant extract from Nicotiana benthamiana 
containing purified VLPs from insect cells (mice 6 - 10) and crude plant extracts from leaves 
expressing L1 (mice 11 - 25) in C57BL/6 mice. Collected sera from individual mice were 
tested by ELISA for induction of specific antibody (y-axis in OD 450 units). CTLs induction 
was measured by ELISPOT analysis of splenocytes recovered from scarified animals. The 
number of CTLs spots was recorded by an ELISPOT reader and expressed as a mean per 106 
splenocytes 
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Fig. 12. (A) The specificity of mAb E2 toward various L1 assembly structures. VLPs, T1-
particles (12 L1-pentamers) and capsomeres produced in insect cells were absorbed on the 
microtiter plates and analyzed by ELISA. Interactions of hybridoma E2 supernatant is 
compared to antibodies obtained after immunization with insect cell-derived VLPs (1.3.5.15, 
E10 and 25C). (B) Neutralization assay. Sera of mice and of E2 hybridoma supernatant were 
tested for neutralization of infection of 293T cells by HPV pseudovirions (Psv). Percent of 
neutralization obtained by incubation with mice sera diluted 1:50 and that of E2 hybridoma 
supernatant diluted 1:5, 1:20, 1:100, 1:500. Neutralization activity of mice sera was compared 
to a high titer rabbit polyclonal anti-L1 antiserum 4543 (100 %) and to the mAb’s 1.3.1 and 
1.3.2 as additional positive controls. 
2.4.5 Plant based therapeutic and second-generation vaccines 
Capsomeres can be used as a potential cost-saving substitute of VLPs, as L1-pentameric 
capsomeres are considered thermo-stable, the advantageous feature for the use in 
developing countries where cold chain administration and delivery of vaccine is difficult to 
maintain (Stanley et al., 2008). A promising step towards a capsomeres-based vaccine was 
described by Yuan et al. (2001) when dogs were completely protected against canine oral 
papillomavirus (COPV) infection by capsomeres vaccination. Capsomeres have been also 
reported to induce neutralizing antibodies and L1-specific cytotoxic T-lymphocytes (CTLs) 
upon oral, intranasal and subcutaneous immunization (Dell et al., 2006; Thönes & Müller, 
2007; Schadlich et al., 2009). To increase immunogenicity, L1_2xCys mutant version of 
HPV16 L1 protein was fused with LTB as an adjuvant and expressed in chloroplasts 
(Waheed et al, 2011a, 2011b). 
Plant expressed HPV antigens to be used as therapeutic vaccine to date are summarized in 
Table 3: 
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Antigen Production system and yield Efficacy data 
HPV-16 E7 
N. benthamiana tobacco leaves 
infected with PVX–E7 
3–4 μg/g fresh leaves 
40% of mice immunized with E7- 
containing crude leaf extract were 
protected from growth of cancer 
induced by E7-expressing C3 cells 
HPV-16 E7 
N. benthamiana tobacco leaves 
infected with PVX–E7; protein 
targeted to secretory pathway 
15–20 μg/g fresh leaves 
80% of mice immunized with E7-
containing crude leaf extract were 
protected from growth of cancer 
induced by E7-expressing C3 cells 
HPV-16 E7 
N. benthamiana tobacco leaves 
infected with PVX–E7; protein 
targeted to secretory pathway 
Mice vaccinated orally with freeze-
dried E7-containing leaf extract mixed 
with feed produced high titer of anti-E7 
antibodies 
HPV-16 E7 N. benthamiana tobacco leaves infected with PVX–E7 
Dendritic cells pulsed with E7-
containing leaf extract were able to 
prime naive lymphocytes to induce E7-
specific CTLs 
LicKM–E7GGG 
N. benthamiana tobacco leaves 
infected with LicKM–E7GGG, using 
a launch vector expression system 
400 μg purified protein per gram of 
fresh leaves 
Purified protein injected into mice 
induced IgG and CTL response and 
protected them against challenge with 
E7-expressing tumor cells in both 
prophylactic and therapeutic 
vaccination regimen 
11-kDa Zera zein-derived 
peptide–E7 mut N. benthamiana via agroinfiltration 
Mice vaccinated with the protein were 
protected against tumor cells 
expressing E7 
PVX CP–HPV-16 E7GGG DNA vaccine 
DNA vaccine was able to protect 
vaccinated mice from the growth of 
tumors induced by E7-expressing TC-1 
cells 
PVX CP–HPV-16 E7 Tobacco chloroplast ND
SAP-KQ–E7GGG a) DNA vaccine b) Expressed in N. benthamiana 
a) DNA vaccine tested in therapeutic 
setting was able to block tumor growth 
in the 40% of challenged mice 
b) Not performed 
HPV-16 L2–PVA CP–E7 
epitope fused protein 
Expressed by PVX in Nicotiana 
tabacum, N. benthamiana using 
Agrobacterium tumefaciens-
mediated inoculation 
ND 
HPV-16 VLPs carrying L1 
fused to a string of 
epitopes from E6 and E7
Tomato seedling cotyledons HPV-16 
VLPs carrying L1 fused to string of 
epitopes from E6 and E7 using A. 
tumefaciens-mediated inoculation
Mice injected with chimeric VLPs were 
able to develop neutralizing antibodies 
and specific CTLs 
Table 3. Plant-derived HPV antigens for the development of therapeutic vaccines. CP: Coat 
protein; CTL: Cytotoxic T lymphocyte; HPV: Human papillomavirus; ND: No data; PVA: 
Potato virus A; PVX: Potato virus X; SAP-KQ: Mutagenized type I ribosome inhibiting 
proteins from Saponaria officinalis; VLP: Virus-like particle. (Giorgi et al., 2010) 
The important proof of the L2 plant-produced nonhuman papillomavirus vaccine efficiency 
was published in connection with the purified rTMV particles displaying cottontail rabbit 
papillomavirus (CRPV) or rabbit oral papillomavirus (ROPV) L2 protein peptides on their 
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surface (Palmer et al., 2006). This pseudovirion system was also used to express entire native 
L1 gene of CRPV. Intramuscular injection with of CRPV L1-containing concentrated plant 
extract derived from transgenic tobacco protected rabbits against CRPV challenge (Kohl et 
al., 2006).   
Since VLPs based vaccines are not effective in the therapy of diseases, an important goal is 
development of anti-HPV vaccines with either therapeutic or both prophylactic and 
therapeutic properties. Few studies were performed with viral oncoproteins expressed in 
plants. HPV-16 E7 was transiently expressed using a viral vector based on potato virus X 
(PVX) in the Nicotiana benthamiana, Nicotiana rustica, Nicotiana tabacum, Chenopodium quinoa 
and the tomato Solanum lycopersicum L. cv. Micro-Tom. The highest expression of HPV-16 E7 
3–4 μg/g of fresh leaves was achieved in Nicotiana benthamiana and the expressed E7 
induced specific humoral and cell-mediated immune responses in mice (Franconi et al., 
2002, 2006). The efficiency of chimeric constructs when E7 is fused to other proteins and 
expressed in plants was also reported. The expression of HPV-16 E7 fused with the PVX CP 
in tobacco chloroplasts has been recently reported. The expression of the fusion protein in 
this system was higher than E7 alone (Morgenfeld et al., 2009). Mutated E7, E7GGG, which 
lacks the retinoblastoma binding site, and thus the native transformation potential, was 
fused to the Clostridium thermocellum b-1,3–1,4-glucanase (LicKM) as a carrier molecule for 
expression in plants. The expression of fusion protein in Nicotiana benthamiana yielded 400 
μg of purified protein per gram of leaf (Musiychuk et al., 2007). Injection of the purified 
LicKM–E7GGG fusion protein into mice induced both E7-specific IgG and cytotoxic T-cell 
responses, and protected mice against challenge with E7-expressing tumor cells (Massa et 
al., 2007). The successful expression of chimeric HPV-16 L1 protein fused to a string of three 
E7 and one E6 epitopes in transgenic tomatoes demonstrates that a combination 
prophylactic ⁄ therapeutic HPV vaccine could be produced in plants (Paz de la Rosa et al., 
2009; Monroy-García et. al, 2011). Unfortunately, while the produced VLPs stimulated both 
antibody and T-cell responses, yields were low in the range 0.05 – 0.1% of total soluble 
protein. Similarly, combined vaccine based on minor capsid protein L2 and an epitope of E7 
oncoprotein was successfully expressed in plants, when an epitope of the L2 protein and an 
epitope of E7 oncoprotein were fused to the N’- and C’-end of PVA CP, respectively. The 
construct was cloned into a PVX-based vector and transiently expressed in plants using 
Agrobacterium-mediated inoculation (Čeřovská et al., 2008). 
3. Vaccine formulation 
3.1 Parenteral administration  
3.1.1 Adjuvants 
The goal of vaccination is to generate a strong immune response to the administered 
antigen. Papillomavirus VLPs themselves are good “inducers” of immune response and 
antigen determinants present on their surface are able to activate dendritic cells (DCs) for 
triggering T-cell activation (Bontkes et al., 2005; Yang et al., 2005). Nevertheless, for efficient 
clinical use additional adjuvants are needed not only to enhance the immune response, but 
also assuring achievement of appropriate type of protective immunity in each situation.  
The aluminum (alum) salts or gel-based adjuvant formulations used e.g. in HPV Gardasil 
vaccine are currently approved in vaccines licensed for human use in the US. Nevertheless a 
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significant number of compounds tested for adjuvant effect are clearly more effective than 
alum, albeit usually accompanied with a higher toxicity as e.g. Freund’s complete adjuvant. 
This is the main reason preventing their use as adjuvants in human vaccine formulations. As 
adjuvants were successfully tested low toxic mutants of the cholera toxin (CT) (Yamamoto et 
al., 1997) and E.coli heat-labile enterotoxin (LT) (Chong et al., 1998). The inactive B-subunits 
of these toxins proved to be a strong mucosal (oral, nasal, vaginal, etc.) adjuvants (e.g. 
Salmonella toxin B subunit is used in commercial Cervarix vaccine) for a wide variety of 
antigens in mice and other animal species so far tested, however their use in humans is 
limited (Chong et al., 1998). This is why there is a growing interest to develop new 
adjuvants eliciting high mucosal, humoral and cellular immune response accompanied by 
negligible or low toxicity. 
Antigen delivery systems Immunopotentiators 
Insoluble aluminum compounds MPL and synthetic derivates 
Calcium phosphate MDP and derivatives 
Liposomes Oligonucleotides (CpG, etc.) 
Virosomes™ Double-stranded RNA (dsRNA) 
ISCOMS® 
Alternative pathogen-associated 
Molecular patterns (PAMPs) (E. coli heat 
Labile enterotoxin (LTB); flagellin) 
Microparticles (e.g., PLG) Saponins (Quils, QS-21) 
Emulsions (e.g., MF59, Montanides) Small-molecule immune potentiators  ( SMIPs) (e.g., resiquimod [R848]) 
Virus-like particles & viral vectors Cytokines & chemokines 
Table 4. Examples of adjuvant classes (O'Hagan & Rappuoli, 2004) 
3.1.2 Adjuvant effect of plant extracts 
Plant extracts are known to contain various compounds, which supposedly have 
immunostimulatory and immunosuppressive effects (Wagner & Proksh, 1985). Plant crude 
extracts and their components were tested for their adjuvant capacity. The extract from 
leaves of Nicotiana bethamiana co-administrated subcutaneously with HPV16E7 (Franconi et 
al., 2002) or HPV16L1 VLP´s (Maclean et. al, 2007; Šmídková et al., 2010) enhanced specific 
humoral and cellular immune response in tested mice. Freund’s adjuvant added to the plant 
extract did not increased noticeably humoral response elicited by HPV16L1 VLP´s in 
subcutaneously immunized mice and results indicate that the addition of Freund’s adjuvant 
to plant extract might be even deleterious (Maclean et. al, 2007). The study of Isfar et al. 
(2004) compares adjuvant effect of CT and of aqueous extract of Solanum torvum (STE). STE 
was shown to evoke an increase in IgA titer comparable to that of CT when co-
administrated with ovalbumin intraperitoneally. No acute toxic effects were evident with 
the used dose range. Plant extract has been shown to induce DC maturation of dendritic 
cells. This effect was not caused by lipopolysaccharide (LPS) but rather by presence of heat-
resistant products mimicking the effect of LPS in foliar extract (Di Bonito et al, 2009).  
Probably the most studied plant compound with adjuvant effect is the saponin fractions 
isolated from Quillaja  saponaria (Newman et al., 1992). The mechanism of saponin effect is 
complex and, apart from direct cellular stimulation, there is also evidence that saponins may 
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enhance oral immunization by protection of antigen from degradation by digestive enzymes 
and by increasing permeability of the intestine to macromolecules (Campbell, 1995).  
All these findings are promising for development of needle-free administration route of 
immunization as an alternative to intramuscular vaccine application. For this purposes 
intranasal, intravaginal, transdermal, sublingual and intramuscular administration routes 
were tested for systemic immune responses against HPV16L1 using (Cho et al., 2010). The 
sublingual route provided the most effective mucosal secretory IgA (sIgA) and serum IgG 
responses, cholera toxin subunit B (CTB) showed the most promising adjuvant activity. 
3.2 HPV L1 antigens as an edible vaccine? 
The majority of currently licensed vaccines are administered parenterally, even though they 
have the disadvantages of patient reluctance to tolerate needle sticks and lack of mucosal 
immune induction (Velasquez et al 2010). Edible vaccine represents further approach to self-
administrated nonparenteral vaccine that could solve the problem of high cost and need for 
appropriate storage of currently available preventive HPV vaccines. 
Thönes & Müller (2007) investigated the oral immunogenicity of different assembly forms of 
HPV 16 L1: T7-VLPs, T1 particles and capsomeres produced from Baculovirus expression 
vector in insect cells and showed that all three assembly forms induce humoral and cellular 
immune responses after oral vaccination of mice. The anti-L1 antibodies were conformation-
specific and showed neutralizing activity in a pseudovirion-based assay. They also 
investigated whether adjuvants have an effect on oral immunogenicity when co-
administrated with different L1 forms. Besides saponins, which were significantly toxic if 
applied orally, co-administration of either CpG DNA or Escherichia coli heat-labile 
enterotoxin LT(R192G) had no apparent enhancing effect on the production of anti-L1 
antibodies. Compared to capsomeres, VLPs induced stronger humoral immune responses 
while the CTL responses were induced at comparable levels.  
To establish an edible HPV16 vaccine Sasagawa et al., (2005) constructed a recombinant 
HPV16 L1-expressing Schizosaccharomyces pombe yeast strain to be administrated as freeze-
dried yeast powder orally as an edible vaccine, with or without the mucosal adjuvant heat-
labile toxin LT (R192G), to mice. After the third immunization, none of the mice that 
received the edible HPV16 vaccine showed specific antibody responses, whereas all of the 
positive controls that were administered intranasally with 5 μg of HPV16-virus-like particles 
(VLP) had serum IgG, and genital IgA and IgG that reacted with HPV16-VLP in enzyme-
linked immunosorbent assays (ELISAs).  
HPV L1 antigens that proof to be highly immunogenic when administrated parenterally 
induce only mild or none response when administrated orally. In light of these experiments 
it seems unlikely that current design of L1 based HPV vaccines will reach the market as an 
edible replacement of existing vaccines. More research is needed to establish vaccine 
concentration and formulation to boost its effect. It is also obvious that the highly phrased 
concept of edible vaccine administrated as plants or fruits for direct consumption in the less 
developed countries is rather romantic dream than reality and have to be corrected. It is 
now clear that if there will be an edible vaccine, it will have complex formulation that will 
be strictly controlled. 
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A good nonparenteral alternative for vaccine delivery could be nasal immunization, which 
already proved to be effective in tests with animals. The obstacles imposed by the normal 
process of mucociliary clearance limiting residence time of applied antigens could be 
circumvent by presence of an inert in situ gelling polysaccharide (GelSite) extracted from 
Aloe vera for nasal delivery of NV VLP antigen (Hefferon, 2010). The nasal cavity is a 
promising site for vaccine delivery because it is easy to access, is highly vascularized, has a 
relatively large surface area, has low proteolytic activity, and is able to induce systemic 
immunity as well as both local and distal mucosal immunity via the Common Mucosal 
Immune System (CMIS)  
4. Conclusions 
The major reason for the vaccine production in plants is that the vaccine antigen production 
is safe and could be potentially cheap and both transient and transgenic productions are 
scalable. Biologically active proteins can be produced more easily in plants than in other 
eukaryotic systems; and that the use of food plants could eventually allow edible and/or 
oral vaccines to be produced cheaper. The recent reports indicate very high yields of human 
vaccine candidates to be obtained via plastid transformation or large scale transient 
expression what could enable to meet the expected requirement of antigen for oral route as 
is required parenterally for the same immune response. A recent review on human trials of 
plant-based oral vaccines summarizing human studies of oral transgenic plant derived 
vaccines against enterotoxigenic E. coli infection, norovirus and HBV adds weight to the 
growing body of evidence that plant-made oral vaccines to these viruses are not only 
feasible, but could effective (Rybicki, 2010). Nevertheless there is still long way to go from 
improvement of antigen yields, to formulation of the vaccine including auxiliary factors 
improving efficacy and stability, to translation of the proposed vaccines into clinical trials 
and, not least, governmental and/or regulatory body approvals. 
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1. Introduction 
From the establishment of etiologic relationship between HPV and cervical cancer, 
researchers have emphasized the importance of prevention by education of people, 
especially teenagers. This virus is associated with diseases of the cutaneous and mucosal 
human epithelia, including benign warts and invasive cancer that affect different anatomical 
regions as skin, cervix, vagina, vulva, anus, penis, head and neck. Controversial evidence 
suggests a relationship between HPV infection and breast cancer (de Villiers et al., 2005; 
Khan et al., 2005; Heng et al., 2009) (Table 1). 
 
Clinical manifestation HPV types often detectable 
Verrucae vulgares, verrucae palmares et plantares 1, 2, 4 
Verrucae planare 3, 10 
Butcher´s warts 7 
Squamous cell carcinoma of the finger, Bowen´s disease 16 
Epidermodysplasia verruciformis (EV) 3, 5, 8 
EV- squamous cell carcinoma 5, 8 
Condylomata acuminata 6, 11 
High grade-squamous intraepithelial neoplasias and invasive 
carcinomas of the anogenital tract 16 
Bowenoid papulosis, erythroplasia of Queyrat 16 
Buschke-Lowenstein tumor 6, 11 
Respiratory Papillomatosis 6, 11 
Heck´s disease 13, 32 
Head and neck cancers (larynx, tonsils, tongue, sinuse, lung) 16, 18, 6, 11 
Breast cancer? 16, 18 
Table 1. Clinical manifestations and associated HPV types (taken and modified of 
Handisurya et al., 2009).  
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Noted that a variety of diseases caused by HPV is largely due to viral tropism, i.e., the 
preference of a certain type of HPV by a tissue or cell group in particular, depending on 
factors of virus and host, mainly receptors, transcriptional activators, enhancers, and tissue-
specific promoters (Graham, 2010). Based on the tropism, HPV has been classified into two 
main phylogenetic genera, the α-HPV and the β-HPV, which correspond to the   mucosal 
and cutaneous infective HPV, respectively (de Villiers et al., 2004). The temporal 
organization of the virus replication cycle is also different between different HPV types 
perhaps reflecting differences in sites of infection and transmission modes. 
Traditionally, cancer and associated lesions have been treated with surgery, radiotherapy 
and chemotherapy, these  treatments produced widely known adverse effects (American 
Cancer Society, 2007; Instituto Nacional del Cáncer, 2008).  However, many efforts have 
been done in order to find effective preventive and curative options less invasive and with 
minimal or no side effects. These options are mainly based on molecular biology techniques 
to develop  vaccines and the use of molecules that stimulate the immune  and cytotoxic 
response against HPV infection and cervical cancer. The development of these vaccines and 
therapeutic procedures is based on in vitro culture and knowledge of the life cycle, genome 
and regulation of viral transcription, which has allowed the identification of potential 
targets to control genes expression in infectious and / or neoplastic processes (Table 2). 
 
Genome 
region 
Gen/ 
protein 
Expression 
site Function 
Early 
E1 
Basal, 
parabasal 
and 
intermedia
te cells of 
the host 
ATP- dependent DNA helicase; unique enzyme 
expressed by the virus, which is essential for 
viral replication 
E2 Helps E1 to locate the origin of replication in LCR, cell cycle and apoptosis regulation 
E4 Cell Cycle arrest, virion assembly, remodels cytokeratin network 
E5 Control of cell growth and differentiation, immune modulation 
E6 Inhibits apoptosis and differentiation 
E7 Cell cycle control, controls centrosome duplication 
Late 
L1 Superficial 
cells 
Major capsid protein 
L2 Minor capsid protein, recruits L1, virus assembly 
Long control 
region (LCR)   
Binds many cellular transcription activators, 
confers keratinocyte specificity to transcription 
Table 2. Role of HPV genome regions  
2. Prophylactic vaccines to prevent HPV infection 
Prophylactic vaccines currently exist to prevent the spread of HPV infections; these vaccines 
have the objective to create antigens capable to induce neutralizing antibodies that prevent 
the entry of virus into host cells.  They are based on preventing infection of HPV types most 
prevalent around the world: types 6 and 11, of low oncogenic risk, associated with the 
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formation of warts and benign condylomata, and types 16 and 18 of high cancer risk, 
associated with cancerous and precancerous lesions, which are responsible for 
approximately 70% of all cervical cancers worldwide (Muñoz et al., 2004).Initially it was 
suggested to produce a vaccine based on attenuated virus, but its implementation and 
evaluation in humans was a very high risk due to the presence of oncogenic viral DNA; in 
addition  the growth of virus in in vitro culture had been limited until recently when a 
researchers  group managed to establish a reproducible and highly efficient production of 
HPV type 18 in human keratinocytes, which has a potential value for establishing research 
models of ex vivo viral expression (Castellsagué et al., 2006; Wang et al., 2009). 
Moreover, although the studies on the immunology of HPV have shown antibodies against 
many different viral products, the best characterized and most type-specific antibodies are 
those directed against conformational epitopes of the L1 capsid protein. In the 90's it was 
possible to produce in vitro, genetically engineered virus-like particles or VLPs, which 
consist of L1 or L1 + L2 recombinant protein, obtained by introducing one or both genes, 
respectively, in cultures of eukaryotic cells (yeast, insect or bacteria). These recombinant 
proteins have the ability to self-assemble to form three-dimensional structures that are 
morphological and antigenically identical to the original HPV virions, but not containing the 
viral genome, so these structures can not replicate or cause infection or cancer (Muñoz et al., 
2008).  
There have been studies in experimental animal models and humans, where there was a 
good tolerance to systemic vaccination with L1- VLPs, and induction of serum antibody 
titers of at least 40 times higher than the titles produced in an natural infection (Lowy & 
Frazer, 2003). The first large multicenter, double-blind study, with phase III results, was 
published in 2002, on a monovalent vaccine developed by Merck Laboratories HPV type 16 
(Brull & Carrera, 2005). This company created another quadrivalent  vaccine called Gardasil,  
synthesized in the yeast Saccharomyces cerevisiae, based on L1- VLPs of oncogenic types most 
commonly found in cervical dysplasia (HPV types 16 and 18) and non-oncogenic types 
responsible for approximately 90% of warts genitals and recurrent respiratory 
papillomatosis (types 6 and 11), which is considered to act on two different 
hyperproliferative diseases (Schiller & Lowy, 2006). It was approved by the U.S. Food and 
Drug Administration (FDA) in 2006 and is administered in 3 doses, spread over 6 months (0, 
2 and 6 months). Follow-up studies for 3 ½ years after vaccination showed an effectiveness 
of 94% in persistent infection with HPV types 16, as well as 100% in preventing high-grade 
intraepithelial lesions associated with types 16 and 18, and prevention of genital lesions 
related to HPV types 6 and 11 (Mao et al., 2006; Villa et al., 2005). The efficacy against vulvar 
and vaginal neoplasia grade II and III was 72-100% (Joura et al., 2007). In well designed 
clinical trials in young women aged 15-25 years who were HPV 16/18 seronegative and 
DNA negative to 14 HPV high-risk types, high levels of immunogenicity and protection 
were sustained for follow-up periods of up to 8.4 years (McKeage & Romanowski, 2011). 
Each 0.5-mL dose contains 20 µg HPV 6 L1 protein, 40 µg HPV 11 L1 protein, 40 µg HPV 16 
L1 protein, and 20 µg HPV 18 L1 protein. VLPs are adsorbed on an aluminum-containing 
adjuvant. Each 0.5-mL dose contains 225 µg amorphous aluminum hydroxyphosphate 
sulfate. The formulation also includes sodium chloride, L-histidine, polysorbate 80, sodium 
borate, and water for injection. The quadrivalent HPV vaccine contains no thimerosal or 
antibiotics. The vaccine should be stored at 2°C--8°C (36°F--46°F) and not frozen.  
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GlaxoSmithKline laboratories developed a bivalent vaccine called Cervarix for HPV types 16 
and 18, produced in insect cells with baculovirus as expression system, which is also 
administered in three doses (0, 1 and 6 months). Studies reported 100% efficacy in 
preventing infections with involved HPV types, with an almost absolute immunogenicity 
for 4 ½ years after vaccination and the detection of antibody titers from 16 to 26 times higher 
than detected after natural infection (McKeage & Romanowski, 2011; Bhatla et al., 2010; 
Muñoz et al., 2008; Harper et al., 2004; Kahn, 2005).  
Both vaccines (Gardasil and Cervarix) use aluminum-based adjuvants, which reduces the 
dose required to induce antibodies peak titer and helps to stabilize the vaccine during 
storage (Schiller & Lowy, 2006). Overall adverse effects reported in vaccination protocols are 
limited and include reactions at the injection site (erythema, pain and swelling) and 
systemic adverse effects (headache, fever and nausea) which were of middle nature, 
transitory and common for individuals receiving the vaccine or placebo (Paavonen et al., 
2007). 
Whereas the onset of sexual activity during adolescence, the FDA approved the vaccine 
Gardasil for girls and women aged between 9 to 26 years, while the Advisory Committee on 
Immunization Practices of the USA Center for Disease Control and Prevention (ACIP) 
recommended vaccination in females aged between 11 to 26 years and added males to the 
population who can benefit from Gardasil vaccination (FDA,  2010). 
There has been controversy regarding the vaccination of women alone or the inclusion of 
men. In this regard, it has been noted that vaccinating girls aged 12 years old, can reduce 
cases of cervical cancer associated with types 16 and HPV 18 in about 95% and the 
introduction of vaccination in children would increase this figure three points (Taira et al., 
2004). We must also take into account the potential role of vector that man can exert on the 
transmission of HPV infection, so the inclusion of the male population in vaccination 
programs could contribute to optimal control of transmission (Tirado-Gómez et al., 2005). 
Currently the vaccine is not recommended for pregnant women. The long-term effects of the 
vaccine on fertility are not known, but no effects are anticipated. Although studies on the 
toxicity to the fetus are inconclusive, FDA has classified the HPV vaccine as a pregnancy 
Category B medication, meaning that the medication does not appear to cause harm to the 
fetus in animal studies. Initially, the trials for Gardasil and Cervarix excluded pregnant 
women. Pregnancy was determined by a sensitive human chorionic gonadotropin (HCG) 
test on the day of expected vaccination. However, some women became pregnant during the 
few weeks or months following the receipt of a vaccine or placebo injection. Overall, the 
proportions of pregnancies with an adverse outcome were comparable in subjects who 
received Gardasil and subjects who received placebo. However, the clinical trials had a 
relatively small sample size. Though receiving the HPV vaccine while pregnant is generally 
considered safe, it is still recommended to wait until after pregnancy to get the vaccine 
(American Cancer Society, 2008).  
Vaccination at early age has led to concerns of parents, researchers and health specialists 
because of the need to talk with children about sexuality and sexually transmitted diseases, 
the vaccination charges received by children, the possibility that immunization may lead to 
the adoption of risky sexual behaviors and concerns about the safety of vaccines (Kahn, 
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2005).  Some researchers have pointed out as risk of vaccination the possible selection of not 
included HPV types in vaccines or the increase in the prevalence of rare oncogenic HPV 
types, which can only be known over time, after the mass vaccination had been effective.  
Other weaknesses of the prophylactic vaccine against HPV is that it only protects against 
specific HPV types, leaving out a wide range of viral types, although rare, are also present, 
and have also been reported conflicting results regarding the existence of cross protection. 
In addition, the vaccine is preventive (not cure existing infections or injuries) and there is a 
low percentage of cervical cancer and precursor lesions in which no association has been 
established with HPV, existing other factors associated with the development of this 
malignancy, as exposure to mutagens, genetic susceptibility, hormonal status and immune 
status (Tirado-Gómez et al., 2005; del Amo et al., 2005); unknown the duration of protection 
provided by the vaccine, it may be necessary to administer a booster dose (Brull & Carrera, 
2005; Diestro Tejeda et al., 2007). In this regard, an  evaluation  showed that the quadrivalent 
vaccine provides strong and sustained protection against condiloma and vulvovaginal and 
cervical low grade neoplasia, related to types 6, 11, 16 and 18, for more than four years. The 
same study suggests that the effectiveness of the vaccine might be less in cases where 
coinfection with HPV types absent in the vaccine is present (Dillner, 2010). 
It is important to take into account the high cost of the vaccines listed, however, this is not 
comparable to the loss of life or money spending for the treatments of lesions associated 
with HPV infection. Since vaccines are prophylactic and only provide preventive (no 
therapeutic) effect, most benefits are gained by vaccinating before infection occurs, ideally 
before the onset of sexual intercourse. In this sense, the ACIP has recommended the 
introduction of HPV vaccine in national immunization programs of governments 
worldwide. It is therefore essential to determine the HPV types circulating in each region 
and assess the potential impact of preventive vaccination in the respective populations. 
Various researchers have emphasized that even with the globalization of preventive 
vaccination, screening schemes should continue due to multifactorial nature of cervical 
cancer, only 2 of 15 oncogenic HPV types are included in the vaccine and vaccination 
programs initially cover women into a limited range of ages, anticipating that at least during 
2-3 decades unvaccinated sexually active women remain at risk for the disease (Giuliano, 
2007; Stanley, 2008; Hutchinson & Klein, 2008). 
The efficacy of L2 vaccination has been proved in pre-clinical and clinical studies. Natural 
infection does not induce anti-L2 antibodies and many L2 epitopes are not on the virus 
surface, but during the infection cellular protease furin removes an L2 N-terminal sequence 
rendering L2 accessible on the capsid surface and displaying the L2-neutralizing epitopes. 
The L2-neutralizing epitope was inserted on the surfaces of VLPs increasing the titers of  
neutralizing antibodies approximately 10-fold. A synthetic L2 lipopeptide with 
concatenated multitype L2 fusion proteins from different papillomavirus types have already 
been utilized in inducing cross-neutralizing antibodies against several clinically relevant 
HPV types. This polymeric L2 approach gives rise to antisera, that neutralize at higher titers, 
not only the types included in the multimeric immunogen but also other types. So, 
immunization against L2 could be a candidate prophylactic pan-human papillomaviruses 
vaccine (Alphs et al., 2008; Jagu et al., 2009).  
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3. Therapeutic vaccines and gene therapy for treatment of cervical cancer 
Another line in the study of cervical cancer treatment has pursued in the implementation of 
therapeutic vaccines and / or gene therapy to cure existing cases, through the transfer of 
DNA, inserting the normal gene or gene expression regulation.  
Therapeutic vaccines are composed of peptides homologous to the viral proteins, as 
indicated in the treatment of dysplasia and invasive cervical cancer or as adjuvant therapy 
for locally recurrent or metastatic (Diestro Tejada et al., 2007). DNA vaccines have also been 
developed, which are considered as stable, safe, can be prepared in large quantities and 
repeatedly administered without significant adverse effects. In addition, the DNA tends to 
be preserved in the receptor cells, ensuring long-term expression of the encoded antigen and 
reinforcing the maintenance of immunological memory.  
Generally, the immune response generated from DNA alone is weak, so it has been tested 
the adjuvant effect of several molecules, and the combination of specific genes (Kim et al., 
2004). However, vaccines have been developed based on naked DNA, viral or bacterial 
vector, tumor cells and dendritic modified cells.  
Other molecules in use for gene therapy of cervical cancer are cytokines which has 
immunoregulatory effect that promotes maturation, activation and migration of effector 
cells of the immune response to the tumor site. Of particular interest are interferons, 
interleukin 2 or IL-2 (which activates T cells, NK cells, macrophages and the release of other 
cytokines) and the aforementioned IL-12 (whose anti-tumor effect individually or in 
combination with E6 and E7 is dependent on the activation of CD8 + cytotoxic T 
lymphocytes and NK cells at the site of immunization). Intratumoral administration of these 
molecules significantly reduced the progression of HPV-associated tumors and inhibited 
recurrent tumor formation after being removed by surgery (Frechtel, 2005; Bubenik et al., 
2003). 
In 1999, a group of researchers developed and tested the vaccine TA-GW based on the L2 
and E7 fusion proteins of HPV type 6, with Alhydrogel as adjuvant, for the treatment of 
condilomas, reporting immunogenicity and cure in approximately 62% of lesions 8 weeks 
after vaccination, without considerables adverse effects (Lacey et al., 1999). 
In 2002, Kaufmann et al. performed one of the first multicenter and multinational studies 
with a recombinant vaccine, TA-HPV, consisting of attenuated vaccinia virus genetically 
engineered to express the E6 and E7 proteins of HPV types 16 and 18. The protocol included 
two doses of the vaccine in patients with early-stage cervical cancer, and the induction of 
humoral and cell-mediated response with low side and/or toxic effects was observed.  
In 2004, Gutierrez et al. evaluated the effect of the recombinant vaccine MVAE2, consisting 
of attenuated vaccinia virus and the E2 gene of HPV, in squamous intraepithelial lesions of 
high and low grade. Treatment consisted in the administration of six doses, one every week, 
injected directly into the cervix. During the observation of treatment results, the reduction of 
injuries was monitored by colposcopy and histological analysis. The immune response was 
determined by measuring of antibodies againts MVAE2 and analysis of cytotoxic 
lymphocyte activity against cancer cells with oncogenic human papillomavirus. The 
presence of viral DNA and viral load were determined using the Hybrid Capture method 
(Digene).  
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After treatment it was possible the elimination of pre-cancerous lesions and even cancer 
(cancer in situ), with an efficiency of 95% in the first and 40% in the latter. All patients 
developed antibodies to the vaccine and a specific cytotoxic response against HPV-
transformed cells. These results were compared with those obtained in a similar group of 
patients treated with cryosurgery, a technique that is able to eliminate low-grade lesions in 
all patients; but there was not observed cytotoxic activity against cancer cells. 
As for of the virus detection, there was no evidence in 50% of the treated sample after 
treatment and in the remaining 50% was only detected 10% of the original viral load. 
Assessments of MVAE2 vaccine in women with cervical cancer are in Phase III, consisting of 
a multicenter study in 250 patients with cancer in situ in the Juarez Hospital of the Ministry 
of Health of Mexico. 
This vaccine was also tested in men for the treatment of urethral condilomas, showing the 
stimulation of the immune response against HPV and regression of lesions in 93% of cases, 4 
weeks after therapy. These assessments are in phase II. The results are promising and show 
that local therapeutic vaccination with MVAE2 is an effective tool for stimulating the 
immune response to HPV infection and the presence of virus-transformed cells, as well as 
regression of high and low grade cancer lesions (Albarran y Carvajal et al., 2007). 
On the other hand, researchers have highlighted the potential utility of gene gun used in the 
administration of DNA-based vaccines as part of the antigenic systems strategy for the 
control of cancer and infectious diseases, projecting itself as an important tool in antigen-
specific immunotherapy (Kim et al., 2008a).  
In the particular case of uterine cancer, Kim et al. (2008b), in a mouse model, used a Helio gun 
to dispense gold microparticles coated with E6 DNA of HPV type 16 attached to an expression 
regulator of major histocompatibility complex  class I molecules (human calreticulin). They 
observed an increased cellular and humoral immune response and antitumor effect, from the 
increased processing and presentation of antigens to T cells, together with the regression of 
tumors, enhanced antigen-specific memory and prolonged survival of vaccinated mice. The 
authors highlight the potential clinical benefits of this therapeutic strategy in humans, which 
may include co-administration of molecules with other properties, e.g. DNA encoding anti-
apoptotic or angiogenic proteins (Kim et al., 2004; Kim et al., 2008b). 
This vaccine was combined with E7 and L2 proteins of HPV, also observed significant 
therapeutic effects against E6/E7 expressing tumor cells, and generate a potent L2-antigen 
specific response, thereby protecting against pseudovirion infection. These results highlight 
the potential clinical benefits of this vaccine (Kim et al., 2008b). 
Ahn et al. (2004) performed in mice, direct intratumoral injection of an adenoviral vaccine 
carrier E7 sequence of HPV type 16 and interleukin 12 (IL-12) as adjuvant, which induces 
cellular immune responses for protection against tumor formation. They observed partial or 
complete regression of the tumors and long-term immunity against recurrence of the 
malignancy, and this effect was much greater with the vaccine formed with the all 
components, compared with the injection of any of the separate components. The IL-12 is one 
of the most widely used cytokine on gene therapy against cervical cancer, due to its effect in 
inhibiting tumor growth and experimental metastasis, dependent on the activation of NK cells.  
However, Sin (2009)  reported that IL-12 and E7 HPV type 16 cDNA-based vaccine lost its 
antitumor and immunoprotective effect when it was combined with nitric oxide (used and 
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known for its adjuvant effect in routine protocols for vaccination), which demonstrates an 
immunosuppressive effect of the compound (nitric oxide) in the system used. 
Peng et al. (2010) in a preclinical model about recurrent respiratory papillomatosis (RRP), 
generated a DNA vaccine that encodes the HPV-11 E6 and E7 genes  in a pcDNA3 backbone 
plasmid. Vaccinated mice generated strong CD8+ T cell response against the E6aa44-51 
peptide, which is presented by the major histocompatibility complex class I molecule. 
Results revealed that the E6aa44-51 peptide contains the most immunogenic region for HPV- 
11 viral type, making it a candidate for the development and evaluation of novel vaccine 
strategies targeting the RRP patient population. 
On the other hand, it has been established that an L1 molecule of various HPV types 
contains several cysteine residues at markedly similar relative positions, strongly suggesting 
that these cysteine residues play important roles in the structure and function of the HPV 
capsids, especially in the viral capsid assembly. Ishii et al. (2007) , in an in vitro model (HeLa 
cells), observed that HPV type 16-pseudovirions lost their infectivity after incubation with 
thiol-reactive reagents that bound to the free thiol of pseudovirions major capsid protein L1, 
due to conformational changes that result in the inhibition of the entry and trafficking of this 
molecules. Therefore, the authors suggest that these reagents might function as practical 
inhibitors of HPV infection. These reagents could be used in drug design or in combination 
with preventive and/or therapeutic strategies.  It would be necessary further evaluation on 
this topic.  
3.1 Antisense molecules and RNA interference in cervical cancer treatment 
Another line of investigation for the treatment of cervical cancer by gene therapy has been 
successful in testing antisense molecules as the ribozyme R434 (which, through its catalytic 
activity, specifically destroys the HPV types 16  E6 and E7 mRNA and prevents the growth 
of immortalized cells in the presence of virus), antisense oligonucleotides (AS-ODN) that 
hybridize with viral messenger blocking viral translation,  and interference RNA (RNAi) 
(Álvarez Salas, 2006; Hamada et al., 1996; Hall & Alexander, 2003) (table 3). 
Both technologies, antisense and RNAi, consist of gene silencing (interruption or 
suppression of the expression of a gene at transcriptional or translational levels).  
Agent Mechanism Result 
Most drugs Bind to target protein Protein inhibition 
RNase H-
independent 
ODNs 
Hybridize to target mRNA Inhibition of translation of the target protein 
RNase H-
dependent ODNs Hybridize to target mRNA 
Degradation of the mRNA 
by RNase H 
Ribozymes and 
DNA enzymes Catalyze cleavage of target mRNA Degradation of the mRNA 
siRNA 
Hybridize to target mRNA by its 
antisense strand and guide it into 
endoribonuclease enzyme complex 
RISC 
Degradation of the mRNA 
Table 3. Comparison of different gene silencing strategies. 
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The second, based on double-stranded RNA has proven to be more powerful than the first, 
based on single-stranded RNA (Mao et al., 2007).  
The antisense oligonucleotides have shown effectiveness in inhibiting the expression of E6 
and E7 oncogenes, and also produced the release and / or activation of molecules 
involved in defense mechanisms (such as cytochrome c and procaspases 3 and 9), the 
induction of apoptosis and inhibition of telomerase activity. However, it has been 
reported that these molecules are unstable and design and management are very 
expensive (Choo et al., 2000). 
RNA interference (RNAi) is a process of RNA-based gene silencing, which relies on 
nucleotide sequence complementarity and is involved in the mobilization of transposable 
genetic elements, in defense mechanisms and in different cellular events (such as 
differentiation, metabolism , stress response, propagation and apoptosis). This natural RNA-
dependent gene silencing process is controlled by the RNA-induced silencing complex 
(RISC) and is initiated by short double-RNA molecules in a cell´s cytoplasm, where they 
interact with the catalytic RISC component, protein argonauta, and the enzyme Dicer 
(Humayun et al., 2008) (figure 1). 
This process occurs through effector molecules identified in many eukaryotes, called 
microRNAs (miRNAs), highly conserved in orthologous species, indicating their importance 
in basic cellular processes. miRNAs are endogenous short RNA molecules with space-time 
independents expression patterns that determine inhibition of translation or degradation of 
target mRNAs when complementarity is incomplete or perfect, respectively (Raia & Calin, 
2011). Hence, this methodology has a potential therapeutic for various diseases, additionally 
it can be used in the evaluation of molecular and metabolic pathways. MiRNAs originate 
from populations of non-coding small RNAs (they are one of several small non-coding 
RNAs, including ribosomal RNA, transfer RNA and small nuclear RNA) resulting from 
transcription of DNA sequences by RNA polymerase II and form secondary structures 
hairpin loop type. Several investigators have found alterations of these molecules 
(particularly single nucleotide polymorphism or SNP) in all cancers studied to date and 
have indicated that miRNAs are expressed abnormally in these patologies and are involved 
in  predisposition, development  and  progression  of  cancer,   so  they  can  be  used  for 
diagnostic and prognostic purposes. In this regard, miRNAs have been detected in body 
fluids, which favors its use as biomarkers, because their assessment would be less invasive 
compared with other conventional markers, such as Pap smears and biopsies. Also, they can 
become as tumor suppressor, inhibiting cancer development, and as oncogenes, stimulate 
their development, depending on its expression pattern (Patel & Sauter 2011, Vitale et al. 
2011). 
In the biogenesis of mature miRNAs,  act two type III Rnases,  Drosha and Dicer, which cut 
precursor RNAs  in double-stranded RNA (dsRNA)  molecules with a length of 21 to 25 
nucleotides, which will separated to generate single strand molecules (Ketting et al., 2001).  
In addition to miRNAs,  in the RNAi mechanism have also identified other endogenous 
small RNAs called short interfering RNAs (siRNA) which, like miRNAs, originate from 
endogenous complementary dsRNA transcripts, but have an exact length of 21 nucleotides 
and most interesting is that they can derive from mRNA-coding sequences, transposons and 
heterochromatin (Ghildiyal et al., 2008). 
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Fig. 1. A simplified model for the RNAi pathway. 
The model has two steps, each involving ribonuclease enzyme. In the first step, the trigger 
RNA (either dsRNA or miRNA primary transcript) is processed into an short, interfering 
RNA (siRNA) by the RNase II enzymes Dicer and Drosha. In the second step, siRNAs are 
loaded into the effector complex RNA-induced silencing complex (RISC). The siRNA is 
unwound during RISC assembly and the single-stranded RNA hybridizes with mRNA 
target. Gene silencing is a result of nucleolytic degradation of the targeted mRNA by the 
RNase H enzyme Argonaute (Slicer). If the siRNA/mRNA duplex contains mismatches the 
mRNA is not cleaved. Moreover, gene silencing is a result of translational inhibition.  
Source: National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/projects/genome/probe/doc/TechRnai.shtml) 
siRNAs can be designed and artificially synthesized by chemical methods or by molecular 
cloning vectors and have been used to induce gene silencing in vitro and in vivo models, 
showing that perform the same biological functions as the natural miRNAs. The synthetic 
siRNAs can be transfected into mammalian cells by cationic lipofection, where they bind to 
liposomes as transport vehicle. In general, although it has achieved the efficient silencing of 
target genes, this strategy has a high cost and initially required the administration of 
multiple dose in mice, because a considerable percentage of the siRNAs is degraded by the 
action of endogenous endonucleases. Recently, the application of liposomes contained in 
Biogels, has overcome this limitation. The main disadvantage is that synthetic siRNAs have 
a short half-life after application (Sioud & Sorensen, 2003; Jiang et al., 2004). 
It has been suggested that the efficiency of silencing by RNAi not only depends on the 
activity of RISC by itself, but also other factors such as accessibility of RISC to the target 
sequence (which is affected by RNA secondary structure and interaction of target mRNA 
with other molecules) and cleavage and release of cleaved RNA. Moreover, recent studies 
have shown that siRNA has nonspecific effects, ie in addition to its complementary target 
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sequence (Schubert et al., 2005); studies of cervical cancer reported the silencing of the gene 
of interest and the production of inflammatory cytokines and  interferon, simultaneously. 
This was particularly evident when using high concentrations of siRNA. That is the reason 
because the researchers recommend dose-response studies on a given system in order to 
select the lowest concentration of siRNA to observe the desired result, eliminating or 
reducing non-specific responses (Yamato et al., 2008). These nonspecific responses may also 
be caused by mismatches present in a siRNA in a tolerable level with its mRNA target 
(Haley et al., 2004). All these elements must be taken into account to design siRNA 
sequences and protocols in order to obtain the greatest effectiveness and specificity. 
Currently there is software that facilitates the design of these molecules. 
The DNA sequence to silence can also be introduced into a vector that allows the 
transcription of siRNA. These vectors include siRNA expression plasmids, in which the 
DNA insert is placed under the control of the promoter of RNA Pol III (H1 gene or U6 gene) 
and form hairpin secondary structures that are processed by RISC and hybridize to target 
mRNA for its degradation (Brummelkamp et al., 2002).  
Another type of widely used vectors are viruses, because they have a wide capacity of cell 
infection, especially retroviruses and adenoviruses. The former have the ability to integrate 
into the genome of replicating cells and therefore are useful for stable transfection of cancer 
cells. However, it has been reported that the transfection rate is low (de Felipe & Izquierdo, 
2000). Adenoviruses have the ability to infect quiescent cells and dividing cells and produce 
a higher transfection rate than the retroviruses, but are more difficult to handle because of 
the size of its genome (Carette et al., 2004). 
Noted that the use of this technology in the treatment of cervical cancer is possible because 
while E6 and E7 sequester the activities of p53 and pRb proteins in HPV-induced 
malignancies, copies of p53 and pRb wild genes are usually conserved, which confers a 
reversible character of the malignancy, whereas reducing the expression of E6 and E7 in 
HPV-transformed cells could restore the activity of  endogenous tumor suppressor and thus 
prevent the proliferation of these cells (Webster et al., 2000). 
It has also been shown that RNAi technology against E6 and E7 genes induces senescence, 
apoptosis or inhibition of cancer cell growth in cell models (Webster et al., 2000; Butz et al., 
2003; Niu et al., 2006) and destroys or suppresses the growth of tumors in mice injected 
directly with short molecules of RNAi (siRNA) against E6/E7 (Niu et al., 2006; Fujii et al., 
2006). The first work on gene silencing by RNAi in uterine cancer was conducted by Jiang 
and Millner (2002). The researchers, in an in vitro model, administered synthetic siRNAs 
against E6 and E7 oncogenes of HPV 16. They observed the degradation of the E6 and E7 
mRNA, with consequent expression of p53, decreased cell proliferation and induction of cell 
death by apoptosis. In particular, the induction of apoptosis or senescence in tumor cells has 
been effective since the introduction of the transcriptional regulator E2 and the reduction or 
inhibition of  E6 and E7 genes expression (Butz et al., 2003).  
At the molecular level, it was observed that E6 silencing induced accumulation of p53 
cellular protein and transactivation of p21 cell cycle control gene (Jiang & Milner, 2005). On 
the other hand, has been demonstrated the specificity of the technique since it was found 
that E6 RNAi  of HPV type 16  was less efficient in silencing  E6 gene in cells infected with 
other HPV types (Niu et al., 2006). These findings support the usefulness of this technique as 
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a tool for investigating the mechanisms involved in the establishment and development of 
malignancy, as for the creation of therapies for treatment and healing. 
It is noteworthy that there are studies that report the simultaneous silencing of E6 and E7, 
while in others there was particular silencing of only one of these oncogenes, when using 
the mechanism of siRNA. It was explained that this is due to the existence of the bicistronic 
E6/E7,  and simultaneous or individual silencing will depend largely on the particulars 
sequences of siRNA used and their positions of complementarity with the target mRNA 
(they may hybridize at a point where affect the expression of both genes or only one). In this 
sense, it has been suggested that alternative splicing events of E6 and E7 oncogenes of HPV 
preced events of silencing by siRNA (Lea et al., 2007). 
Another target in the treatment of cervical cancer with RNAi is the telomerase hTERT gene, 
which has been cloned in several siRNA expression plasmids. This enzyme helps in 
maintaining the genomic stability by synthesizing the telomeres of eukaryotic chromosomes 
to protect them from degradation events, fusion and recombination. Overexpression of this 
enzyme void aging and cell death, as in most somatic cells telomerase activity is very low or 
absent, whereas in undifferentiated or immortal cells is considerable. Using siRNA plasmids 
for hTERT in vivo and in vitro models, it has been observed the target gene silencing, with 
the consequent decrease of telomerase activity, inhibition of cell proliferation, increased 
activity of caspase 3 and death of tumor cells by apoptosis (Wang et al., 2007). 
It has also been observed that the application of siRNA technology increases the sensitivity of 
malignant cells to chemotherapy and radiotherapy. This has been demonstrated with cisplatin 
(study where E6 and E7 oncogenes were silenced), which can then be used in lower 
concentrations with the consequent reduction of its negative effects (Putral et al., 2005).  The 
sensitivity of HeLa cells to radiotherapy increased with the hTERT gene silencing by siRNA, 
which allowed the establishment of a relationship between sensitivity to radiotherapy and 
telomerase activity in this type of cancer (Wang et al., 2007). This observation can be taken into 
account when designing treatment protocols for a given patient. Thus, the combination of 
siRNA with chemotherapy or radiotherapy may be synergistic in reducing cancer resistance to 
conventional therapies, which may promote recovery and / or survival with these therapies. 
4. Conclusions 
While it has been estimated the impact that preventive vaccination may have on the 
transmission of HPV infection and the development of cervical cancer and precursor lesions, is 
important to note the existence of other factors that may affect or influence the development of 
this pathology as well as existing cases prior to vaccination, so the effect of a preventive 
vaccine in the prevalence of cervical cancer may involve several decades. Moreover, 
prophylactic vaccines do not protect against infection (or malignancy) caused by other HPV 
types not contained in them, so cases of disease will still arise and require treatment. 
Faced with these limitations of preventive vaccines, therapeutic vaccines based primarily on 
molecular resources and gene therapy are currently being evaluated and could become as an 
effective tool for the treatment of cervical cancer and low or high grade lesions, contributing 
together to preventive vaccines for a better control of this disease.  
In this regard, studies carried out until to date about the effect of gene therapy on cervical 
cancer, project this technology as an useful and specific tool for the activation of the short 
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and long term immune response, reducing metastasis and regression and even producing 
the elimination of tumors when applied alone or in combination with routine therapies 
(chemotherapy and radiotherapy) and surgery. 
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1. Introduction 
The Human papillomavirus (HPV) is etiologically related to the development of uterine 
cervical and other genital cancers (Bosch et al., 1995; Frisch et al., 1999; Melbye & Frisch, 
1998), and may be involved also in the etiology of cancers of the upper aerodigestive tract 
comprising the head and neck (HN) tumors (Franceschi et al., 1996). Some molecular and 
epidemiological studies support such possibility, once that an increased risk of cancer of the 
oral cavity, pharynx and larynx subsequent to the occurrence of cancer of the cervix has 
been found. Moreover, the incidence of some head and neck tumors has been increasing 
around the world and this high prevalence was attributed to the influence of risk factors, 
being the human papillomavirus important in this role.  
The present chapter aims at investigating epidemiologic features of HPV in head and neck 
cancer worldwide in order to determine the prevalence and the type distribution of HPV by 
means of a literature review of published studies. 
2. Epidemiology of head and neck cancer 
The head and neck cancer comprises malignancies arising in the upper respiratory and 
digestive tracts and is a relatively frequent type of cancer (Parkin et al., 2002). Thus, the term 
“head and neck cancer” includes lesions at several anatomic sites, such as the lip, oral 
cavity, nose and paranasal sinuses, naso-pharynx, oro-pharynx, hypo-pharynx, larynx, 
oesophagus, salivary glands, as well the soft tissues of the neck and ear. Unfortunately, 
many papers lack the exact location of the head and neck lesions, making the material 
poorly characterised. The human papillomavirus (HPV) detection rates reported in the so-
called head and neck cancer do not give us a detailed view of the association of HPV in 
distinct entities, unless detailed anatomic locations are given (Syrjänen, 2005).  
The malignant tumors of the head and neck consist of a rather heterogeneous group of 
neoplasias arising in the epithelium of the upper aerodigestive tract. The most common 
histologic type is squamous cell carcinomas (SCC), occurring in the oral cavity, pharynx 
(nasopharynx, oropharynx and hypopharynx) and larynx (Lassen, 2010).  
Worldwide annually, over 650,000 patients are diagnosed with HNSCC and some 350,000 
die from this disease every year (Ferlay et al., 2010; Syrjänen, 2010). Head and neck cancer is 
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the sixth most common cancer worldwide (Parkin et al., 2002), and the table 1 summarizes 
the global incidence and mortality of head and neck cancer per anatomic site. 
CANCER INCIDENCE MORTALITY 
Oral cavity and lip 
Male 170,496 83,109 
Female 92,524 44,545 
Total 263,020 127,654 
Nasopharynx 
Male 57,852 35,984 
Female 26,589 15,625 
Total 84,441 51,609 
Other pharynx 
Male 108,588 76,458 
Female 28,034 19,092 
Total 136,622 95,550 
Larynx 
Male 129,651 70,336 
Female 21,026 11,556 
Total 150,677 81,892 
Table 1. Global incidence and mortality of head and neck cancer per anatomic site (Ferlay et 
al., 2010). GLOBOCAN (IARC). 
The rates of incidence and mortality around the world of head and neck squamous cell 
carcinomas have been broadly varying, with notably high rates in Southeast Asia and 
Eastern Europe (Franceschi et al., 1996). In addition, there is a considerable global variation 
in the incidence of the disease due to geographic differences in ethnicity, culture and socio-
economics (Lassen, 2010). Figure 1, obtained through the Globocan project (Ferlay et al., 
2010) illustrates the global incidence of head and neck cancer. 
Incidence and survival trends have recently been reported in various types of cancer based 
on 1994–2003 data from cancer registries in a large number of European countries. Oral 
cavity and pharyngeal cancer were analysed as a group and divergent incidence trends were 
observed when different countries were compared. For some countries, there was an 
increase in incidence (England, Wales and Czech Republic), whereas for other countries 
there was no change (a.o. Switzerland and Denmark) or a decrease (a.o. Finland, France and 
Germany) (Karim et al., 2008). 
Jemal et al. (2008) estimated that 47,500 people were diagnosed with head and neck cancer 
in the United States, representing approximately 3% of new cancer diagnoses, and an 
estimated 11,260 people died from this disease, with squamous cell carcinomas in the 
majority of these cases. 
Shiboski et al. (2005) showed, with an analysis of the National Cancer Institute’s 
Surveillance, Epidemiology and End Results (SEER) data from 1973-2001, an annual increase 
in the incidence of oral tongue, palatine tonsil, and base-of-tongue cancers, by 2.1%, 3.9%, 
and 1.7%, respectively, in 20- to 44-year-old white patients, while the incidence of HNSCC at 
other sites declined. 
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Fig. 1. Global incidence of head and neck tumors (oral cavity and lip, larynx, nasopharynx 
and other pharynx). Estimated age-standardized incidence rate per 100,000, both sexes, all 
ages (Ferlay et al., 2010). GLOBOCAN (IARC). 
3. Head and neck cancer and HPV 
Since the first description of a potential link between HPV infection and head and neck 
cancer (Syrjänen, 1984), several studies have strongly supported an etiologic role for HPV in 
cancers arising from specific mucosal sites within the head and neck (D’Souza et al., 2007; 
Gillison et al., 2000; Herrero et al., 2003). Thus, the detection of HPV genomic 
deoxyribonucleic acid (DNA) has been found in approximately 25.9% of 5,046 HNSCC 
cancer specimens from 60 studies using sensitive polymerase chain reaction–based methods 
(Kreimer et al., 2005). 
Head and neck squamous cell carcinoma (HNSCC) typically affects male smokers older than 
55 years.  Recently, an increase in the incidence of HNSCC in young adults has been 
recognized, many of them nonsmokers and females. Functional inactivation of p16 is known 
to be a common event in HNSCC, mainly by either deletion or epigenetic changes. A 
previous study by this group has shown that p16 deletions in HNSCC are significantly 
associated with age. The primary objective of this study was to evaluate additional 
molecular alterations of p16 in HNSCC, specifically in relation to age, site, and human 
papillomavirus (HPV) status. Patients ranging in age from 22 to 76 years with HNSCC were 
prospectively identified (n = 24). Methylation-specific polymerase chain reaction and 
immunohistochemistry were used to evaluate p16 gene inactivation and p16 protein 
expression, respectively. HPV 16 status was determined for each case. Overall, p16 
inactivation was a frequent event detected in 46% of cases. Methylation of p16 was more 
often detected in females than males (P = .05). All cases showing p16 methylation were from 
the anterior tongue, and 75% of them were young patients. The results indicate that p16 
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methylation is a more common event in those younger than 40 years in contrast to p16 
deletions, which are more common in those older than 40 years. Consequently, it appears 
that specific modes of inactivation of p16 in HNSCC are related to specific patient risk 
profiles. Interestingly, HPV 16 messenger RNA was detected exclusively in HNSCC from 
the base of tongue lesions and was only found in males. This differs from the patient profile 
of HNSCC in the young, which affects the anterior tongue and commonly females, thus, 
making it highly unlikely that this virus is a primary causative agent of HNSCC in these 
young adults (O'Regan et al., 2008). 
Despite successful efforts to control tobacco and alcohol consumption in the western world, 
several developed countries report rising oropharyngeal squamous cell carcinoma (OPSCC) 
incidence figures, specifically in young individuals. Similar to anogenital cancers, a 
significant proportion of OPSCC (up to 60%) is caused by sexually acquired HPV infection 
and the rise in OPSCC has been attributed to changing sexual behaviours in the Western 
World. Accordingly, patients with HPV-positive OPSCC report divergent sexual histories 
and absence of classical risk factors as tobacco and alcohol exposure compared to patients 
with HPV-negative OPSCC. The profile of HPV-positive OPSCC differs from HPV-negative 
OPSCC in several other significant aspects, including a unique molecular biologic tumor 
characteristics and improved clinical behaviour. Thus, a further increase in HPV-positive 
OPSCC will impact significantly upon clinical management of OPSCC, unless it is halted by 
adequate preventive measures aimed at reduction of HPV-associated disease. HPV 
vaccination has been recently offered to young females in an attempt to reduce HPV-
induced cervical cancer and may ultimately result in a decline of OPSCC incidence as well. 
Until then, close collaboration between otolaryngologists/head and neck surgeons and 
anogenital/genitourinary specialists is warranted to optimize clinical management of HPV-
induced malignancy and improve detection of second primary tumor development (Monsj 
et al., 2010). 
In addition, some researches revealed differences between positive and negative tumors for 
human papillomavirus being the HPV-positive HNSCC patients approximately 5 years 
younger than HPV-negative HNSCC patients with equal distribution between the sexes 
(Haraf et al., 1996; Cruz et al., 1996; Sisk et al., 2002; Strome et al., 2002). For a better 
understanding, although the epidemiology of HPV in head and neck cancer is the aim in 
this chapter, a brief explanation on the risk factors in HPV infection is necessary before 
beginning this approach. 
3.1 Risk factors 
Over the last two decades, biological agents have been implicated in the etiology of this tumor. 
Among these agents, human papillomavirus (HPV) is particularly important (Badaracco et 
al.,2000;  Cortezzi et al., 2004; Lo Muzio et al., 2004;  Smith  et al., 2004; Ibieta et al., 2005). HPV 
is a DNA virus which encodes two oncoproteins that play an important role in carcinogenesis, 
i.e., E6 which binds, sequesters and degrades p53, and E7 which binds and degrades pRb; thus 
facilitating the development of tumors (Badaracco et al.,2000; Cortezzi et al., 2004; Lo Muzio et 
al., 2004; Remmerbach et al., 2004). Although the relationship between this virus and 
malignant uterine cervix tumors has been well established in the literature, with more than 
90% of these tumors being positive for the virus, the same does not apply to oral 
carcinogenesis (Miller  et al.,  2001; Sugiyama et al., 2003). The HPV detection rates at this 
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anatomical site is very variable, probably due to differences in sample size, in the population 
studied and in the sensitivity of the techniques used. 
The presence of HPV in oral cancers suggests that HPV may play a similar role in 
transforming the oral epithelia. Persistent infection with high-risk types of HPV plays a 
critical role in the pathogenesis of cervical cancer, as well as OSCC. HPVs are 8-kb circular 
DNA viruses that specifically target the basal cells of the epithelial muscosa. The HPV 
family is comprised of more than 100 genotypes, classified in accordance with the type of 
epithelial cells infected and the ability to effect cellular transformation. The ability of HPV to 
transform epithelial cells is divided into high-risk and low-risk types. Low-risk types are 
associated with benign lesions such as warts, while infections with high-risk types progress 
to malignant lesions. The HPV genome is comprised of several early (E1 to E7) and late (L1 
and L2) genes, as well as a non-coding region, all of which play roles in viral replication, 
transcription, and carcinogenesis (Ragin et al., 2007). 
The primary risk factors for the majority of head and neck cancer worldwide are tobacco 
and alcohol consumption (Hennessey et al., 2009). In spite of these traditional risk factors, 
the HPV-positive HNSCC, in particular high-risk HPV type 16, appears more frequently 
than HPV-negative HNSCC in non-smokers and non-drinkers (Gillison et al., 2000; 
Hafkamp et al., 2003; Ritchie et al., 2003; Haraf et al., 1996). In case-control researches, the 
association between tobacco or alcohol use and the development of HPV-positive HNSCC 
was not found (D’Souza et al., 2007; Gillison et al., 2008). Furthermore, human 
papillomaviruses have recognized influence in the development of HNSCC in such sites 
as oropharynx, being considered as an independent risk factor (Schwartz et al., 1998; 
Gillison et al., 2000; Mork et al., 2001; Wiest et al., 2002; Herrero et al., 2003; Hobbs et al., 
2006; Ernster et al., 2007; Andrews et al., 2008). Nevertheless, there is controversy in the 
literature as to the combination of HPV infection with tobacco and/or alcohol increasing 
the risk of cancer. Schwartz et al. (1998) and Smith et al. (2004) showed an additive effect 
between oral HPV infection, tobacco or alcohol use, and oral cancer, but more researches 
are necessary to evaluate possible interactions among these exposures (Vidal & Gillison, 
2008). 
The two most prevalent HPV types in oral carcinomas are HPV 16 and 18, far exceeding the 
detection rate of all the other types (Snijders et al., 1996, 1997, Badaracco et al., 2000; 
Syrjänen and Syrjänen, 2000; Miller and Johnstone, 2001; Ringströmet al., 2002). 
Interestingly, the low-risk HPV types 6 and 11 can also be identified in some oral 
carcinomas, similar to laryngeal carcinomas (Yamaguchi et al., 1991; Fife et al., 1996; Chang 
et al., 2002). A study by Sisk et al. (2000) showed that the incidence of HPV in younger 
patients is not significantly different from older patients, suggesting a similar role for HPV 
in all age groups. 
Sexual contact has been associated to cervical cancer through high-risk mucosatropic 
HPVs (IACR, 1995), but the means by which HPV is transmitted to the upper airways are 
still unclear (Mannarini et al., 2009). Studies showed a rare oral HPV infection in newborn 
babies of infected mothers (Watts et al. 1998) and children prior to sexual activity (Koch et 
al., 1997) being the infections rate increased from the first sexual intercourse (Kellokoski et 
al., 1992). 
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Sexual behavior has an association with HPV-positive cancer in head and neck cancer, as 
observed by D’Souza et al. (2007) in a case-control study of 100 individuals with 
oropharyngeal cancer and 200 control persons, which found that the development of 
oropharyngeal cancer is linked with a high lifetime number of vaginal sex partners (≥ 26) 
and with a high lifetime number of oral sex partners (≥ 6). Gillison et al. (2008) found with a 
case-control study of 240 individuals with oropharyngeal cancer that the risk of developing 
an HPV-16-positive HNSCC increased with increasing numbers of oral sex partners. In 
addition, oral-anal contacts are very strongly associated with the risk of HPV-positive tumor 
(Rosenquist et al., 2005; Rajkumar et al., 2003). 
In a research, Rintala et al. (2006) observed the natural history of oral and genital HPV 
infection. The results showed that oral sex had no association to oral HPV infection; 
however, a persistent oral HPV infection of the spouse increased the risk of persistent oral 
HPV infection 10-fold in the other spouse. 
Although the relation of cannabis sativa with HPV infections of head and neck sites is unclear 
(Mannarini et al., 2009), such behavior has been proposed as a reason for increasing 
numbers of young patients with head and neck cancer (Báez, 2008). Gillison et al. (2008) 
observed a strong association between cannabis sativa use and HPV-16 – positive HNSCC, 
with a relation of increasing intensity and duration of use. 
Among the risk factors for HPV infection in head and neck tumors, there is the immuno-
suppression, as observed in human immunodeficiency virus (HIV)-positive cases 
(Adamopoulou et al., 2008). The genetic susceptibility is also an important risk factor to 
increase the risk of HPV infection, as noted in Fanconi anemia (Park et al., 2010). 
3.2 Epidemiology of head and neck cancer with HPV involvement 
3.2.1 Premalignant lesions 
According to Axell et al. (1996), premalignant lesions, or pre-cancer lesions, of the oral 
mucosa are epithelial changes more likely to undergo malignant transformation than 
normal tissue at other mucosal sites. There are two types of clinical premalignant lesions: 
white lesions (leukoplakia) and reddish lesions (erythroplakia) (Axell et al., 1996). These two 
terms are purely clinical, and have no association with the underlying histopathology 
(Syrjänen, 2005). 
3.2.1.1 Erythroplakia 
Erythroplakia lesions are defined as a bright red patches that cannot be diagnosed as any 
other lesions (Axell et al., 1996). There are few researches about erythroplakia lesions 
involving human papillomavirus in head and neck. Nielsen et al. (1996), in a case-control 
study with 49 patients with oral premalignant lesions, observed 10 cases of oral 
erythroplakia (1 man and 9 women). The presence of HPV was examined 
immunohistochemically, through DNA–DNA in situ hybridization and through PCR. The 
investigations revealed that HPV was found in 50.0% of the erythroplakias and 33.3% of 
erythroleucoplakias. The authors concluded that HPV may be an etiologic co-factor, because 
100% of patients who developed oral cancer within 4–12 years were all positive for HPV, 
with one being HPV-16-positive. This sample had few cases and a critical analysis of these 
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results is necessary. Further confirmatory data are needed before any conclusions can be 
drawn on the possible causal role of HPV in this disease (Syrjänen, 2005). 
 
 
 
Fig. 2. Erythroplakia in soft palate 
3.2.1.2 Leukoplakia 
Oral leukoplakia is considered as a premalignant lesion for the development of oral 
squamous cell carcinoma (OSCC) and several risk factors have been reported to contribute 
to this step-wise carcinogenesis, including human papillomavirus (HPV) (Yang et al., 
2009).  
Syrjänen (2005) observed in the literature 964 leukoplakia biopsies, of which 31.1% 
contained HPV DNA. The HPV types 6/11 were the most prevalent (55.8%), followed by 
HPV types 16/18 evidenced in 28.2% of the cases (Miller & Johnstone, 2001). 
However, Yang et al. (2009) analyzed, using PCR in paraffin sections, 167 patients with 
oral leukoplakia, including 12 who had malignant transformation from the pre-existing 
oral leukoplakia. The HPV prevalence in patients with oral leukoplakia was 
approximately 22.8%, and the most prevalent viral strain was HPV-18 (78.9%). This 
research also suggested that HPV in oral leukoplakia is not a prognostic indicator of 
malignant transformation.  
Ostwald et al. (2003) examined 72 oral leukoplakia for the presence of HPV 6/11, 16 and 18 
DNA through PCR/Southern blot hybridization. The HPV DNA was found in 16/72 
(22.2%) leukoplakias, and HPV 16 and 18 DNA were present in 12/72 (16.7%) leukoplakias, 
being 11.1% the detection rate of HPV 6/11. 
In a case-control study, the HPV presence was found in 62.5% of the verrucous leukoplakias, 
45.5% of the homogeneous leukoplakias and in 12.5% of the nodular leukoplakias (Nielsen 
et al., 1996). 
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
204 
 
Fig. 3. Leukoplakia in buccal. 
3.2.2 Oral cavity and lips 
Clinical presentation of oral cancer is highly variable. On clinical examination, oral SCC 
lesions may be preceded by mucosal alterations with histologically detectable dysplastic 
changes. However, a malignancy involving a complex genetic process may also occur 
directly “de novo” without any pre-existing clinically detectable mucosal changes. All head 
and neck carcinomas tend to be diagnosed late because there is no pain until the late stages. 
Thus, the overall survival is only 40–50% (Johnson et al., 1991; Berrino et al., 1999; 
Franceschi et al., 2000). 
Studies that support a causal relationship between HPV and OSCC include: a consistent 
detection of HPV DNA in tumor specimens (Hansson et al., 2005); E6/E7 viral oncogene 
expression in oral lesions (Braakhuis et al., 2004); the requirement of oral carcinoma cell 
lines to express E6/E7, to maintain a malignant phenotype; and epidemiological data 
highlighting HPV infection as a risk factor for the development of OSCC (Ragin et al., 2007). 
At least three proteins (E5, E6, E7) coded by the high-risk HPVs, which are expressed 
throughout the viral life cycle, are considered oncogenic, due to their transforming and 
growth-stimulating properties. These proteins have the ability to deregulate tumor 
suppressor function by binding to and abrogating the functions of p21 (Tsai & Chen., 2003),  
p53 (Camus, 2007), and pRb (Huh et al.,2007) proteins, resulting in defects in apoptosis, 
DNA repair, cell cycle control, and eventually leading to cellular immortalization. 
Oliveira et al. (2009) showed that the presence of HPV DNA by PCR was detected in only 
29.5% of OSCC cases, 80.8% of which were identified for HPV 18. Although this 
investigation have detected only 29.5% of HR-HPV DNA in OSCC, it is possible that this 
virus contribute to the development of some case of this tumor. Furthermore, it seems that 
the immunohistochemical expression of p53 and bcl-2 and the presence of HPV DNA are 
independent events in OSCC. 
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Cancers involving the oral cavity account for 2–3% of all malignancies and the tongue is the 
subsite with the highest incidence of cancer in the oral cavity (Silverman Jr, 2001). The 
tongue may be the first site of exposure to viral microorganisms in the aerodigestive tract 
and oral tongue cancer could be susceptible to HPV exposure, directly or indirectly. The 
prevalence of HPV in oral tongue cancer is extremely diverse, ranging from 0% to 100% in 
the literature, and the prevalence of HPV in HNSCC is not uncommon (Bouda et al.,  2000, 
Gillison et al., 2001,  Matzow , 1998, Ringström , 2002). The markedly different reports of 
prevalence of HPV in oral tongue cancer may be due to: mixed samples with the 
oropharynx; methodological differences for detecting HPV, including less accurate methods; 
various tumour stages and racial and geographical differences between the studies. 
In a study made in the Republic of Korea for Lee et al. (2010), HPV prevalence in early oral 
tongue cancer was 36% (13/36). In the HPV-positive tumours, 11 cases (84.8%) were infected 
with HPV-16 and the others were infected with non-16 highrisk type and low-risk type HPV 
each and multiple infections were not found in these cases. 
Sugiyama et al. (2007) examined 66 oral squamous cell carcinomas (OSCCs) for human 
papillomavirus-16 (HPV-16) infection to evaluate its prognostic significance. Cox regression 
analysis of 5-year survival demonstrated that patients without nodal metastasis or with 
intratumoural HPV-16 showed better prognoses compared with each counterpart. In 
Kaplan-Meier survival analysis, nodal status but not HPV-16 status was statistically 
significant. The 5-year survival rate of HPV-16 positive patients without nodal metastasis 
(94%) was extremely high, compared with that of HPV-16 negative patients with nodal 
metastasis (25%). These results suggest that HPV-16 status as well as nodal status may 
provide prognostic significance in patients with OSCC. 
 
Fig. 4. Oral cancer in tongue. 
3.2.3 Pharynx 
3.2.3.1 Oropharynx 
The oropharynx is the predominant site where HPV-induced squamous cell carcinomas 
develop (Braakhuis et al., 2009). This region of interest for HPV infection comprises 
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predominantly the vallecula, walls of the oropharynx, and in particular the tonsils (Kreimer 
et al., 2005).  
In some countries, such as the United States and the Netherlands, the incidence of 
oropharyngeal cancer is increasing (Braakhuis et al., 2009; Ernster et al., 2007), and it 
represents an emerging public health problem (St Guily et al., 2011). One potential way to 
explain this increase would be to demonstrate an increasing prevalence of oncogenic HPV in 
palatine or lingual tonsil tissue over time (Ernster et al., 2009). 
Studies found a strong association between oropharynx cancers and HPV infection, with 
detection rates of 50% or more (Hammarstead et al., 2006; Klussmann et al., 2001; Venuti et al., 
2004; Paz et al., 1997). The biological explanation for why the prevalence of HPV is higher in 
tumors from the oropharynx compared with other sites in the head and neck remains unclear 
(Kreimer et al., 2005). However, it is possibly explained because of “specific virus-tissue 
interactions” (Kreimer et al., 2005) that allow a facilitated viral access to basal mucosal cells in 
the tonsillar crypts and an apparent predilection for this anatomic site for transformation by 
HPVs, analogous to the cervical transformation zone (Vidal & Gillison, 2008).   
In a systematic review of HNSCC biopsies that employed PCR-based methods to detect and 
genotype HPV, Kreimer et al. (2005) observed a HPV prevalence significantly higher in 
oropharyngeal squamous cell carcinomas (35.6% of 969) than in oral squamous cell 
carcinomas (23.5% of 2,642) or laryngeal squamous cell carcinomas (24.0% of 1,435). 
Furthermore, the human papillomavirus type 16 was found in a larger majority of HPV-
positive oropharyngeal squamous cell carcinomas (86.7%). However, the HPV18 infection 
was rare in HPV-positive oropharyngeal SCCs (2.8%) compared with other head and neck 
sites. Aside from HPV16 and HPV18, other oncogenic HPVs were rarely detected in 
oropharynx. This research also found geographic differences in HPV-positivity of 
oropharyngeal carcinomas possibly linked to differences in HPV exposure or variation in 
host susceptibility factors among countries. 
From a literature review worldwide, Syrjänen (2004) identified 422 tonsillar SCCs and 51% 
of these tumors contained HPV DNA.  The HPV 16 was the most frequent type, identified in 
84% of the 216 HPV DNA-positive tumors, but also the low-risk HPV types 6/11 DNA have 
been detected in 3% of the HPV-positive carcinomas, and the following HPV types have 
been detected in occasional tonsillar carcinomas: HPV 5, 12, 31, 35, and 59.  
In a research developed in France, the overall HPV prevalence was 57% in tonsil cancers, 
and was significantly higher in female than in male cases (28/35 versus 78/150 in tonsil 
cases). Among HPV positive samples, HPV 16 was found in 89% of tonsil cases, and all 
other HPV types had prevalence below 5% (St Guily et al., 2011). 
In Norway, a study with 137 patients about the prevalence of HPV with tonsillar carcinomas 
observed HPV infection in 52% of the tumors being the HPV-16 the most frequent subtype 
(87%). Furthermore, the study showed that the survival of the HPV-positive group was 
significantly better in males (Hannisdal et al., 2010). 
In Stockholm, 98 pretreatment biopsies of tonsillar squamous cell carcinoma were analyzed. 
The HPV DNA was present in 83 cases (85%) of the tonsillar SCC biopsies and 77 of these 
were HPV-16 positive. HPV-16 E6 and E7 RNA were found in 98% of 52 HPV-16 positive 
cases analyzed. In addition, the incidence rate of HPV-positive tumors almost doubled each 
decade between 1970 and 2007, in parallel with a decline of HPV-negative tumors. The 
 
Epidemiology of HPV in Head and Neck Cancer 
 
207 
study suggested that the incidence of HPV-positive cancers is still increasing in Stockholm, 
and also an epidemic of a virus-induced carcinoma, with soon practically all tonsillar SCC 
being HPV positive, as in cervical cancer (Nasman et al., 2009). 
A study developed in the United States in the state of Colorado through PCR observed an 
increase of oropharyngeal cancer in males from 2.54 per 100,000 to 3.47 or 36.6%. Of the 72 
cases, 50 (69%) were positive for HPV subtype 16. The ratio of HPV-positive to HPV-
negative cases prior to 1995 was 0.72 (8:11), but it was 3.81 (42:11) afterwards. The survival 
was positively affected by HPV status, being 83% in the HPV-positive patients and 15% in 
the HPV-negative group (Ernster et al., 2007).  
A research in Puerto Rico evaluated through PCR 118 head and neck squamous cell 
carcinoma, and 16 cases were found in the oropharynx. Furthermore, in 52 patients, HPV16 
was detected, being 19% or 10 cases in oropharynx that had a slightly higher incidence of 
HPV16 DNA (Báez  et al., 2004). 
In Australia, a study involving 86 tonsil cancers analyzed the HPV status through PCR and 
immunohistochemistry. The HPV status could be established in 67 of the tumors, and 31 
(46%) of these were HPV-positive, predominantly (28/31) for HPV16 (Li et al., 2003).  
Overall, the percentage of HPV-positive oropharyngeal carcinomas varies among different 
reports, which is not only explained by the varying inclusion of tumors from different 
anatomic sublocations among studies (van Monsjou et al., 2010). Therefore, further 
standardized seroepidemiologic studies are important to answer some questions. 
3.2.3.2 Nasopharynx 
Nasopharyngeal carcinoma (NPC) is a tumor that arises in the epithelium surface of the 
posterior nasopharynx and shows a peculiar geographic and ethnic distribution (Parkin et 
al., 1997). Despite the strong association with Epstein-Barr virus (EBV), the human 
papillomavirus (HPV) has also been linked as a cofactor for the development of 
nasopharyngeal carcinoma  (Punwaney et al., 1999).  
Although NPC is rare in most populations, it is a leading form of cancer in a few well-
defined populations, including natives of southern China, Southeast Asia, the Arctic, and 
the Middle East/North Africa. Thus, the distinctive racial/ethnic and geographic 
distribution of NPC worldwide suggests that both environmental factors and genetic traits 
contribute to its development (Chang & Adami, 2006). 
In North Africa, 70 Moroccan patients with NPC were screened for EBV and HPV. The EBV 
was detected in all NPC tumors, whereas HPV DNA was revealed in 34% of cases (24/70). 
Molecular analysis showed that 20.8% (5/24) were infected with HPV31, and the remaining 
were infected with other oncogenic types (i.e., HPV59, 16, 18, 33, 35 and 45). The mean age 
of HPV-positive patients was 37.3, whereas the mean age of HPV-negative cases was 43.0 
years old. Nonetheless, the statistical analysis showed that there’s no association between 
sex or age and HPV infection. The study revealed that EBV is commonly associated with 
NPC in Moroccan patients and that NPC tumors from Moroccan patients harbor high-risk 
HPV genotypes (Laantri et al., 2011). 
In Iran, a retrospective study analyzed the prevalence of EBV and HPV infection subtypes 
6/11 and 16/18 in 20 patients with NPC. Thus, 16 cases were classified as undifferentiated 
carcinoma (WHO type III) and 4 as non-keratinizing SCC (WHO type II). About the HPV 
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infection, two of 20 NPC (10%) contained HPV 6/11 sequences and two of 20 NPC (10%) 
contained HPV 16/18 sequences, and combined EBV and HPV infection was detected in 3 of 
the 20 (15%) patients (Mirzamani et al., 2006). 
A research involving North Americans with NPC showed that five (5.6%) of 89 cases had 
nasopharyngeal carcinoma, all with non-keratinizing histology. Of the 5 patients with NPC, 
4 (80%) were HPV-positive for subtypes 16 (1 patient), 18 (2 patients), and 59 (1 patient). All 
4 cases were white North Americans with age ranging between 58-76 years old. Therefore, it 
suggests that HPV may be the etiologic factor in some EBV-negative, nonkeratinizing NPCs 
among whites (Maxwell et al., 2010). 
An investigation developed by Punwaney et al. (1999) with 30 patients (6 Caucasian 
Americans, 1 Chinese American, 14 and 9 patients from Korea and China, respectively) 
found in 7 (23%) HPV sequences. The human papillomavirus appears to be uncommonly 
(17%) associated with NPC in patients from the Far East and was detected more often (50%) 
in NPC from American Caucasian patients. There appears to be a broad profile in the 
relationship between HPV, EBV, and NPC histologic subtype. However, strong conclusions 
are not possible because of a low number of American Caucasian cases studied.  
In Hong Kong Chinese people, 16 of nasopharyngeal were examined for the presence of 
HPV 16 and 18 using PCR on paraffin-wax-embedded biopsy specimens. However, no DNA 
of either human papillomavirus subtype was detected. The number of cases in this series 
was small, and further studies are warranted using fresh biopsy material and including 
other viral subtypes (Dickens et al., 1992). 
Singhi et al. (2011) analyzed 45 carcinomas of the nasopharynx through 
immunohistochemistry and in situ hybridization for EBV and HPV. In this series, only 4 
cases (9%) were HPV-positive being all these specimens EBV-negative. The HPV was more 
likely to be detected in carcinomas from white patients than non-white patients (16% vs 0%), 
and in 3 HPV-positive patients, there was the finding of an extension into the oropharynx.  
Further studies are still required to associate the coexistence of EBV and HPV in the 
development of nasopharyngeal carcinomas (Mirzamani et al., 2006; Tyan et al., 1993). 
Moreover, epidemiology studies would also be of interest to determine whether the 
incidence of HPV-positive NPC is increasing in concert with the increased frequency of 
HPV-positive oropharyngeal cancers (Maxwell et al., 2010). 
3.2.3.3 Larynx and hypopharynx 
The larynx is among the most significant anatomic sites in terms of HPV involvement, 
exceeded in clinical importance perhaps only by the genital tract and skin infections 
(Syrjänen, 2005). However, the HPV role in anatomic sites in the upper aerodigestive tract 
such as the larynx is less clear (Herrero, 2003), and data on HPV involvement in 
preneoplastic and neoplastic lesions of the larynx and other locations are limited and 
conflicting (Gorgoulis et al., 1999).  
The hypopharynx comprises the postcricoid region, hypopharyngeal region of the 
aryepiglottic fold, and posterior wall of the hypopharynx (Kreimer et al., 2005). 
Unfortunately, there are few researches involving only hypopharynx in association with 
HPV presence in the literature. In this chapter, the hypopharynx and larynx were combined 
because of few reports observed in hypopharynx with HPV involvement and for the reason 
that some manuscripts aggregated these anatomical sites. Therefore, this group of diseases 
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was called ‘‘larynx cancers’’ or laryngeal squamous cell carcinomas (SCCs) in accordance to 
Kreimer et al. (2005).  
3.2.3.4 Larynx cancers 
Most malignancies in the larynx are squamous cell carcinomas (>90%). Similar to oral and 
pharyngeal cancers, multiple case series have reported prevalences of HPV DNA in 
laryngeal cancer (Herrero, 2003). Although the association and clinical significance of 
human papillomavirus (HPV) infections with a subset of head and neck cancers, particularly 
for oropharyngeal carcinoma, has recently been well documented, the involvement of HPV 
in laryngeal cancer has been inadequately evaluated (Torrente et al., 2011). 
In a systematic review worldwide comprising 1,435 cases (1,222 of larynx and 213 of 
hypopharynx cancers), the overall HPV prevalence was of 24% in laryngeal SCCs. The HPV 
was detected in 21.3%, 13.8%, and 38.2% of SCCs of the larynx from Europe, North America, 
and Asia, respectively. In addition, the HPV16 was the most common type detected in 
samples accounted for 69.2% of all HPV-positive laryngeal SCCs, followed by HPV18 
detected in 3.9% of cases (Kreimer et al., 2005). 
A study of Syrjänen & Syrjänen (2000) involving 1,252 cases had a detection rate of 25% for 
HPV DNA in 313 samples. Furthermore, the HPV 16 was the single most common HPV type 
detected in these lesions, with other high-risk types being occasionally reported. 
In the United States, 21 hypopharynx cases and 86 larynx cases were evaluated through 
PCR, Southern blot hybridization and in situ hybridization. Thus, the HPV positivity was 
identified in 10% of hypopharynx samples and 19% of larynx samples (Gillison et al., 2000). 
In Poland, the HPV 16 DNA presence was analyzed using PCR technique in 72 samples of 
laryngeal carcinoma. The human papillomavirus was detected in 26 (36.1%) of the 72 
patients. However, there was no statistically significant correlation HPV positivity and 
clinical-pathological features of the group analyzed (Morshed et al., 2005). 
In France, the human papillomavirus was detected in 5% in larynx squamous cell carcinoma, 
and no patient analyzed had p53 gene mutations in cancer cells (Fouret et al., 1997). 
In Belgium, the laryngeal squamous cell carcinomas were evaluated for the presence of HPV 
DNA through  E6/E7 type-specific PCR, and 75% of patients (44 out of 59) presented high-
risk HPV types with a high prevalence of HPV-16 (Duray et al., 2011). 
In the Puerto Rican population, of 118 head and neck squamous cell carcinoma evaluated 
through PCR, the larynx was the most common site affected (52 out of 118). Separately, the 
HPV 16 detected in larynx was 85.7% and 55.6% in hypopharynx. When aggregated, the 
hypopharynx and larynx showed 56% (29 cases) of all HPV16 DNA detected in the study 
(Báez  et al., 2004). 
In Northeast China, 102 patients with laryngeal squamous cell carcinomas were examined 
for HPV DNA. The HPV DNA was found in 60 cases (58.8%), being the HPV-16, -18, -6, -11, 
and -33 DNA detected in 30 cases, 22 cases, 25 cases, 2 cases and 1 case, respectively. 
Moreover, co-infection either with HPV-6 and -16 or with HPV-6 and -18 was detected in 20 
cases (33.3% of HPV DNA-positive cases) (Ma et al., 1998). 
A retrospective study examining early larynx malignancies from 38 patients detected a rate 
of 16% in HPV DNA, and the HPV types 16, 26, 31, 39, and 52 were identified. Although the 
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HPV-26 is related to uterine cervical cancer, the research found the first evidence of this 
subtype in a laryngeal carcinoma (Baumann et al., 2009). 
Although several researches support the HPV presence in hypopharynx/larynx cancer with 
prevalences ranging of 13.8% to 38.2% (Kreimer et al., 2005), Ribeiro et al. (2011) observed in 
78 fresh tissue biopsies a low prevalence of 3.8% in cases from Central Europe and Latin 
America. These wide variations in HPV prevalence which are reported may depend on the 
HPV diagnostic methodologies, especially in earlier studies (St Guily et al., 2010). 
Researches for the development of accurate, specific, and confirmatory methods for the 
detections of HPV in laryngeal squamous cell carcinoma are necessary, being standardized 
seroepidemiologic studies important to answer some questions. 
Table 2. summarizes some researches of head and neck lesions with HPV involvement. 
 AUTHORS (YEAR) 
GEOGRAPHIC 
LOCATION METHOD* 
HPV 
TYPE**
POSITIVE/
CASES % 
O
R
A
L 
C
A
V
IT
Y 
A
N
D
 L
IP
 
Kreimer et al. 
(2005) 
Australia, Canada, 
China, Cuba, Finland, 
France, Germany, India, 
Ireland, Italy, Japan, 
Korea, Netherlands, 
Norway, Poland, Spain, 
Slovenia, Sudan, 
Sweden, Switzerland, 
Taiwan, United 
Kingdom, United States, 
Venezuela
PCR-based 
HPV testing 
methods 
HPV-16 423/ 2,642 16% 
Oliveira et al. 
(2009) Brazil PCR HPV-18 21/88 23,9% 
Lee et al.
(2010) Republic of Korea 
HPV genotyping 
chip and RT-PCR HPV-16 11/36 30,6% 
O
R
O
PH
A
R
YN
X 
Kreimer et al. 
(2005) 
Australia, Canada, 
Cuba, Finland, France, 
Germany, India, 
Ireland, Italy, Japan, 
Netherlands, Norway, 
Poland, Spain, Slovenia, 
Sudan, Sweden, 
Switzerland, United 
States
PCR-based 
HPV testing 
methods 
HPV-16 299/969 30,9% 
St Guily et al. 
(2011) France 
INNO-LiPA HPV 
Genotypingextra 
test
HPV-16 94/185 50,8% 
Nasman et al. 
(2009) Stockholm PCR HPV-16 77/98 78,6% 
Ernster et al. 
(2007) United States PCR HPV-16 50/72 69,4% 
Li et al. 
(2003) Australia PCR and IHC HPV-16 28/67 41,8% 
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 AUTHORS (YEAR) 
GEOGRAPHIC 
LOCATION METHOD* 
HPV 
TYPE**
POSITIVE/
CASES % 
Báez  et al. 
(2004) Puerto Rico PCR HPV-16 10/16 62,5% 
N
A
SO
PH
A
R
YN
X 
Laantri et al. 
(2011) Morocco PCR HPV-31 5/70 7,1% 
Mirzamani et 
al. (2006) Iran ISH 
HPV-
6/11; 
HPV-
16/18 
2/20; 
2/20 
10%; 
10% 
Dickens et al. 
(1992) Hong Kong PCR none 0/16 0% 
LA
R
YN
X 
A
N
D
 H
YP
O
PH
A
R
YN
X 
Kreimer et al. 
(2005) 
Canada, Cuba, 
Denmark, Finland,  
France, Germany, 
Greece, India, Italy, 
Japan, Netherlands, 
Norway, Spain, 
Slovenia, Sweden, 
Switzerland, United 
Kingdom, United States
PCR-based 
HPV testing 
methods 
HPV-16 238/1,435 16,6% 
Morshed et 
al. (2005) Poland PCR HPV-16 26/72 36.1% 
Ma et al. 
(1998) Northeast China PCR, SB, and IHC HPV-16 30/102 29,4% 
ER
YT
H
R
O
PL
A
K
IA
 
D’Costa et al. 
(1998), 
Giovannelli et 
al. (2002), 
Syrjänen & 
Syrjänen 
(2000) 
India, Italy, ??? PCR, ??? HPV-16 9/32 28,1% 
LE
U
K
O
PL
A
K
IA
 
Ostwald et al. 
(2003) Germany PCR, SB 
HPV-
16/18 12/72 16.7% 
*Abbreviations: PCR = Polymerase chain reaction, RT-PCR = Real Time PCR, IHC = 
Immunohistochemistry, SB = Southern Blotting, ISH = In situ hybridization. 
 **Most common HPV types found in studies. 
Table 2. Prevalence of HPV in lesions of the head and neck. 
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4. Conclusion 
The present review showed heterogeneous prevalence between different anatomical sites in 
HNSCC with HPV involvement around the world. These results must be interpreted with 
caution because most researches conducted for data on HPV and HNSCC have been, with 
rare exception, small (<100 cases). The methods employed for case identification have often 
been unclear, and it is difficult to differentiate studies that enrolled consecutive patients 
from studies that used alternative inclusion criteria. Moreover, poor quality of some biopsy 
specimens may also have affected the prevalence estimates with some false-negative 
findings (Kreimer et al., 2005).  
Further standardized seroepidemiologic studies are important to answer some questions, 
among them the impact of HPV vaccination on HNSCC. Thus, epidemiology studies are 
interesting to determine whether the incidence of HPV-positive is increasing, mainly in sites 
frequently affected such as oropharynx, in particular the tonsils. 
In conclusion, with a clear understanding of the prevalence of oncogenic HPV in specific 
populations, an estimate of the progression rate from HPV infection to HPV-positive 
carcinoma may be derived. This effort could help guide screening and prevention strategies 
in the future (Ernster et al., 2009), such as the development of screening programs, new 
therapeutic approaches and specific methods of prevention, especially in high incidence 
areas (Laantri et al., 2011). 
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1. Introduction 
1.1 Epidemiology 
Head and neck squamous cell carcinomas (HNSCCs) remain a significant cause of 
morbidity worldwide, with as many as 466831 and 168368 cases diagnosed in 2008 among 
men and women, respectively (Globocan, 2008; Grandis et al., 2004; Shah et al., 2003). 
HNSCCs constitute a collection of diseases that, despite their shared location and histology, 
can become different types of tumors that differ in pathogenesis, biology, sub-location and 
treatment and that can affect quality of life, including survival (Grandis et al., 2004; Shah et 
al., 2003). HNSCC patients in the early clinical stages (stages I and II) have similar survival 
rates, with a five-year survival between 70 and 90%, independent of the sub-location 
(Forastiere & Trotti, 1999). In contrast, HNSCC patients in the advanced clinical stages 
(stages III and IV) display completely different survival rates depending on the histological 
type of the tumor and its sub-location (Denis et al., 2004; Forastiere & Trotti, 1999). In 2008, 
Globocan data indicated that HNSCCs constituted the sixth and eighth most frequent cancer 
among men and women, respectively. Their frequency has varied over the last 20 years, 
with an increasing prevalence in women, which is highest in Europe, and a decreasing 
prevalence in men, which is highest in the USA. A comparison of global statistics with 
official data from Belgium reveals a strikingly increased incidence of HNSCCs in both sexes, 
with important regional differences. Indeed, Belgium has a higher incidence of HNSCC 
associated with smoking and alcohol consumption compared with other countries. In 2005, 
HNSCCs were the fourth most common cancer in men after prostate, lung and colorectal 
cancers and the eighth most common cancer in women after breast, colorectal, uterine, lung, 
melanoma, ovarian cancers and non-Hodgkin’s lymphoma (Filleul et al., 2011). We can also 
observe inter-regional heterogeneity; in fact, the incidence is higher in men in Wallonia than 
in the Brussels region where the incidence of HNSCC in women rose. Finally, when we 
compare Belgian and French data, these cancers seem more frequent in French men than in 
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Belgian men, but there is an opposite trend among women, in which carcinomas of the 
larynx are more frequent in Belgium than in France.  
1.2 Treatments of HNSCCs 
The treatment of HNSCC patients in advanced disease stages combines surgery, radiation 
oncology, medical oncology, medical imaging and clinical pathology (Denis et al., 2004; 
Forastiere & Trotti, 1999; Grandis et al., 2004; Shah et al., 2003). This type of collaborative 
medical approach was initiated as early as 1970 when Fletcher and Evers reported the first 
convincing evidence showing the benefits of combining radiotherapy with surgery 
(Adelstein et al., 2003). In this context, cisplatin was investigated for the treatment of 
HNSCC in the early 1970s, and, from the late 1970s to the early 1990s, promising results 
were obtained with the use of various combinations of postoperative chemotherapy with 
radiotherapy in randomized (Al-Sarraf et al., 1998) and non-randomized studies (Jeremic et 
al., 2000). In the early 2000s, the Radiation Therapy Oncology Group (Denis et al., 2004) and 
the European Organization for Research and Treatment of Cancer (EORTC) (Cooper et al., 
2004) conducted two randomized studies to test the relative efficacy of concurrent 
postoperative cisplatin administration and radiotherapy in the treatment of HNSCC. These 
two studies demonstrated that local control of the disease was significantly higher in the 
combined therapy group than in the group that received radiotherapy alone. Unfortunately, 
these combined treatments were frequently associated with adverse side effects. Although 
significant progress has been observed after combined treatments, a number of statements 
concerning HNSCCs currently remain valid: (i) almost two-thirds of HNSCC patients have 
advanced forms (stages III and IV) of the disease at diagnosis, (ii) 50% of HNSCC patients 
die within the two years following the initial diagnosis, and (iii) every year, 5% of the 
patients develop additional primary tumors. Therefore, novel approaches seem to be 
required to provide head and neck oncologists with a more effective armamentarium 
against this challenging disease (Bernier et al., 2004; Lang et al., 2004).  
1.3 Risk factors for the development of HNSCC 
Tobacco use and alcohol consumption are now well-established risk factors for the 
development of HNSCC; however, a proportion of HNSCC patients (15–20%) develop 
tumors even in the absence of exposure to these agents (Gillison et al., 2000) Moreover, 
Sturgis and Cinciripini reported that the overall incidence of HNSCC has declined in the 
United States over the past 20 years, which has been attributed to a decrease in smoking. 
Nevertheless, the study also demonstrated an increase in the frequency of tongue and 
pharyngeal cancers (Sturgis & Cinciripini, 2007). These findings suggest the importance of 
other risk factors, such as human papillomavirus (HPV), in the development of 
oropharyngeal and oral carcinomas.  
2. HNSCC and HPV: incidence, biological pathways and impact on prognosis  
Currently, persistent high-risk HPV (hr HPV) infection is widely accepted as the major 
cause of uterine cervical carcinoma with HPV 16 and 18 being the two most implicated 
types. These oncogenic papillomaviruses have also been related to others lesions, such as 
vulvar, vaginal, penile, anal and more recently, head and neck squamous cell carcinomas 
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(Chung & Gillison, 2009). Since 1983 when Syrjänen published the first study analyzing 
HPV infection in HNSCCs, the etiological role of HPV has become increasingly accepted. 
Indeed, although tobacco and alcohol exposure are established risk factors for HNSCCs, 
HPV infection may act synergistically with these carcinogenic agents. Presently, more than 
120 human papillomaviruses have been identified by complete DNA sequence analysis. 
They are classified by family, genus, species and types according to several criteria. More 
precisely, types are determined on the basis of sequence homology to the gene encoding the 
L1 protein, which is the most conserved gene in the HPV genome (Aubin et al., 2007; de 
Villiers et al., 2004; de Villiers & Gunst, 2009). The genotypes are also more commonly used 
to refer the different types. However, in clinical practice, distinctions between HPV types 
include the type of epithelium infected (cutaneous vs. mucosal HPV) and the ability to effect 
cellular transformation. The capacity to transform epithelial cells is divided into high risk 
and low risk HPV: a benign proliferation is associated with the low-risk (lr) HPV type, and 
malignancy is associated with the high-risk (hr) HPV type (Nebesio et al., 2001; Syrjänen et 
al., 2011).  
The human papillomavirus belongs to the highly diverse Papillomaviridae family. The HPV 
virion has a diameter of 55 nm and consists of circular double-stranded DNA containing 
approximately 8000 base pairs (bp). The HPV genome is encapsulated in a proteic capsid of 
72 capsomers. Notably, the lack of envelope makes this virus resistant to environmental 
conditions, infectious for years and resistant to many therapeutics agents. The HPV genome 
consists of three major regions. The non-coding long control region (LCR) of 1000 bp 
contains the p97 promoter controlling E6 and E7 transcription, transcriptional regulatory 
elements and the binding sites for the E2 and E1 gene products (Neufcoeur et al., 2009; 
Ragin et al., 2007). The 3000bp region encodes two structural capsid proteins, namely, the 
late proteins L1 and L2. The icosahedral capsid can be constituted of L1 proteins alone or 
together with L2. The L1 capsid is comprised of 360 L1 molecules assembled as 72 
pentameric capsomers, and the L1-L2 capsid contains 12 additional L2 molecules (Ishii et al., 
2005). The six early proteins are encoded by a 4000bp region: two of the early proteins, E1 
and E2, are regulatory proteins that modulate the replication and transcription of viral DNA 
and the expression of the other early genes; the early protein E4 acts in association with 
keratin filaments in host epithelial cells; the remaining three early proteins, E5, E6, and E7, 
are oncogenes involved in cellular transformation and maintenance of the malignant 
phenotype (Chung & Gillison, 2009; Doorbar & Myers, 1996).  
2.1 Life cycle of the human papillomaviruses and molecular mechanisms of head and 
neck HPV carcinogenesis 
The HPV life cycle is particularly complex. HPV infection requires abrasion in the stratified 
epithelium, providing access to the basal layer. Attachment of the virus to the host cell may be 
achieved through cell surface receptors or glycosaminoglycans, such as heparin sulfate. After 
this attachment, virions can be internalized via clathrin-dependent endocytosis and, after 
uncoating, the viral DNA is transported into the nucleus by the cytoskeleton. During this early 
infection, the virus maintains its genome as a nuclear episome at a low copy number (10-200 
copies per cell) in the basal cell of the epithelium. This slight proliferation is limited in the basal 
cell layers, due to the expression of E1 and E2 proteins, which maintain the viral DNA as an 
episome (Chung & Gillison, 2009; Doorbar, 2005; Monsonégo, 2007). E1 is an ATP-dependent 
helicase initiating the viral replication in cooperation with E2 (Hughes & Romanos, 1993). 
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Moreover, E2 can act as a transcriptional repressor of E6 and E7 expression by binding to the 
non-coding region LCR, and it has a crucial role in the segregation of the viral genome during 
cell division (Psyrri & Dimaio, 2008; You et al., 2004). This initial infection is followed by a 
proliferative phase corresponding to an increased number of viral episomes. Indeed, normal 
epithelial cells differentiate from the basement membrane toward the apical surface. During 
this proliferative phase, the HPV genome may remain episomal or become integrated into the 
host genome. Next, the HPV DNA replicates to a high copy number and is encapsidated to 
produce virions only in terminally differentiated epithelial cells. Integration of the HPV 
genome into the host chromosome is thought to be a late event and to occur at random with a 
predilection for fragile chromosomal sites. This integration also leads to the loss of the E1 and 
E2 genomic sequences, releasing the HPV oncogenes from repression (Ragin et al., 2007). 
Overexpression of both E6 and E7 stimulate cell cycle progression with S-phase entry, leading 
to proliferation of squamous epithelial cells of the upper aerodigestive tract. These two 
oncogenes alter key tumor suppressor pathways. The third oncogene, E5, exerts its 
carcinogenic effects only during the early stages of infection because its gene sequence is 
deleted when HPV integrates the host genome (zur Hausen & de Villiers, 1994). However, this 
protein stimulates cell growth through binding to the epidermal growth factor receptor 
(EGFR), initiating cascades leading to upregulation of proto-oncogenes. The association of E7 
with the retinoblastoma protein (pRb) is now well characterized. The pRb protein is a negative 
regulator of the cell cycle that prevents S-phase entry under normal conditions by associating 
with the E2F transcription factor. The association between pRb and E2F is broken upon HPV 
infection: E7 binds to pRb, leading to its degradation and the subsequent release of E2F, which 
stimulates cell proliferation. Note that the inactivation of pRb results in a reciprocal 
overexpression of the p16 protein, which is an inhibitor of cyclin-dependent kinases. Indeed, 
the Rb gene also regulates p16 by a negative feedback mechanism; consequently, the 
inactivation of pRb leads to p16 upregulation. The expression of this protein is elsewhere 
considered as a surrogate marker for HPV infection in both cervical and head and neck cancer 
(Klozar et al., 2010; Li et al., 1994). The E6 protein of hr HPVs binds simultaneously to a 
cellular ubiquitin ligase, known as the E6-associated protein (E6-AP), and to the tumor 
suppressor protein p53, resulting in its ubiquitination and subsequent proteolytic degradation. 
Normally, p53 regulates growth arrest and apoptosis after DNA damage and, depending on 
the damage incurred; p53 induces a prolonged cell cycle arrest or triggers apoptosis. 
Moreover, HPV infected cells avoid this process of cell death by E6-mediated inactivation of 
p53. This oncogene interferes with other pro-apoptotic proteins of both extrinsic and intrinsic 
apoptotic pathways, such as Bak, FADD and pro-caspase 8 (Garnett et al., 2006; Narisawa-saito 
& Kiyono, 2007; Thomas & Bank, 1999). Thus, these two oncoproteins are essential factors for 
HPV-induced cellular immortalization, transformation and carcinogenesis. Finally, expression 
of the late proteins L1 and L2 occurs in the upper layer, as cells differentiate and allow the 
encapsidation of the genome and the production of new infectious virions, which are released 
into the extracellular environment to re-initiate infection.  
2.2 Epidemiology and incidence of HPV infection in head and neck region 
In recent years, the relation between the presence of HPV DNA and the development of head 
and neck tumors from different anatomical sites was analyzed. Differences in prevalence were 
found from one site to another. For example, the meta-analysis directed by Kreimer considered 
more than 5000 tumors from 60 studies conducted on five continents; the authors showed that 
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oropharyngeal tumors had the highest HPV prevalence (35.6%). Oral and laryngeal (including 
hypopharyngeal) carcinomas were infected in 23.5% and 24% of cases, respectively (Kreimer et 
al., 2005). Note that HPV16 accounted for 86.7% of all HPV-positive oropharyngeal tumors, 
compared with 68.2% in oral and 69.2% in laryngeal squamous cell carcinomas. Recently, Laco 
and colleagues also demonstrated this higher proportion in their study: 24 oral SCCs and 22 
oropharyngeal SCCs (OPSCCs) were analyzed for HPV presence using the polymerase chain 
reaction (PCR). The results indicated that 82% of OPSCCs were HPV-positive, compared with 
13% of OSCCs (Laco et al., 2011). The biological explanation for this higher HPV prevalence in 
tumors arising in oropharynx is becoming clearer. Both the tonsils and the base of tongue are 
lymphoid tissues that produce cytokines, which may affect HPV transcription and promote 
cell transformation (Klussmann et al., 2001). Furthermore, the tonsil epithelium presents 
morphological similarities to those of genital epithelia, such as deep invaginations of the tonsil 
surface that may facilitate viral particle retention. These invaginations, also called crypts, are 
flanked by stratified squamous epithelium, which facilitate viral access to basal cells. 
Additionally, both genital and tonsillar epithelia derive from the same endodermal embryonic 
layer (Ernoux et al., 2009).  
As previously mentioned, reported rates of HPV positivity in HNSCCs vary widely. This 
inconsistency will be discussed with respect to anatomical site in a later chapter. However, 
this widespread variability must be interpreted with caution, but may be partially explained 
notably by differences in methodology of HPV detection. Indeed, according to several 
studies, multiple HPV detection methods are used, such as the polymerase chain reaction 
(PCR), in situ hybridization (ISH) and Southern hybridization. Among these techniques, 
numerous studies agree that PCR is the most sensitive. In fact, a review of the literature by 
Miller and White showed that HPV was identified with a higher frequency by using PCR 
(37.1%) than by using moderate- or low-sensitivity assays, such as Southern hybridization 
(27.2%) or ISH and immunohistochemistry (25.2%) (Miller & White, 1996). However, despite 
an increase in the use of PCR to detect HPV, variability in prevalence still exists and may be 
attributed to differences in the sensitivity of the PCR primer sets. Different consensus primer 
sets are used to detect and amplify HPV DNA, but the two most frequently used are the 
GP5+/GP6+ and the MY09/11 primers. Moreover, it seems that GP5+/GP6+ primers are 
more sensitive than MY09/11 for HPV detection in oral samples. Remmerbarch also 
recommends the PCR approach with nested GP5+/GP6+ primers (Remmerbach et al., 2004). 
Other explanations for the varying rates of prevalence could be the sample sources and 
collection methods (scalpel biopsy, swabs, brushings, and mouthwash). The geographical 
locations of the studies may also contribute to variations in HPV prevalence. Indeed, HPV 
prevalence in OSCCs is similar in Europe (16%) and North America (16.1%) but significantly 
greater in Asia (33%). For OPSCCs, the prevalence is significantly higher in North America 
(47%) compared with Europe (28.2%) (Kreimer et al., 2005). Finally, patient profiles, such as 
smokers vs. non-smokers and/or drinkers vs. non-drinkers, could also contribute to some 
variations. It turns out that the literature presents conflicting accounts of the association 
between smoking and/or drinking and HPV in the development of HNSCCs. Indeed, we 
can distinguish three distinct categories: studies showing that HPV is clearly associated with 
an increased risk of HNSCC in non-smokers, studies finding no difference in HPV-related 
carcinoma between smokers and non-smokers and studies providing evidence of an 
additive or synergistic effect between smoking and HPV-related HNSCC (Sinha et al., 2011). 
Fouret observed a higher prevalence of HPV in non-smokers, while an additive interaction 
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was observed by Smith. HPV-positive smokers presented a greater risk of HNSCC 
compared with HPV-negative smokers or HPV-positive non-smokers (Fouret et al., 1997; 
Smith et al., 2004a). On the other hand, Paz found no statistical association between tumor 
HPV status and tobacco use (Paz et al., 1997). Biologically, smoking and alcohol can cause 
cellular and structural modifications in oral epithelia, which potentially increase the 
permeability to viral infection. These environmental agents are also known to suppress 
mediators of immune functions, facilitating HPV infection persistence (Pannone et al., 2011; 
Ragin et al., 2007; Sinha et al., 2011).  
2.3 Prognosis of HPV positive head and neck squamous cell carcinoma 
The significance of hr HPV infection and its impact on patient prognosis remains an 
important matter of debate, although a majority of studies have now confirmed an 
improved survival of HPV-positive patients compared with HPV-negative patients (Fakhry 
et al., 2008; Lindel et al., 2001; Lindquist et al., 2007). However, this strong positive 
prognostic factor is often confirmed in tonsillar and oropharyngeal carcinomas. Notably, the 
majority of studies that demonstrated increased survival were reporting on patients with 
oropharyngeal and/or tonsillar tumors (Ang et al., 2010; Lindel et al., 2001; Sedaghat et al., 
2009). The meta-analysis by Ragin et al. examining the relationship between HPV and 
overall survival did not show any survival differences between HPV-positive and HPV-
negative patients with cancer in non-oropharyngeal sites (Ragin et al., 2007). The same 
observation was made by Gillison et al., suggesting that these tumors may have an etiology 
distinct from that of tumors in non-oropharyngeal sites (Gillison et al., 2000). In fact, this 
subset of oropharyngeal HPV-positive cancers possesses distinct clinical features and 
outcomes, and it is particularly common in individuals who lack the traditional risk factors 
of tobacco and alcohol abuse. While it is unclear whether tobacco is a risk factor for HPV-
induced oropharyngeal tumors, it seems that smoking has a negative impact on the survival 
of patients with HPV-positive tumors (Hafkamp et al., 2008). Nevertheless, there are reports 
in the literature on the prognostic significance of HPV infection describing a reduced 
influence on prognosis and other reports demonstrating no influence on prognosis. Indeed, 
two Swedish studies demonstrated that oral HPV infection was associated with a 
dramatically increased risk of OSCC development (Hansson et al., 2005; Rosenquist et al., 
2007). Additionally, in 1994, Clayman et al. also showed that HPV detection significantly 
correlated with decreased survival (Clayman et al., 1994). On the other hand, other studies 
have failed to demonstrate an association between HPV positivity and prognosis (Duray et 
al., 2011a; Ernoux et al., 2011; Koskinen et al., 2003; Morshed et al., 2010). From a biological 
point of view, it is difficult to explain why patients with HPV infections have a worse 
survival than HPV-negative patients. One possible explanation is that HPV infected cells in 
locations with inflammatory activity may be stimulated to divide, facilitating tumor 
development (Dahlgren et al., 2004). Another hypothesis is that immunosuppression may 
favor HPV infection (Duray et al, 2010). In 2004, Kreimer reported that tonsillar HPV 
infection was strongly associated with HIV co-infection and immunosuppression (Kreimer 
et al., 2004). Recently, herpes simplex virus-2 (HSV2) infection was demonstrated to increase 
the risk of HPV infection (Moscicki et al., 2001). Furthermore, a study performed by Tung et 
al. reported the presence of HPV-16 or -18 and Epstein-Barr virus (EBV) in 80% of 
nasopharyngeal carcinoma samples (Tung et al., 1999). These co-infections might play an 
important role in the initiation of neoplastic transformation in human oral epithelial cells. 
HPV infections have also been implicated in several tumor cell immune escape mechanisms, 
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such as the absence of an inflammatory response against tumor cells, the production of 
regulatory cytokines and the downregulation of Toll-like receptor 9 (Lepique et al., 2009). 
3. HPV related head and neck carcinomas versus HPV non-related head and 
neck carcinomas: two different tumor entities 
Head and neck tumors are now defined as two separate clinical entities: HPV-positive 
tumors and HPV-negative tumors. The tumors differ both clinically and molecularly. HPV-
positive tumors present distinct histopathological features, including notably non-
keratinizing basal cells and a prominent “koilocytic” morphology. These features were also 
associated with a basaloid morphology that is a morphologic variant of HNSCC (Williams et 
al., 1996). These HPV-positive tumors are also known to occur in a younger age group, to 
originate more frequently in the oropharynx (especially in the palatine tonsils and at the 
base of tongue), to be poorly differentiated because patients present with later-stage disease 
and to have a lower T-stage than HPV-negative tumors (Marur & Forastière, 2008). Another 
particularity concerns the overall survival, which seems to be better for HPV-infected 
patients. Indeed, the majority of studies agree with that of Gillison and colleagues, who 
found that the risk of dying from disease was reduced in patients with HPV-positive 
HNSCC (Gillison et al., 2000). HPV-positive and HPV-negative tumors also exhibit 
differences in tumor biology with HPV-positive tumors having fewer p53 mutations and 
displaying reduced association with tobacco and alcohol consumption. In fact, 
approximately one-third of the tumors harbor p53 mutations, but a marked difference in p53 
mutation frequency is generally found when comparing HPV-positive and HPV-negative 
oropharyngeal tumors. Thus, this inverse association between p53 mutations and HPV 
detection in the oropharynx further suggests that HPV-positive and HPV-negative HNSCCs 
should be considered to be two distinct cancers with two parallel pathways: one driven by 
environmental agents (tobacco and alcohol) and another driven by infectious agents (high-
risk HPVs). However, these two pathologic agents may interact and act synergistically to 
lead to the development of HNSCCs. All these observations frequently focus on the 
oropharynx, strengthening the etiologic role of HPV in oropharyngeal carcinomas. 
Nevertheless, the implication of HPV in non-oropharyngeal tumors is less firmly established 
(Gillison et al., 2000). Indeed, among HNSCC biopsies, the real HPV prevalence remains 
uncertain, due to the varying incidence rates reported in different studies.  
4. Incidence of HPV in the general population and modalities of transmission 
HPV infection of the oral cavity has not been studied extensively. In fact, the majority of 
studies on the oral and oropharyngeal cavities considered patients with benign or malignant 
lesions and did not include healthy patients. However, to establish the etiology and 
pathogenesis of HPV-associated lesions, it is important to investigate the prevalence of HPV 
in normal tissues. An overview of the literature describing HPV detection in normal head 
and neck mucosa in children and adults is shown in Table 1.  
4.1 Incidence of HPV in normal oral mucosa 
The prevalence of HPV DNA in normal oral mucosa ranges from 0% to 56.7% in healthy 
adults (Table 1). To date, several studies have also evaluated the presence of HPV infection 
in the healthy oral cavity of children. In fact, it is important to know the prevalence of HPV 
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infections in childhood because HPV infection early in life could represent a risk factor for 
the development of head and neck cancer later in life. A prevalence of HPV infection in the 
oral cavities of children aged 0.3-11.6 years ranging from 0% to 47% has been reported 
(Syrjänen, 2010). The highest HPV prevalence rates by age group are detected before 1 year 
of age; the second peak occurs in adolescents aged 13-20 years (Smith et al., 2004b, 2007, 
2010; Summersgill et al., 2001). According to the age studied, there are variations in the 
prevalence rate. In nasopharyngeal aspirates collected immediately after birth, the detection 
rate of HPV varies from 1.5% to 37% (Cason et al., 1995; Castellsague et al., 2009; Mazzatenta 
et al., 1996; Puranen et al., 1996, 1997; Rintala et al., 2005a, 2005b; Rombaldi et al., 2008; 
Sedlacek et al., 1989; Tenti et al., 1997, 1999; Watts et al., 1998). At the age of 1-4 days, Smith 
et al. in two studies found a low HPV incidence (from 0.9% to 1%) in the buccal swabs of 
neonates, whereas other studies showed a higher prevalence varying from 40% to 56% 
(Cason et al., 1995; Kaye et al., 1994; Pakarian et al., 1994; Tseng et al., 1998; Smith et al., 
1995, 2004b). Similarly, the detection rate of HPV in infants between 6 weeks and 6 months 
after delivery varied between 0% and 62% (Cason et al., 2005; Fredericks et al., 1993; Kaye et 
al., 1994; Pakarian et al., 1994; Watts et al., 1998) and among 3-year-old children varied 
between 10% and 40% (Kojima et al., 2003; Puranen et al., 1996, 1997; Szydlowski et al., 
2004). Mant et al. studied the acquisition and the clearance of HPV in the buccal mucosa of 
4- to 9-year-old children and showed that, during a 30-month follow-up, 63% of 19 initially 
HPV-negative children acquired new HPV16 infection, while 40% of 22 initially HPV-
positive children cleared the virus (Mant et al., 2003). In contrast, the Finnish Family HPV 
study found lower rates, which may be due to the fact that the children were younger and 
the detection method less sensitive. In fact, they found that, during the three-year follow-up, 
42% of the children acquired incident infection, while 11% cleared their infection and 10% 
had persistent oral HPV infection (Rintala et al., 2005a, 2005b).  
4.2 Incidence of HPV in normal tonsil 
Regarding the literature, only a few studies have assessed the presence of HPV DNA in 
normal tonsillar tissues, with HPV detection rates varying from 0% to 24.4% in 
children/adolescents and 0% to 100% in adults (Table 1). In order to understand the 
epidemiology of HPV in the healthy population, we detected HPV in the palatine tonsils of 
children and adults who underwent tonsillectomy (recurrent tonsillitis, n=64) or sleep 
surgery (apnea: n=9; snoring: n=7). Among our series of 80 disease-free tonsils, 12.5% (10 
cases) tested positive for hr HPV types [HPV16 (8 cases), HPV18 (1 case) and HPV31 (1 
case)], 15% (12 cases) were positive for lr HPV types and 72.5% (58 cases) were negative. 
Among the hr HPV-positive tonsils, five were from children/adolescents and five were 
from adults (Duray et al., 2011b). By the end of 2002, Syrjänen compiled several studies from 
the United States, Japan, and Western Europe. In total, he determined an 8.5% (17 of 200) 
HPV positivity rate, either type 16 (12 cases) or type 6/11 (5 cases) (Syrjänen, 2004). A Greek 
study determined the presence of HPV DNA in children. They found 9 of 106 tonsils to be 
HPV-positive, with six cases having HPV-16, two cases having HPV-11 and one case having 
an untyped HPV (Mammas et al., 2006). Another study reported HPV-16 infection in 13 of 
206 tonsils (6.3%) with 11 cases from children or young adults aged less than 25 years (Chen 
et al., 2005). These findings differed from those of several other studies in which low 
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prevalence or no prevalence of oncogenic and non-oncogenic HPV was identified in the 
specimens studied (Brandsma & Abramson, 1989; Ernster et al., 2009; Klingenberg et al., 
2010; Klussmann et al., 2001; Niedobitek et al., 1990; Ribeiro et al., 2006; Sisk et al., 2006; 
Snijders et al., 1992). In these anatomical sites, HPV-6 and -11 and HPV-16 and -18 were the 
most common types of lr and hr HPV, respectively (Table 1). According to the literature, 
prevalence rates of oral HPV in normal individuals vary substantially. It is believed that this 
great variation in HPV prevalence rates found in head and neck studies may be due to 
several factors, including the anatomical site, ethnic and geographical differences, the size of 
the cohorts, the sample collection methods (i.e., biopsy, lavages, scrapes), the materials used 
for testing (i.e., formalin-fixed biopsies, frozen or fresh biopsies, exfoliated fresh cells), and, 
probably most importantly, the HPV detection methods used (PCR, in situ hybridization, 
Southern blot hybridization). For example, using PCR and DNA hybridization techniques, 
the results showed a prevalence ranging from 0% to 81% (Castro et al., 2009; Ribeiro et al., 
2006) in oral mucosa swabs of adults, whereas in biopsies, the rate was less variable with 
detection of HPV in 0% to 55% (Table 1). The disadvantages of oral rinsing and cytological 
scraping or brushing are that they collect superficial epithelial cells and that no additional 
tests were performed for validation (Klingenberg et al., 2010). Moreover, no viruses  
from latent infections in the basal or suprabasal layer cells are removed (Esquenazi et al., 
2010). 
4.3 Modalities of transmission of HPV  
4.3.1 Sexual mode of transmission 
It is now well established that, in the case of cervical cancer, HPV infection is a sexually 
transmitted disease, but little is known about transmission of oral HPV infection in the 
general population. In the literature, the majority of the studies evaluated the prevalence of 
HPV and the risk of sexual transmission in HNSCCs, but few studies tried to determine the 
frequency and the modalities of sexual and nonsexual HPV transmission in other groups, 
such as normal children and adult. In fact, Gillison and colleagues conducted a case-control 
study that compared 100 patients with oropharyngeal SCCs and 200 control patients, and 
they demonstrated that oral HPV infection was strongly associated with oropharyngeal 
carcinoma among patients who did not have the classical risk factors of tobacco and alcohol 
use. Moreover, these authors also demonstrated that a high lifetime number of oral sex or 
vaginal sex partners, engagement in casual sex, an early age at first intercourse, and the 
infrequent use of condoms were all associated with HPV-16-positive oropharyngeal cancer. 
These findings suggest that oral HPV infection is sexually acquired and is involved in the 
carcinogenesis of oropharyngeal cancer (D’Souza et al., 2007). More recently, they 
explored whether these sexual behaviors were associated with oral HPV infection in two 
distinct populations (a control patient population and a population of college-aged men). 
The first population (control group), which was enrolled in two case-control studies 
nested within a prospective cohort with HNSCC, consisted of patients at the Johns 
Hopkins outpatient otolaryngology clinic who were ≥ 18 years of age and had no history 
of cancer. The second population (college-aged men population) included male students 
who were > 17 years (women were excluded because some might have received the HPV 
quadrivalent vaccine). Oral HPV infection was detected in 4.8% of 332 control patients 
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and in 2.9% of 210 college-aged men. Among the control group, the odds of developing 
oral HPV infection were significantly greater with increases in the lifetime number of oral 
or vaginal sex partners, whereas among the college-aged men, the odds of developing oral 
HPV infection were significantly greater with increases in the lifetime number of oral sex 
or open-mouth kissing partners, but not with increases in the lifetime number of vaginal 
sex partners. They concluded that oral HPV infection is sexually acquired and is 
transmitted by behaviors such as oral sex and open-mouth kissing (D’Souza et al., 2009). 
However, Smith et al. examined the prevalence of HPV in a large series of pregnant 
women to evaluate the concordance between infection of the cervix and the oral cavity. 
The lack of concordance in HPV types in either of the mucosal sites in pregnant women, 
between detection in the cervix and oral contact, and between females and males, 
suggests that the transmission of infection by auto-inoculation or by oral-genital sex 
between partners is low, suggesting that a number of issues remain unclear about the 
mechanisms of HPV transmission (Smith et al., 2004c). Another study also showed that 
despite a high frequency of oral-penile contact among young adults, the detection of oral 
HPV was rare, and no association between oral-penile contact and oral HPV infection was 
found (Winer et al. 2003). 
4.3.2 Nonsexual mode of transmission 
In children, the modalities of HPV transmission are difficult to explain. Gutman and 
colleagues described anogenital HPV disease in children after abusive sexual contact 
(Gutman et al., 1993). However, the high incidence of HPV infection observed in healthy 
children indicates that the transmission need not be sexual. To explain these pediatric 
HPV infections, several nonsexual modes of transmission can be proposed, including 
vertical transmission, horizontal transmission and autoinoculation. It can be due to a 
vertical transmission, which is divided into three subtypes depending on the assumed 
time of HPV transmission: (1) peri-conceptual transmission (time around fertilization) 
occurs theoretically via the infected oocyte or spermatozoon. Several studies showed the 
presence of HPV DNA in 8 to 64% of semen samples from asymptomatic men and also in 
seminal plasma and spermatozoa (Syrjänen, 2010). (2) Prenatal transmission (during 
pregnancy) has been proposed by studies reporting HPV DNA in amniotic fluid, placenta 
and cord blood samples. In placental samples, the rate of HPV DNA detection varied from 
0% to 42.5% (Syrjänen, 2010). Rombaldi et al. observed an HPV infection in 23.3% of the 
cases studied and transplacental transmission in 12.2%. A significant correlation was also 
observed between placental HPV and the immunosupressive status of the mother 
(Rombaldi et al., 2008). Furthermore, Sarkola and colleagues found that HPV DNA was 
three times more prevalent among women who had smoked compared with never-
smokers (Sarkola et al., 2008a). In amniotic fluid and cord blood, the prevalence of HPV 
varied from 15% to 65% and 0% to 13.5%, respectively. (3) Perinatal transmission occurs 
during birth and immediately thereafter. HPV transmission may be the result of close 
contacts between the fetus and infected cervical and vaginal cells of the mother during 
delivery. Using DNA sequencing, several authors have shown that the mother is the 
source of infection with evidence of virus transcription in some children (Cason et al., 
1995; Kaye et al., 1996). Vertical transmission was considered when the maternal HPV 
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type matches the HPV type isolated from the newborn/child. In 1989, Sedlacek et al. were 
the first to demonstrate HPV DNA in the nasopharyngeal secretions of infants delivered 
vaginally by mothers with genital HPV infection (Sedlacek et al., 1989). Since then, several 
authors evaluated the rate at which HPV is transmitted from mother to newborn/child, 
but this rate is extremely variable among studies. Medeiros and colleagues proposed the 
first systematic review on vertical HPV transmission, which included 2111 pregnant 
women and their 2113 newborns. They showed that pooled mother-to-child HPV 
transmission was 6.5% and was higher after vaginal delivery than after cesarean section. 
The authors also showed that the combined relative risk of mother-to-child HPV 
transmission was 7.3 (Medeiros et al., 2005). Rombaldi et al. determined the rate of 
maternal HPV transmission using PCR and nested multiple PCR on maternal cervical 
swabs and neonatal nasopharyngeal specimens. They reported that the perinatal 
transmission of HPV DNA occurred in 24.5% of the cases studied (Rombaldi et al., 2009). 
Other studies also suggest that vertical transmission is common, occurring in 40% to 80% 
of cases (Puranen et al., 1996; Rintala et al., 2005b; Tseng et al., 1998). These high rates of 
vertical HPV transmission were not confirmed by several studies, which found that the 
risk of vertical transmission to the oral or genital mucosa of newborns was rare (1-5%) 
(Smith et al., 1995, 2004b, 2010; Syrjänen & Puranen, 2000 Tenti et al., 1999; Watts et al., 
1998). In two previous studies by Smith et al., only one mother/newborn pair was 
concordant for an HPV type, and among 203 infants, two had detectable HPV in oral or 
genital swabs (Smith et al., 1995, 2004b). Studies on persistent HPV infection showed that 
the concordance between mother/newborn infections was maintained between 37% to 
83% at six weeks to six months after birth (Cason et al., 1995; Fredericks et al., 1993; Kaye 
et al., 1996), whereas Rintala et al. found that the prevalence declined to 10% in infants at 
24 months of follow-up. This prospective cohort study assessed the dynamics of HPV 
transmission between parents and infants. They showed that the most common HPV 
profile was hr HPV in all family members, followed by HPV-positive mother-infant pairs, 
whereas HPV-positive father-infant pairs were less frequent. No such independent risk 
could be attributed to subclinical HPV infection in the father, but oral and genital HPV in 
the mother affected the risk of infant HPV (Rintala et al., 2005b). Thus, our results support 
the possibility of vertical transmission during pregnancy or perinatal transmission at the 
time of delivery. In other studies, the non-concordance of type-specific HPV between 
mother and newborn or the presence of oral HPV DNA in young children who were born 
to HPV-negative mothers suggest the existence of other transmission routes, such as the 
horizontal transmission of HPV. In these cases, HPV infection can be transmitted by milk 
during breastfeeding, by siblings via kissing, and by householders and friends via digital 
contacts (Syrjänen, 2010). There is one recent article showing the presence of HPV in 4% of 
223 breast milk samples 3 days postpartum, regardless of the mother’s oral or cervical 
HPV status (Sarkola et al., 2008b). Transmission via infected surfaces or other fomites, 
such as clothes, toys or eating utensils, is also possible. Autoinoculation can occur by 
scratching from one site of the body to another or by bathing (Myhre et al., 2003; Syrjänen 
& Puranen, 2000). HPV is known to multiply locally at the site of entry on the skin or 
mucous membranes; by deduction (logically) there is no viremia and no blood spread, but 
one study showed the presence of HPV in peripheral blood mononuclear cells (PBMCs) 
from HIV-infected pediatric patients and from healthy blood donors (Bodaghi et al., 2005). 
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5. Characteristics of infected benign and malignant head and neck lesions 
and prevalence site by site in head and neck region 
5.1 The recurrent respiratory papillomatosis (RRP) 
As briefly described previously, HNSCCs are characterized by varying rates of incidence 
and mortality around the world, such as higher rates in Southeast Asia and Eastern Europe 
(Kreimer et al., 2005). At present, it is known for certain that HPVs are the etiological agent 
of many benign and malignant tumors arising from epidermal tissues. Nearly thirty years 
ago, Gissmann and colleagues were the first team to detect DNA sequences from HPV types 
6 and 11 in laryngeal papillomas (Gissmann et al., 1983). Laryngeal papillomatosis, also 
known as recurrent respiratory papillomatosis (RRP), is characterized by the recurrent 
growth of exophytic, wart-like lesions called papillomas, along the epithelium of the upper 
respiratory tract, such as the vocal cords, the arytenoids, the subglottis, the trachea and most 
commonly, the larynx (Lacey et al., 2006; Mammas et al., 2009). Although the RRPs are 
benign, their recurrent nature and location in the airways require frequent surgical removal 
and can cause significant morbidity and occasional mortality secondary to airway 
obstruction. Smoking and low-risk or high-risk HPV infections have also been proposed to 
be cofactors in the conversion of laryngeal papillomas into carcinomas (Doyle et al., 1994). 
These lesions were first described in the late 1800s by Sir Morrell Mackenzie, who 
recognized papillomas as distinct lesions of the laryngo-pharynx in children. RRPs are 
mostly caused by the low-risk HPV types 6 and 11, with a more aggressive disease course 
for the latter type. The disease is also categorized into juvenile onset (JORRP) and adult 
onset (AORRP) forms based on age at diagnosis. JORRP can be observed immediately 
during the postnatal period, but it is most commonly diagnosed between two and four 
years. In AORRP, the peak incidence ranges from 20 to 40 years of age, with dysphonia and 
hoarseness, and respiratory obstruction being the most common presenting symptoms in 
children and adults, respectively (Larson & Derkay, 2010). In cases of JORRP, lesions are 
suspected to originate from a perinatal infection of mothers with condylomatous lesions, 
which are an overwhelming risk factor. Thus, the virus is generally transmitted during 
gestation or during birth when the baby passes through the infected birth canal. In a Danish 
study, Silverberg and colleagues demonstrated that maternal condyloma during pregnancy 
increased the risk of JORRP in the child more than 200-fold (Silverberg et al., 2003). 
Moreover, 54% of childhood RRP patients were born to mothers with a history of vulvar 
condylomata at the time of delivery (Hallden & Majmudar, 1986). Among AORRP patients, 
the transmission mechanisms clearly vary. The infection probably results from sexual or 
non-sexual contact with an infected lesion. This evidence has been suggested by a case 
control study that showed AORRP patients were more likely to have more sexual partners 
and to have oral sex than controls (Kashima et al., 1992). Additionally, HPV is also able to 
form latent infections in healthy mucosa, suggesting that AORRP could be due to a 
reactivation of a latent HPV infection acquired during birth (Goon et al., 2007; Larson and 
Derkay, 2010). Thus, the relationship between HPV and laryngeal papillomatosis is well 
established. Indeed, it has been shown that 95% of solitary laryngeal papillomas in adults 
were positive for HPV (Lindeberg & Johansen, 1990). Moreover, Dickens et al. reported 
evidence that 59% of laryngeal papillomas showed the presence of the four most common 
subtypes, including the two low-risk dominant types 6 and 11 (Dickens et al., 1991). In 
general, the prevalence of RRP was estimated at between four to seven cases per million 
person-years, and the incidence is about 2 per 100,000 in adults and 4 per 100,000 in children 
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(Goon et al., 2007). A report in the United States estimated the number of new cases of 
childhood onset RRP was 1500 to 2500 each year (Derkay, 1995). 
5.2 Implication of HPV in other benign lesions of the upper aerodigestive area 
As in RRP, HPV is also involved in the development of different benign lesions occurring 
in the oral cavity, the pharynx, the larynx and the nasopharynx. Numerous studies have 
been conducted on benign tumors arising in the head and neck to evaluate the possible 
role of HPV in head and neck neoplasms. However, its implication in carcinogenesis is 
still controversial because of the different frequencies detected. Kashima et al. examined 
the diagnostic and prognostic relevance of HPV in 26 squamous papillomas and 29 
inverted papillomas. They examined the presence of four HPV types using the PCR 
amplification technique. The proportion of tissue samples showing HPV infection was 
15% and 24% for squamous papillomas and inverted papillomas, respectively, with HPV 
types 6 and 11 being the only two types detected in these lesions (Kashima et al., 1992). 
Four years later, HPV was detected with a prevalence of 81.8% in 22 cases of laryngeal 
squamous papillomas (LP) and 42.5% in 40 cases of nasal inverted papillomas (NIP). HPV 
types 6 and 11 were again implicated, with a slight bias for HPV 6 in LP and HPV 11 in 
NIP, suggesting that HPV may play a role in the development of both lesions, and that 
these viral types may exhibit relative differences in their tissue specificity (Shen et al., 
1996). On the other hand, Hoffmann and colleagues had investigated whether HPV was 
implicated in sinunasal polyposis and found a positive signal in only 1 of the 39 
investigated cases (2.6%) (Hoffmann et al., 2000). In oral and oropharyngeal areas, 
squamous cell papillomas are also benign tumors that occur mainly between 30 and 50 
years of age but still represent about 8% of oral tumors in children (Castro & Filho, 2006). 
Many types of tumors can develop in the oropharynx and oral cavity, such as condiloma 
acuminata, the common wart and focal epithelial hyperplasia (FEH). Condiloma 
acuminata (CA) is often considered a sexually transmitted disease, but the trend is to 
consider that it may also be acquired by auto-inoculation or by maternal transmission 
(Castro & Filho, 2006; Syrjänen, 2003). HPV was detected in CA with a positivity rate 
varying between 75% to 85% for the two most frequent lr HPVs, HPV 6 and 11 (Chang et 
al., 1991; Syrjänen, 2003). Common warts, one of the most common skin lesions, are 
frequently located on the lips, hard palate, gums and tongue dorsum. HPV detection rates 
in oral warts have been shown to vary between 43% and 100% (Padayachee, 1994; 
Praetorius, 1997; Zeuss et al., 1991). Although the near 100% positivity of HPV 6 and 11 is 
well established for the majority of benign tumors, it has been shown that HPV 2 and 
HPV 57 were more prevalent in common oral warts (Padayachee, 1994). Finally, oral focal 
epithelial hyperplasia (FEH), also known as Heck’s disease and characterized by multiple 
nodular elevations, is a third benign oral lesion that may be located in the oral mucosa, 
lower lips and tongue. Like for oral warts, HPV 6 and 11 are not the major types found in 
FEH. Indeed, HPV 13 and 32 have been identified in 75% to 100% of the cases (Praetorius, 
1997). These two types were considered specific to focal epithelial hyperplasia, while HPV 
32 was also found in other oral lesions (de Villiers, 1989). In 2002, Schwenger and 
colleagues showed that 100% of FEH cases tested were positive for HPV 13 and/or 32 
(Schwenger et al., 2002). Moreover, in a recent Brazilian study, of sixteen benign tumors 
found among 86 examined oral lesions, 100% were positive for HPV (Lira et al., 2009). To 
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confirm the great prevalence of HPV in benign laryngeal lesions, Arndt et al. assessed the 
presence of HPV genomes 6, 11, 16, 18, 31, 33 and 35 in 17 juvenile laryngeal papillomas 
(JLP), 27 adult laryngeal papillomas (ALP), 15 oral papillomas (OP) and 11 laryngeal 
leukoplakias (LL). The results showed 100% positivity for HPV 6 and 11 in JLP and ALP, 
87% in OP and 63% in LL, whereas hr HPV 16, 18 and 33 were found in 22% of ALP, 20% 
of OP and 36% of LL, suggesting that the role of HPV in malignant transformation is less 
clear than in benign tumors (Arndt et al., 1997). In 2005, a combination of PCR and nested 
PCR was applied to improve the detection level of infected samples. Among 27 biopsies 
from different head and neck regions, such as the larynx, nasal cavities and sinuses, 
pharynx and oral cavity, 16 showed a positive result in either PCR or nested PCR or both, 
suggesting that this PCR system is a reliable tool for the detection of HPV DNA in benign 
lesions of the upper aerodigestive tract (Fisher et al., 2005). Conversely, in a retrospective 
study, 36 head and neck papillomata were tested for HPV 6, 11, 16 and 18 using PCR, and 
the results were not consistent with a role for HPV infection in the etiology of head and 
neck papillomata in adult patients. In fact, only 20% of benign tumors were positive for an 
HPV type (Campos-Bañales et al., 1995). Finally, in 2011, we assessed the presence of HPV 
DNA in a series of 39 laryngeal benign lesions (LBLs) from 20 cases of vocal nodules, 13 
cases of chronic laryngitis and 6 cases of papillomas. The analysis was performed by PCR 
using the GP5+/GP6+ primers that amplify a conserved sequence located within the L1 
region of the HPV genome. Next, all DNA extracts were tested for the presence of 18 
different HPV genotypes using TaqMan-based real-time quantitative PCR. Four out of 39 
specimens had insufficient tissue quantities for DNA extraction after pathological 
evaluation and were, therefore, excluded from further analyses. Note that PCR was also 
performed using β-globin primers to demonstrate the presence of amplifiable DNA in the 
tissue extracts. All 35 LBLs gave positive signals for β-globin. Among these 35 cases, we 
identified 27 lesions (77%) that were positive for HPV 16. In the hr HPV-negative 
subgroup (n=8), two specimens tested positive for HPV using the GP5+/GP6+ consensus 
primers and were considered infected with lr HPV types (Fig. 1). Only six benign lesions 
were negative in both GP5+/GP6+ and type-specific HPV PCR analyses (17%). Among 
the 27 hr HPV-positive lesions, 12 were both positive for GP5+/GP6+ and type-specific 
HPV (hr HPV+ group), whereas 15 were negative for GP5+/GP6+ and positive for type-
specific HPV, which corresponds to the integrated HPV-positive group (int. hr HPV+) 
(Fig. 1) (Duray et al., 2011a).  
This discrepancy observed in varying rates of incidence is mainly attributed to a variation in 
the sensitivity of the methods employed and in the epidemiological factors related to the 
group of patients examined. Indeed, the different methods have been classified in three 
categories according to the detection threshold of viral DNA copy number in the cell: 
techniques having a low sensitivity, such as immunohistochemistry and in situ 
hybridization; techniques with moderate sensitivity, such as Southern blot, dot blot and 
reverse dot blot hybridizations; and techniques displaying high sensitivity, such as the 
polymerase chain reaction, which can detect the virus in less than one copy per cell (Castro 
& Filho, 2005). Nevertheless, each method is limited by its sensitivity, its specificity, its 
practice and its cost, among other limiting factors. In conclusion, it is important to assess the 
efficacy of the different HPV detection techniques in order to establish HPV etiology in oral 
lesions.  
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Fig. 1. HPV PCR results from 39 OSCC cases. Four samples could not be analyzed due to 
insufficient material, and β-globin could be amplified in all samples. Therefore, 35 cases in 
total were analyzed by type-specific real-time PCR and GP5+/GP6+ consensus PCR. Among 
these patients, 77% tested positive for infection with one or several types of hr HPV, 6% 
tested positive for lr HPV and 17% were HPV-negative. 
5.3 Implication of HPV in malignant tumors of the upper aerodisgestive area 
5.3.1 Incidence in hypopharyngeal tumors 
HNSCC represents the sixth most common malignancy with an annual incidence of more 
than 600,000 cases worldwide and is responsible for approximately 350,000 deaths each year 
(Parkin et al., 2005). These cancers mainly comprise the hypopharyngeal, laryngeal, 
oropharyngeal and oral cancers. Depending on the anatomical location of the primary 
tumor, HNSCCs show an HPV prevalence of between 20% and 30% for hypo-, laryngeal and 
oral carcinomas and up to over 50% for tonsillar squamous cell carcinomas, especially 
Waldeyer’s tonsillar ring (Deng et al., 2011). Furthermore, there is a persistent controversy 
on the role of HPV infection in HNSCC progression and on the influence of these infections 
on the final clinical outcome. Hypopharyngeal carcinoma is one of the less documented 
head and neck cancers in the literature. Indeed, few studies are exclusively devoted to 
hypopharyngeal cancers. Thus, the few cases available arise from certain studies that 
 
Implications of Human Papillomavirus Infections in the Biology of Head and Neck Cancers 
 
243 
sometimes include hypopharyngeal cases in their cohort. Based on the literature, we 
observed a prevalence ranging from 0% to 82% (Ernoux et al., 2011; Hafkamp et al., 2003; 
Ringström et al., 2002). In fact, some authors failed to show prevalence higher than 10% 
(Gillison et al., 2000; Hafkamp et al., 2003; Ribeiro et al., 2011; Ringström et al., 2002; 
Stremlau et al., 1987), whereas others found prevalence greater than 50% (Arndt et al., 1992; 
Ernoux et al., 2011; Kleist et al., 2000; Koskinen et al., 2003; Tyan et al., 1993). Recently, we 
examined the presence of HPV DNA in a series of 75 patients with stage IV hypopharyngeal 
SCC (Ernoux et al., 2011). The same methods used previously to detect the virus in our 
paraffin-embedded samples (PCR using GP5+/GP6+ primers and subsequent TaqMan-
based real-time quantitative PCR targeting type-specific sequences of 18 HPV types) were 
employed in the study. Of the 75 specimens, 8 had insufficient tissue for DNA extraction or 
quantitative PCR and were, therefore, excluded from further analysis (Fig. 2). Of the 
remaining 67 cases, another 6 from which were β-globin PCR-negative were also excluded 
from further analysis. Ultimately, 61 β-globin PCR-positive specimens were typed by 
quantitative real-time PCR using primers for 18 different HPV types (Fig. 2). 
 
Fig. 2. HPV PCR results from 75 OSCC cases. Eight samples could not be analyzed due to 
insufficient material, and β-globin could not be amplified in six additional samples. 
Therefore, 61 cases in total were analyzed by type-specific real-time PCR and GP5+/GP6+ 
consensus PCR. Among these patients, 82% tested positive for infection with one or several 
types of hr HPV, 7% tested positive for lr HPV and 11% were HPV-negative. 
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
244 
From this homogeneous group of 61 HSCC tumor specimens, we identified 50 samples 
(82%) that tested positive for the following hr HPV types: HPV 16 (37 cases), 18 (4 cases), 33 
(11 cases), 39 (1 case), 51 (5 cases), 53 (1 case), 58 (2 cases), 59 (1 case) and 66 (4 cases), four 
(7%) were positive for lr HPV types and seven (11%) were negative. Twelve samples were 
infected with multiple types of hr HPV. Among the 50 hr HPV-positive tumors, 38 were 
both GP5+/GP6+ positive and type-specific HPV-positive (hr HPV+ group). However, 12 
tumors were GP5+/GP6+ negative and type-specific HPV-positive, corresponding to an 
integrated HPV+ group (int. hr HPV+) (Fig. 2). 
This disagreement over HPV prevalence may be explained by the sensitivity of the methods 
used and the number of cases enrolled. Indeed, the use of different detection methods and 
HPV-specific probes, as well as varying numbers of tissue samples from different locations, 
has caused confusion over the frequency of HPV-positive lesions. Despite using the most 
sensitive method (PCR), we still observed a large variation in HPV detection rates, which 
can be explained by the relationship between results and sample sizes. In fact, the Kleist et 
al. study observed an 80% positivity among 5 samples, while Ribeiro et al. only detected 
HPV in 3.8% of cases among 78 tumors (Kleist et al., 2000; Ribeiro et al., 2011). 
Concerning prognosis, statistical analysis did not reveal a significant correlation between hr 
HPV positivity and the proportion of disease-free patients. However, 32% (16/50 cases) of 
patients with hr HPV-positive tumors experienced relapse, compared with 8% of patients 
with HPV or lr HPV-positive tumors. The five-year disease-free survival was 88% in HPV 
negative and lr HPV-positive tumors versus 58% in hr HPV-positive tumors (Fig. 3). 
 
Fig. 3. Disease-free survival curves for high-risk HPV+ (hr HPV+) versus HPV negative and 
low-risk HPV+ (lr HPV+) patients. The p-value is not significant (NS) 
As mentioned above, few publications have focused on HPV positivity in hypopharyngeal 
cancers. Evidently, our results are in accordance with a previous study by Morgan et al, who 
described for the first time that 75% of the 16 pharyngolaryngeal carcinomas in their series 
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were HPV-positive (Morgan et al., 1991). Another study found a lower HPV positivity rate 
(46%) in tumors from 78 previously untreated patients with laryngeal and hypopharyngeal 
carcinomas (Clayman et al., 1994). The authors concluded that HPV-positive tumors 
represented a biologically distinct subset of tumors that had a worse prognosis than HPV 
negative tumors (Clayman et al., 1994). In contrast to our results, Paz et al. did not identify 
any HPV-positive tumors in a small series of seven hypopharyngeal carcinoma patients (Paz 
et al., 1997). Indeed, conclusions are difficult to draw, given the lack of interest in the 
prognostic outcomes of these cancers, but it would seem that HPV-associated 
hypopharyngeal carcinomas are characterized by a poorer prognosis, or a tendency towards 
having a poorer prognosis, than HPV-negative hypopharyngeal carcinomas (Clayman et al., 
1994; Ernoux et al., 2011). Thus, HPV infection may be closely associated with the 
development of some hypopharyngeal carcinomas.  
5.3.2 Incidence in laryngeal tumors 
Laryngeal squamous cell carcinoma (LSCC) is the most frequent malignant tumor in the 
upper aerodigestive tract and is found predominantly in males. Although the relationship of 
HPV with SCC in the larynx is not well established, oncogenic HPVs have been proposed to 
be potential pathogenic factors. Studies focusing on HPV infections in LSCCs have reported 
wide variations in infection frequency that range from 0% to 85% (Almadori et al., 1996; 
Boscolo-Rizzo et al., 2009; Gallo et al., 2009; García-Milián et al., 1998; Koskinen et al., 2007; 
Lindeberg & Krogdahl, 1999; Rees et al., 2004). The prevalence varied widely with 
individual investigations. More than ten years ago, Brandwein et al. and Lie et al. reported 
that only 8% of LSCCs in the USA and Norway contained HPV DNA (Brandwein et al., 
1993; Lie et al., 1996). Other authors also showed prevalence lower than 10%. In 1999, 
Lindeberg and Krogdahl demonstrated HPV infection in only one of 30 laryngeal 
carcinomas (Lindeberg & Krogdahl, 1999). More recently, in a cohort of 69 LSCC patients, 3 
(4.4%) had HPV-positive samples, whereas other investigators did not find any HPV-
positive samples among 68 LSCCs (Gallo et al., 2009; Koskinen et al., 2007). These findings 
support the view that the role of HPV in LSCC is less important in the larynx and also 
suggest the existence of other factors that play a more important role than viral infection in 
the carcinogenesis of these lesions. However, when we examine the few studies considering 
more than 80 patients with PCR-based analytical techniques, we observe higher percentages 
than previously demonstrated. Reports that include small sample sizes are subject to a 
potential selection bias. Indeed, the prevalence detected by Morshed et al. rose to 35.5%, but 
they did not find any significantly improved overall or disease-specific survival compared 
to patients with HPV-negative tumors (Morshed et al., 2008). In the same manner, high-risk 
HPV was found in 41 out of 110 LSCCs (37.3%) in a Brazilian study (de Oliveira et al., 2006). 
Larger samples being better, Syrjänen analyzed 116 LSCCs using in situ hybridization to 
demonstrate the presence of HPV DNA from types 6, 11, 16 and 30 in paraffin-embedded 
biopsies. A total of 15 of 116 (12.9%) tumors were shown to contain HPV DNA of at least 
one type (Syrjänen et al., 1987). This low prevalence can be explained by the use of a 
technique with lower sensitivity than PCR, which has the greatest sensitivity. Additionally, 
our study focused on HPV detection in a sample of 67 laryngeal SCCs revealed a 75% 
prevalence of high-risk HPV, as shown in Figure 4 (Duray et al., 2011a). To prevent false 
positives, precautions were taken to prevent tissue contamination. Our results may be 
explained by the fact that we used a sensitive (10-100 copies per PCR reaction) and type-
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specific real-time quantitative PCR analysis with a short amplification product (60-80 bp) 
that is more sensitive to the presence of degraded DNA, which is typically found in 
paraffin-embedded specimens. 
 
Fig. 4. HPV PCR results from 67 LSCC cases. Six samples could not be analyzed due to 
insufficient material, and β-globin could not be amplified in two additional samples. 
Therefore, 59 cases in total were analyzed by type-specific real-time PCR and GP5+/GP6+ 
consensus PCR. Among these patients, 75% tested positive for infection with one or several 
types of hr HPV, 5% tested positive for lr HPV and 20% were HPV-negative. 
In this study, we also considered the prognostic value of the presence of hr HPV DNA in 
laryngeal carcinomas. We observed that positive hr HPV status did not correlate with the 
proportion of disease-free patients (Fig. 5). The five-year disease-free survival was 87% in 
HPV-negative or lr HPV-positive early-stage tumors versus 76% in hr HPV-positive early-
stage tumors (Fig. 5A). The five-year disease-free survival was 60% in HPV-negative or lr 
HPV-positive late-stage tumors versus 58% in hr HPV-positive high-stage tumors (Fig. 5B). 
After grouping the early and late stages, the five-year disease-free survival was 77% in HPV-
negative or lr HPV-positive laryngeal tumors versus 67% in hr HPV-positive laryngeal 
tumors (Fig. 5C). Similarly, Boscolo-Rizzo et al. found no significant differences in overall 
survival and disease-free survival between patients with HPV-positive tumors and patients 
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with HPV-negative tumors (Boscolo-Rizzo et al., 2008). Although there is strong support in 
the literature for the association between HPV-positive tumors and better prognosis, 
especially in oropharyngeal carcinomas, other studies did not find an improved prognosis 
for HPV-associated tumors (Clayman et al., 1994; Dahlstrand et al., 2008; Ernoux et al., 2011).  
 
Fig. 5. Disease-free survival curves for high-risk HPV+ (hr HPV+) versus HPV- and low-risk 
HPV+ (lr HPV+) patients with low- (A) and high-stage (B) laryngeal carcinoma. (C) Disease-
free survival curves for all stages together. The p-values were not significant (NS). 
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Although preliminary results may suggest biological oncogenic activity, the role of HPV 
infection in LSCCs has not been clearly established. Thus, in view of conflicting results, 
reports of the frequency of HPV infection in laryngeal carcinomas should be interpreted 
with caution, and despite low prevalence, there is no doubt that HPV is present in a subset 
of laryngeal carcinomas. Thus, we should not exclude the possibility of a causal relationship 
between HPV and some laryngeal tumors. Prospective studies with large numbers of 
patients and controls are required to confirm this hypothesis. 
5.3.3 Incidence in oral tumors 
Questions remain as to whether HPV is causally associated with cancer development at 
other sites in the upper aerodigestive tract. Its role continues to be a topic of debate, as a link 
with HNSCC was suggested more than 20 years ago (Syrjänen et al., 1983). Based on light 
microscopy examination, they observed koilocytosis, which is the presence of cytopathic 
HPV-induced alterations, in 35% of oral squamous cell carcinoma (OSCC) biopsies that were 
identical to those found in precancerous lesions and in uterine cervical carcinoma. Several 
meta-analyses have been dedicated to the relationship between HPV and OSCC (Kreimer et 
al., 2005; Miller & Johnstone, 2001; Syrjänen et al., 2011; Termine et al., 2008). The prevalence 
reported by these studies is quite different (23.5%, 33.7%, 38.1%, and 46.5%). This variability 
could be explained by different manner: Termine et al. included studies examining more 
than 40 specimens, and they calculated their prevalence exclusively on the basis of paraffin 
embedded (PE) specimens. On the other hand, Miller and Johnstone, similar to Kreimer et 
al., did not report HPV prevalence in PE and fresh frozen (FF) specimens separately. Miller 
and Johnstone were the first to publish a meta-analysis on HPV prevalence in normal and 
cancerous oral lesions. Pooled data from non-controlled studies published between 1982 and 
1997 showed that HPV was 4.7 times more likely to be present in oral carcinomas when 
compared with normal mucosa (Miller & Johnstone, 2001). More recently, the interesting 
systematic review by Syrjänen et al. observed a pooled HPV detection rate of 33.7% in the 
OSCC group compared with 12% in the control group. The authors concluded that HPV 
infection significantly increases the risk for OSCC. It is important to note that the association 
of HPV with OSCC was significant only when HPV was detected in biopsy samples and that 
this significant association was completely lost when only exfoliated cells were used to 
analyze HPV in both cases and controls. Herrero et al. also showed that HPV DNA in 
exfoliated cells was not associated with HPV DNA detection in OSCC samples (Herrero et 
al., 2003). Thus, to obtain the most accurate results for the relationship between HPV and 
OSCC, future studies should only select biopsied tissues for HPV testing. In addition to the 
previously mentioned reviews, studies examining HPV infection in OSCC reported a wide 
range of detection rates from 0 to 61% (Herrero et al., 2003; Koskinen et al., 2003; Mishra et 
al., 2006; Ribeiro et al., 2011; Smith et al., 2004a). Varying sampling techniques together with 
widely divergent PCR methods across the studies explain most of this variability. Other 
criteria have also been considered: i) the specificity and size of PCR primers (e.g., 
GP5+/GP6+, MY09/11,…), ii) the geographical demographics, iii) the number of enrolled 
cases and iv) the prevalence of smoking and alcohol consumption in the studied population. 
A similar prevalence was detected by Zhao et al, who found 40.4% positivity (21 of 52 
samples) with HPV 16 accounting for 63.5% and HPV 18 for 30.8%. Moreover, HPV had an 
independent prognostic effect on the overall survival of OSCC after adjusting for other 
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factors, such as histological grade, TNM stage and tobacco use. Another characteristic was 
the significant correlation with improved survival in OSCC patients (Zhao et al., 2009). In 
2001, Schwartz et al. also demonstrated that HPV16 presence was independently related to a 
favorable prognosis in a population of 254 OSCC patients (Schwartz et al., 2001). Gillison’s 
well-controlled study found that oral cancers containing oncogenic HPV types had 74% less 
risk of disease-specific mortality (Gillison et al., 2000). On the other hand, many studies have 
also demonstrated that the prevalence of high-risk HPV types was low in OSCCs. Indeed, 
recently, only 2% of the PE tissues analyzed tested positive in Lopes study (Lopes et al., 
2011). Almost the same observation was made by several studies using qPCR techniques 
(Boy et al., 2006; Ha et al., 2002; Koskinen et al., 2003). Furthermore, a meta-analysis 
suggested that the association between HPV and cancer was strongest for the tonsils, 
intermediate for the oropharynx and weakest for the mouth and larynx (Hobbs et al., 2006). 
In contrast, a Hungarian study demonstrated that 31 of 65 (48%) oral cancer cases had 
evidence of HPV using qPCR methods, reflecting the impact of geographical variation 
(Szarka et al., 2009). In fact, geographical origin is a well-known variability factor regarding 
HPV prevalence, with Asia having the highest worldwide frequency and Africa having the 
lowest (Termine et al., 2008). A hypothesis was suggested that OSCC HPV prevalence could 
be biased and overestimated because of a non-precise assignment of the anatomical site 
resulting in a “contamination” of the OSCC cohort with oropharyngeal cancers (Lopes et al., 
2011). Once again, the detection methods remain the argument of choice to compare the 
different results obtained. In fact, two teams recently proposed two methods for HPV 
detection: in situ PCR and in situ PCR ISH. These methods combine the sensitivity of 
solution PCR with the subcellular localization provided by traditional ISH (Koyama et al., 
2007; Uobe et al., 2001). Nevertheless, there are currently insufficient data in the literature to 
support the adequacy of these techniques. Finally, in our study, the prevalence of HPV 
infection reached 70%, with 44% being hr HPV-positive and 26% being lr HPV-positive (Fig. 
6) (Duray & Descamps et al., in revision). The high incidence of HPV in our samples may 
also be explained by the fact that a very sensitive PCR (GP5+/GP6+ primers: 10–100 copies 
per reaction) was combined with a type-specific real-time quantitative PCR analysis and a 
short amplification product (60–80 bp). To a similar end, Termine et al. demonstrated that 
PCR-based studies resulted in higher prevalence rates compared with studies using in situ 
hybridization (Termine et al., 2008). Our results confirmed this finding because almost 65% 
of HPV+ specimens where also positive using ISH, whereas the ISH/PCR correspondence 
was excellent for the negative specimens.  
Moreover, high-risk HPV positivity was associated with shorter disease-free survival in 
our cohort of 147 OSCC patients. The five-year disease-free survival was 76% for patients 
with HPV-negative tumors versus 40% for patients with HPV-positive tumors (p=0.007) 
(Fig. 7A). Furthermore, the five-year disease-free survival was 48% for patients with lr 
HPV-positive tumors versus 37% for patients with hr HPV-positive tumors (p=0.015) (Fig. 
7B). These data suggest that HPV infection was significantly associated with a worse 
prognosis. Moreover, Cox multivariate analyses combining the HPV status with clinical 
variables (TNM staging and node status) demonstrated that only HPV status had an 
independent impact on patient prognosis (p=0.01; hazard ratio=2.81). An analysis of viral 
loads in infected patients did not show any statistically significant relationship between 
TNM staging and risk of recurrence.  
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Fig. 6. HPV PCR results from 162 OSCC cases. Six samples could not be analyzed due to 
insufficient material, and β-globin could not be amplified in nine additional samples. 
Therefore, 147 cases in total were analyzed by type-specific real-time PCR and GP5+/GP6+ 
consensus PCR. Among these patients, 44% tested positive for infection with one or several 
types of hr HPV, 26% tested positive for lr HPV and 30% were HPV-negative. 
Although a majority of studies demonstrated an improved outcome for OSCC patients, the 
meta-analysis by Ragin and Taioli examining the relationship between HPV and overall 
survival did not show any survival differences between HPV-positive and HPV-negative 
patients with cancers at non-oropharyngeal sites (Ragin & Taioli, 2007). The same 
observation was made by Gillison et al., suggesting that these tumors may have an etiology 
distinct from that of tumors at non-oropharyngeal sites (Gillison et al., 2008). The poor 
prognosis reported in the hr HPV-positive population in this study has been demonstrated 
in other studies. Indeed, two Swedish studies demonstrated that oral HPV infection was 
associated with a dramatically increased risk of developing OSCC (Hansson et al., 2005; 
Rosenquist et al., 2007). Additionally, in 1994, Clayman et al. also showed that HPV 
detection was significantly correlated with decreased survival (Clayman et al., 1994). Other 
studies have failed to demonstrate an association between HPV positivity and prognosis 
(Ernoux et al., 2011; Morshed, 2010). We hypothesize that immunosuppression may favor 
HPV infection (Duray et al., 2010). In 2004, Kreimer reported that tonsillar HPV infection 
was strongly associated with HIV co-infection and immunosuppression (Kreimer et al., 
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2004). Recently, herpes simplex virus-2 (HSV2) infection was demonstrated to increase the 
risk of HPV infection (Moscicki et al., 2001). Furthermore, a study performed by Tung et al. 
reported the presence of HPV 16 or 18 and Epstein Barr virus (EBV) in 80% of 
nasopharyngeal carcinoma samples (Tung et al., 1999). These co-infections may play an 
important role in the initiation of neoplastic transformation in human oral epithelial cells. In 
conclusion, the effect of HPV on oral cancer remains contentious. Thus, to formally confirm 
the role of HPV as an etiological agent in OSCC, sample processing and PCR analysis 
protocols should be standardized to allow a more precise comparison of the results. 
Furthermore, future studies should report separately the type-specific prevalence rates. This 
information would be very useful in order to evaluate the long-term effects of the recent 
HPV vaccines.  
 
Fig. 7. The HPV+ subgroup (and specifically the hr HPV + subgroup) is associated with a 
worse prognosis (p = 0.007 and p = 0.015). Standard survival time analyses were performed 
using Kaplan-Meier curves, the Gehan-Wilcoxon text and the Log-rank test. 
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5.3.4 Incidence in oropharyngeal tumors 
During the past several years, an increased incidence of oropharyngeal squamous cell 
carcinoma (OSCC), the head and neck cancer in which HPV is commonly found, was 
observed. In 2007, Sturgis and Cinciripini proposed a possible emerging epidemic of HPV-
associated cancers (Sturgis & Cinciripini, 2007). Indeed, accumulating molecular and 
epidemiological data now show that hr HPV types are responsible for a subset of OSCCs 
(D’Souza et al., 2007; Lindquist et al., 2007). Therefore, the International Agency for Research 
on Cancer (IARC) recognized HPV as a risk factor for oropharyngeal cancer. In the United 
States, the prevalence of HPV in OSCC has evolved over the last 30 years. Based on data 
from Colorado, the percentage rose from 33% during the 1980s to 70% in the 1990s and 82% 
during 2000 to 2004 (Ernster et al., 2007). During the 2000s, different prevalence rates were 
reported, ranging from 63% to 92% among oropharynx, tongue and tonsil cases (Brown et 
al., 2011). Tonsillar cancer is the most common oropharyngeal cancer, followed by cancer of 
the base of the tongue, and these two cancers accounts for 90% of all OSCCs (Dahlstrand & 
Dalianis, 2005). In Stockholm, as in the USA, HPV prevalence among tonsil cases increased 
over the years from 23% in 1970 up to 83% in 2003 to 2007 (Nasman et al., 2009). In contrast, 
in Beijing, the prevalence of tonsillar cancers is particularly low, with rates of 0.1% in men 
and 0.0 in women. Interestingly, in places with a marked Western influence, such as Hong-
Kong and Taiwan, rates of tonsillar cancer were 6 to 12 times higher than in Beijing 
(Marklund & Hammarstedt, 2011). Large variations in incidence rates are also observed. In 
Europe, the highest rates were seen in France, particularly in Somme region, where the rates 
were as high as 6.4% for men (Parkin et al., 2002). Similar to HNSCC, the prognosis for 
OSCC is generally low in the more advanced stages with an overall five-year survival rate of 
approximately 25% (Licitra et al., 2002). Nevertheless, in HPV infected OSCC, a major 
feature noted in almost all studies is that HPV is a favorable prognostic factor for clinical 
outcome independently of tumor stage, age, gender and grade of differentiation. In fact, 
patients with HPV DNA-positive tumors appear to have a significant prognostic advantage 
compared with patients having HPV-negative tumors (Ang et al., 2010). However, previous 
studies have suggested that the presence of HPV DNA in tumor tissue was not a sufficient 
factor to indicate an involvement of the viral genes in tonsillar carcinomas. Good indicators 
reflecting an active involvement of HPV are the levels of viral E6-E7 mRNA (Cuschieri et al., 
2008). Thus, E6 and E7 expression are regularly assessed with success, suggesting an active 
involvement of HPV in the etiology of tumors (Lindquist et al., 2007). Recently, an 
interesting study provided strong evidence that HPV status was an independent prognostic 
factor for overall survival among patients with OSCC, which may confirm that HPV-
positive and HPV-negative OSCC constitute two distinct clinical entities with different 
causes, risk factor profiles and survival outcomes. To validate this hypothesis, future clinical 
trials should be designed specifically for patients with HPV-positive or HPV-negative OSCC 
(Ang et al., 2010). Concerning this improved survival, Lindquist et al. observed a difference 
between HPV patients who smoked and did not smoke. In fact, patients with HPV-positive 
tonsillar cancer who had never smoked had a better prognosis than those who were 
smokers, which is in accordance with the studies of Ang and Rotnaglova (Ang et al., 2010; 
Lindquist et al., 2007; Rotnaglova et al., 2010). These observations may be explained by an 
immune response induced by HPV but abrogated by smoking. A different option, also 
suggested by Ang et al, is that smoking and HPV are associated with different categories of 
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tumors and that smoking induces additional genetic alterations in these tumors (Ramqvist & 
Dalianis, 2010, Ang et al., 2010). Some investigators have suggested that the better clinical 
outcome can be attributed either to higher radiosensitivity of HPV-positive tumors or to 
active antiviral cellular immune responses in infected patients (Dahlstrand & Dalianis, 
2005). Treatment of patients with advanced disease often includes both oncological and 
surgical treatment, as both carry acute side effects, such as difficulties in swallowing or 
talking, dry mouth and jawbone necrosis. Oncological treatment has fortunately evolved 
towards the development of altered fractionation radiotherapy, integration of chemotherapy 
with radiotherapy and the introduction of targeted biological therapy. The combined 
modality treatment and the intensified fractionation have improved the outcome for head 
and neck cancer patients in general (Bourhis et al., 2006; Pignon et al., 2009). As a result of 
this intensified therapy, patients have substantial chronic side effects. It is therefore 
important to differentiate patients who do and do not need intensified treatment to increase 
patient survival times and quality of life. The improved response to oncological treatment 
for OSCC HPV-positive patients may also be explained by the presence of an intact p53-
mediated apoptotic response in HPV-positive tumors and by immunological factors related 
to HPV infection (Spanos et al., 2009). In conclusion, HPV-positive OSCC is recognized as a 
distinct subset of head and neck squamous cell carcinomas having a favorable outcome. 
Patients with HPV-positive tonsillar carcinomas may also benefit from a less aggressive 
treatment, but this conclusion will need to be validated by further studies in order not to 
compromise existing, excellent treatment outcomes in patients with HPV-dependent 
tumors.  
6. Impact of HPV on the immune system of head and neck cancers 
6.1 The escape of HPV in the immune system 
The contradiction between the studies examining the correlation between HPV infection and 
prognosis may result from differences in immune status among HNSCC patients. In fact, a 
persistent HPV infection that can lead to the development of cancer requires immune 
tolerance. Therefore, HPV has developed several mechanisms to avoid detection by the host 
immune defense system. In the case of infection by a virus, it is important to distinguish 
between the mechanisms used by tumor cells to evade immune attack and those used by 
HPV. The infectious cycle of HPV is itself an immune evasion mechanism because viral gene 
expression and viral protein synthesis are confined to keratinocytes, which are programmed 
to die; thus, HPV replication does not cause cell death and does not present a danger signal 
to the immune system (Stanley, 2006, 2009). Without cell lysis, there is little or no release of 
the proinflammatory cytokines important for the activation and migration of dendritic cells 
(Stanley, 2006, 2009). Even if there is no cell death, keratinocytes should be activated to 
induce type I interferon responses, which have anti-viral, anti-proliferative, anti-angiogenic 
and immune-stimulatory properties. Several data suggest that E6 and E7 oncogenes have 
evolved mechanisms to interact with components of the interferon pathway and to 
downregulate the effects of type I IFN (Stanley, 2009). For instance, the virus maintains a 
low level of viremia, there is no blood-borne phase and only minimal amounts of replicating 
virus are exposed to the immune system. As a result of these facts, the virus is practically 
invisible to the host (Kanodia et al., 2007; Stanley, 2009). HPV is able to dysregulate the 
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antigen processing machinery (APM) by downregulating peptide-MHC complexes, which 
are essential for recognition of infected cells by T cells. In particular, the E7 oncoprotein of 
HPV-16 and -18 repress the promoter for MHC class I heavy chain expression, and HPV-18 
E7 is also able to repress the promoter that regulates expression of TAP1 (transporter 
associated with antigen protein 1) and LMP2 genes (Georgopoulos et al., 2000). HPV-16 E5 
induces alkalinization of the Golgi complex, leading to disruption of trafficking, including 
transport of the MHC class I complex (Ashrafi et al., 2005). In HPV-positive benign 
laryngeal lesions, there is a decrease of MHC class I and TAP-1 expression, and the low 
expression of TAP-1 was associated with rapid recurrence of the disease (Bonagura et al., 
1994; Vambutas et al., 2000). Another way in which HPV may suppress immune responses 
is via the modulation of chemokine (suppression of MCP-1 expression, downregulation of 
IL-8 expression) and pro-inflammatory cytokine (downregulation of IL-18 expression) 
expression and via skewing the cytokine profile in favor of a Th2 response (IL-4, -5, -6, -10, -
13) instead of a Th1 cytokine expression (IL-2, IFN-γ) (Kanodia et al., 2007). Moreover, the 
E6 and E7 oncoproteins downregulate toll-like receptor 9 (TLR9), which induces 
proinflammatory genes essential for induction of immune responses (Hasan et al., 2007). 
The failure of the immune system to recognize HPV may also be explained by the fact that 
HPV16 E7 protein has widespread similarity to several human proteins, such as xeroderma 
pigmentosum group G complementing protein (XPGC) and the retinoblastoma binding 
protein 1 (RBP-1); thus, the immune system does not recognize them as foreign molecules 
but as self molecules (O’Donovan et al., 1993; Scherly et al., 1993).  
6.2 Defects in the immune system of HNSCC patients 
Patients suffering from head and neck cancers exhibit deficits in the humoral and cellular 
immune systems, which have been shown to be correlated with a worse prognosis. The 
strategies employed by head and neck cancers to escape the immune system are varied: they 
can directly inhibit the immune response by producing soluble mediators or they can target 
the APM via downregulation of HLA class I and/or other components of the APM (Duray 
et al., 2010). In the first steps of carcinogenesis, there is an increase of Langerhans cells, 
whereas in invasive carcinomas, a decrease was observed (Fig.8). The accumulation of 
macrophages in the peritumoral area seems to play a protumoral role by secreting VEGF 
and stimulating angiogenesis (Duray et al., 2010) (Fig.8). Antitumor responses of HNSCC 
patients are compromised in the presence of functional defects or apoptosis of T-cells, both 
circulating and tumor-infiltrating. Functional assays with tumor-infiltrating lymphocytes 
TILs isolated from the tumor bed have identified a number of defects, such as (i) absent or 
low expression of the CD3 zeta chain (CD3ζ), which is the key signaling molecule in the T-
cell receptor pathway (Whiteside, 2005), (ii) decreased proliferation in response to mitogens 
or IL-2 (Whiteside, 2005), (iii) the inability to kill tumor cell targets (Hathaway et al., 2005; 
Hoffmann et al., 2004), (iv) an imbalance in the cytokine profile, with a striking absence of 
IL-2 and/or IFN-γ production (Reichert et al., 1998a), and (v) evidence of pronounced 
apoptotic features in a considerable proportion of TILs (Whiteside, 2005; Young et al., 1996). 
Several studies demonstrated the involvement of the Fas/FasL signaling pathway, the 
mitochondrial pathway, TRAIL, and TNF-α in the apoptosis of T cells in HNSCC patients 
(Duray et al., 2010). Furthermore, changes in the expression of the ζ chain of TILs are 
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biologically significant because the absence or low expression of this chain in TILs in 
patients with stage III or IV HNSCC predicts a poor survival compared with patients 
expressing a normal ζ chain (Reichert et al., 1998b; Whiteside, 1999). Another study showed 
that patients with more aggressive tumors or with a recurrence within the preceding two 
years expressed the lowest levels of the ζ chain (Kuss et al., 1999). Various studies showed 
an increased abundance of T regulatory cells Tregs in TILs and peripheral blood, and their 
immunosuppressive action could be another mechanism employed by the tumor cells to 
escape antitumor immunity. Lau et al. demonstrated an increase of Tregs in patients with 
nasopharyngeal carcinoma, and their suppression of the proliferation of CD4-
positive/CD25-negative T cells could explain the decreased antitumor immunity of T cells 
(Lau et al., 2007) (Fig.8).  
6.3 Effects of HPV on the immune system of patients with benign or malignant lesions 
of the upper aerodisgestive area 
Considering the high HPV prevalence in the population, it remains unclear why a very 
small fraction of HPV-exposed individuals develop RRP. To better understand this result, 
Bonagura and colleagues studied the differences between RRP patients infected with HPV-6 
or -11 and healthy individuals who were also infected with HPV but never developed RRP. 
They provided evidence that there are several immune alterations in patients with RRP, 
such as (i) an adaptative immune response induces a Th2-like/T-regulatory phenotype. In 
fact, patients with RRP displayed elevated levels of Th2-like chemokines (CCL17, CCL18, 
CCL22) and cytokines (IL-4, IL-10), whereas levels of TH1-like chemokines (CCL19, CCL21) 
and cytokines (IL-12, IL-18, IFN-γ) were downregulated. In papillomas, there is an 
enrichment of Tregs, which suppress Th1-like responses to HPV. (ii) Interestingly, the 
expression of IL-4 by CD4-positive T cells was increased in papillomas, whereas the 
expression of IFN-γ was reduced. An expression of IL-10 by CD4-positive T cells was also 
observed in the blood (PBMCs) of patients with RRP. These findings suggest that CD4-
positive T cells express TH2-like cytokines and reduce Th1-like T-cell function. (iii) A 
decrease of CD4-positive and CD8-positive T cell Vβ repertoires. Moreover, they showed 
that HPV-11 E6 can suppress T-cell alloreactivity and that natural killer cells are 
dysfunctional in RRP. Furthermore, they also proposed an inhibitory cycle of immunocytes 
that support the development of RRP. In response to HPV proteins, memory Th2-like T cells 
express IL-4 and IL-10, and T-regulatory cells express IL-10 and TGF-β, inducing resting 
macrophages to become alternatively activated macrophages. These macrophages express 
TH2-like chemokines (CCL17, CCL18) and cytokine (IL-10) that induce naïve CD4-positive T 
cells to become Tregs and memory TH2-like T cells. Together, these cells form a cycle of 
inhibitory immunocytes that block the function of the effector helper type I CD4-positive T-
cells (TH1-like). As a result, HPV infection is not cleared, and papillomas will recur 
(Bonagura et al., 2010). A correlation between the severity of laryngeal papillomas and an 
increase of CD83-positive dendritic cells exists, and this enhancement may be due to an 
impaired migration of matured DC (Kovalenko et al., 2009). These observations suggest that 
patients with RRP have a perturbation in their cellular immune response (or have a defect in 
their cellular immunity) and are, therefore, unable to eliminate their disease with an 
effective HPV-specific T-cell response. This immune imbalance may influence the 
development and severity of respiratory papillomatosis (Bonagura et al., 1999).  
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Fig. 8. Description of immunosuppressive mechanisms during the head and neck tumor 
progression: in the normal epithelia of the upper aerodigestive tracts, LCs are present in the 
suprabasal layers. When mucosae of these areas are exposed to tobacco, the number of LCs 
increases whereas these cells decrease in invasive carcinomas. The mature DCs are 
prominent in the peritumoral area and correlated positively with the expression of VEGF. 
DCs are also more abundant in patients with metastasis. A higher level of TAM is observed 
in HNSCCs and these cells constitute a source of VEGF which play a crucial role in 
angiogenesis. HNSCCs can induce the apoptosis of CD8+ T cells using the mitochondrial 
and/or Fas/FasL pathways. Tregs can induce apoptosis of CD8+ T cells and inhibition of 
the proliferation of CD4+ T cells. 
There are few data on the interaction between the host immune system and HPV infection in 
HNSCCs, meaning that the role of innate and adaptative immunity in the development and 
progression of HPV-positive HNSCCs is largely unknown. As mentioned previously, in 
several studies, HPV positive HNSCC cancer was associated with a favorable outcome. 
From these results, some authors supported the hypothesis that the immune response may 
play a positive role in HPV-positive HNSCC prognosis, but in those cases, an intact immune 
system is necessary. An increased frequency of T cells specific for peptides derived from the 
oncogenic HPV E7 protein was observed in HNSCC patients positive for HPV16 compared 
with HNSCC patients negative for HPV or with healthy volunteers (Albers et al., 2005; 
Hoffmann et al., 2006). Therefore, antiviral immunity exists against E7 oncogenic protein, 
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but these T cells are unable to eliminate the tumor (Hoffmann et al., 2006), perhaps due to 
immune escape of tumor cells from cytotoxic T cells (CTL) recognition (Albers et al., 2005). 
In fact, using immunohistochemistry, a reduced expression of APM components and HLA 
class I antigens was observed in HPV16-positive HNSCCs compared with adjacent normal 
squamous epithelium, which is consistent with the suggestion of a phenomenon of immune 
escape during viral carcinogenesis (Albers et al., 2005). Thus, further studies are necessary to 
explain this type of tumor resistance. Williams et al. investigated whether HPV-specific 
immune mechanisms can result in tumor clearance. For that, they generated HPV-positive 
and HPV-negative tonsil cell lines by transducing primary mouse tonsil epithelial cells, 
which are able to form squamous cell cancers in mice. When they examined immune-
competent and immune-incompetent mice with or without HPV, they observed a difference 
in growth and survival patterns. In fact, in the immune-competent mouse group, about one-
third of the HPV-positive mice cleared their tumors, compared with none of the HPV-
negative mice. Moreover, by comparing the survival of the mice that did not clear their 
tumors, they observed that mice injected with HPV-positive cells had a significantly better 
survival than mice injected with HPV-negative cells. In the mouse group lacking B- and T-
cell immunity, there was no difference in the tumor growth pattern or survival between the 
HPV-positive and HPV-negative groups. Therefore, the difference in growth between HPV-
positive and HPV-negative mice is immune mediated. The data indicated that CD4-positive 
and CD8-positive T cells were required to mount this immune response. They also showed 
that the immune clearance capacity could be transferred from a cleared mouse into an 
immunodeficient mouse. In fact, the splenocytes from cleared mice and HPV-positive tumor 
cells were injected into an immunodeficient mouse, and they observed that all treated mice 
developed and cleared tumors (Williams et al., 2009). In another animal model of HPV-
associated cancer, the authors tried to better understand why HPV-positive cancer may 
represent an advantage in survival, as has been shown in several studies, and they 
compared how these cancers responded to therapies usually used for the treatment of 
HNSCC with responses of HPV-negative tumors. Thus, they looked at the effect of radiation 
and cisplatin co-therapy on HPV-positive and HPV-negative cancer cells in vivo and in 
immunocompetent and immunodeficient mouse models. In vitro, HPV-positive cells were 
more resistant to radiation and cisplatin therapy compared with HPV-negative cells, 
whereas in vivo, HPV-positive tumors were more sensitive to radiotherapy compared with 
HPV-negative tumors. Furthermore, cisplatin was able to clear HPV-positive tumors, but 
not HPV- tumors, in mice. In immunodeficient mice, neither radiation nor cisplatin was able 
to cure their tumors. They also showed that, after an adoptive transfer of wild-type immune 
cells into immunodeficient mice, the clearance of HPV-positive tumors was restored upon 
cisplatin therapy. These findings suggested that an intact immune system was essential for 
tumor clearance with radiation and cisplatin therapy. Moreover, the findings indicate that 
survival does not seem to be due to increased epithelial sensitivity to these therapies and 
that radiation and cisplatin induce an immune response to this antigenic cancer (Spanos et 
al., 2009). More recently, Wansom and collaborators tried to understand better the clinical 
importance of adaptive immunity in patients with HPV16-positive oropharyngeal cancer 
and to examine whether it affects patient outcome. They showed that the percentage of CD8 
cells was significantly higher and the CD4:CD8 ratio was significantly lower in HPV16-
positive oropharyngeal patients. In comparing smokers and nonsmokers, the percentage of 
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CD8 cells was similar in the two groups, suggesting that the difference in CD8 levels was 
associated with HPV status and not with tobacco consumption. This elevated percentage of 
CD8 cells was associated with a response to induction chemotherapy and complete tumor 
response after chemoradiotherapy. These results (high percentage of CD8 cells and low 
CD4:CD8 ratio) were also associated with an improved overall survival. The mechanism by 
which there is an increase of T cells in the peripheral blood of HPV-positive patients has not 
been elucidated. One hypothesis suggested by the authors is that HPV-16-positive tumors 
have increased antigenicity through the E7 antigen, causing enhanced stimulation of the 
immune system, which more readily identifies tumor cells as foreign. This hypothesis is 
supported by a study led by Smith et al., in which the intralymphatic immunization of mice 
bearing E7-expressing tumors with E7 peptide resulted in a considerable expansion of E7-
specific CD8 cells, which are effective in suppressing disease progression (Smith et al., 2009). 
In another animal model, the DNA vaccine with HSP70 fused to HPV-16 E7 has been 
demonstrated to dramatically increase the frequency of E7-specific CD8-positive T cells and 
to enhance the antitumor effects against E7-expressing tumor cells (Chen et al., 2000). All of 
these data support the idea that the clearance of HPV-positive tumor cells is antigen-
dependent. Thus, the authors concluded that circulating CD8 cell levels may be a prognostic 
factor, and improved adaptive immunity may play a favorable role in the prognosis of 
patients with HPV16-positive tumors (Wansom et al., 2010). 
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1. Introduction 
Tobacco and alcohol are well-established risk factors for head and neck squamous cell 
carcinomas (HNSCC), but it can also develop in individuals not exposed to them. However, 
only a small proportion of tobacco exposed individuals have developed HNSCC, and there 
is an emerging tumoral population who lack exposure to these mentioned risk factors, 
suggesting that others factors can play a role in head and neck carcinogenesis. Over the past 
two decades, the role of high-risk human papilloma virus (HPV) has been studied through 
several studies worldwide, and data supporting its role as a causative agent in the 
development and progression of a subset of HNSCC has been controversial, with 
considerable variability in frequency depending on the population studied, tumor 
localization, quality of samples and technical resources utilized for HPV detection. As is the 
case in cervical and anogenital carcinomas, the most frequently detected high-risk HPVs in 
HNSCC are the 16 and 18 genotypes. The tonsils and oropharynx are the specific sites 
associated with higher risk of HPV oncogenic transformation, and investigations suggest 
that HPV infection in these anatomic sites is an independent risk factor for carcinogenesis. 
The establishment and maintenance of HPV genomes in the squamous epithelium and 
HPV-related HNSCC cancer is believed to be originated by oncogenic potential of HPV 
integration into host DNA genome and their ability to manipulate cell cycle regulators, 
resulting in deregulated expression of oncoproteins such as E6, which promotes degradation 
of the tumor suppressor protein p53, allowing cells to evade cell cycle checkpoints, and also 
E7, which binds to retinoblastoma protein (pRb) and could promote the entrance in S1 phase 
of cell cycle, leading to disruption of normal cell cycle controls. Following cell division, 
infected cells leave the basal layer, migrate towards the suprabasal regions and begin to 
differentiate. Increased understanding of cervical pathogenesis has led to confirmation of 
HPV as an etiological agent for cancers and consequently to the development of preventive 
vaccines targeting HPV antigens for the control of cervical cancer. The HPV vaccine was 
developed as a result of the achievement of core technologies able to produce virus-like 
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particles (VLPs). The recombinant DNA was used to generate VLPs able to mimicking the 
natural virus and eliciting high-titers of virus neutralizing antibodies. With the progress 
through advanced stages of clinical trials and further exploration of combinatorial strategies, 
there is a great promise for significant advances also in the field of therapeutic HPV vaccine 
development. We recently conducted a study with the purpose of investigate the presence 
of HPV in a Brazilian population sample of HNSCC patients. In cases with positive 
specimens, the analysis was extended to clinicopathological profile characterization and to 
the correlation between patient survival and HPV DNA presence in primary HNSCC 
tumors as well as in their corresponding matched samples of recurrences, lymph nodal 
metastasis and necropsies. This research was conducted on the medical files of patients with 
head and neck tumors, the histopathological diagnosis of HNSCC was confirmed and 
paraffin-embedded specimens were selected for investigation. Moreover, in this chapter we 
discuss the current status of HPV vaccines as well as the main associated factors that 
interfere on establishment of strategies that better could act to control the infections and 
development of malignant neoplasias. 
2. Historical aspects 
One of the earliest manifestations of HPV infection was observed during an autopsy 
performed in 1974 on the embalmed body of an ancient Egyptian worker from 12th century 
BC who had a wart on the sole of his foot (Onon, 2010, as cited in McCaffery, 1974). The 
Ancient Greeks and Romans had already recognized that genital warts could be sexually 
transmitted (Onon, 2010, as cited in Claude Moore Health Sciences Library, 2011); however, 
the viral origin of warts was only confirmed in the 19th century (Onon, 2010, as cited in 
Ciuffo, 1907). By the early 1970s, the herpes simplex virus type 2 was thought to be the 
sexually transmitted etiologic factor that was responsible for cervical cancer (Onon, 2010, as 
cited in Klein, 1973). However, Harald Zur Hausen, a young German professor of virology, 
was not convinced of this hypothesis, and in 1976, he postulated that papilloma viruses play 
a role in cancer of the cervix. Papilloma viruses have now been well established as the cause 
of almost 100% of cervical carcinomas (Kumaraswamy & Vidhya, 2011).  
The link between HPV and HNSCC was first studied by Syrjänen et al. (1983) in a light 
microcopy examination of 40 biopsy specimens from oral squamous cell carcinomas 
(OSCC), when the authors observed changes that are characteristic of HPV infection in 16 of 
the lesions. Recently, several studies have addressed the presence and prevalence of HPV in 
these types of tumors (Kumaraswamy & Vidhya, 2011). However, although the discovery of 
HPV has suggested that the virus may be a possible etiologic factor of oral pre-cancer and 
cancer, this association has not been as consistent as in cervical cancers. 
3. Head and neck cancer 
Head and neck malignancies compose a heterogeneous group and are believed to originate 
from sequential mutations that can occur as a consequence of progressive genetic instability 
and⁄or environmental factors, such as tobacco and alcohol consumption. These pathologies 
include a number of different types of cancer that arise from a variety of sites in the upper 
aerodigestive tract. Analysis of these tumors has revealed a heterogeneous neoplastic 
process that involves numerous sites with unique sets of epidemiologic, histopathologic, 
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and treatment considerations. Approximately 40% of head and neck cancers occur in the 
oral cavity, 15% occur in the pharynx, 25% occur in the larynx and the remaining tumors 
occur in other sites (Dobrossy, 2005). The most frequent histological type is the squamous 
cell carcinoma, which occurs in over 95% of cases. Squamous cell carcinomas originate from 
the epithelial surface of the oral cavity, oropharynx, hypopharynx, and larynx and affect 
approximately 500.000 patients worldwide each year (Popović et al., 2010). Low survival 
rates have been presented across several studies worldwide and reflect the need for more 
careful attention to HNSCCs. Because the mortality rates have essentially remained 
unchanged over the last several decades, considerable interest lies in discovering prognostic 
markers to guide therapeutic planning. 
4. HPV 
Papillomaviruses are a family of pathogens that infect exclusively the epithelial tissues of 
amphibians, reptiles, birds and mammals (Franceschi, 2007). The viruses are grouped 
according to the anatomic site of infection and their preference for either cutaneous or 
mucosal squamous epithelium. The cutaneous types, or beta papillomaviruses, are usually 
found in the general population and cause common warts. In contrast, the alpha, or 
mucosotropic, papillomaviruses have been implicated in mucosal infections (Snow & 
Laudadio, 2010; Vidal & Gillison, 2008). The mucosotropic group of human papillomavirus 
comprises 15 species and infects the anogenital tract, upper aerodigestive tract and other 
head and neck mucosa. Because they are sexually transmitted and play important roles in 
diseases, these viruses have received much attention and research and clinical investment 
(Chow et al., 2010).  
The HPV genome is a small (55 nm), double-stranded DNA molecule of approximately 8.000 
base pairs, and it contains three identified regions: a late region (L) containing two genes, L1 
and L2, which encode the viral capsid proteins; an early region (E) encoding proteins 
involved in viral DNA replication and the control of viral transcription, such as E1 and E2, 
and the main transforming genes E6, E7 and E5; and a long control region (LCR), found 
between the L and E regions, which contains several binding sites for nuclear and viral 
transcriptional factors, promoter sequences and an open reading frame (ORF) region 
(Fernandes et al., 2009). The early and late gene regions are both protein-encoding, but the 
LCR is non-encoding. The LCR possesses numerous binding sites for many repressors and 
activators of transcription, suggesting that this region may play a role in determining the 
range of hosts for specific HPV types (Tanzi et al., 2009). 
Traditionally, the papillomaviruses have been classified by type and by the ORF L1 region 
because this region is greatly conserved along the viral genome and has been used to detect 
new types of papillomavirus for more than 15 years. However, other genomic regions can 
also be used (i.e., E6 and E7). Each genotype is characterized as being more than 10% 
different from all other genotypes in their specific regions of DNA sequences. Differences of 
2% to 10% define a subtype and less than 2% define a viral variant. Closely related types 
(approximately 80–90% identical) are classified as members of the same species, and they 
tend to share important biological properties, such as tissue tropism, disease manifestation, 
and pathogenicity (Chow et al., 2010; De Villiers et al., 2004). Currently, well over 120 
different genotypes of HPVs have been isolated, sequenced and phylogenetically 
characterized. Thirty-three percent of these 120 genotypes are known to infect the human 
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genital tract (De Villiers et al., 2004; Hennessey et al., 2009, as cited in Longworth & Laimins, 
2004; Martinez et al., 2007). Mucosotropic HPVs can be further classified into non-oncogenic, 
or low-risk, types or as potentially oncogenic, or high-risk, types. Mucosal and genital HPVs 
can be divided into low-risk (HPVs 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81) and high-risk 
(HPVs 16, 18, 31, 33, 35, 51, 52) types according to their presence in malignant lesions (Bosch 
et al., 2002; Muñoz et al., 2003). HPVs 31, 33, 35, 51 and 52 are sometimes regarded as 
“intermediate risk” viruses because they are more common in mild or severe dysplastic 
lesions than in carcinomas (Fernandes et al., 2009). 
The late region units L1 and L2 encode for viral capsid proteins during the late stages of 
virion assembly (Park et al., 1995). The protein encoded by L1 is highly conserved among 
different papilloma virus species; accordingly, antibodies against the bovine papilloma virus 
have been used to identify HPV capsid proteins in human tissues. The minor capsid protein 
encoded by L2 has more sequence variations than that of the L1 protein; hence, the L2 
protein has been a source of antigen for specific types of HPV antibodies. The E1 and E2 
region units encode proteins that are vital for extrachromosomal DNA replication and 
completion of the viral life cycle. The E2 protein is modular and contains an N-terminal 
activation domain that is important for viral transcription and replication and for interaction 
with host chromosomes during mitosis. The E2 region also encodes two proteins, one of 
which inhibits transcription of the early region, while the other increases the transcription of 
the early region (Ward et al., 1989). The HPV E5 proteins are small, extremely hydrophobic, 
and located mainly at the endosomal membranes, Golgi apparatus and, to a lesser extent, 
the plasma membranes. Moreover, E5 proteins are traditionally known to interact with the 
transmembrane domain of the EGF receptor and to modulate its concentration and 
phosphorylation (Villa et al., 2002). When present, E5 interacts with various transmembrane 
proteins, such as the EGF receptors, platelet-derived growth factor β, and colony stimulating 
factor-1 (Talbert-Slagle & DiMaio, 2009).  
The multiplicity of functions of the three small papillomavirus oncoproteins, E5, E6 and E7, 
continues to be amazing. Specifically, more than a dozen protein-protein interactions 
between E6 and cellular proteins have been published (Villa et al., 2002). In the protein-
encoding regions, the E6 and E7 ORF are considered to play the most important roles. These 
units encode for oncoproteins that allow viral replication and the immortalization and 
transformation of the cell that host the HPV DNA (Doorbar et al., 1991). 
Mucosal high-risk E6 proteins are best known for their ability to associate with the cellular 
tumor suppressor p53. The association of E6 with p53 leads to degradation of p53 via 
recruitment of an ubiquitin ligase, E6-AP, and results in the inhibition of the transcriptional 
regulatory activities of the p53 protein in tissue culture cells (Gonzalez et al., 2001; Jones & 
Münger, 1997). Similarly, the high-risk HPV E7 proteins are best known for their ability to 
associate with the cellular tumor suppressor pRb, and this association can promote pRb 
degradation (Jones & Münger, 1997) through a proteasome-mediated pathway that disrupts 
the capacity of pRb to bind and inactivate functionally cellular E2F transcription factors 
(Gonzalez et al., 2001). In addition to binding pRb, high-risk E7 proteins can bind to other 
pocket proteins (p107 and p130) that are related to pRb and interact with different members 
of the E2F family of transcription factors (Dyson et al., 1992). The inactivation of pocket 
proteins by E7 is necessary but not sufficient to elicit the transforming potential of E7 
(Phelps et al., 1992). High-risk E7 is also purported to complex with cyclins (Dyson et al., 
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1992) and to inactivate the cyclin associated kinase inhibitors p21 and p27 (Jones & Münger, 
1997). Thus, E7 can associate with and/or alter the activities of multiple cellular factors that 
normally contribute to the regulation of the cell cycle. The oncogenic properties of E6 and E7 
and their effects on p53 and pRb have provided the general basis for further investigations 
of the role of HPV in carcinogenesis. The research examining the actions of these two 
oncoproteins has shown how they can subvert key cell cycle and regulatory processes, such 
as cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CDIs), 
to transform and immortalize the host cells (Southern & Herrington, 2000). 
Proving the importance of p53 and pRb in cell cycle progression, the repression of HPV 16 
E6 and E7 expression by dual shRNA transfection has been shown to be capable of restoring 
the p53 and pRb tumor suppressor pathways and activating apoptosis (Psyrri et al., 2009, 
Rampias et al., 2009). Thus, the demonstration of this tumor suppressor inactivation by the 
E6 and E7 HPV oncoproteins has provided a basic explanation for how the high-risk HPV 
types exert their oncogenic effects on cervical cells. 
5. The route of cellular conquest by HPV  
Unlike other viruses, HPV does not infect or replicate in antigen-presenting cells of the 
epithelium nor induce cell lysis, so there is no chance for antigen-presenting cells to present 
antigens derived from the virion to the immune system. Despite the observation that more 
than 50% of infections present seroconversion in the patients, the production of antibodies 
usually occurs only months after the initial infection (Vidal & Gillison, 2008, as cited in 
Tindle, 2002). The life cycle of papillomaviruses is closely tied to the epithelial 
differentiation process. Infection occurs exclusively in squamous epithelial cells 
(keratinocytes) with preference for the keratinocyte stem cell as the initial target of HPV 
infection (Vidal & Gillison, 2008). The route of entry for HPV infection is microtraumas or 
small wounds in the skin or mucosal surface. These breaks in the epithelial surface allow the 
virus to access and persist in the nuclei of infected basal layer cells of the epithelium. Until 
now, no single receptor has been definitively identified and established as being responsible 
for HPV entry. Some reports have suggested that a6 integrin may be a candidate receptor 
because it is expressed primarily during wound healing. The glycosaminoglycan heparin, a 
polysaccharide expressed on the cell surface, may also play a role in the attachment 
necessary for the initiation of HPV infection (Vidal & Gillison, 2008).  
HPV uses the host cell DNA machinery to maintain the production of viral progeny. This 
mechanism of viral-induced cell growth is very well known and is analogous to other 
viruses that disrupt the control of cell growth (Hebner & Laimins, 2006). Following cell 
division, as the basal cells divide into squamous epithelial cells, HPV establishes its DNA 
genome in the host cell nuclei, replicates and reaches a high copy number. Infected cells 
then leave the basal layer, migrate toward the suprabasal regions and begin to differentiate. 
In the basal layer phase, the HPV genome is maintained at a low copy number, providing a 
type of stock of viral DNA for further use in cell divisions. At the same time, ‘early’ viral 
genes (E5, E6 and E7) are expressed, resulting in enhanced proliferation of the infected cells 
and their lateral expansion. While the basal cells and viral DNA divide, some daughter cells 
may be maintained in the basal layers, whereas other daughter cells move toward the upper 
layers of the epithelium and begin to differentiate. During the process in which the infected 
cells enter into the suprabasal layers, the viral genome replicates to a higher copy number; 
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‘late’ viral gene (L1 and L2) expression is initiated; and structural proteins, as such capsid 
proteins, are formed. Subsequently, virions are assembled and released as the upper layer of 
epithelium is shed, as shown in Figure 1 (Fehrmann & Laimins, 2003; Scheurer et al., 2005; 
Vidal & Gillison, 2008). 
 
Fig. 1. Representation of normal and HPV-infected epithelium according to the cellular 
differentiation and the differentiation-dependent viral functions (Adapted from Fehrmann 
& Laimins, 2003). 
HPV replication occurs through two mechanisms. The first mechanism occurs in the basal 
layer cells where the viral genome is distributed to daughter cells. In this mechanism, viral 
genome integration ensures a persistent infection in the proliferative cells from the basal 
layer and is associated with a higher risk of malignant cellular transformation. In the second 
mechanism, which is known as episomal or vegetative, HPV replication occurs in the more 
differentiated layers of the epithelium and the integration of viral DNA into the host cell 
genome is not necessary. Despite the fact that the replication processes and gene expression 
are controlled by the cell differentiation process, much about this mechanism is still 
unknown, and cervical cancer serves as a model for understanding HPV pathogenesis in 
other sites, such as in head and neck cancers (Zur Hausen, 2002). During cervical infection, 
the viral genome frequently integrates into the host cell genome. This integration occurs 
preferentially at fragile sites. The integration of viral DNA most likely disrupts the E2 
coding region, causing the loss of the role of E2 in transcriptional control; therefore, the 
expression of the E6 and E7 oncoproteins becomes deregulated (Vidal & Gillison, 2008).   
In tonsillar carcinomas, the absence of integrated HPV DNA does not suppress the 
expression of viral oncogenes, indicating that viral DNA integration is not an essential step 
for carcinogenesis and that the virus continues to be present in an episomal form (Hebner & 
Laimins, 2006; Vidal & Gillison, 2008). The mechanism used by HPV to remain in cancer 
tissue as an episomal form and produce high copy numbers is still unclear. However, some 
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observations have shown that the oncoprotein E2 may serve as an ‘anchor’ that links 
episomal HPV to the cellular mitotic spindles (Psyrri et al., 2009).  
6. How does HPV reach the head and neck sites?  
Generational changes have occurred in sexual practices around the world, where the young 
people are having their first sexual experience at an earlier age, with greater numbers of 
sexual partners and with a higher probability of engaging in oral sex compared to 
individuals from earlier decades (Heck et al., 2010). These differences in sexual behavior can 
also be seen between patients with HPV-positive HNSCCs, especially among those with the 
high-risk type HPV-16 (Gillison et al., 2008).  
In oropharyngeal cancers (OPCs) that are positive for HPV, a frequent association with 
sexual behavior has been found (D’Souza et al., 2007). An investigation of more than 5000 
cases of head and neck cancer and more than 6000 control cases from 12 different countries 
has indicated that a history of six or more lifetime sexual partners and four or more oral sex 
partners increases the odds of developing OPC. In cancer at the base of tongue, this 
association was found among individuals who have two sexual partners compared to those 
with only one, while little evidence has indicated any association between sexual practice 
and cancers of the oral cavity or of the larynx. Additionally, an increased risk of tonsillar 
cancer is associated with a history of four or more oral sex partners (3-fold increased risk), 
age at sexual debut < 18 years among men (2-fold increased risk) and in husbands of women 
who presented cervical dysplasia or cancer (Lajer & Von Buchwald, 2010). In addition to 
oral sexual activity, open-mouthed kissing has been found to be associated with oral HPV 
infections. Because this practice is common among young people in many countries, it may 
contribute to HPV circulation and increase the risk of HPV infection among individuals who 
might not otherwise be exposed. The prevalence of HPV in control patients from the studies 
of oral cancer varies from 5% to 9%; however, the same sexual behaviors associated with 
HNSCC can increase the odds of HPV infection in this population. Interestingly, in patients 
with HNSCCs, heavier smoking and alcohol use is associated with risky sexual behaviors, 
but this association is not observed in control individuals without cancer (D’Souza et al., 
2009). 
No difference was noticed between men and women according the outcomes of oral sex or 
number of oral sex partners and lifetime sexual partners, and the prevalence of oral HPV 
was found to be similar between heterosexual and bisexual women. In contrast, the presence 
of oral HPV infection is unlikely in virgins and women who have sex with women, which 
suggests that oral HPV is more likely to be associated with sexual exposure to male partners 
than to female partners (Ragin et al., 2011). 
7. HPV and oral lesions 
In the oral cavity, 24 types of HPV (1, 2, 3, 4, 6, 7, 10, 11, 13, 16, 18, 30, 31, 32, 33, 35, 45, 52, 
55, 57, 59, 69, 72 and 73) have been associated with benign lesions and 12 types (2, 3, 6, 11, 
13, 16, 18, 31, 33, 35, 52 and 57) with malignant lesions (Bouda et al., 2000; Kojima et al., 
2002). The low-risk HPV types cause benign oral hyperplasias that are usually painless and 
non-ulcerated (Cleveland, 2011). Verruca vulgaris (caused by HPV 2, HPV 4 and other HPV 
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types) usually occurs on the lips, hard palate and gingiva. Condyloma acuminata or genital 
warts (caused by HPV 6 and HPV 11) may also affect the oral mucosa and are found more 
commonly on keratinized mucosa (Cleveland et al., 2011; D’Souza et al., 2007; Dayyani et al., 
2010). Notwithstanding, since the first report of the presence of HPV DNA in head and neck 
cancer, 65 high-risk types have been consistently detected at different sites; however, these 
types are specifically found in transcriptionally active tumor cells (Vidal & Gillison, 2008). 
According to data from a review, 99% of HPV infections in head and neck cancers are by 
high-risk types 16, 18, 31 and 33 (Kreimer et al., 2005). Additionally, several others HPV 
types (6, 11, 35, 45, 51, 52, 56, 58, 59 and 68) have rarely been detected in head and neck 
cancer. Infection with HPV 33 accounts for up to 10% of positive head and neck cancers; 
however, the HPV 16 type is by far the most common type detected in head and neck cancer 
(Fakhry et al., 2008; Kreimer et al., 2005; Snow & Laudadio, 2010), and oropharyngeal 
tumors are more likely to have HPV 16 than other types at head and neck sites. The 
genotype 16 accounts for 78% to 100% of positive oropharyngeal cases, while HPV-18 
accounts for only 1% of cases (Kreimer et al., 2005). Seropositivity for HPV 16 has a greater 
association with an increased risk of OPC (OR = 14.4) than with the development of oral 
cavity cancer (OR = 3.6). This association is particularly strong in individuals without a 
history of smoking or drinking (OR = 33.6) (Hennessey et al., 2009). An interesting 
prevalence profile of the HPV types has been observed in some investigations in the 
countryside of Sao Paulo state in Brazil, where a higher prevalence of HPV 18 than HPV 16 
was found in oral and cervical carcinomas. Furthermore, the presence of HPV 18 was found 
to be associated with metastasis to the lymph nodes and shorter patient survival (Guimarães 
et al., 2010; Lira et al., 2010; Mazon et al., 2011). 
The results from recent studies have suggested that some of these cancers, primarily those 
that originate in the oropharynx (and, more specifically, at the base of the tongue and the 
tonsils), are associated with high-risk HPV infection (Lopes et al., 2011). This association is 
strengthened by the fact that the same oncogenic HPV types detected in cervical carcinomas 
have been identified in head and neck cancers. In recent oral cancer guidelines published by 
the American Dental Association (ADA), HPV was recognized as a risk factor for OPCs, but 
whether HPV is also responsible for some oral cavity cancers was questioned (Rethman, 
2010). 
Several head and neck tumors have been analyzed for the presence of HPV, and HPV DNA 
has been found in different proportions of tumors from different head and neck sites 
(Kreimer et al., 2005; Syrjanen, 2005). Some evidence has indicated that some subtypes of 
HPV are linked to head and neck cancer, especially those arising from some oropharyngeal 
subsites (e.g., tonsil and the base of the tongue) (Gillespie et al., 2009). The overall HPV 
prevalence in HNSCC ranges from 3% to 40% and could vary more according to the specific 
site. HPV has been found in 4-80% of oral cancers, 15-85% of tonsillar cancers, 
approximately 24% of non-tumor site-specific HNSCC and 14-57% of OPCs (IARC, 2007; 
Kreimer et al., 2005; Machado et al., 2010; Syrjanen, 2005; Termine et al., 2008). Brazilian 
observations in the countryside of Sao Paulo state have found a low prevalence of HPV in 
tumors of the larynx (Miranda et al., 2009) and an increase in the presence of HPV DNA in 
oral cavity cancers during the past two decades (Lira et al., 2010; Mazon et al., 2011; Oliveira 
et al., 2008). The wide variation in HPV prevalence can be attributed to different detection 
techniques, small sample numbers, differences in the lesions and sampling techniques and 
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epidemiological characteristics of the populations studied (Feller et al., 2010). Among the 
many methods to detect HPV infections, both polymerase chain reaction (PCR) and in situ 
hybridization assays have been well validated. 
Because of the high sensitivity of the PCR assay, it may detect not only oncogenic infections 
but also productive infections, virions or laboratory artifacts, which are common problems 
in HPV screening for cervical cancer (Leemans et al., 2011). The following additional 
techniques can also provide data regarding the presence of HPV: light and electron 
microscopy, ELISA, gene expression by DNA microarray, Dot blot, Southern blot, hybrid 
capture and ligase chain reaction for probe amplification. Despite the existence of 
innumerable options for HPV detection in HNSCC, a standardization of procedures for 
routine application has yet to be developed (Feller et al., 2010; Kumaraswamy & Vidhya, 
2011; Snow & Laudadio, 2010). 
A global consensus exists regarding the increasing risk of OPCs with HPV, mainly in the 
tonsils and at the base of the tongue (Attner et al., 2010; Heck et al., 2010). A survey of the 
Surveillance, Epidemiology and End Results (SEER) database revealed that the incidence 
rates for HPV at the base of the tongue and in the tonsils increased by 2% and 4%, 
respectively, between 1973 and 2001 in younger US populations (ages 20-44 years). At the 
same time, the incidence in all other oral and pharyngeal sites remained constant or 
decreased (Gillespie et al., 2009). Other countries, such as Sweden, have seen a similar 
increase in the incidence of tonsil cancer from 1997-2002; HPV could be isolated in 23% of 
specimens in the 1970s, 28% in the 1980s, 57% in the 1990s and 68% in specimens since 2000 
(Hammarstedt et al., 2006). A review of 60 studies of HPV prevalence, which was published 
in 2005, observed an overall prevalence of 26% of HPV in HNSCCs, with a greater percent at 
the oropharynx (36%) (Kreimer et al., 2005). Similar numbers were obtained from the results 
of a recent meta-analysis that included more than 5000 patients. Among all HNSCCs, 22% of 
cases presented HPV infection, and the subgroup of OPCs presented a prevalence of 41% 
(Dayyani et al., 2010). In the USA, approximately 40-80% of OPC cases are associated with 
HPV, whereas in Europe, the proportion ranges from 90% in Sweden to 20% in populations 
that contain a great number of heavy smokers (Marur et al., 2010). 
Confirming the importance of HPV infection in HNSCC, the 2007 International Agency for 
Research on Cancer (IARC) monograph on HPV found sufficient evidence for HPV 
carcinogenicity in the oral cavity and oropharynx and limited evidence for HPV 
carcinogenicity in the larynx (IARC, 2007). Currently, the identification of distinct 
epidemiological profiles in HPV-positive and HPV-negative HNSCCs is possible. Although 
studies have shown no concordance regarding some of these epidemiological aspects, we may 
have to look at HPV-positive and HPV-negative HNSCCs in a separate manner in the future, 
including scientific, diagnostic, epidemiological and clinical aspects and the management of 
treatment. The main factors studied are heavy or no tobacco/marijuana exposure, heavy or 
mild alcohol consumption, poor or intact dentition, low or high oral sex exposure, age > 50 
years or < 45 years, lower or higher socioeconomic status and deceasing or increasing 
incidence (Gillespie et al., 2009). The epidemiological trend suggests that HPV-positive 
HNSCC occurs more often in younger patients (age < 50 years), which differs from the typical 
characteristics of head and neck cancer (which is more frequent in men above 40 years old). 
The tumors associated with the presence of HPV usually appear strawberry-like and exophytic 
on gross inspection and occur more frequently in the tonsil and the base of tongue with a 
basaloid aspect, poor differentiation and cystic changes within metastatic lymph nodes 
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(Gillespie et al., 2009). In addition, gene expression profiles are known to be different in HPV-
positive OPCs compared with HPV-negative cases (Lajer & Von Buchwald, 2010). 
8. HPV in oropharyngeal cancer 
The OPCs comprises tumors arising in posterior regions of oral cavity, and its incidence has 
been increasing, especially between individuals aged 40 to 55 years. It is accepted that a 
great part of OPCs, especially in lingual and palatine tonsils, are originated by HPV 
infection. Compared to non-contaminated individuals, the relative risk is 15- to 200- fold in 
HPV infected patients, and may not show a history of known risk factors for OPC, such 
tobacco and alcohol consumption, highlighting a different pattern for non-HPV-related OPC 
(Marur et al., 2008). Moreover, the presence of HPV is also associated to positive cervical 
lymph nodes of patients in different sites of HNSCCs, but mainly in oropharynx 
(Goldenberg et al., 2008; Lira et al., 2010; Machado et al., 2010). 
Although oral and oropharyngeal HPV infections are primarily sexually acquired, other 
methods of contamination such as mouth to mouth contact between partners and between 
family members, besides autoinoculation, are also potential routes where HPV infection of 
oropharyngeal sites can be established. As oral and oropharyngeal subclinical HPV infection 
is not uncommon, it is possible that the epithelium may serve as a reservoir of virus (Feller 
et al., 2010).  
The most common morphological presentation of HPV-related OPC is different of non-HPV 
tumors. The HPV OPCs usually are not associated with dysplasia of surface epithelium, 
show lobular growth, are usually infiltrated by lymphocytes and have prominent basaloid 
morphology. Two microscopic features of HPV-related OPCs are likely to cause diagnostic 
ambiguity. First, HPV-related HNSCC is customarily misperceived as a poorly 
differentiated carcinoma based on the immature appearance of the tumor cells. In point of 
fact, the appearance of the tumor cells closely emulates the appearance of the reticulated 
epithelium—the specialized epithelium lining the tonsillar crypts from which HPV-related 
cancers arise. Thus, HPV-related OPCs are in fact highly differentiated. Clinically, HPV-
related tumors present mostly at an early T stage, but show an advanced nodal stage, 
generally presenting as stage III or IV tumors, although HPV-related OPCs usually have a 
better prognosis when compared to non-HPV tumors. Despite the HPV-associated OPC 
patients have a relatively better disease-free survival rate, some individuals develop 
recurrence of their cancers after treatment and dies from recurrent disease. Based in this 
condition, screening tests could be beneficial for the detection of disease persistence or of 
early disease, using unique markers associated with HPV infection (Feller et al., 2010). 
9. HPV in laryngeal cancer 
The relative frequency of HPV genotypes in carcinoma of the larynx is still unknown; 
several studies have demonstrated variable frequencies ranging from 8 to 58.8% (Hobbs et 
al., 2006; Psyrri et al., 2008). The larynx forms of contamination and transmission of the virus 
are sometimes speculative. Infections of the larynx, pharynx and esophagus can occur, 
especially at birth when the newborn passes through the birth canal and comes in contact 
with the fluid-contaminated site. Together with oral-genital transmission, puerperal 
infection is one explanation for the presence of HPV in the oral cavity, larynx and esophagus 
(Zur Hausen, 1996).  
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The potential oncogenic importance of low-risk types of HPV in the development of laryngeal 
papillomas is well established, and the predominant types are HPV 6 and 11 (Herrero et al. 
2003; Madkan et al., 2007), which are pathogens of laryngeal papillomatosis. According to the 
clinical characteristics and natural history of disease, four different forms of laryngeal 
papillomas exist, namely isolated juvenile papillomatosis, juvenile multiple, adult and adult 
isolated multiple (Madkan et al. 2007; Torrente & Ojeda, 2007). More recently, this 
nomenclature has been replaced by recurrent respiratory papillomatosis (RRP), which more 
accurately describes the extent of the disease and its tendency to recur (Muenscher et al., 2008). 
Juvenile-onset laryngeal papillomas are associated with HPV transmitted by vertical 
transmission from a mother with active or latent anogenital infection. More than 30% of 
mothers with genital warts gave birth to children who developed juvenile-onset laryngeal 
papillomatosis. This disease occurs most commonly in first-born children and those who were 
delivered vaginally to young mothers with genital warts. Cases of children with laryngeal 
papillomatosis who were born by cesarean section are rare. The progression of papillomas is 
slow, causing the progressive symptoms of shortness of breath, persistent cough and 
dysphonia. Juvenile laryngeal papillomatosis affects both sexes equally. The most worrisome 
aspect of the disease is the spread of the virus thorough the tracheobronchial tree, progressing 
to pulmonary papillomatosis and often resulting in an uncontrollable and fatal infection. 
Another important event is the malignant transformation of laryngeal papillomas, which 
despite being a rare event, occurs in approximately 3-7% of cases.  
The laryngeal papillomas of adult onset generally affect individuals with a higher number 
of sexual partners and greater frequency of orogenital contacts. The oral-genital 
transmission hypothesis is based on the fact that laryngeal papillomatosis and genital warts 
have the same associated HPV infections (HPV 6 and 11). The area of transition from 
cuboidal and cylindrical epithelium in the larynx and uterine cervix may favor the 
occurrence of HPV in this location (Torrente & Ojeda, 2007).  
The premalignant lesions of the larynx are defined as morphologically altered tissue in which 
the occurrence of cancer is more likely than in apparently normal tissues. The detection of HPV 
DNA in premalignant lesions shows that HPV infection can be involved in the development of 
some lesions. Premalignant oral lesions usually develop as a result of several factors, such as 
tobacco and alcohol, and the synergistic interaction of HPV infection with these factors may 
play a role in the progression to cancer (Torrente & Ojeda, 2007). However, although HPV has 
been found in a large proportion of laryngeal cancers, more epidemiological and experimental 
studies are needed to clarify the role of HPV in laryngeal carcinomas. 
10. Interaction between traditional risk factors and HPV infection in HNSCCs  
Smoking and alcohol consumption are characteristics of patients with oral, oropharyngeal, 
hypopharyngeal, and laryngeal cancer. However, in the last 30 years, the presence of HPV 
associated with the increase in the incidence of HNSCCs at specific sites has suggested that 
the HPV infection can be a potential risk factor, independent of tobacco abuse and ethanol 
consumption (Blomberg et al., 2011; Chaturvedi et al., 2008; D’Souza et al., 2007; 
Hammarstedt et al., 2006; Klozar et al., 2010).  
Several clarifying findings have recently been made in the scene of HPV in the head and 
neck. The traditional prototype of an OSCC patient used to be an older man who had 
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smoked and consumed alcohol for many years. However, this profile no longer represents 
patients who are now diagnosed with oral cancer. The patients now are usually younger (< 
60 years) Caucasians with no history of smoking or alcohol drinking (D’Souza et al., 2007; 
Gillison et al., 2008). The main risk factors, tobacco and alcohol, have been supplanted by 
other risk factors associated with HPV and sexual behavior, which include the number of 
sexual partners, a history of oral-genital and oral-anal sex. As a biomarker, the detection of 
HPV infection is emerging as a powerful method for identifying oral cancer. The presence 
and progress of the disease affects the selection of patients for specific treatments and tumor 
surveillance (Westra, 2009, as cited in Begum et al., 2003).  
Whether the use of tobacco or alcohol and HPV are synergistic in the etiopathogenesis of 
oral and oropharyngeal cancers is not yet clear (Feller et al., 2010). Notably, many studies of 
HPV infection and exposure to tobacco have concluded that patients with tumors containing 
HPV DNA are characterized by moderate or no consumption of tobacco and alcohol, unlike 
individuals in the typical head and neck cancer patient population (D’Souza et al., 2007; 
Hafkamp et al., 2008; Klussmann et al., 2003). In research performed by Koch et al. (1999) a 
2-fold higher rate of HPV-associated tumors was observed in noncurrent smokers compared 
to current smokers, although the group classified as noncurrent smokers included both 
never and former smokers (Sinha et al., 2011). However, small sized groups, weak statistical 
evidence, and inconsistent definitions of smoking status could limit some of these studies. 
No consensus exists regarding the definition of current, never or former smokers or the 
criteria of light vs. heavy smoking (Sinha et al., 2011).  
In contrast, most of the studies that have noted a positive association between tobacco and 
HPV infection have had large sample sizes and adequate controls, which support consistent 
conclusions. A study that evaluated 201 cases of HNSCC using an ELISA assay to assess 
anti-HPV virus-like particles observed no interaction with alcohol in the oral cavity or 
oropharynx cancer, but a significant interaction between HPV and tobacco among 
oropharyngeal cases was obtained (Herrero et al., 2003; Smith et al., 2010). Other 
information provided by these studies is the influence of smoking intensity on disease 
survival. Heavy smoking of more than 20 pack-years has been associated with an increased 
hazard ratio of death (hazard ratio, 1.79) in patients with HPV-positive OPC compared to 
patients who smoke less than 20 pack-years (Gillison et al., 2009). 
Although much of our understanding of HPV in HNSCCs is based on the model of cervical 
cancer, the degree of interaction between smoking and HPV in this type of cancer is still not 
well known. Biologically, smoking can suppress the mediators of immune function, 
facilitating the persistence of HPV infection and the development of cancer (Sinha et al., 
2011). The DNA damage caused by smoking may impede the cell’s ability to recuperate 
from mutagenic insults; together with an increase in p53 mutations, this impairment can 
produce fragile sites or “hot spots” of DNA breakage, which facilitates the integration of the 
virus into the host DNA (Sinha et al., 2011). Thus, genetic or epigenetic alterations caused by 
tobacco have also been postulated to accelerate disease progression in HPV-infected 
individuals (Maxwell et al., 2010; Sinha et al., 2011).  
11. What can HPV tell us about prognosis and treatment?  
Due to locoregional recurrences, distant metastases and second primary tumors, no 
substantial improvement in survival has been observed in patients with HNSCCs in recent 
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decades (Leemans et al., 2011). Because multivariate analyses have pointed to HPV status as 
significant prognostic information in addition to the traditional established factors, the data 
suggest that HPV is the most important independent prognostic factor in HNSCC 
(Hannisdal et al., 2010; Lajer & Von Buchwald, 2010). HPV-infected HNSCCs have favorable 
prognoses upon treatment compared with HPV-negative tumors at a similar clinical stage 
(Leemans et al., 2011). Most investigations that have evaluated HPV infection and survival 
agree that HPV-positive patients have a significantly better survival (5-year survival of 
approximately 70%) than HPV-negative patients (5-year survival of approximately 35%) 
(Fakhry et al., 2008; Klozar et al., 2008; Vidal & Gillison, 2008). A prospective multicentric 
study has shown that individuals presenting HPV-positive OPCs had better response rates 
to chemotherapy than individuals with no HPV infection (Fakhry et al., 2008). Numerically, 
in the same study, the overall 2-year survival rate for those presenting HPV-positive tumors 
was 95% (95% CI = 87%-100%), compared with a 2-year survival rate of 62% (95% CI = 49%-
74%) for those without HPV infection (Henessey et al., 2009). In other multicenter 
prospective trials evaluating treatment responses in oropharyngeal or laryngeal carcinomas, 
the HPV-positive OPCs were found to have higher response rates to chemotherapy (82% 
versus 55%) than HPV-negative cases (Fakhry et al., 2008). Other similar findings have been 
obtained in treatment response to radiotherapy associated with the presence and titer of the 
high-risk HPV 16 (Dayyani et al., 2010; Vidal & Gillison, 2008). This improved survival is 
more pronounced in OPCs (Dayyani et al., 2010; Hannisdal et al., 2010), and even in 
investigations with no significant associations, there is a tendency toward HPV positivity in 
patients with longer survival.  
Although the improved prognosis conferred by HPV seems to be independent of the 
treatment strategy, the mechanism responsible for this survival difference is still unclear. 
Several hypotheses have been proposed, which include the fact that patients presenting 
HPV-related HNSCCs are usually non-smokers and non-drinkers and do not show 
comorbid disorders. Moreover, despite the lack of conclusion regarding the correlation of 
HPV positivity in some HNSCC sites with p53 status, an enhanced radiosensitivity of HPV-
positive tumors due to an improved apoptotic response secondary to the absence of 
mutations in TP53 of HPV-positive tumors has been proposed, as has immune surveillance 
to viral-specific tumor antigens (Vidal & Gillison, 2008) and lack of field cancerization 
characteristics of individuals with tobacco- and alcohol-related HNSCCs (Hennessey et al., 
2009). 
12. Our results regarding HPV infection in Brazilian oral squamous cell 
carcinoma patients 
The true prevalence of HPV DNA in OSCC and its role as a possible oncogenic agent are 
still controversial. We performed a study that aimed to investigate the HPV frequency in 
Brazilian patients with OSCC in order to establish a clinicopathological profile and its  
possible influence on prognosis (Oliveira et al., 2008). We examined the correlation between 
patient survival and HPV expression in primary tumors (PTs), and their matched samples 
(MSs) of recidives, lymph nodal metastasis (LNM) or necropsies. Eighty-seven PTs and  
their corresponding 87 MSs were tested for HPV infection through PCR using general and 
type-specific HPV primers. For HPV DNA detection, we utilized the GP5+/GP6+  
(Bioneer Inc.) consensus general primer pair to amplify a 150-bp fragment from the L1 gene of 
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general HPV types (GP5+, 5'-TTTGTTACTGTGGTAGATACTAC-3'; GP6+, 5'-
GAAAAATAAACTGTAAATCATATTC-3'). After, PCR was then performed on the  
HPV-positive DNA samples to determine if they contained genotypes 16 and 18, using  
specific primers targeting ~100 bp in the E7 ORF: HPV-16E7.667 (5'-
GATGAAATAGATGGTCCAGC-3'), HPV-16E7.774 (5'-GCTTTGTACGCACAACCGAAGC-
3'), HPV-18E7.696 (5'-AAGAAAACGATGAAATAGATGGA-3') and HPV-18E7.799 (5'-
GGCTTCACACTTACAACACA-3') (Bioneer Inc.). Of the 87 patients investigated, 17 (19.5%) 
were found to have HPV DNA in their tumors. An investigation of all the paraffin-embedded 
specimens revealed the presence of HPV DNA in 18 of the 174 samples (10.4%), 10 (11.5%) 
from PTs and 8 (9.2%) from MSs. Notwithstanding, no virus infection was detected in the 
corresponding PT of 7 (8.1%) MSs, and only a patient demonstrated HPV DNA positivity in 
both samples. The HPV genotypes 16 and 18 were detected in 4 (22.2%) and 3 (16.7%) of the 
positive samples, respectively. Infection with both genotypes was found in 6 (33.3%) 
investigated samples, and the HPV genotype was unidentified in 5 (27.8%) samples. The 
tongue was the most prevalent infected anatomical site. Our main result was a significant 
number of positive HPV samples among non-smoking patients, and albeit a possible influence 
of HPV on tumoral induction cannot be ruled out, the low frequency of HPV positive OSCC 
cases found in our investigation does not suggest that this virus has the same etiological 
influence on patients as tobacco consumption does, and although we cannot rule out a 
possible transient role for HPV in the induction of OSCC, we think that the occasional 
detection of HPV in OSCC resulting from the incidental colonization of tumoral lesions might 
reflect the true involvement of HPV in most investigations. 
13. HPV vaccine 
In many countries, vaccines against some HPV types are administered to girls and young 
women with the goal of protecting them against HPV-induced cervical cancer (Villa et al., 
2005; Muñoz et al., 2010). The introduction of HPV vaccines has also drawn more attention 
to the fact that HPV is associated not only with cervical cancer and genital warts but also 
with other tumors, such as head and neck and anogenital cancers (Zur Hausen, 2006). 
Although the majority of HPV vaccine research has focused on cervical cancer, some vaccine 
developers have targeted other diseases related to different strains of HPV, including two 
types of HPV (6 and 11) that can cause genital warts and recurrent respiratory 
papillomatosis in the larynx. Vaccines against these other strains have attracted the interest 
of vaccine developers because these vaccines may qualify for orphan drug status and fast-
track licensing in the United States (Nventa Biopharmaceuticals Corporation, 2005; Path, 
2006). 
Emerging results from vaccine trials have suggested that some cross-protection is possible. 
Vaccines against cervical cancer also have the potential to prevent other cancers that are 
caused by the same types of HPV, including a subset of head and neck cancers (notably the 
OPC) (Herrero et al., 2003, Kreimer et al., 2005), and half or more of anogenital cancers 
outside the cervix, including cancer of the vulva, vagina, penis, and anus (Daling et al., 2005, 
Gross & Pfister 2004). Theoretically, these vaccines should also work against the same 
viruses at other anatomical sites. If proven to do so, this approach would represent a major 
conceptual breakthrough, not only in prevention of these diseases, but equally importantly, 
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by providing the ‘missing link’ in the chain of evidence for the final proof of HPV etiology 
of these tumors (Syrjänen, 2010). 
13.1 Types of HPV vaccines 
The development of prophylactic and therapeutic vaccines targeting HPV antigens for the 
control of tumors caused by HPV is increasing worldwide. These upcoming vaccines are 
part of a new generation of vaccines that employ genetic engineering, using the ability to 
manipulate and transfer genes from one organism to another (Path, 2006).  
Prophylactic vaccines work primarily by stimulating humoral immunity and inactivating 
HPV before the virus infects the host cells (Zinkernagel, 2003). This strategy requires high 
levels of antibodies at mucosal surfaces over long periods of time (Path, 2006). Maintaining 
these high levels is difficult, so it is recommended that prophylactic vaccines should also 
stimulate a cellular immune response that is capable of eliminating early stages of infection 
in host cells (Duggan-Keen et al., 1998; Galloway, 1998). 
In contrast, therapeutic vaccines aim to generate cell-mediated immune responses using 
killer T cells that actively destroy HPV-infected cells and may exert immediate effects on 
lowering HPV-related disease incidence. To be effective, therapeutic HPV vaccines must 
prompt cell-mediated immunity because antibodies cannot reach and eliminate the virus 
once it has been incorporated into host cells (Ling et al., 2000; Chu, 2003; Maclean et al., 
2005). This type of vaccine could help people who are already infected with HPV. Used 
alone or in combination with standard therapies, a therapeutic vaccine could help prevent 
the progression of low-grade disease and cause existing lesions to regress, avoiding the 
recurrence of cancer lesions after treatment (Chu, 2003; Stanley, 2003).  
In a broad revision, Path (2001) described the existence of five types of HPV vaccines: 
recombinant live vector vaccines; protein and peptide vaccines; virus-like particles (VLPs); 
“naked” DNA vaccines; and edible vaccines (in which plants are genetically engineered to 
express HPV antigens in fruits and vegetables, leading to immunization through ingestion 
of the modified foods).  
The following three categories of HPV proteins represent potential targets for vaccines, each 
of which is expressed during different stages of infection and disease: 
1. The capsid proteins L1 and L2 compose the outside coat of HPV particles. These 
proteins interact with the surface molecules of epithelial cells during early stages of 
infection to gain entry for the viral DNA. Because L1 and L2 are present during the 
initial infection, they are ideal targets for a prophylactic vaccine (Lowy & Schiller, 1998). 
However, once HPV has integrated into the tumor cells, the capsid proteins are not 
always present and they are not reliable targets for a therapeutic vaccine. 
2. The oncoproteins E6 and E7 continue to be expressed during later stages of disease and 
are the primary targets of therapeutic vaccines. These proteins bind the human tumor 
suppressor genes p53 and pRB (Duggan-Keen et al., 1998) and are involved in the 
malignant transformation of HPV-infected cells (Van Driel et al., 1999).  
3. The proteins E1 and E2 are necessary for HPV replication within cells before the virus 
integrates into the host DNA (Duggan-Keen et al., 1998; Van Driel et al., 1999). Because E1 
and E2 are expressed at higher levels than E6 and E7 at the early stages of HPV infection, 
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they may represent the best targets for a therapeutic vaccine designed to treat the early 
stages of disease, such as low-grade dysplasias (Tindle, 1996; Lowy & Schiller, 1998). 
13.2 The HPV prophylactic vaccines 
The current HPV prophylactic vaccines are based on VLPs (Van Monsjou et al., 2010). At 
present, two prophylactic HPV vaccines are commercially available: the bivalent (HPV 
16/18) vaccine Cervarix® (GlaxoSmithKline, Middlesex, UK) and the quadrivalent (HPV 
6/11/16/18) Gardasil® (Merck, NJ, USA). Licensed globally, these two vaccines have 
produced great expectations that they will prevent infections and tumors induced by 
different HPV types (Syrjänen, 2010). 
The US Food and Drug Administration (FDA) approved Gardasil for females ages 9–26 in 
2006. In October 2009, the FDA approved Cervarix for use in females ages 10–25 and 
approved Gardasil for use in males ages 9–26 to prevent genital warts and to prevent the 
spread of cervical cancer. Moreover, the FDA (2010 and 2010a) has proclaimed that the 
dosing and administration schedule should be 0.5 mL administered intramuscularly 
(preferably in a deltoid muscle) on a 3-dose schedule. The second dose should be 
administered 1 to 2 months later, and the third dose should be administered 6 months after 
the first dose.  
These vaccines target the HPV major capsid protein L1 and can assemble to form VLP 
morphologically resembling native virions to generate robust antibody responses and 
prevent HPV infection. However, Gardasil and Cervarix differ in their adjuvants, which are 
substances added to a vaccine to enhance its impact by stimulating immune responses. In 
Gardasil, each type of VLP is purified and adsorbed on an aluminum-containing adjuvant 
(amorphous aluminum hydroxyphosphate sulfate), which is widely used. In contrast, 
Cervarix is formulated with a novel adjuvant, AS04, developed by the Corixa Corporation to 
strengthen and prolong the immune response to vaccines. Like aluminum hydroxide, AS04 
includes MPL® (3-deacylated monophosphoryl lipid A), which is a derivative of the lipid A 
molecule found in gram-negative bacteria and a potent immune system stimulant because it 
primes innate immunity and may stimulate adaptive immunity and enhance antibody titers 
(Ma; Roden; Wu, 2010). 
Although clinical trials of Gardasil and Cervarix have been extremely promising, these first 
generation VLP vaccines may not be the ideal vaccine candidates, especially in low-resource 
settings. Researchers are now actively working to develop other prophylactic HPV vaccines 
that may be effective against a broader range of HPV types and have a longer shelf life. 
13.3 The HPV therapeutic vaccines and its perspectives  
Immunotherapy offers an attractive alternative treatment strategy because it can address 
both the underlying HPV infection and the visible lesions. Moreover, immunotherapy can 
target all HPV-associated lesions, regardless of location, and induce long-lasting immunity, 
thus preventing recurrence (Chu, 2003; Stanley, 2003).  
A judgment of whether therapeutic HPV vaccine candidates have a real effect on disease has 
been difficult because most trials have not been placebo-controlled. The vaccines have also 
shown, at best, limited efficacy in eradicating established tumors, although the fact that they 
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have mostly been tested in advanced stage cancer patients with compromised immune 
systems may have limited their impact (Brinkman et al., 2005).  
Perhaps the most effective HPV vaccine strategy calls for a vaccine that possesses both 
prophylactic and therapeutic properties. A chimeric vaccine of this type could both prevent 
new HPV infections and clear existing infections. Moreover, such a vaccine would benefit 
and could be administered to both sexually inexperienced young individuals and older 
individuals who already harbor HPV (Franceschi, 2005). Opportunities for primary and 
secondary prevention should be assessed, including the use of HPV vaccines to prevent 
infection and therapeutic vaccines in the adjuvant setting for locoregional recurrence and 
distant disease (Marur et al. 2010). Combined with the fact that no therapeutic vaccines 
currently exist for other diseases, this goal makes therapeutic HPV vaccine development a 
challenging task.  
The eventual routine of HPV prophylactic vaccination will most likely have an impact not 
only on the incidence of cervical and anogenital cancers in women and men but also on the 
incidence of some groups of head and neck tumors, as in OPC. The increasing proportion of 
HPV-positive head and neck cancers underlines the increasing importance of routine 
prophylactic vaccination against HPV, and together with tobacco and alcohol control, this 
vaccination could have a decisive position in the prevention of head and neck cancer (Klozar 
et al., 2010). Vaccines directed against HPV 16, which accounts for 80–90% of all HPV-
positive HNSCC, currently exist in Europe and USA (Dahlstrand & Dalianis, 2005; Sturgis & 
Cinciripini, 2007; Hammarstedt et al., 2006; Lindquist et al., 2007; Mellin et al., 2002; Gillison 
et al., 2008; Ang et al., 2010; Marur et al., 2010; Näsman et al., 2009; Attner et al., 2010).  
14. Final considerations 
Several aspects still remain to be discovered in the field of head and neck cancers and HPV 
infection, but the epidemiological analysis of the last decade demonstrates a rapid increase 
in the incidence of HPV-associated HNSCCs, and sufficient evidence now exists for a causal 
role of HPV in HNSCC. The genomic detection of HPV DNA, primarily in OPCs, provides 
stronger support for a viral etiology in HNSCC. Although some synergies between HPV 
oncogenes and other carcinogens have been hypothesized, non-smoking and non-drinking 
patients and those who sexually debut at a younger age have an increased risk of HPV-
positive HNSCCs but show a favorable prognosis. Specifically in oral mucosa, some authors 
have suggested that the occasional finding of HPV DNA in OSCC specimens might not 
result from viral infection but rather from an incidental HPV colonization. However, a 
relative HPV contribution to oral carcinogenesis may occur in a subgroup of patients, 
mainly in areas where tobacco use is less common. 
Targeted therapy for HNSCCs now demands more predictive biomarkers, such as the HPV 
infection status and mutation status of crucial genes, which could contribute to personalized 
treatment for individual patients and decrease the inherent morbidities. However, for a 
better understanding of whether the HPV status of tumors has real therapeutic implications 
in affecting the clinical outcome, upcoming clinical trials should be significantly 
standardized in their design and performed on HNSCCs that have been adequately selected 
and classified with respect to the different head and neck anatomical sites. Moreover, we 
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suggest that other methodologies should be utilized to improve HPV detection and that 
additional population studies should be performed to confirm these findings. 
We believe that the increasing proportion of HPV-positive HNSCCs highlights the 
importance of vaccination against HPV. Although detection of the true effects of HPV 
vaccination on cancer incidence will probably continue for several decades, monitoring the 
current effects of HPV vaccination is crucial, not only in cervical cancer, but also in head and 
neck cancer. 
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1. Introduction 
1.1 Epidemiology of HPV 
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) 
worldwide that affects women as well as men. Around 75% of sexually active people will 
have an HPV infection at some point of life [1].  
HPV’s are small, non-enveloped DNA viruses and infect both cutaneous and mucosal 
squamous epithelia. They have been categorized as either low-risk types (lrHPV) or high-
risk types (hrHPV) depending on their oncogenic potential [2]. Following HPV types are 
considered as high risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 68, 73, and 82. Types 26, 53, 
and 66 are considered as probable high risk (phr). The category low-risk HPV types are 
types 6, 11, 40, and 42. HPV type 67 is of undetermined risk. The most commonly detected 
types of HPV in cancers are 16 and 18 [1]. The most commonly detected HPV HPV in 
cancers are 16, 18 and 45. 
Most HPV infections are subclinical and transient in nature. A persistent oncogenic HPV 
infection has been found to be a necessary but insufficient risk factor in almost all cervical 
cancer cases [3] and an important risk factor in a subset of penile [4], vulvar, vaginal, and 
anal cancers [5], anogenital warts [6], recurrent respiratory papillomatoses [7, 8], and a 
fraction of head, and neck tumours [9, 10]. Table 1 [11]. 
Men are considered to carry the virus on them, function as a reservoir and act as transmitters 
of the virus. HPV DNA has been detected in samples of internal and external anogenital sites.  
Rintala found HPV in the vas deferens (18.5%): five of 27 vas deferens samples (of 
vasectomized men) contained HPV 6, 11, or 16 [12].  
Svec found HPV in the epididymis: lrHPV 6 and hrHPV 16, 33, 35, 55 and 73 were detected 
in the epididymis of 7/17 patients, treated with epididymectomy because of nontuberculous 
epididymitis [13].  
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Site and histological type Incidence (per 100,000) HPV DNA range (%) 
CERVIX 8-10 76-97 
VULVA 0.0-3.5  
VIN3  72-100 
Vulva warty-basaloid  75-100 
Vulva squamous  2-23 
VAGINA 0.0-1.5  
VAIN  82-100 
Vagina squamous  64-91 
PENIS 0.0-3.7  
PIN  90 
Penis warty-basaloid  46-100 
Penis squamous verrucous  31-35 
ANUS 0.1-2.8 males/0.0-2.2 females  
AIN  NA 
Anus squamous  >80 
OROPHARYNX & TONSILS 0.3-21.5 males/0.0-2.8 females 33-72 
VIN: vulvar intraepithelial neoplasia 
VAIN: vaginal intraepithelial neoplasia 
PIN: penile intraepithelial neoplasia 
AIN: anal intraepithelial neoplasia 
Table 1. Epidemiological traits of HPV and cancers. 
Martorell found HPV DNA in 12 testicular biopsies of 185 infertile men (6.5%). The HVP 
DNA was found in Leydig cells, in Sertoli cells, and probably in germinal cells [14]. Table 2 
Also the external anogenital areas have been extensively brushed to examine if these 
samples can be used to measure the presence of HPV DNA in a general population. Often 
they were combined with semen and urine samples, which are easy and painless to obtain. 
Furthermore, it was assumed that HPV DNA positivity in urine of semen reflected the 
presence of an  ‘’internal’’ HPV reservoir. 
HPV DNA is found on the foreskin, glans/coronal sulcus, penile shaft, scrotum, perianal 
region, urine, and urethra. Table 2 
Weaver found most HPV on the foreskin [15]. Giovannelli used penile brushes (PB), urethral 
brushes (UB), and semen (SE).  The HPV DNA detection rate in PB, UB, SE, PB and UB, and PB 
and SE were 88.9%, 50.0%, 33.3%, 100% and 97.2%, respectively. He concluded that the use of 
PB and UB appeared to be the most accurate method to screen; as an alternative to UB (which 
is a rather painfull swab), the use of SE with PB could be used to improve the detection rate 
[16]. Giuliano [17] examined penile shaft, glans penis/coronal sulcus, scrotum, urethra and 
semen and concluded that urethral swabs and seminal samples were adequate swabs, which 
contained sufficient human DNA and beta-Globin, but that HPV DNA presence was very low. 
She concluded that these two samples did not contribute to optimal sampling: exclusion of 
urethra, semen, scrotum and perinanal region resulted in a < 5% reduction in prevalence. 
Nielson [18] did extensive sampling of the anogenital region in healthy, heterosexual men and 
concluded that the more complete the sampling was, the more HPV DNA was found. 
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Secondly, she stated that anogenital HPV prevalence in asymptomatic men is higher than 
expected (previously). The penile shaft was most likely to be positive for HPV. 
Author Site HPV DNA (%) Types  
Rintala, 2002 Vas deferens 18.5 6, 11, 16 Post-vasectomy samples 
Svec, 2003 Epididymis 41.2 6, 16, 33, 35, 55, 73 Nontuberculous epididymitis 
Martorell, 2005 Testis 6.5  Testicular biopsies of infertile men 
     
Weaver, 2004 Penile shaft 24  Men attending STD clinic 
 Glans 16   
 Foreskin 28   
 Scrotum 17   
 Urine 6   
Giovannelli, 2007 Penile brushing 88.9  Partners of HPV positive women 
 Urethral brushing 50.0   
 Semen 33.3   
Giuliano, 2007 Penile shaft 49.9  Heterosexual men 
 Glans penis/sulcus 35.8   
 Scrotum 34.2   
 Urethra 10.1   
 Semen 5.3   
Table 2. Anogenital sites and prevalence of HPV DNA 
2. HPV, semen and transport 
2.1 Interaction of semen and HPV 
The idea that sperm and seminal fluid could act as a vector for HPV transportation is not a 
new one. In 1979, epidemiological evidence had already suggested a correlation between 
some male penile cancers and female partner cervical carcinomas [19]. A few years later 
there was proof that male sexual partners of women with various benign or premalignant 
cervical lesions were at high risk for having penile lesions [20]. The incidence of HPV DNA 
in men is lower than in women, so questions rose about the possible modes of sexual 
transmission of HPV. Possibilities are that HPV DNA is present as free virus particles 
(virions) or is integrated in shed cells. Corollary questions are: 1)if the virus, once integrated 
in the cell’s DNA, can also express certain genes: 2) if the infected sperm cell can transfer 
HPV DNA into an embryo or to a sexual partner. 
To explore these questions Ostrow et al. (1986) examined the semen of patients with 
epidermodysplasia verruciformis and chronic lymphatic leukemia and found HPV 2 and 
HPV 5 [21]. About 95% of HPV DNA was found associated with extracts of the washes and 
not with the sperm pellet. They concluded that HPV DNA is not associated with the sperm 
itself, but is present as free HPV DNA or free virus particles. Green et al. (1989, 1991) 
demonstrated the presence of HPV DNA in the semen of patients with intrameatal and 
penile warts. They concluded that HPV DNA transmission occured from warts from which 
surface epithelial cells are shed during ejaculation [22, 23]. They found HPV DNA in the 
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pellet fraction and suggested that HPV DNA is associated with cellular material since 
virions are supposed to be found in the supernatant fraction of the semen. More recent 
studies confirmed convincingly the presence of HPV DNA in semen [16, 17, 18, 24]. 
Question 1 was approached by Lai et al. (1996): they wanted to examine the presence and 
expression of HPV in human plasma and sperm cells. They examined semen of 24 randomly 
selected patients who attended the Fertility Clinic. Type 16 E6-E7 DNA and RNA were 
found in 8.3 and zero % of seminal plasma specimens, respectively, and in 25 and 8.3% of 
sperm cells specimens, respectively. DNA and RNA sequences of HPV type 18 were found 
in 33.3 and 8.3% of seminal plasma specimens and in 45.8 and 20.8% of sperm cells 
specimens, respectively. They suggested that HPVs not only infect human sperm cells, but 
also succeed in expressing certain genes in the infected sperm cells [25].  
The second question was addressed by Chan et al. [26]. They developed an in vitro model 
that allowed sperm cells, carrying DNA fragments from HPV 16, 18, 31, and 33, from one 
end of an artificial reproductive tube and to come in contact with hatching mouse 
blastocysts at the other end of the tube. After washing the blastocysts were analyzed for the 
presence of foreign DNA fragments. Especially transference of DNA HPV type 18 to the 
blastocyst was shown. Not all DNA fragments were transferred equally. These results 
seemed to suggest that sperm can serve as a non-invasive gene delivery system to transport 
gene fragments into pre-implantation embryos. The fact that some parts of DNA were more 
easy to deliver, supports the assumption that a variety of factors and mechanisms are 
involved in transporting HPV DNA.   
Pao et al. (1996) examined the take up or retaining of different regions of HPV 18 by sperm 
cells [27]. They collected sperm samples of 23 subfertile men and found that the oncogenic 
regions of the viral genome were preferentially retained: 30% (E6) and 83% (E7), vs. 17% 
(upstream regulatory region), 22% (E1), and 4% (L1). 
In 2009, Perez-Andino et al. [28] compared the adsorption of HPV 16 to live human sperm 
cells in freshly ejaculated, undiluted human semen and in conditions that resemble the 
female genital tract. Fluorescent HPV 16 capsids were added to semen (concentration 80 
microg/l) and the mixture was incubated at 37oC. Even after several hours of incubation, no 
HPV 16 capsids were detected on the surface of sperm. When the vaginal environment (with 
a more acidic pH) was mimicked, viral binding was observed on 52% (pH 8.6) and on 72% 
(pH 7.4) of live sperm. Their conclusion was that association of HPV16 with sperm will 
probably not occur in neat semen, but may happen in the female genital tract, at low pH, 
following the dilution of the sperm. Furthermore they found that the HPV 16 capsids bind 
to two specific sites at the equatorial region of the sperm head surface. They suggested that 
by means of competitive binding on the virus, attachment to the sperm head may be 
inhibited. If applicable, this would be a way of protection of sperm cells, and consequently 
of blastocysts, of embryos, and of sexual partners.  
In 2011, Foresta et al. confirmed the binding of the virus at the equatorial region of the 
sperm head and demonstrated that this happened through interaction between the HPV 
capsid protein L1 and the receptor syndecan-1.Furthermore, they showed (using hamster 
egg-human sperm penetration test) that sperm transfected with HPV E6/E7 genes and 
sperm exposed to HPV L1 capsid protein are capable to penetrate the oocyte and transfer 
the virus into oocytes. Inside the oocytes, viral genes are activated and transcribed [29].  
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2.2 Effect of sperm washing 
Fertility clinics use washing methods to clean the sperm cells from unwanted viruses. 
However, HPV seems resistant and sperm washing does not eliminate HPV DNA. 
Olatunbosun [24] performed routine ‘’swim up’’ washing of 27 semen samples that 
contained HPV DNA: 21 samples were from men with genital lesions, six from sperm 
donors without prior or current HPV infection. Dodson[30] on the other hand, separated 
sperm cells by percoll gradient centrifugation in a 1ml aliquot and washed four times with 
sterile phosphate-buffered saline. All samples, coming from men with genital lesions, still 
contained HPV DNA after the washing procedure (100%). In six men, without genital 
lesions, the procedure reduced HPV DNA below detectable levels in only two (33.3%). 
Czegly [31] washed sperm cells in Percoll [Pharmacatia] or in Sperm RinseTM [Vitrolife] and 
found no change in HPV status.  
In 2011, Foresta and al. [32] performed semen analysis and in situ hybridization for HPV 
detection before and after sperm washing, discontinuous gradients, and swim-up protocols. 
Sperm washing centrifugation did not change the presence of HPV DNA; Ficoll density 
gradients and swim-ups brought about only a slight reduction. 
3. HPV, semen and fertility 
3.1 Effect on the sperm parameters 
The actual significance of HPV infection in sperm might be poorly understood and reports 
are conflicting, but it is a concern for those working in the field of reproductive medicine. 
Recent articles mention a negative influence on the quality of the sperm and on the 
pregnancy outcome.  
Connelly et al. [33] examined sperm samples of six subfertile patients. He found that specific 
sperm DNA fragmentation only occurred after exposure of the sperm to DNA of HPV types 
16 and 31.These viruses caused breakage characteristics of apoptotic but not necrotic sperm. 
His data suggest that these viruses do adversely affect subsequent embryonic development 
after fertilization. HPV DNA of types 6, 11, 18, and 33 did not compromise sperm DNA 
integrity: apparently sperm DNA is able to resist these types, or repairing mechanisms 
occur.  
In 1997 Lai [34] examined 24 samples of subfertile men for the presence of HPV DNA and 
RNA. HPV 16 DNA and RNA were found in 25% and 2% of sperm samples, respectively. 
HPV 18 DNA and RNA in 46% and 21%, respectively. The incidence of asthenozoospermia 
among patients infected with either HPV was significantly higher than in those without 
HPV in their sperm cells (75% vs. 8%). Performance of curvilinear velocity, straight-line 
velocity, and mean amplitude of lateral head displacement  was significantly lower in HPV-
infected specimens; the differences of linearity, beat cross frequency, and straightness were 
not statistically significant. Lai concluded: 1) that certain HPV-specific genes are actively 
transcribed; 2) that the presence of HPV in sperm cells may affect sperm motility 
parameters; 3) and that asthenozoospermia may be associated with sperm HPV infection. 
Recent studies (2009, 2010) by Foresta and al. confirmed these findings [35, 36].  
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In the first study he examined 200 samples from healthy, young volunteers. Ten persons had 
HPV DNA positive samples, which was associated with reduced sperm motility [35]. 
In the second study he collected 290 sperm samples from varying populations: patients with 
genital warts (n=26), HPV positive partners (n=66), infertile patients (n=108), and fertile 
controls (n=90). HPV semen infection in these groups was as follows: 53.8%, 40.9%, 10.2%, 
and 2.2%. The infertile patients had a higher prevalence of HPV DNA in their sperm 
samples than the other groups. Comparison of sperm parameters showed a more frequent 
reduction of sperm motility in infected samples, especially when the infection was present 
in the sperm itself [36].  
Rintala [37] examined sperm samples of 65 fathers-to-be; no assisted reproductive 
techniques (ART) were involved in the pregnancies. Ten men (15.4%) had seminal hrHPV 
DNA, without any affect on semen parameters such as semen volume, sperm concentration, 
motility and vitality of spermatozoa. No oligo- or asthenozoospermia was associated with 
seminal HPV DNA. However, there was a lowering of sperm pH in HPV DNA positive 
samples, with borderline statistical significance (7.4 vs. 7.5). Ejaculate acts as a potential 
alkaline buffer (pH 7.2-7.8) neutralizing vaginal acidity (pH 4.0-4.5) within seconds after 
ejaculation, keeping the vagina neutralized (pH 6.0-7.0) and semen motile. At pH 4.0, sperm 
cells are immobilized within one minute and are irreversibly immobilized and lose their 
vitality within 10 minutes [37]. 
3.2 Effect on pregnancy 
Nothing is known about the exact interference of an HPV positive sperm cell, injected in the 
oocyte cytoplasm (like during the ICSI procedure), with embryo development. Some studies 
mention an influence on the pregnancy outcome, while others do not find any different rates 
of spontaneous abortions and major birth defects in an HPV-exposed vs. an HPV-unexposed 
population [38]. 
Perino assessed the relation ship between HPV infection in 199 infertile couples and the 
outcome of ART. He found a significant correlation between pregnancy loss rate and 
positive HPV DNA testing in the male partner of infertile couples, compared with HPV 
negative male partners [39]. 
3.3 Effect on offspring 
Czegledy used six HPV positive sperm samples for in vitro fertilization (IVF) and intra- 
cytoplasmic sperm injection (ICSI). Three washed samples carried hrHPV 16. She tested the 
native sperm, the washed sperm cells, and the connected blastocysts for HPV sequences. All 
expectant mothers were HPV negative (negative PAP, negative colposcopy, negative HPV 
test). She found that (1) the washing procedures (Percoll [Pharmacatia] or Sperm RinseTM 
[Vitrolife]) did not change the HPV status of the sperm cells; (2) that HPV-positive 
spermatozoa kept their procreative capacity (gestation); (3) that HPV positive sperm cells 
create healthy offspring (follow-up 5 years) [31]. 
3.4 (Cryo)banking 
In an Italian cryobank, in 6/98 thawed samples of oncologic patients and in 2/60 samples of 
controls, HPV DNA was found.  Seven samples carried hrHPV’s 16, 18, 53 and 61. Only the 
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sperm head was infected by the virus [40]. Besides the possible effect of the presence of the 
virus on the sperm parameters, or on the offspring, or on the partners, another question was 
if HPV-infected sperm is able to cross-contaminate cryovials and impair also the outcome of 
ART of other couples or infect other partners. 
4. HPV, semen and cervical cancer 
Cervical cancer is the second most common malignancy among sexually active women 
worldwide. The pivotal, though insufficient, role of persistent oncogenic HPV infection in 
almost all cancer cases (99.7%) is well established. Factors in the acquisition of HPV are 
related to sexual behavior: young age at sexual debut and multiple sexual relations. Still, it 
usually takes several decades between the initial HPV infection and the onset of cervical 
cancer.  
Wang (2010) postulated that human semen may play a role in genital transmission of HPV 
and in cervical carcinogenesis itself, based on the following arguments [41]. 
- Intact genital epithelium is resistant to HPV infection. Tiny tears are necessary to make 
passage of HPV particles to the basal epithelial cell surface possible, and to initiate 
infection. Besides spermatozoa semen also contains various chemical components, 
which may be able to disrupt the normal architecture of cervical epithelium [42].  
- Secondly, the immunosuppression of human semen allows interaction with the female 
and the zygotes. The cell-mediated immunity is considered as the major protection 
against HPV infection [43]. So, it is possible that semen-mediated immunosuppression 
may facilitate HPV transmission and/or may reactivate latent HPV infection. 
- Chronic inflammation is generally considered a major risk factor for most cancers [44]. 
Prostaglandins are present in semen at 10,000-fold higher concentrations than those 
detected at the site of inflammation with PGE2 being the predominant type [45]. Up-
regulated PGE2-synthesis is regarded as a possible promoter of cervical carcinogenesis 
[46]. Consequently, in sexual active women, repeated exposure of HPV infected cervical 
epithelial cells to high concentrations of PGE2, may be seen as a paracrine modulation 
of cervical carcinogenesis. 
- Degradation of the extracellular matrix by matrix metalloproteinases (MMP’s) is 
essential to tumor invasion and metastasis [47]. Semen has the capacity to stimulate the 
production of messenger ribonucleic acid (m-rna) for MMP-9 [48], which is correlated 
with the invasive behavior of cervical cancer [49]. 
- Furthermore, as mentioned above, HPV capsids could adsorb to spermatozoa, which 
are highly motile to traverse the thick mucus layer in the female genital tract [28]. 
However, this hypothesis is in conflict with the first results published on this issue by 
Nieminen et al. They did not find (dot blot DNA hybridization) any HPV DNA in the sexual 
partners of 27 women positive for HPV DNA [50]. The method used for the processing of 
the samples can be an explanation. 
5. Study in the Fertility Clinic of the University Hospital of Antwerp 
From the above observations, it is clear that sperm cells may be necessary co-promotors of 
cervical carcinogenesis and that they compromise male fertility. 
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Furthermore, we wanted to objectify the presence of HPV in sperm samples of subfertile 
men and of sperm donors. 
5.1 Materials and methods 
The study protocol was approved by the local Ethics Committee (UA A08 22). 
Written informed consent was obtained from all couples/sperm donors. 
5.2 Semen samples 
Samples were obtained from 41 subfertile men and 21 sperm donors.  All samples had been 
approved for IVF/IUI and ICSI procedures. They were submitted to real time-PCR to 
determine the presence of 18 HPV types. 
5.3 Semen collection and analysis 
Samples were collected after 3-6 days of sexual abstinence by masturbation. After 
liquefaction, a basic semen analysis was performed and scored according to World Health 
Organisation (WHO 1992) guidelines. These guidelines were adopted after successful 
training of lab technicians via ESHRE (European Society for Human Reproduction and 
Embryology) Basic Sample Analysis Courses. Quality assurance was guaranteed by 
applying standardized methods accompanied with regular internal and external quality 
controls.  
5.4 Semen processing 
A part of the semen sample was treated with a two-step discontinuous density gradient [51] 
using Puresperm® (Nidacon, International AB, Gothenburg, Sweden). Briefly, 40% and 80% 
Puresperm® density gradient were prepared using 1.0ml of each suspension. Semen was 
layered on the top of each gradient and centrifuged for 15 mins at 300g. After which the 
upper layer seminal plasma and the 40 – 80% interface were discarded and the remaining 
spermatozoa in the 80% pellet was collected from the bottom of the tube and washed once 
with Earle’s Balanced Salt solution (EBSS, Life Technologies, Paisley, Scotland) 
supplemented with sodium pyruvate (0.011 g/l) and penicillin-streptomycin (50,000 units/l 
and 50,000 µg/l, Life Technologies, Paisley, Scotland). Samples were kept at -20°C. 
5.5 DNA extraction 
DNA is bound to the surface of carboxylated magnetic particles under conditions of high 
polyethylene glycol and salt concentrations (Magnetic Beads extraction Abott M 2000), 
following the manufacturer’s instructions [52]. Briefly, Abbott RealTime HR HPV test 
procedure consists of sample preparation, reaction assembly, real-time PCR, and result 
reporting. During sample preparation, 0.4mL of sample is processed using the Abbott 
mSample Preparation SystemDNA where sample is lysed with chaotropic reagents, and 
DNA is captured with magnetic microparticle technology. Unbound sample components 
and inhibitors are washed away and the bound purified DNA is eluted and is ready for 
amplification. Abbott RealTime HR HPV is currently validated for use with cervical 
specimens collected in PreservCyt solution (Hologic Inc., Marlborough, MA, USA). 
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Specimens can be transported at room temperature or refrigerated, and may be stored up to 
4 months at room temperature or up to 6 months refrigerated or at 10°C or colder following 
collection. At the completion of sample preparation, an amplification master mix is created 
with AmpliTaq Gold enzyme (Roche Molecular Systems, Inc. Branchburg, NJ, USA), 
magnesium chloride, and oligonu- cleotide reagent containing primers, probes and dNTPs. 
As a preparation method we used the fully automated m2000sp for medium-to-high test 
volume that processes up to 96 samples in a run.. 
5.6 Real time quantitative PCR analysis of HPV DNA 
Presence of 18 different HPV geno-types was determined using TaqMan-based real-time 
quantitative PCR’s targeting type specific sequences of viral genes: 6 E6, 11 E6, 16 E7, 18 E7, 31 
E6, 33 E6, 35 E6, 39 E7, 45 E7, 51 E6, 52 E7, 53 E6, 56 E7, 58 E6, 59 E7, 66 E6, 67 L1 and 68 E7. 
Analytical sensitivity of the different PCR assays ranged from 1-100 copies and was calculated 
using standard curves for 16 type-specific PCRs constructed with plasmids containing the 
entire genome of the different HPV types [53].  Real-time quantitative PCR for ß-globin was 
always performed and was used to verify the quality of DNA in the sample and to measure 
the amount of input DNA [54]. The amount of ß-globin DNA (in nanograms) present in each 
sample was divided by the weight of 1 genome equivalent (i.e., 6.6 pg/cell) and a factor of 2 
(since there are 2 copies of ß-globin DNA / cell) to obtain the number of genome equivalents 
in the sample. Viral loads in each specimen were expressed as the number of HPV copies / 
cell. The 18 HPV types we tested for were divided according to Munoz [55] 
5.7 Questionnaire and screening 
Standard questionnaire with questions about: 
•  Life style: use of tobacco, alcohol, and drugs 
• Sexual history: Number of partners during the past 6 months, homosexual partners, 
anal sexual activities, SOI.  
• Motivation to donate sperm. 
Routine: 
•  screening for HIV, Hepatitis B, Hepatitis C, Syphilis, Chlamydia trachomatis, Neisseria 
gonnorhea. 
• HBA1C, FSH, Testosteron, SHBG, Inhibine B 
6. Results 
All samples were adequate and contained sufficient beta-Globin. In the native sperm of two 
patients high risk HPV type 39 was found: one in a sample of a man visiting the fertility 
clinic, one in a sample of a sperm donor. In the gradient specimens, no HPV DNA was 
found. 
7. Discussion  
Investigation of sperm in our fertility clinic resulted in only 2 HPV DNA positive samples, 
out of 82.  Our samples came from subfertile, but healthy men and sperm donors. Foresta 
[40] found a significant number of HPV DNA in thawed sperm samples from patients with 
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testicular cancer (6.1%), when compared to the samples of controls (93.3%). The HPV types 
involved in the patients were 4x hrHPV, 1 medium-risk HPV, and 1 lrHPV. 
Questions concerning HPV DNA in a cryobank are whether the virus can cross-contaminate 
other vials and if contamination has clinical consequences for the outcome of the ART, and for 
the health of the offspring and the receiving partner. To answer these questions, more research 
is needed to understand more about the exact interaction of the human papillomavirus with 
sperm cells and the clinical consequences of (the use of) HPV positive sperm cells. 
We feel that, at this moment, routine screening of sperm for HPV, will not contribute to the 
safety of the procedure. 
8. Overall conclusion 
Research on the prevalence of HPV DNA in semen and its effect on sperm quality and 
pregnancy outcome is growing. 
It seems that the lower pH in the vaginal environment has a double effect: it increases the 
capacities of the virus to adsorb to sperm cells.  Consequently it affects capacities of the 
sperm cells in a negative way, especially the motility. Other studies mention consequent 
problems with embryogenic development and a worse outcome of pregnancies [39]. 
Therefore, it has been suggested to discourage the use of fresh semen for artificial donor 
insemination program, until accurate, rapid diagnostic tests are available to exclude the 
presence of HPV infection, and to us only frozen semen that has been appropriately 
screened [24]. 
Some author’s hypothesized that the presence of HPV in semen may be a co-risk factor for 
women to develop, cervical cancer, later on in life. Therefore, they promote the use of 
condoms to prevent genital transmission of HPV and reduce the incidence of cervical cancer 
[41]. This advice is difficult to follow for couples with a long-lasting, monogamous sexual 
relationship. 
The conclusions of the different studies are not unanimous and further research has to focus 
on the mechanisms involved, the clinical consequences, and on the  prevalence of these 
problems. 
Furthermore, the number of women vaccinated with one of the prophylactic vaccines is 
growing. This protection may reduce the possible risks, caused by the presence of HPV 
DNA in semen. Wise examined the effect of the prophylactic quadrivalent vaccine on 
reproductive organs and semen. He vaccinated male and female rats. All rats had a specific 
antibody response to the four types after each injection. There were no effects on the 
reproductive parameters of cohabited male rats: they had normal sperm count and sperm 
motility. Also the histomorphology of testis and epididymis were unchanged [56].   
The vaccine will probably cause no harm to the fertility of its users, and will in addition, 
provide protection for the development of cervical lesions [57]. 
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1. Introduction  
Infection with human papillomavirus (HPV) is necessary for the development of the cervical 
cancer. Although, the relationship between HPV and cervical cancer is well documented 
and well established in the literature, the relationship between men and HPV-associated 
cancers is just emerging (Palefsky,2010).  
The HPV has been shown to play a causative role in anal, head, neck, oral and penile 
carcinomas. The latter is a rare tumor accounting of a 1 per 100.000 incidence rate in 
Western countries, including Europe and North America, and representing less than 1% 
of all male cancers. On the contrary, the incidence in some emerging countries is much 
higher, reaching 18% to 20% of all male tumors (Salvioni et al., 2009). General 
socioeconomic factors and access to health-care systems might contribute to the 
discrepancies in this incidence.  
The incidence rate increases with age, although the disease has also been reported in young 
men. Early diagnosis may be not only lifesaving but also essential to functionally and 
esthetically acceptable treatment. Many patients still seek medical attention at a late stage, 
when a conservative therapeutic approach is no longer feasible. Awareness of penile cancer 
and its prevention are at the heart of the recent controversies about circumcision and about 
the necessity to treat HPV infections (Micali et al., 2006). 
There has been little progress in managing penile cancer during the past decade. The overall 
survival figures remain unchanged and its etiopathogenesis is still not fully understood 
(Chaturvedi, 2010; Dillner et al., 2000). Researchers have focused their investigation on a 
potential association between HPV infection and penile cancer development. However, this 
association is not absolute and other factors are implicated in the initiation and progression 
of the disease. The following chapter focuses on the natural history of penile cancer, 
addressing the probable mechanism by which HPV leads to malignant transformation of the 
penile epithelium, the relationship of genital HPV for risk penile cancer, and the preventive 
strategies to reduce HPV infection in men.  
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2. The role of human papillomavirus infection in etiology of penile cancer  
Among men and women, cancers of the anogenital tract and their precursor lesions have 
been strongly linked to infection with sexually transmitted HPV (Wilkin & Chiasson, 2004). 
HPV causes virtually all cervical cancers and the virus is found in association with at least 
90% of cervical carcinomas (de Sanjosé et al., 2007; Moscicki et al., 2006). The variability in 
HPV-attributable proportions for non cervical cancers arises partially from differences in 
HPV detection methods across studies as well as from true geographic differences in HPV 
distribution world-wide (Chaturvedi, 2010). Despite the reported variability, 90%–93% of 
anal cancers, 12%–63% of oropharyngeal cancers, 36%–46.9% of penile cancers, 40%–64% of 
vaginal cancers, and 40%–51% of vulvar cancers are potentially attributable to HPV 
infection (Caltellsagué et al., 2002; Chaturvedi 2010; Gillison, 2008; Giuliano et al., 2008; 
Giuliano et al., 2010; Miralles-Guri et al., 2009). See fig. 1 to identify average prevalence of 
HPV infection associated with anatomical cancer sites. 
 
Fig. 1. HPV DNA prevalence among cases of cancer 
Acquisition of HPV is very common, particularly among sexually active young adults, and 
incidence of infection with oncogenic HPV types appears to be higher than the incidence of 
infection with non-oncogenic types (Baseman & Koutskyl, 2005). Oncogenic HPV types 16 
and 18 and history of other concurrent sexually transmitted diseases were found to be 
significantly associated with progression to cervical cancer (Cavalcanti et al., 2000). 
Carcinoma of the uterine cervix is the sixth most common cancer among women worldwide, 
with very high mortality rates in developing countries. It was observed more than 20 years 
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ago that some types of HPV were more frequent in malignant than in benign lesions, and 
infection with high-risk types of HPV is now considered the major risk factor for the 
development of cancer of the uterine cervix (Villa, 2006).  
The advent of screening to identify and treat cervical cancer precursor lesions and cervical 
intraepithelial neoplasia (CIN) has led to a substantial reduction in the incidence of cervical 
cancer in those countries where routine screening is in place. Conversely, most cervical 
cancer-related mortality occurs in countries where there is no routine cervical screening. On 
the other hand, it is clear that HPV infection in men is a serious clinical issue (Palefsky, 
2010). The role of men in HPV infection of women was investigated in early epidemiological 
studies using questionnaires that addressed the sexual behavior of the husbands or sexual 
partners of women with and without cervical cancer. More recent studies had, in addition, 
been able to detect the presence of HPV DNA in exfoliated cells from the penile shaft, the 
coronal sulcus, and the distal urethra (Bosch et al., 2006). Squamous Cell Cancers (SCC) of 
the penis have a low association with HPV, whereas warty/basaloid cancers are strongly 
associated with HPV. Depending on the proportion of samples that are squamous vs 
warty/basaloid in any given report, the proportion of penile cancers associated with HPV 
varies considerably (Palefsky, 2010). 
HPV positivity is higher in penile intraepithelial neoplasias (PIN1/2/3) and in the basaloid 
histological type, ranging from 75 to 80% and decreasing to a range between 30 to 60% in 
invasive SCC. Cancers of the penis are largely SCC (IARC 2007; Rubin et al., 2001). Provide 
that identification of HPV implies a casual role of the virus with the carcinogenic process, 
the attributable fraction of penile cancer related to HPV could estimated to be 40%-50% of 
penile cancer and molecular studies have confirmed the role of the HPV 16 and 18 (Miralles-
Guri, 2009). On the other hand, the majority of studies included at least one case of cancer 
with HPV 6 or 11, which in several studies were more common than HPV 18 (Levi et al., 
1998; Miralles-Guri et al., 2009; Rubin et al., 2001). HPV 31 and 33 were detected only rarely 
(IARC 2007).  
The epidemiologic association of HPV with penile cancer fulfills the criteria for causality: 
strength and consistency of the association, with increased risk of these cancers among 
HPV-infected individuals; specificity of the association; temporality of the association, with 
HPV infection preceding the development of cancer by several years; biologic gradient of 
increasing risk with increasing exposure to HPV infection; coherence, plausibility, and 
experimental evidence of oncogenic potential of HPVs; analogy of the association of HPV 
with increased risk of penile cancer; and experimental evidence through the necessity for 
consistent expression of HPV oncogenes for maintenance of the malignant phenotype 
(Chatuverti, 2010). 
2.1 Epidemiology and natural history of penile cancer 
Penile cancer prevalence varies according to geographic region, socioeconomic status and 
ethnic origin. Penile squamous cell carcinoma (SCC) is a relatively rare disease and accounts 
for less than 0.5% of all cancers in men worldwide (Backes et al., 2009). In Europe and 
United States penile cancer incidence rates vary from 0.1 to 1.5 per 100,000 men (Backes et 
al., 2009; Bigot, 2011; Curado et al., 2007; Reis et al., 2010a). In 2010, there were about 1,250 
new cases of penile cancer in the United States, resulting in 310 deaths, with an incidence 
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rate of 0.3 to 1.8 per 100,000 men (Lawindy et al., 2011). The estimated lifetime direct 
medical cost for incident penile cancer was $ 4.4 million in 2003 and an estimated 240 
associated deaths occurred in 2005 (Smith et al., 2010).  
The wide variation of penile SCC prevalence is likely explained by the large variance in risk 
factors, in particular, the practice of neonatal circumcision (Minhas et al., 2010). The 
incidence is very low among Jewish populations that commonly practice neonatal 
circumcision (0.1 per 100,000) [Morris et al., 2011; Pow-Sang et al., 2010]. Typical SCC is the 
most frequent type of invasive penile cancer, representing about 95% of all cases 
(Hernandez et al., 2008; Pizzocaro et al., 2010). Penile cancer is much more common in 
African, Asian, and South American countries, constituting about 10% of the malignant 
diseases in those countries and thus posing a considerable public health concern (Lawindy 
et al., 2011). Penile SCC is a common male cancer with an incidence of 2–5 per 100,000 men, 
constituting up to 10–22% of all male cancers in some regions in Central and South America 
(Goiania, Brazil), Asia (Chiang Mai, Thailand) and Africa (Kyadondo, Uganda) than in other 
parts of the world (Parkin et al., 2003; Tornesello et al., 2008). Higher incidence rates are 
found in some countries such as Uganda (4.4/100,000) and Paraguay (4.2/100,00) [Lawindy 
et al., 2011; Pow-Sang & Astigueta, 2009].  
Brazil has one of the highest rates of penile cancer in the world, 6-14 per 100,000 males per 
year, comprising 2-6% of all males malignancies with 7% of cases occurring in men aged 
under 35 y.o. and 39% in men older than 66 y.o. Among cases, 87% are uncircumcised. All 
tumors seen in men circumcised in childhood were of low grade, whereas 12% of those 
circumcised in adulthood had high-grade tumors (Favorito et al., 2008). At least in two 
Brazilian States (Maranhão and Pernambuco), penile cancer is reportedly the 2nd highest 
cause of carcinoma death in men, second only to lung cancer. At the main oncology hospital 
in Recife-Pernambuco, in the Northeast region of Brazil, on average one or two men each 
week need to undergo penile amputation due to cancer, with very poor prognosis (Morris et 
al.,2011).  
Despite the large Brazilian migration from the Northeast to the Southeast, motived mainly 
by the population seeking for life opportunities in the most developed economic region in 
the country. Koifman (2011) reported that penile cancer was more prevalent in patients 
born in the state of Rio de Janeiro. According to the data from the Brazilian Ministry of 
Health, there is an estimated 850 partial or complete penile surgical procedures 
performed in the context of malignancy yearly within Brazil, with approximately 50% of 
these procedures being performed in the North and Northeast regions of the country 
(Favorito et al., 2008).  
The presence of an intact foreskin has been identified as an important risk factor for 
developing penile cancer (Lawindy et al., 2011). Circumsicion protects against HPV 
infection, in a cohort study involving men in the USA, Mexico and Brazil, both low-risk and 
high-risk HPV types were less frequent in circumcised men (Giulliano et al., 2011). Male 
circumcision is the commonly performed surgical procedure in the world. The surgical 
technique is determined by social circumstances, together with the indication for the 
operation and the patient's age. There is no therapeutic male circumcision, which by 
definition does not treat an underlying pathological process. The motivations underling the 
procedure may be religious, cultural, social or prophylactic (Perera et al., 2010).  
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In most cases, the reason for circumcision is of religious or cultural origin. Both Jewish and 
Islamic laws promote male circumcision. Jewish male infants are circumcised on the eighth 
day, according to Biblical teaching, whereas among Muslims variations in the timing of 
circumcision do exist, with some communities delaying the procedure until the age of 10 
years. Ritual circumcision is also performed in several African tribes as a ceremony of 
passage into adulthood (Micali et al., 2006).  
Circumcision is the most common operation performed in males in the United States, where 
approximately 60% of male infants are routinely circumcised in the neonatal nursery, in 
most cases due to parental choice and nonreligious reasons. In Canada, approximately 48% 
of males are circumcised (Micali et al., 2006). In Australia the annual incidence of penile 
cancer was 0.8 per 100,000 men, which is similar to the US figure. As in the USA, over two-
thirds of older men in Australia are circumcised. However, since the 1970s, Australia 
experienced a decline on the number of infant male circumcision. Thus, an increase on 
penile cancer has been expected in that population (Morris et al., 2011). 
In most of Europe, in South and Central America, and in most Asian countries, including 
the People’s Republic of China, Taiwan, Japan, and North Korea, male circumcision is 
uncommon. In a medical setting, postnatal circumcision is regarded as both a treatment for 
phimosis and a possible prophylactic measure for the prevention of penile cancer and other 
infectious or inflammatory conditions (Micali et al., 2006). In countries where circumcision is 
not practiced routinely, such as those in South America and parts of Africa, penile cancer 
can be ten times more common than in high-income countries, representing 10-22% of all 
male cancer (Morris et al., 2011). 
The first suggestion linking circumcision and penile cancer was reported in 1932, when, 
among, 1.103 penile cancer cases in USA, none where Jewish despite 3% of the population 
being Jewish (Wolbarst, 1932). Circumcision as a measure to prevent penile cancer has been 
repeatedly related by different investigators. Maden et al. (1993) found that the risk of penile 
cancer was 3.2 times larger among men who had never been circumcised in comparison to 
men circumcised at birth and 3.0 times higher among men circumcised after the neonatal 
period. Schoen et al. (2000) reported that of 89 men with invasive penile cancer whose 
circumcision status was known, 2 (2.3%) had been circumcised as newborns and 87 had not 
been circumcised. The relative risk of invasive penile cancer for uncircumcised to 
circumcised men was 22:1. In a population-based case-control study in western Washington 
state carried by Daling et al. (2005), men who had not been circumcised in childhood had a 
1.5 fold increased risk of developing penile cancer. Morris & Rose (2007) reported 
circumcision as a biomedical imperative for the 21st century, not only for the reduction of 
penile cancer, but also for a decrease in urinary tract infections, inflammatory dermatoses, 
and sexually transmitted diseases.  
Studies have consistently reported neonatal or childhood circumcision to be associated with 
reduced risk of penile cancer, which geographically corresponds to reduced rates of penile 
SCC in populations that culturally practice neonatal circumcision (Maden et al., 1993; Micali 
et al., 2006; Morris et al., 2011; Perera et al., 2010; Tseng et al., 2001). The protective effect of 
childhood circumcision, but not of adulthood circumcision, seems to be attributable to the 
elimination of inflammatory conditions related to poor genital hygiene, such as phimosis 
and balanitis (Pizzacaro et al., 2009). On the other hand, the preventive effect of newborn 
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circumcision on SCC development is still unclear. It occurs only if circumcision is performed 
at birth or early in life, whereas late or adult circumcision seems to be ineffective in risk 
reduction. 
Beyond lack of circumcision there are others factors related with penile cancer such as 
phimosis. A history of phimosis also imposes a significant risk for the development of penile 
cancer, which is. Approximately 25% - 60% of patients with penile cancer have phimosis  
(Lawindy et al., 2011). Precancerous lesions are found in an additional 15% to 20% of 
patients with phimosis (Pow Sang et al., 2002). Thus, phimosis is considered one of the 
strongest risk factors for penile cancer. The relative risk of penile cancer among men with 
phimosis was 64.6. The frequency of phimosis in men with penile carcinoma is high, ranging 
from 44% to 85%. Phimosis leads invariably to retention of the normally desquamated 
epidermal cells and urinary products (smegma) resulting in conditions of chronic irritation 
with or without bacterial inflammation of the prepuce and the glans. However, there is no 
supporting evidence of the role of smegma as a carcinogen. Therefore, much debate still 
exist regarding this risk factor, as smegma is not yet believed to contribute to the 
development of penile cancer (Lawindy et al., 2011). 
In a meta-analysis reported by Larke et al. (2011), four studies evaluated the association 
between phimosis and penile cancer (OR range 4.9-37.2). The effect of childhood/adolescent 
circumcision on invasive penile cancer may be largely mediated through elimination of 
phimosis, since there was no evidence of an association of circumcision with invasive 
disease when analyses were restricted to individuals with no history of phimosis.  Morris et 
al., (2011) related that 45-85% of men with penile cancer have a history of phimosis and 
causes dysplastic (pre-cancerous) changes in the skin of the preputial sac. The authors 
demonstrated 52% of penile cancer with a long foreskin had phimosis. These findings have 
led to conclusion that circumcision in early childhood by elimination phimosis may help 
prevent penile cancer. Thus, the phimosis is a stronger risk factor for invasive disease 
compared to in situ cancer which further supports the argument that circumcision acts 
through prevention of phimosis and that some in situ cancers develop through a different 
pathway to invasive cancer (Daling et al., 2005; Larke et al., 2011).   
Poor genital hygiene in uncircumcised men, even in the absence of phimosis, may also lead 
to the retention of microorganisms and secretions, including smegma. Whether good 
standards of genital personal hygiene in uncircumcised males may provide the same level of 
protection of circumcision against penile SCC has been questioned. Although a lower 
incidence of penile SCC, even among uncircumcised individuals, is noted in countries and 
communities with a high standard of genital hygiene and widespread diffusion of private 
bathing facilities (Micali et al., 2006).  
Smith et al. (2010) reported that flat penile lesions are much more frequent in uncircumcised 
men and associated with higher prevalence of HPV and higher viral loads. The authors 
suggest that circumcision reduces the prevalence of HPV associated flat lesions and may 
ultimately reduce male to female HPV transmission. The increased risk of HPV infection 
among uncircumcised men observed and has important implications regarding HPV 
associated malignancies in men and their female partners. However, despite some favorable 
medical evidence, the promotion of circumcision as a mean of controlling HPV and other 
sexually transmitted infections remains  controversial (Hernandez et al., 2008; Van Howe, 
2007). 
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HPV infection alone is insufficient to cause epithelial malignancy in men. Unlike cervical 
cancer, evidences suggest that HPV infection is not a necessary cause of penile cancer with 
HPV prevalence ranging between 15 and 71% among penile cancer tissues (Rubin et al., 
2001). Daling et al., (2005) measured the percentage of HPV DNA-positive tumors in their 
study and concluded that there was a consistent association between HPV infection and the 
development of most penile cancers.  
The role of circumcision in penile cancer prevention is unclear: it could possibly be ascribed 
to a lower baseline risk of disease due to a decrease in the amount of susceptible tissue, 
prevention of potential cofactors with HPV (such as phimosis) from promoting disease or 
another mechanism. 
However, male circumcision has been widely debated as a preventive measure for sexually 
transmitted infection human immunodeficiency virus/acquired immune deficiency 
syndrome (HIV/AIDS), urinary tract infection and penile cancer (Gray et al., 2010; Perera et 
al., 2010). Individuals with HIV/AIDS are at increased risk of HPV-associated cancers. This 
increased risk among persons with HIV or AIDS is consistent with a high incidence and 
persistence of HPV infections (Chaturvedi et al., 2009). On the other hand, circumcision can 
be considered an important cofactor in the natural history of HPV infection, since it may 
influence the risks of the acquisition and transmission of HPV as well as of cervical cancer. 
Castellsague et al., (2002) has provided epidemiologic evidence that male circumcision is 
associated with a reduced risk of genital HPV infection in men and with a reduced risk of 
cervical cancer in women with high-risk sexual partners. Thus, male circumcision may 
potentially reduce exposure of female partners to HPV infection.  
Early age at first sexual intercourse, high lifetime number of female sexual partners, 
smoking, and lack of condom use are identified risk factors for penile SCC (Maden et al., 
1993; Reis et al., 2010a). Some studies have also identified chronic smoking as an associated 
risk factor for the development of penile cancer (Pow-Sang et al., 2010). Tseng et al. (2001) 
found that the incidence of penile cancer among men who had ever smoked cigarettes was 
2.4 times that of men who had never smoked. Harish & Ravi (1995) found a significant 
association between smoking or chewing tobacco and the development of penile carcinoma. 
In 503 men and age-matched controls, a multivariate analysis demonstrated a significant 
association and dose-dependent relationship. Maden et al. (1993) found that the risk of 
penile cancer among men who smoked at diagnosis was 2.8 times that of men who had 
never smoked, and lifetime smoking of >45 pack-years of cigarettes elevated the risk to 3.2 
times that of men who had never smoked.  
The efficacy of latex condoms for reducing risk of contracting sexually acquired HPV 
infection is not well established, although some degree of protection is likely provided. In 
vitro studies demonstrated the impermeability of latex condoms to HPV during conditions 
simulating sexual intercourse. Thus, condom use could be effective in reducing HPV-
associated outcomes such as genital warts, cervical, anal and penile cancers (Shew & 
Fortenberry, 2005).  
The incidence of penile cancer is lower compared to that of cervical cancer (Curado et al., 
2007), likely due to the lower susceptibility of the penis to the malignant transformation 
virus-induced as compared to the cervix. Additionally, penile cancer, like cervical cancer, 
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is caused by high-risk HPV, but penile cancer is 10 times less common than cervical 
cancer (Morris et al., 2007). In a large case series, HPV DNA was positive in invasive 
penile cancer in 40% to 50% of cases. Thus, many studies have shown a strong correlation 
of the presence of HPV types 16 and 18 with penile carcinoma (Daling et al., 2005; Gentile 
et al., 2006; Pascual et al., 2007; Senba et al., 2006; Tornesello et al., 2008; Villa & Lopes., 
1986). 
2.1.1 Human papillomavirus infection in men who have sex with men 
HPV infection is considered to be a sexually transmitted disease, and the risk of HPV 
infection is increased by certain sexual behaviours (Sirera et al., 2006). HPV associated 
malignancies have been reported to occur in excess among patients with HIV or AIDS 
(Frisch et al.,2000). Co-infection with HIV and HPV has been investigated in studies due to 
the increased risks of warts and malignant neoplasias in the anal and genital tracts. Several 
studies conducted in men infected with HIV focus on the anal canal due to the high rates of 
HPV infection, anal intraepithelial neoplasia (AIN) and anal cancer. On the other hand, few 
studies have examined the penile region for HPV infections in men infected with HIV (Silva 
et al., 2011).  
HPV infection is an independent risk factor for acquiring human immunodeficiency virus 
(HIV) infection and some forms of cancer. Men who have sex with men (MSM) may be 
difficult to identify in general practice because many of them do not self identify as 
homosexuals or bisexuals or are still having sex with women as they develop their sexual 
identity. The incidence of anal cancer among MSM is higher than cervical cancer rates 
among women. HPV has been definitively associated with more than 85% of all cancerous 
or precancerous anal lesions worldwide (Dietz & Nyberg, 2011). 
The vast majority of HPV infections in immunocompetent individuals is transient, and the 
amount of persistent infections is rather low. This contrasts to immunosuppressed 
individuals, as patients with HIV infection exhibits high rates of persistent HPV infection. 
Consequently, these individuals have a high risk for HPV-associated malignant disease. 
Within the last decade, sufficient data were published to conclude that AIN and anal cancer 
continuously increase in HIV-positive MSM despite the use of highly active antiretroviral 
therapy. In contrast, only limited data are currently available on HPV-associated diseases at 
other anatomical sites of HIV-positive MSM, for example, oral cavity or penis (Kreuter 
&Wieland, 2009).  
Giuliano et al. (2011) designed a cohort study to estimate the incidence and clearance of 
type-specific genital HPV in men and to assess associated factors. The incidence of a new 
genital HPV infection was 38.4 per 1000 person in 1159 men studied (95% CI 34.3–43.0). 
Oncogenic HPV infection was significantly associated with having a high number of lifetime 
female sexual partners (hazard ratio 2.40, 1.38–4.18, for at least 50 partners vs not more than 
one partner), and number of male partners who carried out anal intercourse  (2.57, 1.46–4.49, 
for at least three male partners vs no recent partners). The median duration of HPV infection 
was 7.52 months (6.80–8.61) for any HPV and 12.19 months (7.16–18.17) for HPV 16. 
Clearance of oncogenic HPV infection decreased in men with a high number of lifetime 
female partners (0.49, 0.31–0.76, for at least 50 female partners vs not more than one partner), 
and in men in Brazil (0.71, 0.56–0.91) and Mexico (0.73, 0.57–0.94) compared with the USA. 
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Clearance of oncogenic HPV was more rapid with increasing age (1.02, 1.01–1.03). The 
results from that study provided much needed data about the incidence and clearance of 
HPV infection in men. These data are essential for the development of realistic cost-
effectiveness models for male HPV vaccination internationally. 
Current data on the spread of HPV infection to the different body parts implicated in sexual 
practices in both MSM and heterosexual men are limited. A cross-sectional study was 
carried out to evaluate the prevalence of HPV infection in the anus, mouth and penis in this 
specific population. The authors found the prevalence of penile HPV infection in HIV-
positive men was 36% (95% CI, 26–48%), with a prevalence of 38% (95% CI, 25–53%) in 
MSM and 32% (95% CI, 14–55%) in heterosexual men, p= 0.43. (Sirera et al., 2006). The first 
study to address HPV DNA persistence and clearance in the genital area among men 
infected and non-infected with HIV. The authors observed that more men infected with HIV 
presented with multiple HPV types compared to the men seronegative to HIV. This finding 
may be attributed to the two groups’ different immunodeficiency levels. Multiple infections 
with different types of HPV including high-risk HPVs are more frequent in men who are 
infected with HIV (Silva et al., 2011). However, there are few available studies on the 
persistence and elimination of HPV infection in men, such as HPV associated with penile 
carcinoma. 
2.2 Mechanism of neoplastic transformation in cells 
Papillomaviruses (PV) are small, non-enveloped, double-stranded DNA viruses that infect 
mucosal and cutaneous epithelia in a wide variety of higher vertebrates in a species-specific 
manner and induce cellular proliferation. PV isolates are traditionally described as ‘‘types’’. 
PV types have been detected in all carefully examined mammals and birds, with the 
possible exception of laboratory mice. In the only extensively studied host, humans, more 
than 100 human PV (HPV) types have been described based on the isolation of complete 
genomes, but independent studies indicate that many more exist, with a yet larger number 
presumed to exist based on the detection of subgenomic amplicons (Bernard et al., 2010, de 
Villiers et al., 2004). From the HPV types identified, approximately half of them infect the 
genital tract (Bosch et al., 2008). Many of these HPV types have been shown to be ubiquitous 
and globally distributed (de Villiers et al., 2004).  
HPV are small DNA viruses that infect epithelial tissues. Whether cutaneous or mucosal, the 
more than 100 types of HPV described have in common a circular DNA genome of about 
8.000 base pairs. A double-stranded circular DNA genome encodes approximately eight 
open-reading frames (ORFs). These small genomes are organized into an early, a late, and a 
long control region. The products of 3 genes from the early control region, genes E6, E5 and 
E7, are essential in the HPV-induced processes of cellular transformation and 
immortalization (Moddy & Laimins, 2010), and 2 genes from the late control region, genes 
L1 and L2, encode the viral capsid proteins (Villa, 2006). The figure 1 shows the general 
organization of the HPV genome (Ghittoni et al., 2010; Villa, 2006).  
The process by which HPV facilitates tumor initiation and fosters tumor progression is an 
exceptional model to understand the development of many human cancers and also allows 
identification of additional signaling pathways targeted in malignant progression (Moddy & 
Laimins, 2010). An explanation for this is that the expression of viral genes E6 and E7 is 
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increased in cells with integrated high risk HPV genome, and these genes products, the 
oncoproteins E6 and E7, respectively bind and inactivate cell tumor suppressor proteins p53 
and pRb (Ghittoni et al., 2010).  
The association between HPV and human cancer was first proposed more than three 
decades ago by Harald zur Hausen (2002). Subsequently, his group isolated several mucosal 
HPV types from cervical lesions, including the high-risk HPV16 (Bosch et al., 2008). 
Additionally, several studies have demonstrated the direct role of HPV infection in the 
development of several human cancers (Bosch et al., 2008; Caltellsagué et al., 2002; Gillison 
et al., 2008; Giuliano et al., 2008; Giuliano et al., 2010). HPV 16 and HPV 18 are the most 
frequently found HPV types in cervical cancers worldwide (Bosch et al., 2008; Munoz et al., 
2003). 
 
Fig. 1. The genome of the HPV. The diagram indicates the ORFs of the early (E) and Late (L) 
genes, and the long control region (LCR).  Functional of viral proteins. 
For this reason, the majority of the biological studies were focused on these two HPV types 
(Moddy & Laimins, 2010; Villa, 2006). High-risk HPVs are also associated with many vulvar, 
anal, and penile carcinomas and contribute to oral cancer (Parkin & Bray, 2006). On the 
other hand, carcinomas from different anatomical sites, in contrast to cervical cancer, appear 
to be preferentially associated with HPV 16 (Chaturvedi, 2010; Gillison, 2008; Miralles-Guri 
et al., 2009). For instance, in the subset of penile cancer attributed to HPV infection,  HPV 16 
was found in 60,23% of cases (Miralles-Guri et al., 2009). 
HPV-associated cancers are intimately linked to HPV persistence and the accumulation of 
chromosomal rearrangements in the infected tissue (Moody & Laimins, 2010). Studies 
suggest an association between HPV infection and penile cancer. The mechanism by which 
HPV leads to malignant transformation is likely mediated through two viral genes E6 and 
E7, which are actively transcribed in  HPV infected cells (Pow-Sang & Astigueta, 2009). The 
products of the early genes, E6 and E7, of the high-risk HPV types play a key role in both 
events.  Indeed, these proteins have developed a number of strategies to evade host immune 
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surveillance allowing viral persistence, and to alter cell cycle and apoptosis control, 
facilitating the accumulation of DNA damage and mutations. Often, the oncoproteins target 
the same cellular pathways with different mechanisms, showing a strong synergism in 
promoting cellular transformation and neutralizing the immune response (Ghittoni et al., 
2010). 
In cervical carcinogenesis, recombination between HPV and chromossomal DNA is frequent 
and likely necessary for cancer progression. Moreover, DNA methylation, specifically on the 
L1 gene, has been accepted as an important biomarker for cancerous progression in the 
cervix. The term DNA methylation refers to the transfer of a methyl group to cytosines that 
are part of CpG dinucleotides (meCpGs), which results in the binding of meCpG specific 
transcriptional repressors, for example MeCP2. In undifferentiated cervical cells, HPV-16 
acquires a low and sporadically distributed CpG methylation, which disappears completely 
upon differentiation. During carcinogenesis, upon integration of HPV-16 and 18 into cellular 
DNA, the L1 gene, and to a lower extent adjacent long control region (LCR) sequences, 
become hypermethylated, a fate of HPV DNA shared with most unrelated external DNA 
sequences that enter mammalian cells. The same mechanisms apparently occur during 
penile carcinogenesis, according with the study of Kalantari et al. (2008), which investigated 
the properties of HPV genomes in penile carcinomas from Brazilian patients. Their 
observations of frequent viral DNA methylation, chromosomal integration, and the 
prevalence of high-risk variants suggest that HPV dependent carcinogenesis of the penis 
and cervix follow similar etiological and epidemiological parameters. 
A single nucleotide polymorphism (SNP) in codon 72 of TP53 has attracted wide attention 
over the past decade. The most common polymorphism at codon 72 results in a non-
conservative change of arginine to proline within a proline-rich region of p53, in a domain 
known to be important for growth suppression and apoptotic functions (Tornesello et al., 
2008), may be involved in multiple steps of carcinogenesis and may also account for genetic 
differences in susceptibility to cancer (Reis et al., 2010b; Tornesello et al., 2008, Almeida et 
al., 2008). It has been demonstrated that the TP53 polymorphism distribution varies 
according to ethnic and geographical backgrounds, like most human genetic 
polymorphisms (Reis et al., 2010b).  
Storey et al. (1998) found that women who are homozygous for TP53Arg are seven times 
more susceptible to HPV-associated squamous carcinoma of the cervix than are 
heterozygous women. Since then, many groups have reported an effect of the TP53 codon 72 
polymorphism on cervical cancer and others carcinomas. A meta-analysis of several studies 
on TP53 polymorphism at codon 72 confirmed that arginine homozygous genotype is 
associated with an increased risk of invasive cervical cancers, but not with squamous 
intraepithelial lesions,  supporting the hypothesis that the polymorphism may have a main 
role in the progression of HPV-related cancers, rather than in the tumor initiation (Koushik 
et al., 2004). On the other hand, very few studies have been designed to investigate TP53 
polymorphisms in penile carcinomas.  
In a case-control study, Tornesello et al. (2008) analyzed the polymorphism of the gene TP53 
at codon 72 and found the polymorphism associated with increased risk for 78 penile SCC 
biopsies (n = 17 from Uganda and n = 61 from Italy). Despite, significant differences in 
arginine and proline allele distribution were observed when the cases were stratified by 
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HPV status. Thus, no evidence of association between homozygosity for p53 arginine and 
HPV-related or HPV-unrelated penile SCC was observed among Ugandan or Italian 
populations. In another study, the TP53 Arg/Arg genotype did not appear to represent a 
risk factor for the development of genital SCC in men, and no correlation was found 
between the TP53 polymorphism at codon 72 and the presence of HPV DNA in the tumour 
tissue (Humbey et al., 2003). 
The role of several tumour suppressor genes and cellular oncoproteins has been 
characterized by studying HPV E6 and E7 and or other related viral oncoproteins. The 
knowledge of HPV and cancer association obtained during the past three decades is 
extremely relevant. Worldwide, this knowledge has led to clinical and scientific 
achievements such as the generation, commercialization, and distribution of cervical cancer 
high-risk HPV vaccines. As a consequence of research studies on virus and cancer 
association, the Nobel Prize in Physiology or Medicine 2008 was awarded to Dr. Harald zur 
Hausen for his discovery of HPV causing cervical cancer (Ghittoni et al., 2010).  
Certainly, the expression of viral oncoproteis is needed to induce and maintain the 
neoplastic phenotype of cervical cancer cells. The similarity of the tissues leads one to 
assume that a similar mechanism may play a role in the development of HPV-induced 
penile cancer (Kayes et al., 2007). Provided that identification of HPV implies a causal role of 
the virus with the carcinogenic process, the attributable fraction of penile cancer related to 
HPV has been estimated at 47%. The etiology of penile carcinomas is likely to be 
heterogeneous, co-existing both HPV related and HPV-independent pathways. Based on 
cervical cancer studies, penile cancer could also arise from initial HPV infection which 
persists over time, causing genetics alterations within the infected penile epithelium, leading 
to the cancer development. However, the molecular mechanisms underneath HPV-induced 
penile cancer remain to be completely understood (reviewed in Miralles-Guri et al., 2009). 
2.3 High risk HPV-associated penile cancer 
Molecular biology techniques with different sensitivity and specificity have facilitated the 
characterization of the entire HPV genome, where different functional regions are identified, 
as a profile of their gene expression. The techniques of Southern blotting and in situ 
hybridization have been used extensively in the past to identify viral sequences in tissues. 
Additionally, polymerase chain reaction (PCR) and its variants have been recognized as the 
most appropriate method to identify and type HPV genomes because of its higher 
sensitivity and specificity (Campisi et al., 2007).  
The most studies in penile cancer use PCR consensus primers for HPV DNA detection, such 
GP5+/6 and My9/11. However, a small set of PCR studies included the SPF10 primers to 
identify HPV genomes. Almost all studies used previously stored formalin-fixed and 
paraffin-embedded samples (Table 1). However, sample preparation and fixation lead to 
DNA degradation, decreasing PCR efficiency and reducing the size of amplifiable DNA 
(Miralles-Guri et al., 2009).  
When using PCR as a strategy to identify viral genome, false-negative results may occur due 
to variations of the primer binding sites on target DNA, which in turn would lead to lower 
amplification signals of some HPV genotypes. Because of this problem, the PCR method 
may not detect all HPV genotypes present in the sample. Recently, studies involving 
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genotyping of HPV with genotype-specific oligonucleotides and DNA microarray analysis 
have been reported. A novel DNA biochip is described based on a plastic substrate, onto 
which small polymer droplets and single-stranded DNA are printed in the form of 
microarrays. After DNA isolation, PCR and biochip read-outs were compared, the chip 
allowed for genotyping of the most common virus strains, which, according to current 
prevalence studies, cover 85–95% of all infections. Following the biochip approach, as little 
as 10 virus copies can be detected within a short exposure time. Even using paraffin-
embedded material and 104 copies per PCR are sufficient to allow rapid and reliable HPV 
genotyping (Brandstetter et al., 2010). The biochip technique has become more successful for 
early cervical and non-cervical cancer diagnosis and might become the methodology of 
choice for HPV detection in the near future. 
As HPV E6 and E7 expression is necessary for the induction and the maintenance of the 
transformed phenotype, HPV-associated tumors are valuable tools to investigate important 
aspects of human carcinogenesis. Molecular evidence for a causal association includes the 
presence of HPV genomes in tumor cells, integration and specificity of HPV genomes, high 
HPV viral load in tumors, and elevated and constitutive expression of E6 and E7 oncogenes 
in tumor cells (Chaturvedi, 2010). Presence of HPV was found to be a risk factor for penile 
SCCs (Rubin et al., 2001; Gregoire et al., 1995). Several molecular techniques with different 
sensitivity and specificity have been used for HPV detection and genotyping among the 
different epidemiological studies. Considering that the incidence of penile and cervical 
cancers is high in the same geographical areas, it is reasonable to assume that both types of 
cancer share the same etiological factors. However, less than half of penile cancers are 
related to HPV infection (Gross & Pfister, 2004; Rubin et al., 2001) whereas the virus is found 
in almost all cervical SCCs (Chaux et al., 2010). 
Additionally, studies have reported a heterogeneous prevalence of high risk HPV types, 
suggesting that only a subset of cases can be attributed to viral infection (See table 1). In the 
two recent studies of the HPV type distribution in penile carcinoma, a global HPV 
prevalence was found to be approximately 46.9% and  47,9%, (Backes et al., 2009; Miralles-
Guri et al., 2009). About half of the penile tumors were associated with HPV 16 (64.07%) and 
18 (9.70%) with little presence of other genotypes, 45 (1.45%), 33 (0.97%) and 31 (0.36%), 
respectively. As expected, the literature confirmed a higher prevalence of HPV 16 and 18 in 
penile tumors (73.78%). This finding was in agreement across of all 36 studies presented in 
table 1. 
Virtually all of the studies in Table 1 used PCR to detect HPV DNA, a method slightly more 
sensitive than southern blotting and in situ hybridization. The higher the sensitivity of the 
method used, the more likely the prevalence of HPV is closer to the real prevalence 
associated with penile cancer. The relatively wide range of HPV prevalence in penile tumors 
in the published literature confirms that in addition to geographic differences. The greatest 
percentage of studies used PCR consensus primers for HPV DNA detection, such as 
GP5+/6+ and MY09/11. 
In the study of Gregoire et al. (1995), HPV DNA was detected in 26 (22.2%) of 117 
specimens. In 23 (88.5%) of the 26 HPV-positive specimens, only HPV type 16 was 
identified. HPV DNA was frequently associated with SCC in areas showing basaloid and/or 
warty changes virus DNA was more often associated with high-grade tumors (p=0.0278) 
exhibiting aggressive growth (p=0.0382) localized to the penile glans (p=0.0324). Stepwise 
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logistic regression analysis revealed that only tumor histopathology was a significant 
predictor of an HPV association. Heidman et al. (2007) detecetd HPV DNA in 46 of 83 (55%) 
and HPV16 was the predominant type, appearing in 24 (52%) of 46 of penile SCCs. In a case 
control study in Denmark, of the 37 penile SCC patients whose tumor tissues were PCR-
examined for the presence of HPV DNA, 24 (65%) were  high-risk HPV positive, and 1 (3%) 
was positive to a low-risk HPV type (HPV 6) [Madsen et al., 2008]. 
Author Year Country Sample Method Cases HPV HPV 16 
HPV 
18 
HPV 
31 
HPV 
33 
HPV 
45 
Villa & Lopes 1986 Brazil Frozen Southern Blot (SB) 18 8 0 7 0 0 0 
Kiyabu et al. 1989 USA PE PCR TS 5 2 2 0 0 0 0 
Varma et al. 1991 USA PE PCR TS 6/11/16 30 23 15 0 0 0 0 
Wiener et al. 1992 USA FFPE PCR TS 16/18 / SB 29 9 8 1 0 0 0 
Sarkar et al. 1992 USA FFPE 
PCR TS 
6/11/16/1
8 
12 9 9 0 0 0 0 
Iwasawa et al. 1993 Japan FFPE PCR TS 16/18 111 70 68 2 0 0 0 
Suzuki et al. 1994 Japan Fresh /PE PCR TS 13 7 4 0 1 2 0 
Chan et al. 1994 China PWE PCR TS 16/18 41 6 2 2 0 0 0 
Cupp et al. 1995 USA FFPE 
PCR 
My9/11 TS 
16/18 
45 23 17 2 0 0 0 
Gregoire et al. 1995 USA/ Paraguay FFPE 
PCR TS 
6/11/16/1
8 SB 
117 26 23 0 0 0 0 
Cubilla et al. 1998 USA /Paraguay FFPE PCR TS 11 0 0 0 0 0 0 
Nasca et al. 1999 Italy FFPE PCR TS 4 3 2 0 0 0 0 
Poblet et al. 1999 Spain FFPE PCR TS 2 2 2 0 0 0 0 
Levi et al. 1998 Brazil Frozen
PCR 
My9/11 TS 
16/18 
50 28 16 3 0 0 0 
Picconi et al. 2000 Argentina FFPE PCR GP5+/6+ 38 27 6 8 0 0 0 
Bezzera et al. 2001 Brazil FFPE PCR TS 82 25 13 4 0 0 1 
Gil et al. 2001 Brazil FFPE My9/11 PCR TS 55 17 3 0 0 0 0 
Rubin et al. 2001 USA/ Paraguay FFPE PCR SPF 142 60 36 2 0 0 4 
Perceau et al. 2003 France FFPE 
PCR 
GP5+/6+ 
TS 
17 6 3 0 0 0 0 
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Author Year Country Sample Method Cases HPV HPV 16 
HPV 
18 
HPV 
31 
HPV 
33 
HPV 
45 
Liegl et al. 2004 Austria FFPE PCR TS 5 5 5 0 0 0 0 
Nascimento et al. 2004 Brazil Fresh /PE 
My9/11 
PCR TS 16 10 1 0 0 1 0 
Daling et al. 2005 USA FFPE My9/11 94 75 65 0 0 0 0 
Salazar et al. 2005 Mexico FFPE PCR TS 16 46 28 28 0 0 0 0 
Gentile et al. 2006 Italy FFPE 
PCR 
My9/11 
GP5+/6+
11 8 5 2 0 0 0 
Lont et al. 2006 Nerther-lands FFPE 
PCR 
GP5+/6+ 171 50 38 3 0 2 3 
Dorfman et al. 2006 Venezuela FFPE My9/11 5 5 0 0 0 0 0 
Senba et al. 2006 Thailand FFPE PCR SPF 65 53 1 36 0 0 0 
Protzel et al. 2007 Germany FFPE 
PCR TS 
6/11/16/1
8 
18 4 3 0 0 0 0 
Pascual et al. 2007 Spain FFPE 
PCR 
My9/11 
GP5+/6+
49 38 32 4 0 0 0 
Heidman et al. 2007 Nerther-lands FFPE - 83 46 24 3 0 1 2 
Guerrero et al. 2008 Spain FFPE PCR GP5+/6+ 24 11 11 0 0 0 0 
Yanagawa et al. 2008 Japan FFPE PCR - RFLP 25 3 3 0 0 0 0 
Scheiner et al. 2008 Brazil frozen PCR My9/11 80 58 12 1 2 2 2 
Madsen et al. 2008 Denmark - 
PCR 
GP5+/6+ 
TS 
37 25 24 0 0 0 0 
Prowse et al. 2008 UK FFPE PCR SPF 26 14 11 0 0 0 0 
Tornesello et al. 2008 Uganda /Italy FFPE 
PCR 
My9/11 
GP5+/6+
78 40 36 0 0 0 0 
Total 1655 824 528 80 3 8 12 
PE=paraffin-embedded 
FFPE= formalin-fixed paraffin- embedded 
PCR TS= polymerase chain reaction type specific 
PCR-RFLP= polymerase chain reaction – restriction fragment length polymorphism 
Table 1. Prevalence for HPV in 36 studies (n=1.644) Adapted from Backes et al., 2009; 
Miralles-Guri et al., 2009. 
The objective of the Senba et al. (2006) study was to determine the relation between penile 
cancer and the prevalence of HPV genotypes in northern Thailand. Eighty-eight specimens 
of penile tissue (65 malignant, 1 pre-malignant, and 22 benign cases) were examined to 
determine the association of HPV infection. HPV DNA was detected in 81.5% of cases of 
penile cancer using PCR. The high-risk HPV16, most commonly associated with penile 
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cancer in previous reports, was found in only one case in this study. The most prevalent 
genotype was the high-risk HPV-18, found in 55.4% of the cases (32.3% single and 23.1% 
multiple infection) followed by the low-risk HPV-6, found in 43.1% of the cases (24.6% 
single and 18.5% multiple infection). In this study, penile cancer was found to be highly 
correlated with HPV DNA.  
Several studies have confirmed a predominance of penile cancer in the North and Northeast 
of Brazil which are regions with lower human development indexes (Favorito et al., 2008; 
Koifman et al., 2011; Reis et al., 2010a). Scheiner et al. (2008) in Rio de Janeiro, Brazil found 
that HPV infection may have contributed to malignant transformation in a large proportion 
of their penile cancer cases but only inguinal metastasis was a prognostic factor impacting 
survival of those patients. In another Brazilian study the patients having HPV type-16 in 
their tumors were submitted to major surgical procedures to remove the primary tumor 
(p=0.04). The relative risk of death for patients with HPV type-16 was 7.59 times greater 
than that for the virus negative group. Also, patients presenting HPV type 16 in the tumor 
presented a lower tendency for survival (without statistical significance). Coilocitosis was 
detected in 12 patients, presenting a significant correlation with the presence of HPV type-16 
(p=0.026). The authors concluded the infection by HPV was strongly associated with penile 
epidermoid carcinoma (30.9%). The presence of HPV type-16 in the tumors was associated 
with increased tumor-related mortality. No HPV 18 was detected in their samples (Gil et al., 
2001). The presence of genomic DNA of HPV 16 and 18 in penile cancers identified by 
Southern blotting (Villa & Lopes, 1986) and polymerase chain reaction (PCR) (Bezerra et al., 
2001) assays also in Brazil.  
In a case control study to analyze the genetic susceptibility involving TP53 polymorphism, 
78 penile SCC biopsies (n= 17 from Uganda, n= 61 from Italy) and blood samples from 150 
healthy controls (n = 57 from Uganda, n = 93 from Italy) were collected. Among Uganda 
cases the heterozygous, proline homozygous and arginine homozygous genotype frequency 
was 41.2%, 52.9% and 5.9%, respectively, and among controls was 40.3%, 54.4%, and 5.3%, 
respectively (P = 0.9917). Conversely, among Italian cases genotype distribution was 42.6%, 
4.9%, and 52.5%, and among controls was 34.4%, 7.5%, and 58.1%, respectively (p=0.5343). 
No significant differences in arginine and proline allele distribution were observed when the 
cases were stratified by HPV status. Therefore, no evidence of association between 
homozygosity for p53 arginine and HPV-related or HPV-unrelated penile squamous cell 
carcinoma was observed among Ugandan or among Italian populations (Tornesello et al., 
2008). 
Poblet et al. (1999) described two cases of penile SCC in HIV-positive patients with 
distinctive clinicopathologic characteristics. The tumors appeared in patients infected with 
HIV and were located in the glans of the penis. Histologically, the tumors were well-
differentiated, infiltrating, penile SCC. The entire spectrum from benign condyloma to 
infiltrative SCC was present in the two patients. The reported cases suggest a synergic 
interaction of HPV and HIV in the carcinogenic process of some penile carcinoma. In fact, 
the immune system efficiency is a key to control HPV replication, which was evident in the 
increased incidence of lesions caused by HPV and recurrent infections in the group 
seropositive for HIV. However, the cellular and molecular mechanisms responsible for 
protection from and elimination of HPV infection are not fully established (Silva et al., 2011). 
Based on cervical cancer studies, penile cancer could also arise from an initial HPV infection 
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which persists over time and causes genetic alterations, leading to an interference of the cell 
division cycle and apoptosis. The International Agency for Research on Cancer (IARC) has 
concluded that there is sufficient evidence to classify HPV infection as a Group I carcinogen 
for cancers of the cervix, anus, oropharynx, penis, vagina, and vulva (IARC, 2007). 
However, epidemiologic and molecular data in support of a causal association are currently 
sparse and do not extend beyond detection of HPV genomes in tumor cells in these cancers 
(Chaturvedi et al. 2010). 
The most serious consequences of genital HPV infections in women are high-grade 
squamous intraepithelial lesions, which can progress to invasive cervical cancer (IARC, 
2007). Numerous studies have investigated the potential risk factors for HPV among 
heterosexual men, men who have sex with men (MSM), and men with HIV/AIDS. 
Universal HPV risk factors described have included the number of lifetime sex partners, 
frequency of condom use, race/ethnicity, educational level, presence of a concomitant 
sexually transmitted infections (STIs) [especially HIV/AIDS infection], and a positive 
history of tobacco use. 
High-risk male populations, most notably MSM and HIV/AIDS-infected males, as a 
community, characteristically have a lifestyle that may incorporate psychosocial, physical, 
and sexual practices that place them at greater risk for STIs such as HPV infections. This 
population falls increasingly vulnerable to HPV-associated cancers because of frequent 
high-risk behaviors, increased likelihood of concomitant infections, and a current lack of 
male cancer screening guidelines (Kreuter et al., 2009). However, studies have shown that 
uncircumcised men have an additional anatomical risk factor as there is a lower incidence of 
HPV infection and HPV-associated penile cancer in circumcised men, especially in those 
men who were circumcised at a younger age (Castellsague et al.,2002).  
Studies have demonstrated that HPV infection in the penis is highly prevalent among 
heterosexual men who are seronegative for HIV, with rates ranging from 52% to 72% 
(Giuliano et al., 2008; Silva et al., 2011). In a recent longitudinal study to assess the 
persistence and clearance of HPV DNA from the penis of men infected and non-infected 
with HIV, the results demonstrated 66% of men without HIV infection presented with some 
type of HPV. The vast majority of such infections are transient, and virus elimination occurs 
rapidly in immunocompetent individuals (Silva et al., 2011) 
The quadrivalent HPV vaccine was licensed in 2006 for use in women aged 9 to 26 to 
prevent infection with HPV serotypes (6, 11, 16 and 18) to prevent HPV related cervical 
cancer. The immunization protocol covers the most prevalent HPV serotypes (Garland et al., 
2007). In 2009, the vaccine approval was extended to boys and men aged 9 to 26 based on 
prevention of infection with serotypes 6 and 11, and subsequent prevention of genital warts. 
In 2010, the vaccine received an additional indication for prevention of anal cancer in men 
and women. However, given multiple etiologies and the low incidence of penile cancer, 
vaccination also will likely provide marginal benefit on a population level. Nevertheless, the 
vaccine should decrease penile cancer caused by HPV 16 and 18, which are the most 
common subtypes associated with penile carcinomas. Vaccination is likely to have a more 
substantial benefit for benign HPV-related diseases of the penis, such as condyloma 
acuminata, which are far more common in any population (Barroso et al., 2011). 
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When considering the impact of a vaccine on cancer incidence, it is useful to consider the 
past experience with Hepatitis B virus (HBV) (Franceschi et al., 2002). Like HPV, HBV is the 
cause of cancer, specifically hepatocellular carcinoma – in chronically infected individuals. 
Unlike HPV, however, HBV is also associated with acute disease at the time of infection and 
substantial morbidity and mortality from causes other than cancer (Plummer & Franceschi, 
2002). In the case of HPV vaccination, it is likely that secular trends in cervical cancer 
incidence or mortality will provide convincing evidence of its effectiveness. Thus, a decline 
in the incidence and in the mortality rates from cervical and non-cervical cancers is expected 
in many populations after the introduction of screening and immunization programs.  
2.4 Prevention for penile cancer 
Two HPV vaccines were developed, a quadrivalent vaccine that provides protection against 
HPV types 6, 11, 16, and 18 and a bivalent vaccine that protects against HPV types 16 and 
18. The quadrivalent and bivalent vaccine were approved by the U.S. Food and Drug 
Administration (FDA) for the prevention of HPV associated cervical cancer, 
adenocarcinoma in situ, cervical intraepithelial neoplasia (CIN) grades 1–3, vulvar 
intraepithelial neoplasia, vaginal intraepithelial neoplasia grades 2/3, vaginal cancer, vulvar 
cancer, and genital warts in women aged 9–26 years (Chaturvadi et al., 2010). The 
quadrivalent  Gardasil™  (Merck and Co. Inc - Whitehouse Station, NJ) vaccine is currently 
approved for sale in 85 countries. Cervarix®, the HPV vaccine produced by GlaxoSmith 
Kline, has been approved in the European Union, Australia, and Kenya, with applications 
pending  elsewhere (Agosti and Goldie, 2007). According to the researchers, the vaccine was 
89% effective in preventing infection with HPV types 16 and 18, and 100% effective in 
preventing the diseases associated with these types (Chaturvadi et al., 2010). 
The L1 virus-like particles (VLP) for specific HPV types is a highly efficacious vaccine 
antigen in humans. Clinical trials of multivalent L1 VLP vaccines intended to be 
disseminated in public health programs have shown safety, immunogenicity, and high 
efficacy (Bosch & Harper, 2006). Studies have shown that serologic diagnosis of HPV 
infection using genetically engineered HPV capsids (VLPs) correlates well with HPV DNA 
presence in cervical smears. The L1 VLP vaccines are unlikely to be effective as a treatment 
of women currently positive for a persistent HPV infection of the same type. Because the 
vaccines are prophylactic and not therapeutic, vaccination is not effective in clearing either 
established infections or pre-existing disease. Although the duration of protection is as yet 
unknown, current data indicated that both vaccines are immunogenic and efficacious for up 
to 4 years after vaccination (Chaturvadi et al., 2010). The antibodies produced recognized 
type-specific conformational epitopes present on VLPs, particularly against the viral capsid 
protein L1 and the humoral response against HPV, i.e., the production of IgG, is stable over 
time (Chatuverti et al., 2010; Villa, 2006). Both the quadrivalent and the bivalent 
prophylactic vaccines have demonstrated high efficacy (90%–98%) against persistent HPV 
infection and vaccine type–related CIN 2 or above (Paavonen et al., 2007). Additionally, both 
vaccines are safe and immunogenic among adolescent males aged 10–18 years and 9–15 
years, respectively. The quadrivalent vaccine has demonstrated high efficacy in preventing 
persistent HPV infection (85.6%), external genital lesions (90.4%), condyloma (89.4%), and 
PIN (100%) among adolescent boys and young men aged 16 to 26 years (Chaturvadi et al., 
2010). 
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Some studies have demonstrated a strong association between lifetime number of sexual 
partners and genital HPV acquisition. The acquisition of new sexual partners continues 
throughout all age groups. In addition, studies have shown consistently that the risk of 
cervical cancer can be predicted as much by a woman's own sexual behaviour as by the 
sexual behaviour of her husband/partner. The presence of HPV DNA in the penis and 
urethra of her sexual partner(s) is directly related to her HPV carrier status and, therefore, 
her increased risk of developing cervical cancer (Castellsague et al., 2009).  
Jasen & Shaw (2004) presented three major issues to be resolved in order to take full 
advantage of the promise of HPV vaccines. First, the global infrastructure must be 
reinforced to accommodate the logistics of delivery of a new vaccine to a, perhaps, non 
pediatric population. This is a rather tall order, and in practice, this may become a pediatric 
vaccine in developing countries even if the developed world makes a different choice. There 
are no adolescent vaccination programs in most parts of the world. The World Health 
Organization’s Expanded Program for Immunization delivers the “basic six” vaccines 
(diphtheria, tetanus, pertussis, polio, measles and BCG) to a large fraction of the world’s 
birth cohort. If effective immunity could be shown to last into adulthood, then pediatric 
administration may be the easier solution for developing countries. Second, the capacity for 
producing HPV vaccines on a global scale must be created. The “chicken-and-egg” aspect of 
this problem might not be as obvious to those outside the vaccine industry. In order to 
justify the capital and other ancillary investments necessary to create manufacturing 
capacity approximately ten times greater than one might normally contemplate, there must 
be some reasonable assurance of a market for the product. This is tightly linked to the third 
issue, funding. In most of the world, vaccines are paid for by governmental or international 
donor agencies. Until recently, the vaccines provided through such funding mechanisms 
have been “traditional” vaccines such as the "basic six" mentioned above. 
To deliver an HPV vaccine for cervical cancer to the women in greatest need, many of whom 
live in the very poorest countries around the world, one can only hope that industry, 
governments, and donor organizations will make similar efforts and alliances to guarantee 
the proper deliver of the vaccines for those who truly need them. Clinical studies to date 
have focused on women because they suffer most from the pathology of HPV infection. 
Men, however, are considered important vectors in the chain of HPV infection and 
dissemination. With the notable exception of penile warts and some cases of penile and anal 
cancer, there is little obvious pathology associated with HPV in heterosexual males, making 
HPV very difficult to be detected in that population. This is partly because of the lack (until 
recently) of an acceptable method of sampling. MSM how practice anal intercourse are 
subjected to development of anal intraepithelial neoplasia. The anal epithelium has a 
transition zone similar to that of the cervix, and this is the most frequent site of HPV 
infection in this group. Since vaccines work best when given to large proportions of the 
population, vaccination trials to show some efficacy in men are also being considered 
(Jansen & Shaw, 2004). 
As a consequence of the recent licensing of the quadrivalent and the bivalent HPV vaccines, 
important questions have emerged regarding investment policies for vaccination programs. 
The decision for an individual country, such as Brazil, over others developing countries, to 
introduce a new public health intervention must take into consideration multiple factors. 
These include the disease burden, effectiveness of the intervention, the financial costs 
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
338 
required to initiate and sustain the program, the cost-effectiveness of the intervention, the 
programmatic capacity and infrastructure necessary to successfully deliver the intervention, 
and the likelihood of cultural acceptability, political will and public support (Goldie et al., 
2007). 
The quadrivalent vaccine also dominates the bivalent vaccine as it lacks cross-reactivity 
against non-16/18 oncogenic HPV types and it also reducces the incidence rates of on 
genital warts (Dee &Howel, 2010). In a recent study, Malasya (2011) reported for the cost-
effectiveness analysis, the cost per life year saved vaccine compared to no vaccine, as 
$12,866 and $12,827 for the quadrivalent and the bivalent vaccines, respectively. Comparing 
the bivalent to the quadrivalent vaccine, the cost-effectiveness ratio (ICER) is $12,488, 
showing that the bivalent vaccine saves more lives per cost. However, the cost per Quality-
Adjusted Life Years (QALY) saved for the quadrivalent vaccine compared to no vaccine was 
estimated as $9,071, while it was $10,392 for the bivalent vaccine, with the quadrivalent 
vaccine dominating the bivalent vaccine due to the additional QALY effect on the reduction 
of genital warts (Lee et al., 2011). 
A study also investigated the cost-effectiveness of HPV vaccination in France, using a 
quadrivalent HPV vaccine. This study compared screening plus vaccination at age 14 years 
with screening alone. The ICER for the addition of vaccination to screening was 
€13,809/QALY when considering all direct healthcare costs. This is somewhat higher than 
the finding of €9,706/QALY for the bivalent vaccine,. Although it should be noted that no 
study undertook a direct head-to-head comparison of the two products and the results may 
therefore not be directly comparable (Bergeron et al., 2008). 
For a country like Brazil, the clinical benefits of an HPV 16/18 vaccine is likely to be 
substantial. The most influential factor on cost-effectiveness is the vaccine cost. If the cost 
per vaccinated woman is less than I$ 25,00 implying a per dose cost of approximately I$ 5,00 
vaccination is likely to be extremely cost-effective in Brazil. The most effective strategy, 
within a framework that would still be potentially cost-effective in Brazil, would be 
vaccination before age 12, followed by screening three times per lifetime between ages 35 
and 45. Assuming a coverage rate of 70%, this strategy would be expected to prevent more 
than 100,000 cases of invasive cervical cancer over a 5-year period. Finally, vaccination 
strategies we have identified as cost-effective may be unaffordable in low and even middle 
income countries without international financial aid. The results from the studies carried out 
in North America and Europe can provide guidance to the global community by helping to 
identify health investments of highest priority and with the greatest promise and best 
effectiveness to the population at risk (Goldie et al., 2007). 
After a vaccination campaign begun, the population will be a mixture of younger, 
vaccinated women and older unvaccinated women. The impact of vaccination is not seen in 
the population as a whole until the vaccinated group dominates in the high-risk age group 
(Bosch & Harper,2006). Thus, screening programs will be required to complement vaccine 
programs for many decades, providing the epidemiological means to understand the actual 
effect of the vaccination on the selected group. On the other hand, educational actions to 
prevent cervical and non cervical cancers, which are part of basic health actions, should be 
implemented as a professional commitment to the population’s quality of life and a health 
care quality, emphasizing patients’ autonomy in self-care.  
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Recently, a Brazilian study aimed to evaluate the applicability of an educational booklet that 
contained information for the general population about promotion and prevention of 
infections and neoplasic diseases caused by the HPV. The study was arranged in two 
phases. First, the booklet was given to 2000 volunteers who evaluated the applicability of 
the booklet without previous education or discussion about the subject. The educational 
material was published and 2000 copies were distributed during a health social event. In the 
event, the booklet raised the interest of the general public and gave the volunteers a chance 
to participate in a study that investigated the presence of the HPV as part of the genital 
microbiote. In a second phase, a detailed analysis of the data was made and the booklet 
revealed applicable. The authors concluded that managing and presenting the information 
beforehand is an important step to promote and improve preventive campaigns and 
strategies aimed to the population at large regarding HPV infection and its potential role on 
carcinogenesis (Reis et al., 2010c).  
Education should not only be considered an extra activity, but an effective action to redirect 
health promotion practices as a whole. Reis et al. (2010c) suggested that preventive 
knowledge about the natural history of cervical and non cervical cancers and, including the 
feasibility of HPV vaccination programs for both sexes, will decrease the incidence of HPV 
associated cancers and has the potential to be of great significance to health management of  
high-risk female and male populations. 
Proper condom use as a primary prevention measure for STI should remain a top priority 
for health official campaigns. The preventive strategies should keep on focusing primarily 
on the increase of STI. This knowledge is proven powerful to elicit individual awareness 
responsible for influencing individual risk perception amongst those sexually active. 
However, the campaigns must understand that modifying individual risk perception does 
not effectively translate into changes of preventive behaviors. To reach the public health 
goal of reducing STI prevalence, barriers to engaging in STI prevention need to be 
addressed, including education strategies. 
3. Conclusion  
Penile SCC is a severe and uncommon disease with devastating medical psychological 
consequences for the patients. The disease is mainly related to poor hygiene, sexual history, 
and smoking. Male circumcision has been used as a preventive measure for sexually 
transmitted infection with positive impact on the reduction of penile cancer incidence rates 
when neonatally performed. Penile cancer development is facilitated by phimosis. In 
general, penile SCC imposes an increase in the relative risk of invasive disease compared to 
an in situ cancer. The understanding of the natural history of penile cancer is fundamental to 
promote effective preventive strategies. Globalization and promiscuity are expected to be 
the major causes leading to the increase of penile SCC incidence. The oncoproteins of high 
risk HPV types target cellular pathways promoting cellular transformation and neutralizing 
the immune response. FDA recently approved and licensed the first vaccine for HPV-6, -11, -
16, and -18 for early prevention in teenagers and young adults. Vaccination is likely to have 
a more substantial benefit for prevent cervical and non cervical cancers. Novel preventive 
strategies are important to complement the immunization programs that should always take 
educational strategy as an important step on primary prevention. 
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